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SUMMARY: The Food and Drug 
Administration (FDA) is amending its 
regulations on nutrition labeling to 
require that trans fatty acids be declared 
in the nutrition label of conventional 
foods and dietary supplements on a 
separate line immediately under the line 
for the declaration of saturated fatty 
acids. This action responds, in part, to 
a citizen petition from the Center for 
Science in the Public Interest (CSPI). 
This rule is intended to provide 
information to assist consumers in 
maintaining healthy dietary practices. 
Those sections of the proposed rule 
pertaining to the definition of nutrient 
content claims for the ‘‘free’’ level of 
trans fatty acids and to limits on the 
amounts of trans fatty acids wherever 
saturated fatty acid limits are placed on 
nutrient content claims, health claims, 
and disclosure and disqualifying levels 
are being withdrawn. Further, the 
agency is withdrawing the proposed 
requirement to include a footnote 
stating: ‘‘Intake of trans fat should be as 
low as possible.’’ Issues related to the 
possible use of a footnote statement in 
conjunction with the trans fat label 
declaration or in the context of certain 
nutrient content and health claims that 
contain messages about cholesterol-
raising fats in the diet are now the 
subject of an advance notice of proposed 
rulemaking (ANPRM) which is 
published elsewhere in this issue of the 
Federal Register.
DATES: This rule is effective January 1, 
2006.
FOR FURTHER INFORMATION CONTACT: Julie 
Schrimpf, Center for Food Safety and 
Applied Nutrition (HFS–832), Food and 
Drug Administration, 5100 Paint Branch 
Pkwy., College Park, MD 20740, 301–
436–2373.
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I. Background
A. Nutrition Labeling
The Nutrition Labeling and Education 
Act of 1990 (the 1990 amendments) 
(Public Law 101–535) amended the 
Federal Food, Drug, and Cosmetic Act 
(the act) to provide, among other things, 
that certain nutrients and food 
components be included in nutrition 
labeling. Section 403(q)(2)(A) and 
(q)(2)(B) (21 U.S.C. 343(q)(2)(A) and 
(q)(2)(B)) of the act state that the 
Secretary of Health and Human Services 
(the Secretary) (and, by delegation, 
FDA) can, by regulation, add or delete 
nutrients included in the food label or 
labeling if he or she finds such action 
necessary to assist consumers in 
maintaining healthy dietary practices.
In response to these provisions, in the 
Federal Register of November 27, 1991 
(56 FR 60366), FDA published a 
proposed rule entitled ‘‘Food Labeling; 
Reference Daily Intakes and Daily 
Reference Values; Mandatory Status of 
Nutrition Labeling and Nutrient Content 
Revision.’’ In that document, the agency 
proposed to require that foods bear 
nutrition labeling listing certain 
nutrients and the amount of those 
nutrients in a serving of the food. Given 
the scientific knowledge about trans 
fatty acids at the time, FDA did not 
propose to require that trans fatty acids 
be listed. However, FDA requested 
comments on whether the listing of 
trans fatty acids should be voluntary (56 
FR 60366 at 60371). (Note: throughout 
this preamble, FDA has used the term 
‘‘trans fatty acids’’ and ‘‘trans fat’’ 
interchangeably; likewise, for the terms 
‘‘saturated fatty acids,’’ and ‘‘saturated 
fat’’).
In the Federal Register of January 6, 
1993 (58 FR 2079), FDA issued a final 
rule implementing the 1990 
amendments entitled ‘‘Food Labeling; 
Mandatory Status of Nutrition Labeling 
and Nutrient Content Revision, Format 
for Nutrition Label’’ that prescribes how 
nutrition labeling is to be provided on 
foods that are regulated by the agency. 
In that document, the agency required 
the declaration of total fat and saturated 
fat in the nutrition label, with the 
declaration of both monounsaturated fat 
and polyunsaturated fat (both defined as 
the cis isomers only) required, when 
claims are made about fatty acids and 
cholesterol. Based on its review of the 
comments, the agency stated that it was 
premature to include trans fatty acids in 
nutrition labeling because of a lack of 
agreement on the dietary implications of 
trans fatty acid intake. However, the 
agency acknowledged that it might be 
necessary to revisit the labeling of trans 
fatty acids in the future (58 FR 2079 at 
2090–2092).
FDA received a citizen petition, dated 
February 14, 1994, from CSPI (docket 
number 94P–0036/CP1) stating that an 
increasing body of evidence suggests 
that dietary trans fatty acids raise blood 
cholesterol levels, thereby increasing 
the risk of coronary heart disease (CHD). 
The petitioner argued that the 1993 final 
rules implementing the 1990 
amendments do not adequately reflect 
the effect of dietary trans fatty acids on 
CHD and that label values for saturated 
fat underestimate the total amount of 
‘‘heart-unhealthy’’ fats because trans 
fatty acids are not declared. CSPI 
requested that FDA amend the 
definition of saturated fat in 
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§ 101.9(c)(2)(i) (21 CFR 101.9(c)(2)(i)) to 
include trans fatty acids so that the 
declaration of saturated fat on the 
nutrition label would provide 
consumers with complete information 
on all ‘‘heart-unhealthy’’ fatty acids. In 
addition, the petitioner requested that 
all saturated fat claims in § 101.62(c) (21 
CFR 101.62(c)), the saturated fat 
threshold on all cholesterol claims in 
§ 101.62(d), the claims for ‘‘lean’’ and 
‘‘extra lean’’ in § 101.62(e), and 
disqualification and disclosure levels 
for health and nutrient content claims 
be amended to reflect the combined 
levels of saturated and trans fatty acids. 
Further, CSPI requested that FDA: (1) 
Limit ‘‘vegetable oil’’ claims (e.g., 
‘‘made with vegetable oil’’) to foods that 
are low in both saturated and trans fatty 
acids, and (2) require that ‘‘partially 
hydrogenated’’ fat be listed on food 
labels as ‘‘partially saturated.’’
On July 13, 1998, CSPI amended its 
petition in a way that would maintain 
the definition of saturated fat in 
§ 101.9(c)(2)(i), yet provide consumers 
with information on the trans fatty acid 
content of the food. Specifically, CSPI 
suggested that FDA either: (1) Disclose 
the sum of trans and saturated fats next 
to the term ‘‘saturated fat*’’ with an 
asterisk at the bottom of the label that 
states ‘‘contains ___ grams of trans fat,’’ 
or (2) disclose the sum of trans and 
saturated fats next to the term 
‘‘saturated + trans fat’’ when trans fat 
was present.
In response to CSPI’s petition, FDA 
issued a proposed rule in the Federal 
Register of November 17, 1999 (64 FR 
62746), entitled ‘‘Food Labeling: Trans 
Fatty Acids in Nutrition Labeling, 
Nutrient Content Claims, and Health 
Claims’’ (hereinafter identified as ‘‘the 
November 1999 proposal’’). In that 
document, FDA proposed to amend its 
nutrition labeling regulations to require 
that the amount of trans fatty acids in 
a food, including dietary supplements, 
be included in the amount and percent 
Daily Value (%DV) declared for 
saturated fatty acids, with a footnote 
indicating the amount of trans fatty 
acids in a serving of the product, when 
the product contains 0.5 or more grams 
(g) trans fatty acids per serving. FDA 
reviewed recent research that showed 
that consumption of diets containing 
trans fatty acids, like diets containing 
saturated fats, results in increased 
serum low-density lipoprotein 
cholesterol (LDL–C), a major risk factor 
for CHD. The proposed rule was issued 
to assist consumers in maintaining 
healthy dietary practices (64 FR 62746 
at 62754).
B. Nutrient Content and Health Claims
In the Federal Register of November 
27, 1991 ( 56 FR 60478), FDA also 
published a proposed rule entitled 
‘‘Food Labeling: Definitions of Nutrient 
Content Claims for the Fat, Fatty Acid, 
and Cholesterol Content of Food.’’ 
Although the agency proposed 
definitions for fat, fatty acid, and 
cholesterol nutrient content claims, it 
did not propose a definition for the 
nutrient content claim ‘‘saturated fat 
free.’’ However, the comments in 
response to that proposal recommended 
that FDA define the claim ‘‘saturated fat 
free.’’
In the Federal Register of January 6, 
1993 (58 FR 2302), FDA issued a final 
rule entitled ‘‘Food Labeling: Nutrient 
Content Claims, General Principles, 
Petitions, Definition of Terms; 
Definition of Nutrient Content Claims 
for the Fat, Fatty Acid, and Cholesterol 
Content of Food,’’ (hereinafter the 
‘‘nutrient content claims final rule’’). In 
that rule, the agency stated that it did 
not set a trans fat criterion for most 
claims because the evidence suggesting 
that trans fatty acids raise serum 
cholesterol was inconclusive at that 
time (58 FR 2302 at 2332 and 2340). 
However, FDA did set a trans fat 
criterion for the ‘‘saturated fat free’’ 
claim stating that ‘‘because of the 
uncertainty regarding this issue, the fact 
that consumers would expect a food 
bearing a ‘saturated fat free’ claim to be 
free of saturated fat and other 
components that significantly raise 
serum cholesterol, and the potential 
importance of a saturated fat free claim, 
the agency believes that it would be 
misleading for products that contain 
measurable amounts of trans fatty acids 
to bear a ‘saturated fat free’ claim’’ (58 
FR 2302 at 2332). The trans fat criterion 
for the claim ‘‘saturated fat free’’ was set 
at a level not to exceed 1 percent of total 
fat in the food (58 FR 2302 at 2419). The 
agency stated that 1 percent was the 
appropriate threshold because analytical 
methods for measuring trans fatty acids 
below that level were not reliable (58 FR 
2302 at 2332). This action was taken 
under the authority of section 
403(r)(2)(A)(vi) of the act, which 
prohibits a claim if it is misleading in 
light of the level of another nutrient in 
the food.
Some comments that FDA received 
after publication of the nutrient content 
claims final rule objected to the 1 
percent criterion for trans fatty acids in 
the definition of ‘‘saturated fat free.’’ 
One comment pointed out that a cookie 
containing 1.5 g of total fat would be 
allowed to have only 0.015 g of trans 
fatty acids, an amount that could not be 
accurately measured. In response to 
these comments, in the Federal Register 
of August 18, 1993 (58 FR 44020 at 
44032), the agency amended the 
definition of ‘‘saturated fat free’’ to 
require that a food contain less than 0.5 
g of trans fatty acids in addition to less 
than 0.5 g of saturated fat per reference 
amount customarily consumed 
(hereinafter referred to as ‘‘reference 
amount’’) and per labeled serving to be 
eligible to bear the claim.
In the November 1999 proposal, FDA 
concluded that dietary trans fatty acids 
have adverse effects on blood 
cholesterol measures that are predictive 
of CHD risk (64 FR 62746 at 62754). 
Consequently, to avoid misleading 
claims, the agency proposed that the 
amount of trans fatty acids be limited 
wherever saturated fat limits are placed 
on nutrient content claims, health 
claims, or disclosure and disqualifying 
levels. In the November 1999 proposal, 
the agency did not propose to take 
action requested by CSPI to amend 
§ 101.65(c)(3) (21 CFR 101.65(c)(3)) to 
state that ‘‘made with vegetable oil’’ is 
an implied claim that the product is low 
in saturated fat and trans fats combined 
(64 FR 62746 at 62762) because the 
agency proposed to amend nutrient 
content claims for saturated fat to 
include a trans fatty acid criterion. The 
agency stated that the proposed 
amendments to nutrient content claims 
and the requirements for implied 
nutrient content claims in § 101.65(c)(3) 
adequately addressed the petitioner’s 
request.
In addition, in the November 1999 
proposal, FDA requested comment on 
whether ‘‘trans fat free’’ claims would 
help consumers maintain healthy 
dietary practices and whether they 
would provide incentive to the food 
industry to reduce the amount of trans 
fat in the food supply (64 FR 62746 at 
62759). FDA proposed a definition for 
the trans fat free claim. FDA concluded 
that there was no basis for defining ‘‘low 
trans fat’’ without quantitative 
recommendations for daily intake of 
trans fat. Further, FDA did not define a 
‘‘reduced trans fat’’ claim because it was 
concerned that a reduced trans fat claim 
would detract from educational 
messages that emphasize lower intakes 
of saturated fat. Persons who believed 
that a ‘‘reduced trans fat’’ claim would 
be useful were advised to submit a 
petition under § 101.69 (21 CFR 101.69).
In the November 1999 proposal, FDA 
proposed to deny CSPI’s request that the 
agency require that ‘‘partially 
hydrogenated’’ fat be listed as ‘‘partially 
saturated’’ fat (64 FR 62746 at 62762). 
Among other reasons, the agency stated 
that ‘‘hydrogenated’’ and ‘‘partially 
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hydrogenated’’ are not intended to 
describe the nutritional properties of the 
fat or oil. It explained that the purpose 
of the ingredient statement is to identify 
the ingredients in a food by listing the 
common or usual names of each 
ingredient (64 FR 62746 at 62762–
62763).
Comments to the November 1999 
proposal requested that the final rule 
define the nutrient content claim 
‘‘reduced trans fat.’’ Other comments 
suggested a ‘‘reduced saturated fat’’ 
claim that would be defined as a 
reduction of saturated and trans fats 
combined. The agency considered these 
comments and determined that all 
interested parties should have an 
opportunity to comment on whether the 
final rule should define claims that 
address reduced levels of trans fat. 
Therefore, FDA reopened the comment 
period for the November 1999 proposal 
on December 5, 2000, for a period of 45 
days (65 FR 75887) stating that it would 
consider only comments that addressed 
‘‘reduced trans fat’’ and ‘‘reduced 
saturated and trans fat’’ claims.
Subsequent to FDA’s November 1999 
proposal, the Institute of Medicine of 
the National Academy of Sciences 
(IOM/NAS) issued a report entitled 
‘‘Dietary Reference Intakes for Energy, 
Carbohydrate, Fiber, Fat, Fatty Acids, 
Cholesterol, Protein and Amino Acids’’ 
(the IOM/NAS macronutrient report) 
(Ref. 140) and found, similar to the 
effect of saturated fat, ‘‘a positive linear 
trend’’ between trans fatty acid intake 
and total and LDL–C concentrations, 
and therefore increased risk of CHD. 
Because trans fats are unavoidable in 
ordinary diets, the IOM/NAS report 
recommended that ‘‘trans fat 
consumption be as low as possible 
while consuming a nutritionally 
adequate diet.’’ Likewise, the 
conclusions in two other scientific 
reports, which became available 
subsequent to the November 1999 
proposal, i.e., the Dietary Guidelines for 
Americans, 2000 (Ref. 88) and 
guidelines from the National Cholesterol 
Education Program (NCEP) (Ref. 89), 
were similar with recommendations to 
limit trans fat intake in the diet. 
Although the IOM/NAS report (Ref. 140) 
underscored the relationship between 
the intake of trans fat and the increased 
risk for heart disease and emphasized 
that consumers need to limit trans fat in 
their diets, it did not provide a Dietary 
Reference Intake (DRI) value for trans fat 
or information that FDA believes is 
sufficient to support the agency’s 
establishing a Daily Reference Value 
(DRV) or other information on the label, 
such as a %DV, for trans fat.
In response to the recommendations 
of the new scientific reports to limit the 
intake of trans fat and to provide 
consumers with label information that 
may better assist them in understanding 
the quantitative declaration of trans fat 
in the context of a total daily diet, FDA 
reopened the comment period of the 
November 1999 proposal for a period of 
30 days (67 FR 69171, November 15, 
2002). In that document the agency 
proposed to require an asterisk (or other 
symbol) in the %DV column for trans 
fat, when it is listed, that is tied to a 
similar symbol at the bottom of the 
Nutrition Facts box that is followed by 
the statement ‘‘Intake of trans fat should 
be as low as possible.’’ The agency 
stated that the statement is taken from 
the IOM/NAS macronutrient report and 
is consistent with the dietary guidance 
in the other recent scientific reports 
identified in that document (67 FR 
69171 at 69172).
In the November 15, 2002, Federal 
Register document to reopen the 
comment period the agency also stated 
that it would consider the exercise of its 
enforcement discretion for those 
manufacturers who wanted to begin 
labeling the trans fat content of food 
products prior to publication of the final 
rule (67 FR 69171 at 69172). The agency 
cautioned manufacturers that the trans 
fat final rule may differ from what was 
being proposed in the November 15, 
2002, document to reopen the comment 
period and that manufacturers would 
then be required to change their labels 
to conform to the final rule.
C. Comments
FDA received over 1,650 letters in 
response to the November 1999 
proposal, over 45 letters in response to 
the December 5, 2000, notice reopening 
the comment period, and over 25 letters 
in response to the November 15, 2002, 
proposal and notice to reopen the 
comment period. Each of these letters 
contained one or more comments. 
Responses were received from industry, 
trade associations, consumers, 
consumer advocacy organizations, 
academia, health care professionals, 
professional societies, city and State 
governments, other Federal agencies, 
and other countries. Some of the 
comments supported the proposal 
generally or supported aspects of the 
proposal. Other comments objected to 
specific provisions and requested 
revisions. Some comments requested 
that the proposal be withdrawn or 
reproposed. A few comments addressed 
issues outside the scope of the proposal 
and will not be discussed here. On 
September 18, 2001, the Office of 
Information and Regulatory Affairs 
(OIRA), Office of Management and 
Budget, sent to the Secretary of the 
Health and Human Services (the 
Secretary) a letter requesting that the 
Secretary and FDA consider giving 
greater priority to the November 1999 
proposal (Ref. 156) in light of the 
growing body of scientific evidence 
suggesting that consumption of trans 
fatty acids in foods increases the 
consumer’s risk of developing CHD. The 
estimated public health benefits from 
increased consumer awareness of trans 
fat content in foods that were described 
in FDA’s preliminary Regulatory Impact 
Analysis in the November 1999 
proposal, and the subsequent evidence 
found in more recent studies, strongly 
support the interests of the Government 
to lower the incidence of and economic 
burden of CHD in the United States. 
This final rule summarizes the relevant 
comments that were received in 
response to the November 1999 
proposal and provides the agency’s 
conclusions regarding the labeling of 
trans fat on the Nutrition Facts panel.
A summary of the relevant comments 
that pertain to nutrition labeling of trans 
fat, the agency’s responses to the 
comments, and a discussion of the 
agency’s conclusions follow.
II. Highlights of the Final Rule
In this final rule and given the current 
state of scientific knowledge, FDA is 
requiring the mandatory declaration in 
the nutrition label of the amount of 
trans fatty acids present in foods, 
including dietary supplements. The 
declaration of this nutrient must be on 
a separate line immediately under the 
declaration for saturated fat but it will 
not include a %DV that is required for 
some of the other mandatory nutrients, 
such as saturated fat. In addition, the 
agency is withdrawing those sections of 
the proposed rule pertaining to the 
definition of nutrient content claims for 
‘‘free’’ and for ‘‘reduced’’ levels of trans 
fatty acids, and limits on the amounts of 
trans fatty acids, wherever saturated 
fatty acid limits are placed on nutrient 
content claims, health claims, and 
disclosure and disqualifying levels. 
Further, the agency is withdrawing the 
proposed requirement to include a 
footnote stating: ‘‘Intake of trans fat 
should be as low as possible.’’
The action the agency is taking in this 
final rule is based on its evaluation of 
comments received in response to the 
November 1999 proposal, the reopening 
of the comment period on November 15, 
2002, and on scientific evidence that 
shows that consumption of trans fatty 
acids increases LDL–C, a primary risk 
factor for CHD. The scientific evidence 
includes current authoritative reports, 
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such as Dietary Guidelines 2000 (Ref. 
87), that recommend that Americans cut 
back on trans fats when reducing fat 
intake. The agency concludes that the 
declaration of this nutrient on a separate 
line, will help consumers understand 
that trans fat is chemically distinct from 
saturated fat and will assist them in 
maintaining healthy dietary practices. 
The agency intends to promote 
consumer awareness and understanding 
of the health effects of trans fat as part 
of an educational program. FDA is 
issuing an ANPRM elsewhere in this 
issue of the Federal Register that will 
solicit comment and additional 
consumer research that potentially 
could be used to establish new nutrient 
content claims about trans fat, to 
establish qualifying criteria for trans fat 
in certain nutrient content claims and 
health claims, and to establish 
disclosure and disqualifying criteria for 
trans fat. In addition, the ANPRM is 
soliciting comment on whether it 
should consider statements about trans 
fat, either alone or in combination with 
saturated fat and cholesterol, as a 
footnote in the Nutrition Facts panel or 
as a disclosure statement in conjunction 
with claims to enhance consumer’s 
understanding about cholesterol-raising 
lipids.
III. Legal Authority
General Comments
FDA received a number of comments 
from trade associations and others in 
industry asserting that FDA did not 
meet its burden under the first 
amendment in proposing to mandate 
nutrition labeling of trans fat. Further, 
the comments asserted that FDA did not 
meet its first amendment burden for 
establishing restrictions on specific 
claims by virtue of how FDA defined 
nutrient content claims or established 
disqualifying and disclosure levels, 
including the effects that those actions 
would have on restricting certain health 
claims on food. In addition, comments 
raised questions about whether the 
agency’s proposed action was consistent 
with the Administrative Procedure Act 
(APA) and whether the agency was 
acting consistent with its authority 
under the act.
As stated in section VI of this 
document, FDA is withdrawing those 
sections of the rule pertaining to the 
definition for nutrient content claims 
that were proposed, and to limits on the 
amounts of trans fatty acids wherever 
saturated fatty acid limits are placed on 
nutrient content claims, health claims, 
and disclosure and disqualifying levels. 
Further, the agency is withdrawing the 
proposed requirement to include a 
footnote stating ‘‘Intake of trans fat 
should be as low as possible.’’ The 
agency provides an overview of 
comments received on these withdrawn 
sections in section VI of this document, 
and therefore, is not addressing those 
comments here. Thus, the agency is 
addressing only those comments that 
pertain to legal issues about the agency’s 
action to require mandatory trans fat 
labeling.
A. Statutory Authority
Several comments question whether 
the agency’s proposed requirement for 
mandatory trans fat labeling would 
prevent consumer deception or would 
assist consumers in maintaining healthy 
dietary practices. The comments suggest 
that the data do not support mandatory 
trans fat labeling, unless the label 
contains a nutrient content or health 
claim related to fat or cholesterol or 
unless polyunsaturated fat or 
monounsaturated fat is voluntarily 
declared on the label. Specifically, the 
comments assert that mandatory trans 
fat labeling in the absence of claims, or 
statements about other fats, would not 
assist consumers in following healthy 
dietary practices or would not prevent 
consumer deception.
A few comments suggest that there 
was no basis for concluding any health 
benefit can be expected from disclosure 
of trans fat levels on foods when present 
in amounts that have not been clinically 
shown to have a material impact on 
human health or disclosure on foods 
with a trivial contribution of fat.
Another comment argues that the 
agency could only require mandatory 
labeling of trans fat under the statute 
where the absence of such labeling 
constitutes the omission of a material 
fact under section 201(n) of the act (21 
U.S.C. 321(n)), such as when nutrient 
content claims are made about 
cholesterol or fatty acids, or when 
polyunsaturated and monounsaturated 
fats are voluntary listed. A related 
comment suggests that trans fat labeling 
would be appropriate where the 
declaration of ‘‘total fat’’ and ‘‘saturated 
fat,’’ that did not explicitly include 
trans fat, were established as misleading 
under section 201(n) of the act (without 
trans fat listed). The comment seems to 
suggest that the declaration of ‘‘total fat’’ 
and ‘‘saturated fat’’ in that situation 
would be misleading if the actual 
nutrition contribution from trans fat that 
such products make to the diet was 
greater in comparison to other products. 
In addition, one comment suggests that 
mandatory nutrition labeling of trans fat 
can only be ‘‘material’’ where there is 
sufficient trans fat present in the food to 
significantly impact the overall fatty 
acid contribution that the food makes to 
the diet, such that only having total fat 
and saturated fat on the label would 
misrepresent the nutritional value of the 
product in a material way.
FDA believes it has adequate 
authority to adopt this rule. FDA’s 
authority under the act to require trans 
fat labeling includes sections 201(n), 
403(a)(1) and (q), and 701(a) of the act 
(21 U.S.C. 371(a)). FDA has authority 
under section 701(a) of the act to issue 
regulations for the efficient enforcement 
of the act. FDA can require labeling of 
certain facts that are material in light of 
representations made in the labeling or 
with respect to consequences which 
may result from the use of the article in 
order for a product not to be misbranded 
under sections 201(n) and 403(a) of the 
act. Further, under section 403(q)(2)(A) 
of the act, the Secretary (and FDA, by 
delegation) may require that information 
relating to a nutrient be in the labeling 
of food for the purpose of ‘‘providing 
information regarding the nutritional 
value of such food that will assist 
consumers in maintaining healthy 
dietary practices.’’
The agency believes that the data in 
the record supports mandatory trans fat 
labeling to ensure that consumers are 
not misled and are adequately informed 
about the product’s attributes. 
Accordingly, FDA believes that 
mandatory trans fat labeling is 
necessary for foods not to be 
misbranded under section 403(a) of the 
act. The absence of information about 
the content of trans fat in foods that are 
subject to mandatory labeling would 
constitute an omission of a material fact 
under section 201(n) of the act.
Under the act, the agency has the 
mandate to ensure that labeling 
provides truthful and nonmisleading 
information to consumers. Thus, the law 
provides the agency with authority to 
require specific label statements when 
needed for reasons other than to ensure 
the safe use of food. Under section 
403(a)(1) of the act, a food is 
misbranded if its labeling is false or 
misleading in any particular. Section 
201(n) of the act amplifies what is 
meant by ‘‘misleading’’ in section 
403(a)(1) of the act. Section 201(n) of the 
act states that, in determining whether 
labeling is misleading, the agency shall 
take into account not only 
representations made about the product, 
but also the extent to which the labeling 
fails to reveal facts material in light of 
such representations made or suggested 
in the labeling or material with respect 
to consequences which may result from 
use of the article to which the labeling 
relates under the conditions of use 
prescribed in the labeling or under such 
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1 FDA’s regulation regarding the failure to reveal 
material facts (§ 1.21) states that ‘‘affirmative 
disclosure of material facts * * * may be required, 
among other appropriate regulatory procedures, by 
* * * regulations in this chapter promulgated 
pursuant to section 701(a) of the act; or direct court 
enforcement action (emphasis added).’’ Thus, 
establishing a requirement for mandatory trans fat 
labeling is consistent with § 1.21.
conditions of use as are customary or 
usual (see § 1.21 (21 CFR 1.21)). Thus, 
the omission of certain material facts 
from the label or labeling of a food 
causes the product to be misbranded 
within the meaning of 21 U.S.C. 
343(a)(1) and 321(n).
In general, the agency believes the 
concept of ‘‘material fact’’ is one that 
must be applied on a case-by-case basis. 
The agency has required special labeling 
in cases where information is necessary 
to ensure that consumers are aware of 
special health risks associated with 
consumption of a particular product. 
For example, although protein products 
intended for use in weight reduction are 
not inherently unsafe, FDA requires a 
warning statement for such products 
that states, in part, that very low calorie 
protein diets may cause serious illness 
or death. Another example of required 
information is the use of the term ‘‘milk 
derivative’’ following the ingredient 
declaration of sodium caseinate when 
used in a product labeled ‘‘non dairy’’ 
(21 CFR 101.4(d)).1
Consumption of trans fat results in 
consequences to the consumer. 
Consumers may increase or decrease 
their risk of CHD based on the level of 
trans fat in their diets. Thus, the 
presence or absence of trans fat in a 
food product is a material fact under 
section 201(n) of the act.
Consumers must know—and the 
agency believes is material information 
that the reasonable consumer should 
know—the amount of trans fat in food 
products that they select as part of their 
total daily diet to choose products that 
would allow them to reduce their intake 
of trans fat, and thus, reduce the risk of 
CHD. Section IV of this document 
discusses the scientific evidence for 
why trans fat consumption places 
consumers at risk for CHD. Absent 
mandatory labeling, consumers would 
not be able to understand the relative 
contribution that foods make to their 
total daily intake of trans fat. First, 
because polyunsaturated and 
monounsaturated fats are not subject to 
mandatory labeling, simply including 
trans fat as part of the total fat 
contribution would not allow 
consumers to calculate the trans fat 
content by finding the difference 
between the sum total of all the 
mandatory fats listed on the label and 
the total fat content. Second, even if all 
component fats were required to be 
listed, it would not be realistic to expect 
consumers to do such calculations on 
each product to compare the relative 
trans fat contribution of each. Further, 
the fact that an individual food product 
may contain zero gram trans fat is still 
a ‘‘material fact’’ for that food. In the 
context of mandatory labeling of 
nutrients in a nutrition facts panel, the 
relative contribution of various food 
products to the total day’s consumption 
of a heart unhealthy fat is important for 
consumers ‘‘to readily observe and 
comprehend the information and to 
understand the relative significance of 
that information in the context of the 
total daily diet’’ (section 2(b)(1)(A) of 
Public Law 101–535). Further, foods in 
which trans fat has replaced saturated 
fat would appear to be heart healthy 
based on the saturated fat grams listed 
on the nutrition facts panel, when, in 
fact, such foods may not be heart 
healthy due to the large contribution of 
trans fat to the total fat content. 
Consumers would be misled without 
having trans fat information available 
on the label. Thus, for the reasons set 
forth previously, FDA concludes that it 
is acting within its statutory authority 
under the act to require trans fat 
labeling.
Moreover, Congress provided the 
agency with the express authority to add 
to the list of nutrients on the label under 
section 403(q)(2)(A) of the act. As stated 
in section V.A of this document, section 
403(q)(2)(A) gives FDA the authority to 
require that information on additional 
nutrients be included in nutrition labels 
if FDA determines that providing such 
information will assist consumers to 
maintain healthy dietary practices. 
Section IV of this document provides 
ample evidence of the heart unhealthy 
effects from consumption of trans fat 
over a range of intakes, information the 
agency believes is material information 
that the reasonable consumer should 
know. When scientific evidence 
supports such labeling, the agency has 
discretion to determine whether to 
require the addition of a particular 
nutrient to the label of food products. 
Thus, the agency is well within its 
statutory authority for requiring 
mandatory labeling of trans fat and is 
not limited to requiring such 
information only when certain claims 
are made or only when other fats are 
listed on the label.
Further, the agency disagrees with the 
comments that assert that mandatory 
trans fat labeling would not assist 
consumers to maintain healthy dietary 
practices, unless the label also carries a 
nutrient content or health claim or 
information about other fats. The agency 
also disagrees with comments 
suggesting that there is no basis for 
concluding any health benefit can be 
expected from disclosure of trans fat if 
foods contain a trivial amount of trans 
fat or if trans fat is not present in 
amounts that have not been clinically 
shown to adversely affect human health.
The agency is exercising the 
discretion that Congress gave it in the 
1990 amendments to include trans fat as 
a mandatory nutrient in food labeling, 
based on the state of the scientific 
evidence on the increased LDL–C levels 
from intake of trans fat (see section IV 
of this document). The scheme that 
Congress established would require all 
mandatory nutrients be listed on the 
food label, including those that the 
agency determines are necessary under 
section 403(q)(2)(A) of the act. Congress 
wanted one uniform statutory scheme 
for food labeling and discussed the 
importance of maintaining consistency 
in the format and content of the food 
label to ‘‘help all consumers to better 
understand and improve their eating 
habits by providing uniform information 
in a coherent and understandable 
format.’’ (136 Cong. Rec. S 16607 at 
16609 (statement of Senator 
Metzenbaum)). The statute does not 
require other mandatory nutrients to be 
listed, for example, saturated fat, only 
when monounsaturated and 
polyunsaturated fat are voluntarily 
listed. Mandatory nutrients are listed for 
each food that bears a nutrition facts 
panel. Food that bears a nutrition label 
must contain certain required nutrients 
as part of that label to not be 
misbranded.
Further, section 403(q)(2)(A) provides 
that mandatory labeling would be 
appropriate when information about a 
nutrient would assist consumers to 
maintain healthy dietary practices. 
Information on the trans fat content of 
food would assist consumers in this 
way. Consumers need the information 
on trans fat content of all foods that they 
consume so that they can reduce their 
intake of trans fat. The fact that a food 
may have no trans fat or a small amount 
of trans fat is useful information to the 
consumer so that food choices can be 
made and the consumer can put that 
product, along with many other 
products consumed as part of the daily 
diet, into the context of the total daily 
diet to maintain healthy dietary 
practices. Consumers would have 
information on the amount of trans fat 
in a product, along with other 
information about the amount of 
saturated fat and cholesterol. Consumers 
could use information about all three 
fats, not just saturated fat and 
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2 The agency does not need to address the 
comments that asserted that proposing to treat trans 
fat the same as saturated fat in the November 1999 
proposal would be the same as requiring false 
labeling. Since the agency is requiring separate line 
labeling in this final rule, those comments are moot.
cholesterol, to incorporate nutrition 
education information about 
recommended contributions for all three 
fats to the diet when making healthier 
food choices. There is ample discussion 
in section IV of this document about the 
heart unhealthy effects of consuming 
trans fat and there is a new and strong 
consensus among the scientific 
community for reducing trans fat intake. 
Thus, the agency believes it is within 
the bounds of its statutory authority 
under section 403(q)(2)(A) of the act to 
require the listing of trans fat on the 
food label, which listing is not 
dependent on the presence of claims or 
other voluntary fat information.
B. The First Amendment
Several general comments were 
received asserting that the agency’s 
action to mandate labeling is subject to 
review under the first amendment. The 
comments assert that mandatory 
labeling of trans fat is commercial 
speech, and thus, such speech is 
entitled to the full range of first 
amendment protections as all 
commercial speech (citing to Pearson v. 
Shalala, 164 F.3d 650 (D.C. Cir. 1999)). 
The comments further assert that 
‘‘compelled speech’’ is entitled to the 
same protections as speech ‘‘bans,’’ 
(citing to Central Hudson Gas & Elec. 
Corp. v. Public Service Comm’n of New 
York, 477 U.S. 557 at 566 (1980)). One 
comment explained that the court in 
Pearson emphasized that the first 
amendment does not allow FDA to 
restrict truthful, nonmisleading 
information as a ‘‘paternalistic’’ means 
of directing consumer food choices (164 
F.3d at 656 (citing Bates v. State Bar of 
Arizona, 433 U.S. 350 at 377(1977) 
(‘‘[W]e view as dubious any justification 
that is based on the benefits of public 
ignorance.’’)); 44 Liquormart, Inc. v. 
Rhode Island, 517 U.S. 484, 503 (1996) 
(opinion of Stevens, J. joined by 
Kennedy, J., and Ginsburg, J.) (‘‘The 
First Amendment directs us to be 
especially skeptical of regulations that 
seek to keep people in the dark for what 
the government perceives to be their 
own good.’’). The comment further cited 
several cases for the proposition that the 
government cannot compel speech 
when disclosures are not necessary to 
materially alleviate real consumer harm 
(citing to IDFA v. Amestoy, 92 F.3d 67, 
73 (2nd Cir. 1996); Ibanez v. Florida 
Dep’t of Business and Prof’l Regulation, 
512 U.S. 136 (1994); and Edenfield v. 
Fane, 507 U.S. 761 (1993)). Another 
comment suggests that the agency 
needed to consider the limitations 
imposed by the first amendment to 
avoid unjustified burdens and costs on 
food labeling where there is no genuine 
public health benefit from a rule that 
does not materially alleviate a genuine 
harm of potential consumer deception.
Some comments assert that FDA’s 
proposal to mandate trans fat labeling 
does not remedy a concrete harm as 
required by the first amendment. One 
comment suggests that a trans fat 
labeling rule could be supported if 
carefully crafted to remedy consumer 
deception but not where risk of 
consumer deception cannot be 
established as a genuine harm. Other 
comments state that FDA did not tailor 
its approach to labeling and would be 
requiring mandatory labeling of trans fat 
for foods containing as little as 0.5 g 
trans fat, which would not alleviate a 
genuine harm. The comment seems to 
further suggest that including trans fat 
in the total fat content on the label 
would be sufficiently tailored to 
alleviate a genuine harm. Another 
comment states that there is mere 
speculation in the record that providing 
information on trans fat would assist 
consumers to maintain healthy dietary 
practices, and thus, is not narrowly 
tailored to materially alleviate a genuine 
harm.
A few comments state that treating 
trans fats the same as saturated fat on 
labeling would be the same as proposing 
to require false information on labels. 
Such an outcome, the comments state, 
would be indefensible on Constitutional 
grounds. One comment states that 
mandatory declaration of trans fat can 
only be justified under constitutional 
provisions when the absence of such 
declaration would constitute an 
omission of a material fact.
FDA believes that this regulation is 
consistent with the first amendment. As 
noted previously, the failure to disclose 
the amount of trans fat in a product is 
an omission of material fact. When a 
manufacturer makes explicit or implicit 
health claims, the failure to provide 
trans fat information is likely to mislead 
the consumer. Moreover, the reasonable 
consumer would expect that the 
information on the label would give 
them the most important nutrition 
information relative to the healthfulness 
of a product. Yet the omission of trans 
fat runs counter to that expectation, 
impeding rational consumer choice. As 
the agency has explained earlier, 
consumers need information about trans 
fat on all foods, not just those that 
contain a certain threshold level of trans 
fat, to reduce overall intake of trans fat 
in the diet. Consumers can use that 
information to compare products and 
make selections that can reduce their 
risk of CHD.
Accordingly, FDA believes that this 
final rule passes muster under the four-
part test in Central Hudson primarily 
because, as discussed previously, 
requiring the factual information on the 
amount of trans fat in labeling ensures 
that the label is not false or misleading. 
Under the first prong of Central Hudson, 
commercial speech must be related to 
lawful activity and not be misleading. 
Speech that is false or misleading is not 
protected and may be prohibited 
(Central Hudson, 447 U.S. 557 at 563–
564).2
Given this determination, arguably 
the agency need not address the other 
three parts of the Central Hudson test at 
all. Nonetheless, and particularly in 
light of FDA’s showing that such 
information is important to ensuring 
that consumers are adequately informed 
about the products they are buying, the 
proposed requirement satisfies the next 
three prongs. Turning to the second 
prong, the asserted governmental 
interest must be substantial. FDA’s 
interest is clearly substantial, for at least 
two reasons. As noted previously, the 
FDA has a substantial interest in 
protecting and promoting public health 
and in preventing consumer deception 
by ensuring the accuracy and 
completeness of trans fat information in 
labeling. (See Pearson, 164 F.3d at 656.) 
The food labeling regulations seek to 
ensure that consumers have access to 
information about food that is 
scientifically valid, truthful, reliable, 
and not misleading. (58 Fed. Reg. 2478, 
2526 (1993)). Consumers have a first 
amendment interest in obtaining 
information on which to base a 
decision, particularly one that has 
health consequences, regarding whether 
to buy a product, and this interest is 
‘‘served by insuring that the information 
is not false or deceptive.’’ (National 
Comm’n on Egg Nutrition v. FTC, 570 
F.2d 157, 162 (7th Cir. 1977), cert. 
denied, 439 U.S. 821 (1978)).
Moreover, FDA has a substantial 
governmental interest in assisting 
consumers to maintain healthy dietary 
practices. Such interest is consistent 
with the purpose of section 403(q)(2)(A) 
of the act; to provide information to 
consumers on nutrients (trans fat 
content of food) when such information 
is of public health importance. The 
government is not confined to asserting 
a substantial government interest in 
preventing consumer deception for a 
regulation before that regulation can 
sustain a first amendment review (Rubin 
v. Coors Brewing Co., 514 U.S.476, 484–
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85 (1995) (finding that the protection of 
the health, safety, and welfare of 
citizens is a substantial government 
interest)). In fact, FDA’s interest in this 
rule includes an interest in ensuring 
consumers have information they need 
to help them maintain healthy dietary 
practices by providing factual 
information to consumers on food labels 
so that they can reduce CHD risk.
Under the third prong of Central 
Hudson, the regulation must directly 
advance the government’s interest 
asserted (Central Hudson 447 U.S. 557 
at 566). Requiring mandatory trans fat 
labeling on food products directly 
advances the government interest. As 
stated in section V.A of this document, 
analyses of survey data show that 
consumers rely on the Nutrition Facts 
label as a guide to choosing foods that 
meet their dietary objectives. The most 
frequently reported label use and the 
one that increased the most following 
the implementation of the 1990 
amendments was to see how high the 
food was in nutrients such as fat. 
Mandatory trans fat labeling would help 
consumers maintain healthy dietary 
practices because it would provide 
needed information about the amount of 
trans fat in a given product so that 
consumers could plan a daily diet in a 
way that would reduce their intake of 
trans fat. Further, as stated in section 
V.A of this document, consumers need 
to be able to see the trans fat content of 
all foods subject to mandatory labeling 
so that they can compare the relative 
contribution of trans fat from each and 
make purchasing decisions accordingly.
Finally, under the fourth prong of 
Central Hudson, the regulation must be 
no more extensive than necessary to 
serve the government interest (Central 
Hudson 447 U.S. 557 at 566). That is the 
case here. Given, as stated in section 
V.A, that consumers need to understand 
the relative contribution of trans fat 
from all foods subject to mandatory 
labeling to make choices among 
products that will reduce their intake of 
trans fat, there are not ‘‘numerous and 
obvious less-burdensome alternatives’’ 
(Cincinnati v. Discovery Network, 507 
U.S. 410, 418 n.13 (1993)) than the 
requirement imposed here. Imparting 
truthful, factual, noncontroversial 
information about the presence or 
absence and amount of trans fat in food 
products on the label will provide 
consumers with information to help 
them to reduce their risk of CHD. Thus, 
the agency’s action to require factual 
information be imparted to consumers 
about trans fat content of foods by 
requiring such information in labeling is 
sufficiently narrowly tailored to meet 
the fourth prong of Central Hudson. The 
‘‘government is not required to employ 
the least restrictive means conceivable’’ 
rather it is required to have ‘‘‘a fit that 
is not necessarily perfect, but 
reasonable; that represents not 
necessarily the single best disposition 
but one whose scope is in proportion to 
the interest served’’’ (Greater New 
Orleans Broadcasting Ass’n, Inc. v. U.S., 
527 U.S. 173 at 177 (citing Board of 
Trustees of State Univ. of N.Y. v. Fox, 
492 U.S. 469, 480 (1989))). Requiring 
disclosure of trans fat content would 
assist consumers to maintain healthy 
dietary practices, provide complete, 
factual information on a food label to 
help them to reduce trans fat intake and 
thereby reduce their risk of CHD. 
Further, it would prevent them from 
being misled by providing information 
on trans fat that can help them make 
product comparisons and choose 
products that are heart healthy.
The agency disagrees with the 
suggestion that narrow tailoring under 
the fourth prong of Central Hudson 
requires that trans fat content be 
included in the figure for total fat 
content. Such an approach would not 
provide consumers with labeling 
information on the amount of trans fat 
in a product. To provide consumers 
with a way to calculate the amount of 
trans fat in a product, all other fats 
(including monounsaturated and 
polyunsaturated fats) would be required 
to be on the label. The comment 
provided no basis for why 
monounsaturated fat and 
polyunsaturated fat should be made 
mandatory, why it would make sense 
for consumers to have to calculate the 
value for trans fat content from each 
label under the statutory scheme in 
section 403(q)(2)(A) of the act, and why 
such an approach would be less 
burdensome under the fourth prong of 
Central Hudson to support its assertion.
Moreover, there is a substantial 
argument that the agency need not 
satisfy the Central Hudson test because 
that test applies to prohibitions on 
speech, and not compelled commercial 
speech, which is at issue here. Although 
consumer curiosity alone is an 
insufficient interest to compel factual 
speech (International Dairy Foods Ass’n 
v. Amestoy, 92 F. 3d 67, 74 (2nd Cir. 
1996)), the government can compel 
manufacturers to disclose information 
that ‘‘bears on a reasonable concern for 
human health or safety or some other 
sufficiently substantial government 
concern.’’ Id. FDA’s rule to require 
mandatory trans fat labeling is one that 
would require manufacturers to disclose 
such information.
Further, the U.S. Court of Appeals for 
the second circuit upheld a regulation 
compelling speech where the goal of the 
statute was to reduce the amount of 
mercury released into the environment; 
a goal that was ‘‘inextricably 
intertwined with the goal of increasing 
consumer awareness of the presence of 
mercury in a variety of products’’ 
(National Electrical Manufacturer’s 
Ass’n v. Sorrell, 272 F. 3d 104, 115 (2d 
Cir. 2001)). FDA is providing 
information that will assist consumers 
to maintain healthy dietary practices 
and prevent consumers from being 
misled if incomplete nutrition 
information on trans fat were provided 
on the food label, i.e., information that 
did not include the presence or amount 
of trans fat in foods. Similar to the goal 
the State of Vermont has in increasing 
awareness of consumers to prevent the 
harmful consequences of mercury 
containing products entering the 
environment, FDA wants to prevent the 
harmful consequences (increased risk of 
CHD) to consumers from trans fats. 
Thus, the agency’s action to require 
trans fat labeling in this rule comports 
with similar actions in other compelled 
commercial speech cases which have 
been upheld under the first amendment.
For all of the foregoing reasons, the 
agency believes it has complied with its 
burdens under the first amendment to 
support mandatory disclosure of the 
amount of trans fat in food labeling. The 
information that FDA is requiring in 
food labeling for trans fat, i.e., the 
amount of trans fat listed in grams or an 
optional footnote stating ‘‘Not a 
significant source of trans fat’’ if zero 
grams are present, is purely factual 
information. FDA’s action to compel 
trans fat labeling does not ‘‘prescribe 
what shall be orthodox in politics, 
nationalism, religion, or other matters of 
opinion or force citizens to confess by 
word or act their faith therein.’’ Rather, 
it simply provides for factual and 
uncontroversial information that can be 
supported if such labeling is reasonably 
related to FDA’s government interests 
(Zauderer, 471 U.S. at 650–51 
(distinguishing between the level of 
review necessary under the first 
amendment where factual and 
uncontroversial information is required 
and recognizing that the constitutionally 
protected interest in not providing such 
information is minimal); see also 
Glickman v. Wileman Brothers & Elliott, 
Inc., 521 U.S. 457, 472 (1997) 
(distinguishing compelled financial 
contributions that promote speech to 
encourage consumer purchases from 
speech in which the content of the 
message focuses on political or 
ideological differences). FDA’s interests 
in requiring mandatory trans fat labeling
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is to protect the public health by 
providing consumers with information 
that will assist them in maintaining 
healthy dietary practices and by 
preventing misleading labeling by 
providing factual, truthful, and 
noncontroversial information.
Providing information to consumers 
about the trans fat content of foods on 
food labeling is reasonably related to the 
agency’s interest of assisting consumers 
to maintain healthy dietary practices. As 
explained in section IV of this 
document, there is a relationship 
between the level of trans fat in the diet 
and risk of CHD. To reduce this risk, 
consumers need information about the 
level of trans fat in food products. The 
agency has evidence that consumers 
refer to product labels when purchasing 
food products and use labels to 
determine how much fat is in a product 
(Ref. 96). Thus, by requiring that trans 
fat information be on a food label, the 
agency will be assisting consumers in 
making food purchasing decisions that 
can result in a reduction in trans fat 
intake so that they can reduce their risk 
of CHD. Moreover, because the presence 
or absence of trans fat is a material fact 
under section 201(n) of the act, as 
explained earlier, mandatory labeling 
that provides information about the 
presence or absence of trans fat, and if 
present, at what levels, is a reasonable 
means for imparting full, factual 
information to consumers so that they 
will not be misled in purchasing 
decisions because they have no 
information about trans fat content and 
may not even be able to calculate it 
based on information on other fats on 
the label.
The agency has carefully considered 
the limitations imposed by the first 
amendment to avoid unjustified 
burdens and costs of food labeling 
where there is no genuine public health 
benefit from the rule that does not 
alleviate a harm of potential consumer 
deception. The agency did carefully 
calculate the costs and benefits of food 
labeling (see section IX of this 
document) and determined that the 
scope of mandatory trans fat labeling 
was in proportion to the government 
interest served. Cincinnati v. Discovery 
Network, Inc., 507 U.S. 410 (1993) 
(stating that a regulation ‘‘should 
indicate that its proponent ‘carefully 
calculated’ the costs and benefits 
associated with the burden on speech 
imposed by its prohibition’’ (quoting 
Fox, 492 U.S. at 480)). Moreover, the 
agency has documented that there is a 
public health benefit to the final rule. 
To the extent that those who 
commented ‘‘believe that their money is 
not being well spent, ‘does not mean 
that they have first amendment 
complaint.’’’ Glickman, 521 U.S. at 472.
Administrative Procedure Act
One comment asserts that FDA must 
adopt regulations that are supported by 
the rulemaking record and that are not 
otherwise arbitrary and capricious in 
light of the statutory limitations on the 
agency’s authority. This comment and 
another assert that the data do not 
support a basis for treating trans fat and 
saturated fat the same either chemically 
or for purposes of one’s health, and that 
therefore, FDA is proposing to require 
food labels that provide false 
information. One comment said that to 
equate trans fat and saturated fat on the 
existing body of evidence would be 
arbitrary and capricious in violation of 
the APA. Another comment asserts that 
FDA did not account for legal and 
policy considerations that are necessary 
to construct an appropriate trans fat 
regulatory framework and thus, does not 
have a rulemaking record that satisfies 
the agency’s burden of proof under the 
APA. The comment seemed to relate 
deficiencies in the record necessary to 
satisfy first amendment requirements to 
a failure to satisfy APA requirements. 
One comment asserts that the 
rulemaking record for FDA’s proposal 
does not support the expansive scope of 
the mandatory trans fat labeling 
proposal, and therefore, fails to satisfy 
the requirements of the APA. The 
comment states that the body of 
scientific evidence did not establish a 
genuine ‘‘harm’’ from trans fat 
consumed at ordinary intake levels from 
foods that would be subject to the 
mandatory labeling requirements.
To the extent that comments were 
raising concerns about the agency going 
to a final rule based on including trans 
fat in the amount and % DV for 
saturated fat and that doing so would be 
the same as requiring false information 
on labels, those comments are now moot 
since the agency is requiring a separate 
line for labeling trans fat. FDA disagrees 
with the comment that suggests that 
FDA did not account for legal and 
policy considerations necessary to 
construct an appropriate trans fat 
regulatory framework, and that the 
rulemaking record does not support the 
scope of this rule. As stated previously, 
the agency is using the statutory 
framework that Congress provided in 
section 403(q)(2)(A) of the act to require 
mandatory trans fat labeling. Further, 
the agency has explained its rationale, 
based on the science, for why it believes 
that it is necessary for consumers to 
have information on the trans fat 
content of foods to maintain healthy 
dietary practices. To the extent that the 
comments assert that the body of 
scientific evidence did not establish a 
‘‘harm’’ from trans fat consumed at 
ordinary intake levels from foods, and 
thus, would preclude the agency from 
requiring mandatory trans fat labeling 
under the APA, the agency disagrees. 
The science supports adverse health 
effects from consumption of trans fat 
among a range of intakes that includes 
intakes at average intake levels among 
the U.S. population (see section IV of 
this document). That said, mandating 
the disclosure of this information does 
not require FDA to find that trans fatty 
acids actually cause CHD. In mandating 
the disclosure of this information, FDA 
need not meet the standard of proof 
required to establish causation in a 
private tort action (Glastetter v. Novartis 
Pharmaceutical Corp., 252 F.3d 986, 
991 (8th Cir. 2001)).
‘‘The distinction between avoidance of risk 
through regulation and compensation for 
injuries after the fact is a fundamental one. 
In the former, risk assessments may lead to 
control of a toxic substance even though the 
probability of harm to any individual is small 
and the studies necessary to assess the risk 
are incomplete; society as a whole is willing 
to pay the price as a matter of policy. In the 
latter, a far higher probability (greater than 50 
percent) is required since the law believes it 
is unfair to require an individual to pay for 
another’s tragedy unless it is shown that it is 
more likely than not that he caused it 
* * *.’’
In re ‘‘Agent Orange’’ Product Liability 
Litigation, 597 F. Supp. 740, 781 
(E.D.N.Y.) 1984), aff’d 818 F. 2d 145 (2d. 
Cir. 1987). In making its decision, the 
agency follows ‘‘the preventive 
perspective that agencies adopt in order 
to reduce public exposure to harmful 
substances.’’ Glastetter, 252 F. 3d at 991, 
quoting Hollander v. Sandoz 
Pharmaceuticals Corp., 95 F. Supp. 2d 
1230, 1234 n.9 (W.D. Okla. 2000). 
Accordingly, so long as we conclude 
that the consumer would reasonably 
expect this information to be disclosed 
and that it is scientifically justifiable to 
require its disclosure, we are justified in 
taking this action.
The agency has determined, based on 
this scientific evidence, that consumers 
need this information to maintain 
healthy dietary practices. Thus, the 
agency is not precluded under the APA, 
as the comment suggests, from issuing 
this final rule. In addition, the agency 
has discussed why it believes that this 
final rule comports with the first 
amendment, and thus, disagrees with 
the comment that suggests that because 
it did not meet its burdens under the 
first amendment, it did not satisfy the 
APA requirements.
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IV. Review of the Science
A. Reviews by the Federal Government 
and the Institute of Medicine (IOM)/
National Academy of Sciences (NAS)
In the November 1999 proposal, FDA 
reviewed reports published by the U.S. 
Federal government and the IOM/NAS. 
These reports, which were published 
between 1988 and 1995, showed that 
conclusions about the role of trans fat in 
raising LDL–C, the primary risk factor 
for CHD, and dietary recommendations 
were evolving as results from new 
studies became available (64 FR 62746 
at 62749). For example, the 1988 
Surgeon General’s Report (Ref. 2) and 
the 1989 IOM/NAS Report (Ref. 4) 
found no adverse effects of trans fat. 
Later, the 1993 publication from the 
NCEP stated that ‘‘trans fatty acids raise 
LDL–C levels nearly as much as do 
cholesterol-raising saturated fatty acids’’ 
(Ref. 5). The fourth edition of Dietary 
Guidelines for Americans, a joint 1995 
publication from the U.S. Department of 
Health and Human Services and the 
U.S. Department of Agriculture (USDA) 
stated that, ‘‘Partially hydrogenated 
vegetable oils, such as those used in 
many margarines and shortenings, 
contain a particular form of unsaturated 
fat known as trans-fatty acids that may 
raise blood cholesterol levels, although 
not as much as saturated fat’’ (Ref. 6).
Subsequent to the November 1999 
proposal, new expert panels have been 
convened to update, in light of new 
scientific evidence, the conclusions and 
recommendations in the reports 
discussed previously. FDA has reviewed 
these new reports to evaluate whether 
their updated conclusions reversed or 
significantly altered its earlier 
conclusions.
The Dietary Guidelines 2000 (Ref. 87) 
makes the following statements 
regarding trans fatty acids and food 
sources of trans fat:
Foods high in trans fatty acids tend to raise 
blood cholesterol. These foods include those 
high in partially hydrogenated vegetable oils, 
such as many hard margarines and 
shortenings. Foods with a high amount of 
these ingredients include some commercially 
fried foods and some bakery goods. (Ref. 87, 
p. 28);
Aim for a total fat intake of no more than 
30 percent of calories, as recommended in 
previous editions of the Guidelines. If you 
need to reduce your fat intake to achieve this 
level, do so primarily by cutting back on 
saturated and trans fats. (Ref. 87, p. 30);
Limit use of solid fats, such as ... hard 
margarines, ... and partially hydrogenated 
shortenings. Use vegetable oil as a substitute. 
(Ref. 87, p. 30).
In the report describing the basis for 
its recommendations, the Advisory 
Committee on Dietary Guidelines 2000 
(Ref. 88) suggested that information be 
provided to help the reader of the 
Dietary Guidelines 2000 distinguish 
among the different kinds of fats—
saturated, trans, and unsaturated. The 
advisory committee summarized the 
scientific evidence on trans fatty acids 
as follows:
Trans fatty acids are included because a 
definitive body of recent experimental 
evidence indicates that trans fatty acids raise 
the concentration of the most dangerous form 
of serum cholesterol (LDL-cholesterol).
The advisory committee further states:
Trans fatty acids also tend to lower a 
protective form of serum cholesterol (HDL-
cholesterol). Prospective epidemiological 
studies further note that higher intakes of 
trans fatty acids are associated with a higher 
incidence of coronary heart disease. (Ref. 88, 
p. 37).
Recent guidelines from the National 
Cholesterol Education Program (NCEP) 
(Ref. 89) provide an update to the 1993 
NCEP report (Ref. 5). The 2001 NCEP 
report is an evidence-based report that 
extensively references the scientific 
literature. The expert panel concluded 
that:
Trans fatty acids raise serum LDL-
cholesterol levels. Through this mechanism, 
higher intakes of trans fatty acids thus should 
increase risk for CHD. Prospective studies 
support an association between higher 
intakes of trans fatty acids and CHD 
incidence. (Ref. 89, p. V–15).
Based on these conclusions, the 
Expert Panel recommended for 
individuals at increased risk for CHD 
that:
Intakes of trans fatty acids should be kept 
low. The use of liquid vegetable oil, soft 
margarine, and trans fatty acid-free margarine 
are encouraged instead of butter, stick 
margarine, and shortening. (Ref. 89, p. V–15).
Lastly, a recent report of the IOM/
NAS found ‘‘a positive linear trend 
between trans fatty acid intake and LDL 
cholesterol concentration, and therefore 
increased risk of CHD’’ (Ref. 140). The 
report summarized that this would 
suggest a Tolerable Upper Intake Level 
(UL) of zero, but because trans fats are 
unavoidable in ordinary diets and 
achieving such a UL would require 
extraordinary changes in dietary intake 
patterns that might introduce other 
undesirable effects and unknown health 
risks, a UL was not proposed. Instead, 
the report recommended ‘‘that trans fat 
consumption be as low as possible 
while consuming a nutritionally 
adequate diet.’’
In summary, the recently updated 
Dietary Guidelines (Ref. 87 ), NCEP (Ref. 
89), and IOM/NAS (Ref. 140) reports, 
based on current scientific evidence, 
consistently find that trans fatty acids 
are associated with increased LDL–C 
levels and, therefore, that lower intakes 
of both saturated and trans fatty acids 
are important dietary factors in reducing 
the risk of CHD in the general 
population and for those at increased 
risk for CHD. In addition, these new 
reports (Refs. 87, 89, and 140) either 
reversed previous scientific conclusions 
of no deleterious effects of trans fatty 
acids (Refs. 2 and 4), or strengthened 
previous scientific conclusions of an 
adverse effect of trans fat intakes on 
CHD risk (Refs. 5 and 6). Thus, based on 
the current body of scientific evidence, 
there is strong agreement among the 
expert panels that the available 
evidence is sufficiently compelling to 
conclude that trans fat intakes increase 
CHD risk. Accordingly, these expert 
panels recommended, in addition to 
their longstanding recommendations 
that Americans consume diets limited 
in saturated fat, that consumers also 
select food products that are low in 
trans fat. Although the expert panels’ 
primary emphases remain on limiting 
intakes of saturated fat (which 
contributes on average about 11–12 
percent of calories in U.S. diets), they 
also have recommended limiting intakes 
of trans fats (which contribute, on 
average, about 3 percent of calories in 
U.S. diets). These recommendations are 
made for the general population (Refs. 
87 and 140) and persons at increased 
risk for CHD whose LDL–C is above goal 
levels (Ref. 89).
(Comment 1) Several comments on 
the November 1999 proposal questioned 
whether the conclusions regarding trans 
fat would be supported by pending 
scientific reviews. Some of these 
comments recommended that FDA not 
issue a final rule until after publication 
of Dietary Guidelines 2000. Other 
comments recommended waiting until 
the IOM/NAS completes work on a 
review of dietary reference values for 
macronutrients.
The Dietary Guidelines 2000 have 
been published (Refs. 87 and 88). While 
they do not mention trans fat in its 
broad guideline, ‘‘Choose a diet that is 
low in saturated fat and cholesterol and 
moderate in total fat,’’ the 
recommendations from the Dietary 
Guidelines 2000 and the accompanying 
advisory committee review clearly state 
that foods high in trans fatty acids tend 
to raise blood LDL–C which increases 
the risk of CHD. Reductions in intakes 
of both saturated and trans fats are 
suggested for maintaining total fat to no 
more than 30 percent of calories. 
Substitutions of foods low in trans and 
saturated fatty acids (e.g., vegetable oils) 
for foods with higher levels of trans 
fatty acids (e.g., hard margarines, 
partially hydrogenated shortenings) are 
also recommended. Thus, in the Dietary 
Guidelines 2000, the recommendations 
to reduce trans fat intake are definitive, 
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not tentative. Additionally, the 
recommendations in the Dietary 
Guidelines 2000 are reinforced by 
similar findings and recommendations 
from other recent expert panels (Refs. 89 
through 91, and 140), including those of 
the IOM/NAS report on macronutrients 
(Ref. 140), which has also been 
published. The IOM/NAS report 
recommends that ‘‘trans fat 
consumption be as low as possible 
while consuming a nutritionally 
adequate diet.’’
(Comment 2) One comment suggested 
that trans fat is a healthier choice than 
saturated fat, quoting 1994 and 1998 
statements that it attributed to the 
American Heart Association (AHA) 
recommending that margarine be used 
instead of butter and that trans fats 
displace saturated fats in the diet. The 
comment suggested that, if AHA or 
others in the scientific community 
recommend margarine be used instead 
of butter, this establishes that 
hydrogenated vegetable oils and trans 
fat have health benefits, at least in 
comparison to saturated fatty acids. 
Several other comments stated that 
trans fats displace saturated fats in the 
diet, thus implying that they are 
healthful alternatives to saturated fats.
FDA disagrees with the comments’ 
conclusions that the recommendations 
of the AHA and other scientific bodies 
that margarine be substituted for butter 
provides a basis for concluding that 
trans fat has health benefits or is a 
healthier choice than saturated fats. The 
recently updated 2000 AHA Guidelines 
(Ref. 91) recommend that intakes of 
foods with a high content of cholesterol-
raising fatty acids (i.e., trans and 
saturated fats) be limited because both 
raise serum LDL–C levels, and 
consequently, increase CHD risk. 
Specifically, the AHA recommends 
limiting the intake of: (1) Foods rich in 
saturated fatty acids (e.g., full-fat dairy 
products, fatty meats, tropical oils), and 
(2) trans-fatty acids, the major 
contributor of which is hydrogenated fat 
(Ref. 91). Relative to trans fat, the 2000 
AHA guidelines state that, ‘‘It has been 
established that dietary trans-
unsaturated fatty acids can increase LDL 
cholesterol and reduce HDL 
cholesterol’’ (Ref. 91). Moreover, the 
AHA recommendations are consistent 
with the recommendations of the other 
scientific bodies described earlier in this 
document. All of these reports 
recommend substituting vegetable oils 
for animal fats; and, within the 
vegetable oil category, recommend 
selecting those products that are lower 
in or free of trans fat (e.g., liquid 
vegetable oils, soft margarines, and 
trans-free margarines) in place of more 
hydrogenated oil products (e.g., stick 
margarines and shortenings). More 
recently, the IOM/NAS concluded that 
there is no evidence of health benefits 
associated with trans fat intakes, but 
that trans fat does increase LDL–C and, 
therefore, the risk of CHD (Ref. 140). 
Thus, the comment’s premise that the 
current recommendations of the AHA 
and other scientific bodies support the 
conclusion that trans fat is a healthful 
alternative to butter and animal fats is 
not consistent with, nor supported by, 
the full context and intent of 
recommendations by the AHA and other 
scientific bodies.
Those comments that said trans fat is 
a healthful alternative to saturated fat 
also are not consistent with the 
recommendations of the AHA and other 
scientific bodies. These expert bodies all 
concluded that both trans and saturated 
fatty acids increase the risk of CHD by 
increasing serum LDL–C levels and, 
therefore, they recommended limiting 
intakes of both trans and saturated fatty 
acids.
It should be noted that 
recommendations to consume margarine 
instead of butter are based on the fact 
that the combined amount of 
cholesterol-raising lipids (trans and 
saturated fats) are lower in margarines 
than in butter (Ref. 92). Additionally, 
butter, unlike margarine, contains 
dietary cholesterol which also has 
cholesterol-raising effects (Ref. 139).
B. Published Studies
To evaluate the evidence that dietary 
trans fat increases the risk of CHD, FDA 
reviewed the scientific evidence cited in 
the petition and recent human studies 
from its own literature search. In the 
November 1999 proposal, FDA 
summarized its review of the findings of 
intervention and observational studies 
on the relationship between intakes of 
trans fatty acids and CHD (64 FR 62746 
at 62749–62754). FDA considered the 
findings from human studies to 
constitute evidence that is more directly 
relevant and persuasive than findings 
from animal studies. FDA gave greater 
weight to results from dietary 
intervention studies than to 
observational (epidemiological) studies 
because of an intervention study’s 
ability to provide evidence for a cause-
effect relationship. FDA regarded results 
from observational studies as indirect 
evidence for a relationship between 
trans fatty acid intake and CHD risk. 
FDA also reviewed estimates of dietary 
intakes of trans fatty acids in the U.S. 
population (64 FR 62746 at 62752–
62753).
In the November 1999 proposal, FDA 
evaluated results of 12 dietary 
intervention studies (Refs. 7 through 15, 
34, 36, and 82). FDA focused on the 
physiological measures of serum and 
plasma LDL–C concentrations to 
evaluate whether trans fatty acid intakes 
influence the risk of CHD because such 
measures are recognized as valid 
predictors of increased risk for CHD 
(Ref. 5). FDA concluded that controlled 
intervention studies, in different 
population groups in the United States 
and other countries, consistently 
indicate that consumption of diets 
containing trans fatty acids, like diets 
containing saturated fats, results in 
increased serum LDL–C (a major risk 
factor for CHD) compared with 
consumption of diets containing cis-
monounsaturated or cis-polyunsaturated 
fat sources (64 FR 62746 at 62753). The 
agency also compiled reports of changes 
in serum total and high density 
lipoprotein cholesterol (HDL–C) and 
serum lipoproteins to present a more 
complete picture of serum lipid changes 
(64 FR 62746 at 62799–62821).
In the November 1999 proposal, FDA 
also reviewed nine publications that 
examined associations between trans 
fatty acids, serum lipids and CHD 
endpoints: Four publications describing 
three prospective cohort studies (Refs. 
19 through 21 and 38), one publication 
describing an inter-cohort study (Ref. 
22), three publications describing case 
control studies (Refs. 16 through 18), 
and one publication describing a cross-
sectional study (Ref. 23). FDA stated 
that these epidemiological 
investigations of associations between 
dietary trans fatty acids and risk of CHD 
must be interpreted cautiously because 
of the imprecision associated with the 
dietary collection methodologies used, 
the difficulty of eliminating 
confounding factors, and because no 
dose-response relationship has been 
demonstrated in the studies (64 FR 
62746 at 62752). FDA also stated that 
despite these generally recognized 
deficiencies in the observational 
studies, the repeated and consistent 
findings from these studies show that 
consumption of trans fatty acids is 
associated with adverse effects on CHD 
risk in humans, which supports the 
findings from intervention studies (64 
FR 62746 at 62752).
Thus, in the November 1999 proposal, 
FDA concluded that controlled 
intervention studies in different 
population groups in the United States 
and other countries consistently 
indicate that consumption of diets 
containing trans fatty acids, like diets 
containing saturated fats, results in 
increased serum LDL–C compared with 
consumption of diets containing cis-
monounsaturated or cis-polyunsaturated 
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fat sources (64 FR 62746 at 62753). FDA 
also concluded that these findings are 
consonant with findings from 
observational studies among free-living 
persons in the United States and other 
countries (64 FR 62746 at 62753).
In the November 1999 proposal, FDA 
also summarized the results of estimates 
of dietary intake of trans fatty acids in 
the U.S. population (64 FR 62746 at 
62752). FDA noted that estimates of 
mean consumption of trans fatty acids 
in the United States ranged from about 
3 g/day to about 13 g/day. Based on 
national food disappearance data, 
estimated mean values for the daily per 
capita consumption of total trans fatty 
acids were variable: 12.8 g/day (Ref. 24), 
10.2 g/day (Ref. 39), and 8.1 g/day (Ref. 
25). Based on a nationally representative 
sample of the U.S. population, the 
estimated mean intake of trans fatty 
acids was 5.3 g/day (2.6 percent of 
calories) and the 90th percentile intake 
was 9.4 g/day for individuals 3 years of 
age and older in the U.S. population 
(Ref. 12). Estimates of mean trans fatty 
acids intake were 4.4 g/day for men and 
3.6 g/day for women in one 
observational study in the United States 
(Ref. 18) and 3.4 g/day for men in 
another (Ref. 23). Some studies 
presented mean or median intakes for 
quintiles of the population studied. 
Median intakes were 3.1 g/day for men 
and 3.0 g/day for women in the lowest 
quintile and 6.7 g/day for men and 6.8 
g/day for women in the highest quintile 
(Ref. 18). Another study reported 
intakes of 1.5 g/day and 5.3 g/day, 
respectively, for the lowest and highest 
quintiles of male health professionals 
(Ref. 19). For female nurses in the 
United States, mean energy-adjusted 
intakes of trans fatty acids were 2.4 and 
5.7 g/day, respectively for the lowest 
and highest quintiles of trans fatty acid 
intakes (Ref. 21). FDA concluded that, 
overall, the estimates of mean trans fatty 
acids intakes are similar to intakes of 
trans fatty acids in the U.S. intervention 
studies (the selected intervention 
studies used in this comparison were 
those in which trans fatty acid contents 
were determined by chemical analysis 
of duplicate portions of the diets and for 
which statistically significant increases 
in serum LDL–C were reported 
compared to diets containing cis-
polyunsaturated fatty acids (Refs. 13, 34, 
and 82) or cis-monounsaturated fatty 
acids (Ref. 12)). The intakes of trans 
fatty acids for which the increases in 
serum LDL–C were statistically 
significant in the intervention studies 
ranged from 7.6 g/day to 13 g/day (Refs. 
12, 13, 34, and 82). FDA stated that 
these levels are very similar to the 
estimated intakes of the many 
individuals in the United States whose 
trans fatty acid intake is greater than the 
mean of 5.3 g/day (64 FR 62746 at 
62753).
Subsequent to the November 1999 
proposal, additional studies on the topic 
of trans fatty acid intakes and CHD risk 
have been published (Refs. 98 through 
102). FDA reviewed the findings from 
these new studies to evaluate whether 
they differ significantly from the 
findings of studies included in the 
proposed rule. In general, the results 
from these recently published 
intervention and prospective studies are 
consistent with the results from the 
studies included in the November 1999 
proposal in that they also found that 
diets containing trans fat increased 
LDL–C, and therefore, CHD risk (Refs. 
98 to 101) and that, in free-living 
populations, consumption of trans fat 
was associated with increased risk of 
heart attack and death from CHD (Ref. 
102). In addition, a cross-sectional 
observational study has been published 
(Ref. 93). This study, which was the 
subject of several comments, suggests no 
relationship between current intakes of 
trans fat in European countries and CHD 
risk. FDA has addressed this study in 
Comment 4 of this document.
(Comment 3) Many comments 
discussed the strength of the scientific 
evidence for establishing whether trans 
fatty acids adversely affect CHD risk by 
raising LDL–C levels. A number of 
comments found the evidence to be 
strong and supportive of trans fatty acid 
labeling on foods. Other comments 
questioned whether there was sufficient 
evidence to warrant labeling of trans fat 
content. Several comments stated that 
the health impact of the intake levels 
reported in population-based surveys 
and observational studies was minimal.
A few comments to the November 15, 
2002, proposal to reopen the trans fat 
comment period questioned the 
scientific validity of the IOM/NAS 
report based on the underlying science 
and regression equations relied upon. 
The comments argued that one of the 
articles relied upon (Ref. 83) was an 
opinion essay and was not peer-
reviewed by the New England Journal of 
Medicine (NEJM) where it was 
published.
Based on an evaluation of the 
scientific evidence, FDA concludes that 
the scientific evidence is sufficient to 
require nutrition labeling of trans fat. In 
the November 1999 proposal, FDA 
systematically summarized and 
reviewed the available individual 
human studies (64 FR at 62749–62754 
and 62798 to 62821). In re-examining 
this review in light of the comments, 
FDA finds no basis to alter its earlier 
conclusion that, in general, there is 
consistency in finding adverse effects of 
trans fat on CHD risk. Controlled 
intervention studies in different 
population groups in the United States 
and other countries consistently 
indicated that consumption of diets 
containing trans fat results in elevations 
of LDL–C, and therefore, increased risk 
of CHD (Refs. 7 to 15, 34, 36, and 82). 
In addition, positive statistical 
associations are consistently reported in 
observational studies between estimated 
trans fat intake in free-living 
populations and incidence of CHD 
manifested as heart attack or death from 
CHD (Refs. 16 to 22, and 38) or 
increased risk of CHD as assessed by 
higher levels of LDL–C (Ref. 23) (64 FR 
62751 to 62753). Thus, FDA continues 
to find that a large body of the most 
persuasive types of evidence (i.e., 
intervention trials and prospective 
cohort observational studies) 
consistently show that trans fat intakes 
adversely affect CHD risk under both 
controlled trial conditions and in free-
living populations following their usual 
dietary patterns. This consistency was 
seen across studies done: (1) In the 
United States and several European 
countries, (2) using a variety of test and 
control products and study designs, (3) 
using a range of intake levels for trans 
fatty acids (less than (<) 1 percent to 7 
percent of calories), (4) by different 
investigators and research groups, (5) 
with different populations and 
selection/exclusion criteria, and (6) 
within different total dietary contexts. 
This relationship was also consistently 
found in comparisons of high vs. low 
consumers of trans fats in free-living 
U.S. populations consuming their 
normal diets. Thus, whether controlled 
intervention trials or among free-living 
U.S. populations consuming their usual 
diets, the adverse effects of trans fat 
intakes on CHD risk were consistently 
observed.
Moreover, FDA’s conclusions were 
consistent with those of independent 
Federal Government expert panels that 
published dietary recommendations for 
U.S. population groups subsequent to 
publication of the November 1999 
proposal (Refs. 87 and 89 through 91) 
that were cited in the Federal Register 
to reopen the comment period on 
November 15, 2002. These expert 
panels, reviewing the same scientific 
evidence as FDA described in the 
proposed rule, and given their 
knowledge of U.S. dietary patterns, 
consistently concluded that trans fat 
intakes are associated with increased 
CHD risk and recommended that U.S. 
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consumers and those who need to lower 
their LDL–C level minimize their 
intakes of trans fat to reduce their risk 
of CHD. For example, the IOM/NAS 
noted ‘‘a positive linear trend between 
trans fatty acid intake and total and 
LDL–C concentrations, and therefore, 
increased risk of CHD, thus suggesting 
an upper limit of zero’’ (Ref. 90). 
However, they further stated that, 
because trans fatty acids are 
unavoidable in ordinary diets, a 
complete avoidance of these fats is not 
possible without extraordinary changes 
in patterns of dietary intake. Such 
extraordinary adjustments may 
introduce other undesirable effects (e.g., 
elimination of foods such as diary 
products and meats that contain trans 
fatty acids may result in inadequate 
intakes of protein and certain 
micronutrients). For these reasons, the 
IOM/NAS recommended that trans fatty 
acid consumption be as low as possible 
while consuming a nutritionally 
adequate diet. In response to the 
comments about the scientific validity 
of an article used in the IOM/NAS 
report, FDA notes that the paper by 
Ascherio and coworkers (Ref. 83) is not 
the only information that the IOM/NAS 
relied on to conclude that trans fatty 
acid consumption should be as low as 
possible relative to CHD risk. Moreover, 
FDA did not find the LDL/HDL 
cholesterol ratio used in the Ascherio et 
al. analysis to be a useful endpoint for 
purposes of the trans fatty acid rule-
making (see Comment 10). Additionally, 
FDA’s independent evaluation of the 
scientific evidence concluded that there 
is consistency in finding adverse effects 
of trans fat on risk of CHD. Therefore, 
even though the independent reviews of 
FDA and the other expert panels 
differed to some degree in how they 
used the available scientific evidence, 
the resultant consistency of the 
conclusions across these reviews 
provides strong credence to the finding 
that trans fatty acid consumption 
increases CHD risk via increases in 
LDL–C.
In summary, based on the consistent 
results across a number of the most 
persuasive types of study designs (i.e., 
intervention trials and prospective 
cohort studies) that were conducted 
using a range of test conditions and 
across different geographical regions 
and populations, the agency now agrees 
with the comments that stated that the 
available evidence for an adverse 
relationship between trans fat intakes 
and CHD risk is strong. FDA also finds 
the results from the large prospective 
cohort studies among free-living U.S. 
population groups to be persuasive 
evidence that the trans fat intakes 
associated with U.S. dietary patterns 
can have a significant adverse effect on 
CHD risk for U.S. consumers. The 
scientific agreement for this relationship 
among the various expert groups and 
consensus among these expert groups in 
recommending that U.S. consumers 
limit their intakes of saturated and trans 
fats now provide further evidence of the 
strength of the science and the public 
health importance of lowering trans fat 
intakes for U.S. consumers. Therefore, 
the comments do not persuade FDA to 
change its position in the proposed rule 
that labeling of trans fatty acids is 
warranted based on: (1) The scientific 
evidence; and (2) the public health 
importance of the guidelines 
recommending that consumers limit 
their intakes of both of the LDL–C-
raising fats: trans and saturated fats. 
Thus, FDA concludes that its tentative 
conclusion in the proposed rule that 
‘‘under conditions of use in the United 
States, consumption of trans fatty acids 
contributes to increased serum LDL–C 
levels, which increases the risk of CHD’’ 
(64 FR 62746 at 62754) is no longer 
tentative. FDA continues to find the 
overall weight of scientific evidence in 
support of this conclusion to be 
sufficiently compelling to now warrant 
trans fatty acid labeling.
(Comment 4) Several comments stated 
that a new observational study by van 
de Vijver et al., ‘‘Association between 
trans fatty acid intake and 
cardiovascular risk factors in Europe: 
The transFAIR Study’’ (Ref. 93) showed 
no association between average total 
trans fat intake in Europe and LDL–C or 
HDL–C so that average trans fat intake 
in the United States is probably not 
detrimental to human health.
FDA disagrees with the comments. 
The transFAIR study had a cross-
sectional design, measuring trans fatty 
acid intake and serum lipids in 327 men 
and 299 women, ages 50 to 65 years, in 
8 European countries from 
approximately 1997 to 1999. The study 
reported no statistically significant 
association between total trans fat 
intake and serum LDL–C. The habitual 
intake of trans fat was estimated to be 
about 2 g/day (e.g., approximately 1 
percent of calories).
FDA notes that cross-sectional 
designs, such as the one used by van de 
Vijver et al., are relatively weak designs 
for showing associations between diet 
and serum lipids (Ref. 93). As an 
observational study, they are generally 
considered to be less persuasive than 
intervention trials. Moreover, compared 
with other types of observational studies 
(e.g., prospective (cohort) observational 
studies and retrospective (case-control) 
studies), they are considered 
particularly weak. Considering the 
weaknesses of the cross-sectional design 
used in the transFAIR study compared 
with the much larger body of evidence 
from more persuasive types of studies 
(i.e., intervention trials and prospective 
observational studies) that consistently 
demonstrate an adverse effect of trans 
fat intakes on LDL–C, FDA does not find 
the transFAIR study to be sufficiently 
compelling to override the overall 
weight of the scientific evidence 
reviewed in the November 1999 
proposal or to override the independent 
conclusions of recent expert panels 
convened by the Federal Government 
(Refs. 87 and 89), the IOM/NAS (Ref. 
90), and the AHA (Ref. 91).
For the reasons cited previously, FDA 
disagrees with the comments that a lack 
of association between trans fat intake 
and serum lipids in the European 
transFAIR study indicates that average 
trans fat intake in the United States is 
probably not detrimental to human 
health.
(Comment 5) Many comments 
emphasized the inadequacies in the 
assessment of intakes of trans fatty acids 
by the U.S. population and noted that 
the current data are insufficient in 
regard to the trans fatty acid content of 
foods. One comment noted that USDA’s 
data for the trans fatty acid content of 
foods are limited to a few foods with a 
small number of samples. Thus, the 
comment concluded that extrapolation 
of trans fatty acid content from a few 
foods must be used to estimate the 
content of trans fat in the large number 
of foods that make up the total diets of 
the U.S. population. This extrapolation 
results in intake estimate errors with 
unknown effects. Some comments assert 
that the data are an over-estimate of the 
U.S. population’s trans fatty acid intake 
and other comments assert that the data 
are an under-estimate.
FDA agrees that estimates of dietary 
intakes of trans fat, as with all intake 
estimates based on participant reports 
and limitations in compositional data 
bases, are subject to multiple sources of 
error. In the November 1999 proposal, 
the agency reviewed intake estimates 
from three different types of data: (1) 
National food consumption survey, (2) 
national disappearance data, and (3) 
observational studies done in U.S. 
population groups. By examining results 
from multiple methods of estimating 
intakes, the agency was able to assess 
some, but not all, of the uncertainties in 
current intake estimates. In discussing 
these data, FDA noted the very limited 
composition data available for the trans 
fatty acid composition of foods and the 
difficulties in determining the accuracy 
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of reported trans intakes with current 
knowledge and methods (64 FR at 
62752–62753).
In the November 1999 proposal, FDA 
reviewed an analysis that used the 
results of the 1989–1991 Continuing 
Survey of Food Intakes by Individuals 
(CSFII), a national food consumption 
survey of the U.S. population conducted 
by the USDA (Ref. 26). This study 
reported a mean trans fatty acid intake 
of 5.3 g/day (2.6 percent of calories) for 
persons 3 years and older. One way to 
evaluate the accuracy of survey intake 
estimates is to compare the reported 
caloric intakes to known requirements, 
or to levels from intervention trials that 
have been shown to maintain body 
weight for some period of time. The 
authors of this study stated that these 
reported caloric intakes were 20–40 
percent below known physiologic 
requirements, suggesting significant 
under-reporting of intakes (Ref. 26). The 
reported caloric intakes in the CSFII 
were also approximately 265 to 1,000 
calories/day below levels required to 
maintain body weights for U.S. subjects 
in intervention trials (Ref. 26). 
Therefore, the estimates of intakes from 
the CSFII survey data are likely 
significantly under-reported, 
particularly when expressed on a gram 
per day basis.
The second type of trans fatty acid 
intake estimate considered in the 
November 1999 proposal was derived 
from estimates of trans fatty acids 
available in the U.S. food supply 
calculated from USDA-Economic 
Research Service fats and oils 
production figures and food 
disappearance data for fats and oils. 
Three studies provided daily per capita 
estimates of trans fatty intakes of 12.8 g, 
10.2 g, and 8.1 g. (Refs. 24, 39, and 25, 
respectively). Although all three 
estimates were ‘‘corrected’’ for losses 
due to waste in processing and use, per 
capita intake estimates based on 
disappearance data generally 
overestimate intakes (Ref. 4).
Finally, observational studies 
conducted in U.S. populations also can 
provide intake estimates. In the 
November 1999 proposal, FDA reviewed 
several observational studies, including 
several prospective cohort studies 
conducted in U.S. populations who 
were healthy at the time of enrollment 
(Refs. 19, 21, and 38). Estimates of daily 
trans intakes ranged from 1.3 to 3.2 
percent of calories and from 1.5 to 6.4 
g/day for adult participants in these 
studies. These ranges of intake estimates 
are somewhat lower than those in the 
CSFII survey so are therefore also likely 
underestimated. However, even with 
these relatively low intake estimates, 
these studies found that among free-
living adults, those adults consuming 
trans fatty acids at the highest quintiles 
of intake had increased relative risk of 
CHD as compared to adults consuming 
trans fatty acids at the lowest quintiles 
of intake.
In summary, the different types of 
studies, and different studies within a 
study type, estimated different intake 
levels for the U.S. population. The 
estimates from the food disappearance 
data are likely overestimated. The 
estimates from the observational studies 
and the national food consumption 
survey are likely underestimated. All 
estimates used the same compositional 
data base which, as noted above, has 
very limited data on the trans fat 
content of foods. Although we have no 
external ‘‘gold standard’’ against which 
to determine which estimate is most 
accurate, the available intake estimates 
suggest that average intakes of U.S. 
consumers probably fall within the 
range of 1.3 g to 12.8 g/day.
Because of the multiple sources of 
uncertainty in intake estimates, caution 
must be exercised to avoid over-
interpretation of the available dietary 
intake estimates and their relationship 
to the trans fat levels used in the 
intervention trials. It is important to 
note, however, that the agency’s 
determination of the scientific basis for 
and public health importance of trans 
fat labeling was based on the totality of 
the scientific evidence. In this 
evaluation, FDA weighted the results of 
the intervention trials most heavily. The 
intervention trials clearly demonstrate, 
in a cause and effect manner, an adverse 
effect of trans fat intakes on LDL–C 
levels, and therefore on CHD risk, across 
a broad range of intakes (less than 1 
percent to 7 percent of calories), dietary 
patterns, and population groups. For the 
purposes of determining that the 
scientific evidence was sufficient to 
conclude that trans fat labeling was 
warranted from a public health 
perspective, FDA finds that the 
intervention and observational studies 
provided strong evidence of both a 
causal relationship between trans fat 
intake and risk of CHD and applicability 
to the general U.S. population. 
Therefore, FDA does not need to rely 
solely on dietary intake estimates to 
make this determination.
Because of the serious public health 
consequences of CHD in the U.S. 
population, prudent public health 
dictates that we help consumers control 
those risk factors which they can alter 
directly through their own behavior. 
Heart-healthy diets that limit the intakes 
of both saturated and trans fats can 
serve this purpose as is evidenced by 
recommendations in the recent expert 
panel reports (Refs. 87, 89 through 91, 
and 140).
(Comment 6) Many comments 
addressed the issue of the relevance of 
intervention study intakes to usual 
conditions of use in the United States. 
Some comments expressed concern that 
FDA’s conclusions relied on 
intervention studies in which the 
intakes of trans fatty acids were very 
high and not representative of U.S. 
intakes of about 5.3 g/day (3 percent of 
calories).
FDA disagrees with the comments 
that it relied heavily on intervention 
trials with high trans fat intake. A range 
of fatty acid intakes was included in the 
dietary intervention assessments. For 
example, the four U.S. research 
investigations with chemical analyses of 
the diets included a total of 15 study 
diets (Refs. 12, 13, 34, and 82). These 
studies included diets with little or no 
trans fat (e.g., 0.4 to 0.6 percent of 
calories), diets that contained moderate 
levels of trans fat (e.g., 3 to 4 percent of 
calories), as well as diets with a higher 
intake of trans fat (e.g., 6 to 7 percent 
of calories). FDA relied on the totality 
of the evidence, i.e., intervention 
studies that had trans fat intakes that 
ranged from very low levels (less than 
1 percent of calories) to intakes up to 6 
to 7 percent of calories and on findings 
from observational studies that showed 
an adverse relationship between trans 
fat intakes and CHD risk among U.S. 
population groups consuming their 
usual diets.
Thus, in the aggregate, the U.S. 
intervention studies included an 
assessment of the effect of a wide range 
of trans fatty acid levels that overlap the 
range of intake estimates for the U.S. 
population. As noted in FDA’s response 
to Comment 5, the relevance of the 
findings from the intervention studies 
for the U.S. population are shown by the 
consistent findings of an adverse 
relationship between trans fat and CHD 
risk in the prospective studies of free-
living U.S. population groups. Thus, the 
relevance of the trans intakes used in 
the intervention studies for the U.S. 
population was confirmed by the 
consistent findings in the prospective 
studies that showed an adverse 
association between trans intake and 
CHD risk among free-living U.S. 
population groups. The 
recommendations of recent expert 
panels that Americans limit their 
intakes of trans fat shows that a broad-
based scientific agreement exists as to 
the public health merits of trans fat 
labeling for the U.S. population within 
the context of current dietary intakes.
VerDate Jan<31>2003 15:26 Jul 10, 2003 Jkt 200001 PO 00000 Frm 00014 Fmt 4701 Sfmt 4700 E:\FR\FM\11JYR2.SGM 11JYR2
41447Federal Register / Vol. 68, No. 133 / Friday, July 11, 2003 / Rules and Regulations 
(Comment 7) Other comments 
suggested that the study populations 
were not representative of the U.S. 
population. For example, one comment 
said that the intervention studies 
included individuals at high risk with 
serum cholesterol levels greater than (>) 
320 milligrams (mg)/deciliter (dL) or 
LDL–C > 130 mg/dL. Another comment 
stated that the agency failed to reflect 
that relative risk will depend on the 
base risk of the population used for 
comparisons with the U.S. general 
population.
FDA disagrees with these comments. 
Of the 512 subjects included in the 
dietary intervention studies cited in the 
November 1999 proposal, 48 percent of 
the dietary intervention population had 
an LDL–C level of 100 to 120 mg/dL that 
is categorized as near or above optimal 
level according to the NCEP lipid 
classification scheme (Ref. 89). Thirty-
eight percent had an LDL–C of 130 to 
159 mg/dL, categorized as borderline 
high; and 14 percent had a LDL–C of 
greater than or equal to (≥)160 mg/dL, 
categorized as high. Only 5 percent of 
the participants had a low HDL–C level, 
< 40 mg/dL; and another 7 percent had 
a high HDL–C level, ≥60 mg/dL. Most 
(88 percent) had mean HDL–C levels in 
the range of 41 to 59 mg/dL. Also, 73 
percent of the population was in the age 
group where the CHD risk is lower, e.g., 
men <45 years of age and women <55 
years of age. The study populations 
were described as participants who had 
normal cardiac, kidney and liver 
function, and were not taking 
medications that affect lipid levels. 
Many participants had near or optimal 
LDL–C levels and most had HDL–C 
levels that were neither high nor low by 
the NCEP criteria. The data that FDA 
relied on included a dietary 
intervention population that is 
representative of the U.S. general 
population.
(Comment 8) Some comments 
suggested that the test products were 
not representative of available 
commercial products in the U.S. 
marketplace. One comment suggested 
that several studies were designed to 
study the effects of different food oil 
sources and not designed to specifically 
study the effect of trans fat on blood 
lipid levels.
FDA disagrees with these comments. 
In general, the test products used in 
studies done by U.S. research groups 
were either commercially available 
products or were produced specifically 
for a study by U.S. manufacturers using 
oil sources commonly used in the U.S. 
market (Refs. 12 through 15, 34, and 82). 
However, regardless of whether studies 
used products typical of those 
commercially available in other 
countries, products commercially 
available in the United States, or 
products developed specifically for the 
study at hand, results were generally 
consistent across all these studies and 
consistent with the larger body of 
evidence that included studies done in 
Europe and with European oils. That is, 
there was consistency across studies in 
finding that higher intakes of trans fat 
resulted in increased levels of LDL–C 
and, therefore, in increased risk of CHD. 
Moreover, the observational studies in 
U.S. populations, where participants 
were consuming products commercially 
available in the U.S. marketplace, also 
consistently showed that higher intakes 
of trans fat were associated with adverse 
effects on CHD risk (Refs. 19, 21, and 
38).
FDA also recognizes that the 
intervention studies were designed with 
a variety of objectives in mind. Some 
were designed to compare two different 
sources of hydrogenated oils (e.g., Refs. 
9, 14, 15, and 36). Many were designed 
to compare the effects of different types 
of fatty acids by varying the source oils 
to achieve the desired fatty acid types 
and levels (e.g., Refs. 7, 8, 10, 11 
through 13, and 34). The study designs 
also varied significantly in how they 
identified controls for the comparisons 
of interest. Despite these differences in 
objectives and study design, the general 
consistency across studies in finding 
that trans intakes are adversely related 
to CHD risk provides evidence that the 
relationship is likely real and not 
simply an artifact of a particular type of 
study design (Ref. 94).
Thus, most of the intervention trials 
provide enough information about test 
products, study population, and study 
diets to evaluate their relevance to the 
U.S. general population. The wide range 
of trans fatty acid intakes, products, and 
population characteristics in these 
studies overlaps with those found for 
U.S. consumers in the general 
population. Important, however, is that 
there is remarkable consistency across 
the intervention studies, regardless of 
population, products and diets used, in 
finding that higher intakes of trans fatty 
acids are associated with increased 
levels of serum LDL–C, a major risk 
factor for CHD. Thus, the available 
intervention studies show consistent 
results across a broad range of use 
conditions and population 
characteristics. FDA, therefore, 
disagrees with comments that suggest 
that the test products used in 
intervention studies are not applicable 
to the U.S. marketplace, or the study 
designs are not applicable to evaluating 
the relationship of trans fat to CHD risk 
in the U.S. population.
(Comment 9) Many comments 
questioned whether the scientific 
evidence shows that the physiological 
effects of trans fat on CHD risk are 
equivalent to, greater than, or less than 
those of saturated fat on a gram-for-gram 
basis. Some comments noted that the 
intervention studies show that the 
increase in LDL–C levels associated 
with trans fat is greater than that from 
unsaturated fats but less than that from 
saturated fat. Some comments noted 
that in the review of science for the 
November 1999 proposal, FDA 
concluded that the available studies do 
not provide a definitive answer to the 
question of whether trans fatty acids 
have an effect on LDL–C and CHD risk 
equivalent to saturated fats on a gram-
for-gram basis, but in the preliminary 
regulatory impact analysis, FDA 
estimated that the effects of saturated 
and trans fatty acids on LDL–C levels 
are about equivalent.
FDA notes that the intervention 
studies demonstrate that the net 
physiologic effect of a particular fatty 
acid or category of fatty acids is 
dependent upon the composition of 
both the intervention diet and the 
comparison diet. In the dietary 
intervention research reviewed, the 
study investigators used a variety of 
study designs to assess the effect of a 
defined quantity of trans fatty acids 
(provided by food sources of 
hydrogenated oil) on levels of serum or 
plasma lipids. The best study designs 
controlled the variation in the ranges of 
protein, fat, cholesterol, and 
carbohydrate with particular attention 
given to the fatty acids. The effect of 
trans fat study diets were compared by 
replacement with food sources of: (1) 
Cis-unsaturated fatty acids, (2) 
monounsaturated (oleic) fatty acids, and 
(3) saturated fatty acids. As FDA stated 
in the November 1999 proposal (64 FR 
62745 at 62750), the intervention study 
data showed the following: (1) Trans 
fatty acids increased LDL–C in 
comparison with cis-polyunsaturated 
fatty acids (Refs. 8, 13, 15, and 82); (2) 
trans fatty acids increased LDL–C levels 
in comparison with cis-
monounsaturated fatty acids (Refs. 7, 11 
and 12); and (3) trans fatty acids 
increased LDL–C, or there was no 
significant difference, in comparison 
with saturated fatty acids (Refs. 7 
through 12). Based on these results, 
FDA concluded in the science review 
section of the November 1999 proposal 
that the available studies do not provide 
a definitive answer to the question of 
whether trans fatty acids have an effect 
on LDL–C and CHD risk equivalent to 
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saturated fats on a gram-for-gram basis. 
However, FDA also stated that the 
studies that compared a saturated fat 
diet with a diet in which some of the 
saturated fat was replaced with trans fat 
showed that trans fat, like saturated fat, 
increases LDL–C.
For purposes of its regulatory impact 
analysis in the proposal, FDA needed a 
basis for quantifying its estimates of the 
compliance costs and benefits 
associated with given changes in trans 
fat intakes and the associated changes in 
CHD risk. The available evidence 
always presents some uncertainty for 
these types of analyses, as there is with 
other inputs into regulatory decisions. 
Given these caveats, FDA, in order to 
develop the tools required for a 
quantitative evaluation of benefits and 
costs, reviewed a meta analysis of five 
intervention trials that included six 
levels of trans fat intakes (Refs. 62 and 
69). Using multiple regression to 
statistically control for differences in 
other fatty acids between trans-enriched 
diets and reference diets, the authors 
projected linear increases in LDL–C as 
a function of level of increasing trans fat 
intake. According to the regression 
equations, each additional percent of 
energy from trans fat, when substituted 
for the same percent of calories from cis-
monounsaturated fatty acids, was 
predicted to increase LDL–C by 1.5 mg/
dL. This relationship was then used as 
the basis for estimating the benefits and 
costs of the proposed rule and not for 
purposes of establishing whether there 
is a gram-for-gram relationship between 
trans and saturated fatty acids on LDL–
C levels and CHD risk. FDA notes that, 
in rulemaking to implement the 1990 
amendments, the agency also found it 
necessary to use coefficients derived 
from regression equations to estimate 
the benefits and costs of various 
regulations (56 FR 60856, November 27, 
1991; 58 FR 2927, January 6, 1993). In 
one such analysis, FDA used the 
equation of Hegsted and Keys to predict 
how changes in total serum cholesterol 
would be affected by projected changes 
in saturated fat intake (56 FR 60856 at 
60869, November 27, 1991). Because the 
Hegsted and Keys equations did not 
include coefficients for trans fat or 
information on components of total 
cholesterol (e.g., LDL–C), FDA found it 
necessary to find regression equations 
that included trans fat intakes and LDL–
C levels. The equations of Katan et al. 
and Zock et al. (Refs. 62 and 69), 
together with the equations of Mensink 
and Katan (Ref. 65), which summarized 
the results of 27 clinical trials, were 
available to meet this need for a 
quantitative basis on which to estimate 
the benefits and costs of the proposed 
rule.
In estimating the benefits and costs, 
FDA also recognized that the type of 
macronutrient substituted for trans fat 
in the diet would affect the magnitude 
and nature of the changes in LDL–C in 
response to decreases in trans fatty acid 
intakes. Thus, FDA also estimated how 
the benefits and costs would be altered 
if saturated fat, cis-polyunsaturated fat 
or carbohydrate, rather than cis-
monounsaturated fat, were used to 
replace some of the trans fat in the diet. 
In this analysis an intermediate step in 
the calculation showed that when 
saturated fat was substituted for cis-
monounsaturated fat, LDL–C was raised 
by 1.52 mg/dL, an amount similar to 
that found when trans fat was 
substituted for cis-monounsaturated fat 
(1.50 mg/dL).
Regardless of whether FDA reviewed 
the effects of saturated fat and trans fat 
on LDL–C and CHD risk for the science 
section or the regulatory impact section, 
the conclusion about those effects is the 
same. That is, both trans fatty acids and 
saturated fatty acids raise LDL–C levels, 
a major risk factor for CHD risk. 
Consumers need to minimize their 
intakes of both types of fatty acids 
within a moderate fat intake to 
implement dietary guidelines for 
healthful diets. These conclusions are 
consistent with those reached 
independently by expert panels (Refs. 
87, 89, 90 and 91).
(Comment 10) Many comments 
addressed the issue of the potential 
adverse effects of trans fat on HDL–C 
levels. Some comments suggested that 
trans fat has more adverse health effects 
than saturated fat because trans fat, in 
addition to raising LDL–C, also lowers 
HDL–C, the so-called ‘‘good’’ 
cholesterol, whereas saturated fat raises 
HDL–C. Some comments noted that 
trans fat raises the LDL/HDL ratio 
approximately twice as much as 
saturated fat. Other comments stated 
that, in the prospective studies, the risk 
of CHD associated with trans fat intake 
was much greater than the risk 
associated with saturated fat, and much 
greater than would be predicted based 
on the effect on serum lipids. In 
contrast, one comment stated that it is 
premature to conclude that trans fat 
intake lowers HDL–C because many 
intervention studies showed that trans 
fat intake causes only a small decrease 
or has no effect on HDL–C.
Based on the recommendations of the 
1993 NCEP Expert Panel (Ref. 5), in the 
November 1999 proposal, FDA 
concluded that an examination of the 
effects of trans fatty acids on serum 
LDL–C would provide the strongest 
evidence, and should be the primary 
criterion, to evaluate whether trans fatty 
acids influence CHD risk. In the 
November 1999 proposal, FDA 
tentatively concluded that the available 
evidence demonstrated that under 
conditions of use in the United States, 
consumption of trans fatty acids 
contributes to increased serum LDL–C 
levels, which increases the risk of CHD. 
The evidence for this relationship alone 
was sufficient for the agency to 
tentatively conclude that addressing 
trans fatty acids in nutrition labeling is 
important to public health.
FDA’s review of the intervention trials 
showed that HDL–C decreased when 
trans fats replaced saturated fats. 
Further, Federal Government advisory 
groups (Refs. 88 through 90, and 140) 
and an advisory group of health 
professionals (Ref. 91) have stated that 
substitution of trans fat for saturated fat 
lowers HDL–C.
To date, lowered HDL–C levels have 
been shown to be a useful predictor of 
heart disease risk because of its 
correlation with CHD risk. However, it 
is not known whether lowering HDL–C 
is related to CHD risk in a cause and 
effect manner. Until this relationship is 
confirmed by appropriate study designs, 
the use of HDL–C as a surrogate 
biomarker for CHD risk must be done 
with caution and clear recognition of 
the uncertainty surrounding this use. 
For example, FDA notes that the NCEP 
2001 Report (Ref. 89) makes several 
statements that both recognize and 
qualify the relationship between trans 
fatty acids, HDL–C, and CHD risk. While 
the NCEP Report states that a low HDL–
C level is strongly and inversely 
associated with risk for CHD, the NCEP 
Report also states that, because of the 
association of low HDL levels with other 
atherogenic factors, a low HDL–C is not 
as strongly independent in its 
prediction as suggested by usual 
multivariate analysis.
Therefore, while FDA did not place 
primary reliance upon the relationships 
among trans fat intakes and adverse 
effects on HDL–C and CHD risk in 
deciding that nutrition labeling was 
warranted, FDA also recognizes this 
possible relationship, so concerns about 
possible adverse effects cannot be 
ignored (64 FR 62746 at 62798 to 
62821). For this reason, FDA included 
information on the effects of trans fatty 
acids on HDL–C levels when reviewing 
the available human studies in the 
science review section. Additionally, 
because of the possibility of an adverse 
effect on HDL–C levels from trans fat 
intake and a correlation between such 
an effect with CHD risk, the possible 
impact on HDL–C levels from trans fat 
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intake was used in the regulatory impact 
section as one of several possible 
approaches for determining cost benefit 
ratios of trans fat labeling. The agency 
would have been remiss in evaluating 
the full range of possible cost/benefit 
relationships if it had failed to include 
this potential adverse effect from trans 
fatty acid intakes to CHD risk in these 
analyses.
The question of interpretation of LDL/
HDL ratios is more difficult. For 
example, concurrent small changes in 
both LDL–C and HDL–C could result in 
a similar LDL/HDL ratio as would 
concurrent large changes in both LDL–
C and HDL–C assuming the changes are 
in the same direction. Or, large changes 
in HDL–C with moderate changes in 
LDL–C could give similar LDL/HDL 
ratios as would moderate changes in 
HDL and small changes in LDL. 
However, it is likely that the magnitude 
of the change in the individual blood 
cholesterol levels is as, or more, 
important than is a change in the ratio 
of the two. Thus, interpretation of the 
LDL/HDL ratio is unclear and until 
there is evidence by which its meaning 
can be more precisely defined, use of 
this ratio requires considerable caution. 
However, even with these caveats, 
regardless of whether results are 
expressed as increased levels of LDL–C 
or as increases in LDL/HDL ratios, the 
conclusion is the same: trans fat intakes 
increase CHD risk.
(Comment 11) A number of comments 
emphasized that, in addition to HDL–C, 
trans fat has other adverse effects that 
may contribute to CHD risk but 
saturated fat does not. The comments 
mentioned that trans fat has adverse 
effects on various CHD risk factors 
including serum lipoprotein(a), serum 
triglycerides, insulin resistance and 
diabetes risk. These comments also 
stated that trans fat has adverse effects 
on aspects of lipid metabolism that may 
cause increased CHD risk, such as 
interference with metabolism of omega–
3 fatty acids, interference with enzymes 
such as delta–6–desaturase, promotion 
of essential fatty acid insufficiency, and 
increase in free radical formation. 
Several of the comments argued that 
some of these CHD risk factors represent 
additional biological mechanisms 
related to trans fat that could account 
for the amount of CHD risk observed in 
prospective studies beyond that 
explained by changes in LDL–C and 
HDL–C.
Some comments stated that trans fat 
may have adverse effects on other health 
conditions, besides CHD. One of these 
comments requested that, in order to 
provide the full picture of health issues 
involved with trans fats, FDA review 
trans fat effects on cancer, obesity, 
immunity, reproduction, development, 
and diabetes when publishing the final 
rule. Another comment characterized 
trans fatty acids as being atypical fatty 
acids with an insidious nature in 
disrupting lipid metabolism. Some 
comments identified potential adverse 
effects of trans fat on lowered birth 
weights and decreased visual acuity in 
infants exposed to high levels of trans 
fatty acids in utero or via breast milk. 
The comments suggested that FDA 
advise pregnant and lactating women to 
limit their trans fat intake.
FDA recognizes that the relationship 
of biomarkers, other than LDL–C, and to 
a lesser degree, HDL–C, with CHD risk 
is less well established and difficult to 
interpret. Moreover, at this time, the 
findings suggesting effects of trans fat 
on non-heart disease risks are 
preliminary. Therefore, FDA finds that 
its focus on LDL–C provides a sufficient 
basis for concluding that the labeling of 
trans fat levels in food products is 
warranted.
V. Nutrition Labeling of Trans Fats
In the November 1999 proposal, FDA 
proposed that when trans fats are 
present in a food, including dietary 
supplements, the declaration of 
saturated fat must include the combined 
quantitative amount by weight of both 
saturated and trans fats. Further, FDA 
proposed that when 0.5 or more grams 
per serving of trans fats are present, the 
declaration be followed by a symbol that 
refers to a footnote at the bottom of the 
nutrition label stating the number of 
grams of trans fat present in a serving 
of the product, i.e., ‘‘Includes ___ g trans 
fat.’’ The agency also had discussed, in 
addition to the one proposed, several 
other options for declaring trans fat in 
the Nutrition Facts panel. These 
included: (1) Declaring the combined 
amount of both saturated fat and trans 
fat as ‘‘Saturated fat’’ without 
identifying the amount of trans fat, (2) 
declaring the combined amount of both 
saturated fat and trans fat as ‘‘Saturated 
+ trans fats’’ without identifying the 
amount of trans fat, (3) declaring the 
combined amount of both saturated fat 
and trans fat as ‘‘Saturated + trans fats’’ 
with an explanatory footnote stating the 
amount of each fat separately, and (4) 
declaring the amount of trans fat as a 
separate line item under saturated fat. 
The agency proposed that with all of 
these options the term ‘‘trans fatty 
acids’’ and ‘‘trans fat’’ could be used 
interchangeably.
A. Voluntary v. Mandatory Declaration 
of Trans Fatty Acids in Nutrition 
Labeling
(Comment 12) The majority of the 
comments supported the November 
1999 proposal, which required the 
mandatory declaration of trans fat in 
nutrition labeling when it is present in 
a food, including dietary supplements. 
An overwhelming majority of comments 
supporting the mandatory declaration of 
trans fat did so because of public health 
concerns. Some comments stated that 
the scientific evidence clearly 
demonstrates that consumption of trans 
fat contributes to increased LDL–C and, 
hence, increased risk of CHD. Several 
comments noted that consumers are 
increasingly aware of the relationship 
between dietary fat and chronic disease, 
especially CHD, and look to the 
nutrition label for information about 
‘‘heart-unhealthy’’ fat. A few comments 
noted that another benefit of mandatory 
labeling of trans fat is that it may 
provide an incentive to manufacturers 
to reduce the trans fat content of their 
foods.
A few comments stated that 
mandatory labeling of trans fat was not 
warranted because the scientific data 
linking trans fat to CHD is weak and 
because the average intake of trans fat, 
estimated as 2.91 percent of energy in 
the proposal, is minimal. Other 
comments also opposed mandatory 
labeling stating that the effect of trans 
fat on LDL–C or CHD risk was not 
sufficient to establish public health risk 
at ordinary levels of intake.
Some comments stated that, although 
mandatory labeling of trans fat was not 
warranted, a requirement for label 
declaration of trans fat could be justified 
in certain circumstances. Several of 
these comments stated that required 
label declaration of trans fat was 
justified if it was needed to prevent the 
label from being misleading because of 
the level of trans fat in light of other 
information on the label about total fat 
or fatty acids. Several comments that 
opposed mandatory declaration of trans 
fat suggested that, in order to prevent 
consumer deception, trans fat 
declaration should be required when 
nutrient content claims or health claims 
are made about fatty acids or dietary 
cholesterol or when there is label 
declaration of monounsaturated and 
polyunsaturated fats. One comment 
stated that there is no evidence that 
trans fat declaration would assist 
consumers in following healthy dietary 
practices unless certain claims are made 
or unless monounsaturated and 
polyunsaturated fats are declared on the 
label. One comment stated that the 
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amount of trans fat is ‘‘material’’ only 
when trans fat is present at greater than 
1 g per serving because it would then 
significantly impact the overall fatty 
acid contribution to the diet. Another 
comment stated that trans fat 
declaration should be required only 
when trans fat is present at greater than 
2 g per serving because that threshold 
would capture the food categories that 
contribute the vast majority of trans fat 
to the diet but would exclude products 
that contain only a trivial amount of 
trans fat. This comment stated that 
mandatory trans fat labeling of products 
with 2 g trans fat or less per serving 
would have a significant labeling 
burden although the foods make little 
overall contribution to trans fat in a 
mixed diet and have not been shown to 
have any public health impact. Another 
comment suggested that, if no claims are 
made, trans fat declaration should be 
voluntary if trans fat is present at 0.5 g 
or less per serving. One comment 
suggested that, if there are no claims 
about fatty acids or cholesterol, trans fat 
declaration should not be required 
when the food is ‘‘low’’ in total fat. The 
comment stated that a food ‘‘low’’ in 
total fat conforms with dietary 
recommendations; that no material 
improvement in food choices can be 
made from knowledge of the specific 
trans fat level in a ‘‘low fat’’ food; and 
that the level of trans fat in a ‘‘low fat’’ 
food is not enough to have any adverse 
impact on public health.
One comment stated that trans fat 
declaration should be optional because 
consumers prefer simplicity and clarity 
in nutrition labeling and consumers are 
unlikely to benefit from added verbiage 
about a nutrient that is not familiar to 
them. One comment suggested that 
trans fat declaration should be 
voluntary, but should be required under 
the same conditions that declaration of 
monounsaturated and polyunsaturated 
fat is required. The comment stated that 
trans fat declaration would then be 
required when fatty acid or cholesterol 
claims are made, and this would be the 
case for important food sources of trans 
fat, such as margarines, which often 
make such claims. According to the 
comment, although not all foods would 
choose or be required to disclose trans 
fat, the foods that are predicted to 
reformulate and that generate the 
expected health benefits of trans fat 
labeling would do so. After the initial 
disclosure of trans fat by these foods, 
additional foods would disclose trans 
fat due to competitive pressure 
(described by the comment as ‘‘the 
unfolding principle’’). The comment 
stated that market incentives and 
facilitation of information flow, rather 
than mandatory disclosure, are the best 
ways to achieve trans fat disclosure.
FDA disagrees with comments 
opposed to mandatory declaration of 
trans fat. The 1990 amendments 
mandated nutrition labeling on most 
foods to provide consumers with 
information about specified nutrients 
that would help them maintain healthy 
dietary practices, as well as to create an 
incentive to food companies to improve 
the nutritional qualities of their 
products. Section 403(a) requires that 
food be adequately labeled and that 
material facts about a food’s 
characteristics be disclosed to 
consumers. Section 403(q)(2)(A) of the 
act gives the Secretary (as delegated to 
FDA in § 5.10 (21 CFR 5.10)) the 
authority to require that information on 
additional nutrients be included in 
nutrition labels, if the Secretary 
determines that providing such 
information will assist consumers to 
maintain healthy dietary practices. In 
the legislative history of the 1990 
amendments, Congress noted that 
‘‘Scientific evidence has clearly linked 
dietary habits to good health. For this 
reason, it is important for FDA to 
provide consumers with better 
information about the foods they eat.’’ 
(Ref. 141). As described in section IV of 
this document, scientific studies have 
demonstrated consistently that 
consumption of trans fat increases LDL–
C, a major risk factor for CHD.
New studies and recent expert reports 
(Refs. 87, 90, 95, and 140) have been 
published and confirm the relationship 
between trans fat intake and risk of 
CHD. These studies’ reports corroborate 
the agency’s earlier finding in the 
proposed rule that information on trans 
fat on the nutrition label will assist 
consumers to maintain healthy dietary 
practices. Dietary Guidelines 2000 
cautions consumers that foods high in 
trans fatty acids tend to raise blood 
cholesterol and gives examples of food 
sources of trans fat (Ref. 87). The 
Guidelines advise Americans who need 
to reduce fat intake to ‘‘do so primarily 
by cutting back on saturated and trans 
fats’’ (Ref. 87). Likewise, the Executive 
Summary of the NCEP 2001 report urges 
primary prevention of CHD in the 
United States through lifestyle changes 
(Ref. 95). The NCEP’s Therapeutic 
Lifestyle Changes Diet recommends that 
those who wish to lower their LDL–C 
level reduce their intake of saturated fat 
and keep consumption of trans fat low 
(Ref. 89). Similarly, the IOM/NAS report 
recommends ‘‘that trans fat 
consumption be as low as possible 
while consuming a nutritionally 
adequate diet’’ (Ref. 90). It is clear that 
persons interested in following these 
recommendations and maintaining 
optimal LDL–C levels must be able to 
determine levels of both saturated and 
trans fats in individual food products. 
This information provides consumers 
with the ability to maintain healthy 
dietary practices. Information on 
saturated fat content is already available 
in Nutrition Facts panels on food labels. 
The practical way to inform consumers 
of the level of trans fat in individual 
food products is for the information also 
to be included in the Nutrition Facts 
panel.
Government and industry surveys 
consistently find that a majority of 
American consumers report looking at 
the nutrition label the first time they 
purchase a food product (e.g., about 75 
percent according to FDA surveys (Ref. 
96) and 51 percent according to a 1997 
industry survey (Ref. 97). According to 
the FDA surveys, the most frequently 
reported label use and the one which 
increased most following the 
implementation of the 1990 
amendments was ‘‘to see how high or 
low the food is in things like calories, 
salt, vitamins, fat, etc.’’ (70 percent in 
1995, up 12 percent from 1994) (Ref. 96, 
table 16.1).
These survey data show that 
consumers rely on the Nutrition Facts 
label as a guide to choosing foods that 
meet their dietary objectives. As 
consumers learn more about the dietary 
significance of trans fat and the dietary 
advice to limit its consumption, the 
Nutrition Facts panel is where label 
users will expect and want to find this 
information. If they cannot find 
information on trans fat content there or 
if it is only there when claims are made 
about fatty acids or cholesterol, they 
will be hampered in their ability to 
implement the most recent dietary 
guidance, and are likely to be misled 
about a food’s basic characteristics.
Therefore, FDA, as delegated by the 
Secretary, has concluded that trans fat 
is a material fact which cannot be 
omitted from the label. In addition, 
information on the trans fat content of 
food will assist consumers in 
maintaining healthy dietary practices. 
As such, FDA is acting in accordance 
with section 403(a) and (q)(2)(A) of the 
act to require that information on trans 
fat content be included in nutrition 
labeling. Including trans fat as a 
mandatory component of nutrition 
labeling will allow consumers to choose 
foods that will reduce their intake of 
trans fat, along with saturated fat, 
within the recommended intake level 
for total fat in a manner that is 
consistent with the most recent dietary 
guidance.
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FDA disagrees with the comments 
that stated that mandatory labeling of 
trans fat is not warranted because 
average trans fat intake is minimal or 
because trans fat consumption is not a 
matter of public health risk at ordinary 
levels of intake. As described in section 
IV of this document, subjects in 
intervention studies showing that trans 
fat intake raises LDL–C levels had a 
wide range of trans fat intake levels, 
including levels that overlap the range 
of intake estimates for the U.S. 
population. The findings from 
intervention studies are supported by 
findings of a positive association 
between trans fat intake and increased 
CHD risk in the prospective 
observational studies, among free-living 
subjects consuming ordinary diets. 
Taken together, these studies 
demonstrate that trans fat consumption 
in the United States is a matter of public 
health concern at ordinary levels of 
intake.
FDA disagrees with the comments 
that suggested that the nutrition label 
would not be misleading if grams of 
trans fat were not listed, except where 
claims about fatty acids or cholesterol 
were made, monounsaturated fats and 
polyunsaturated fats were declared, or 
where trans fats were present at less 
than 2 g, 1g or 0.5 g per serving. The 
agency believes that the absence of 
information of the amount of trans fat in 
a product, when labeling of trans fat as 
a mandatory nutrient is required, even 
where trans fat is present at less than 
0.5 g, would be misleading. The 
presence or absence of trans fat in a 
product is a material fact as to the 
consequences that may result from the 
use of the product. Consumers need to 
know when a product contains less than 
0.5 g trans fat just as much as they need 
to know when a product contains 1, 2, 
or more grams of trans fat in order to 
understand how each product impacts 
their overall dietary intake of trans fat. 
Such need is not based solely on the 
presence or absence of claims, levels of 
other fats, or declaration of other fats on 
the label. Consumers need to 
understand how each product 
contributes to their overall intake of 
trans fat in order to maintain healthy 
dietary practices which call for reducing 
trans fat intake as low as possible while 
consuming a nutritionally adequate diet. 
Consumption of several foods, each 
with 0.5 to 1 g trans fat per serving, over 
the course of a day may result in a 
significant overall trans fat intake for 
the day. The association between the 
intake of trans fat over a range of intakes 
and the risk of CHD are discussed in 
section IV of this document. Because 
low levels of trans fats may have 
significant impacts on increased CHD 
risk, there are important public health 
reasons for excluding foods high in 
trans fat intake and for including foods 
lower in trans fat intake. Consumers 
need the trans fat information on 
products in order to determine how 
each product fits into their individual 
health goal for reducing trans fat intake 
in the context of their total daily diet. 
Thus, the agency is requiring trans fat 
labeling, regardless of whether claims 
are made or the levels of other fats are 
declared, to prevent products from 
being misleading under sections 
403(a)(1) and 201(n) of the act. 
Therefore, as described in section III of 
this document, in this rulemaking FDA 
is relying on its authority under those 
sections as well as its authority under 
section 403(q)(2)(A) of the act to require 
that information on trans fat be 
included in nutrition labeling to assist 
consumers in maintaining healthy 
dietary practices. Requiring such 
information on labels, whether or not 
voluntary nutrients are listed or claims 
are made about fatty acids or 
cholesterol, is consistent with statutory 
directives for nutrition labeling in 
section 403(q)(1) of the act, where 
amounts of nutrients of public health 
significance are required to be listed, 
regardless of other information on the 
label. FDA also disagrees with the 
comments that stated that trans fat 
declaration would assist consumers in 
maintaining healthy dietary practices 
only under certain circumstances, such 
as when certain claims are made, when 
monounsaturated and polyunsaturated 
fats are declared on the label, when 
trans fat is present at greater than 0.5 g, 
1 or 2 g per serving or when the food 
is not ‘‘low’’ in total fat (i.e., more than 
3 g fat/reference amount). As described 
previously, consumers need information 
on both saturated and trans fats in 
individual food products so that they 
can follow current dietary 
recommendations and maintain optimal 
LDL levels. It is the provision of trans 
fat information on foods consumed 
throughout the day that can assist 
consumers in maintaining healthy 
dietary practices, and the usefulness of 
this information is not limited to foods 
with certain nutritional characteristics. 
In addition, the consumption of several 
foods with 0.5 or 1 g of trans fat per day 
that may provide a total of 8 g of trans 
fat to the diet would be expected to have 
the same effect on LDL–C levels as 
consumption of one food with 8 g trans 
fat. Requiring trans fat to be declared 
only when present at a specified level 
would be inconsistent with statutory 
directives for nutrition labeling in 
section 403(q)(1) of the act, where 
amounts of nutrients of public health 
significance are required to be listed, 
regardless of the amount present.
Similarly, tying mandatory 
declaration of trans fat to the 
declaration of monounsaturated and 
polyunsaturated fats overlooks the 
difference in health effects of these fatty 
acids and the basic premise of section 
403(q) of the act that requires the listing 
of nutrient information necessary to 
assist consumers in maintaining healthy 
dietary practices. Unlike information on 
trans fat, FDA has not determined that 
information on monounsaturated and 
polyunsaturated fat is necessary to assist 
consumers in maintaining healthy 
dietary practices. Accordingly, the 
declaration of those fatty acids is not 
mandatory. Rather, unless claims are 
made about fatty acids or cholesterol, 
the agency provides that their listing is 
voluntary (§ 101.9(c)(2)(ii), (c)(2)(iii), 
and (c)(3)), consistent with the authority 
in section 2(b)(1)(C) of the 1990 
amendments that stipulates that 
regulations shall ‘‘permit the label or 
labeling of food to include nutrition 
information which is in addition to the 
information required by such section 
403(q) and which is of the type 
described in subparagraph (1) or (2) of 
such section * * *.’’
Regarding the comment that 
consumers prefer simplicity and clarity 
in labels, FDA does not agree that 
providing a listing of the amount of 
trans fat on a label is not simple or clear 
nor did the comment provide any 
rationale for its assertion. Further, FDA 
does not agree that trans fat listing on 
a label would be ‘‘added verbiage’’ 
about an unfamiliar nutrient that likely 
will not benefit consumers. The 
comment presented no information to 
support its assertion. The addition of 
trans fat as a mandatory nutrient on a 
separate line will not significantly 
change the appearance of the nutrition 
information that consumers are already 
familiar with. Having consistent 
information about trans fat present on 
all food labels will facilitate consumer 
education efforts about trans fat, as 
discussed later in this document (see 
Comment 28).
FDA is not persuaded by the comment 
that it is not necessary to make trans fat 
labeling mandatory because, after an 
initial disclosure of trans fat by certain 
foods, additional foods would disclose 
trans fat due to competitive pressure 
(unfolding principle). Although some 
disclosure of trans fat under competitive 
pressure might occur, the overall extent 
of such voluntary disclosure is not 
certain. Before the 1990 amendments 
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were enacted, provision of nutrition 
labeling information was voluntary 
except in certain circumstances. At the 
time when nutrition labeling was 
voluntary, many foods did not provide 
nutrition labeling, demonstrating that 
the disclosure suggested by the 
‘‘unfolding principle’’ was incomplete. 
To remedy this situation, Congress 
enacted the 1990 amendments, 
mandating that nutrients of public 
health significance be declared on food 
labels under section 403(q) of the act.
As mentioned earlier, section 
403(q)(2)(A) of the act provides for the 
inclusion of an additional nutrient(s) if 
the Secretary (as delegated to FDA in 
§ 5.10) determines that it should be 
included in nutrition labeling to assist 
consumers in maintaining healthy 
dietary practices. FDA is not asserting, 
as its basis for mandatory trans fat 
nutrition labeling, a rationale that is 
different from that which Congress 
declared by statute for such mandatory 
labeling. Lacking any congressional 
direction to do otherwise, the agency 
considers it implicit that any such 
added nutrients would be listed in a 
similar manner to those specified in 
section 403(q)(1) of the act. Accordingly, 
the agency is amending § 101.9 
Nutrition Labeling of Food, to add trans 
fat as a mandatory component of 
nutrition labeling on all foods in 
accordance with section 403(q)(2)(A) of 
the act.
B. Format, Including Percent of Daily 
Value (% DV), for Nutrition Labeling of 
Trans Fat
FDA received many comments 
regarding the proposed option for 
nutrition labeling of trans fatty acids 
and other options discussed in the 
preamble. In addition, comments were 
received suggesting that trans fat be 
listed in conjunction with the listing of 
total fat.
The agency did not receive comments 
supporting either of the two options that 
would declare only the combined 
amount of saturated fat and trans fat 
rather than the individual amounts 
present. In light of the lack of support 
for these two options and the fact that 
these options do not allow consumers to 
determine the individual amounts of 
saturated fat and trans fat, the agency is 
not considering them further.
FDA also received a few comments 
that supported the proposed footnote 
statement ‘‘Intake of trans fat should be 
as low as possible’’ or a modification of 
it. However, the overwhelming majority 
of comments opposed the use of the 
footnote.
1. Proposed Option
(Comment 13) Many comments 
supported the proposed option of 
having the amount of trans fat included 
in the amount declared for ‘‘Saturated 
Fat’’ and in the calculation of the 
corresponding % DV with a footnote 
stating ‘‘Includes ___ g trans fat’’ when 
the food contains trans fat. Comments 
stated that combining both saturated 
and trans fat in the declaration of 
saturated fat maintains a consistent 
public health message and provides 
consumers with a less confusing means 
to identify ‘‘heart-unhealthy’’ fats in one 
place on the label. Comments suggested 
that, to assist consumers, trans fat 
should be included with saturated fat 
because saturated and trans fats have 
similar physiological and functional 
properties and because there is no DV 
for trans fat. Comments suggested that 
combining saturated and trans fats will 
decrease the likelihood that consumers 
would look only at the declared level for 
trans fat and choose a food because it 
has little or no trans fat, even though it 
contains a high amount of saturated fat. 
Furthermore, the comments suggested 
that combining trans with saturated fats 
would create an incentive for 
manufacturers to decrease ‘‘heart-
unhealthy’’ fats in foods.
Comments supporting inclusion of 
trans fat in the calculation of the % DV 
for saturated fat stated that such action 
is reasonable for purposes of consumer 
information. One of these comments 
argued that trans fats are already 
included in recommendations to limit 
total fat to 30 percent of calories, a 
number that should not be increased, 
and are excluded from definitions of 
unsaturated fats for labeling purposes 
(i.e., § 101.9(c)(2)(ii) and (c)(2)(iii)). This 
comment acknowledged that including 
trans fat would in effect lower the 
reference value for saturated fat. The 
comment argued that this would help 
Americans reduce their risk of heart 
disease, quoting from the IOM/NAS 
report ‘‘Diet and Health’’ which states 
that ‘‘saturated fatty acid intake [should] 
be maintained at less than 10 percent of 
total calories by individuals,’’ but that 
‘‘further reduction, to 8 or 7 percent of 
calories or lower, would confer greater 
health benefits.’’ The comment said that 
including trans fat in the % DV would 
help Americans follow this advice.
However, many comments opposed 
this option of including trans fat with 
saturated fat, arguing that including 
trans fat with saturated fat is 
scientifically inaccurate and misleading 
because trans and saturated fats are 
chemically, functionally, and 
physiologically different. Comments 
pointed out that chemically trans fats 
are unsaturated fatty acids that contain 
one or more double bonds in a trans 
configuration while saturated fats do not 
contain double bonds. Moreover, 
comments stated that trans fatty acids 
do not have the same functional 
characteristics as saturated fats because 
their melting and crystallization kinetics 
are quite different. Comments also 
pointed out that trans fat is 
physiologically distinct from saturated 
fat, stating that trans fat decreases HDL–
C levels and that saturated fat does not. 
In addition, there were comments 
suggesting that trans fat adversely 
affects other factors that contribute to 
CHD, such as lipoprotein(a), and may 
cause adverse effects unrelated to CHD. 
For these reasons, the comments were 
adamant that trans fat should not be 
treated as though it is ‘‘bioequivalent’’ 
to saturated fat and, consequently, the 
listing of trans fat should be 
disassociated from the listing of 
saturated fat.
In addition, several comments 
objected to combining both trans and 
saturated fats on the grounds that it is 
inconsistent with FDA’s regulatory 
precedent of classifying nutrients based 
on their chemical definition or 
structure, rather than their physiological 
effect. Specifically, the comments cited 
FDA’s decision when implementing the 
1990 amendments to establish a 
chemical definition for saturated fat 
rather than a physiological definition 
(58 FR 2079 at 2089).
A few comments expressed concern 
that by including trans fat with 
saturated fat, FDA is creating a category 
of ‘‘bad’’ or ‘‘cholesterol-raising’’ fat that 
is inconsistent with the current 
nutrition label, which provides 
consumers with information about the 
nutrient profile of a product rather than 
providing information about perceived 
health effects. Other comments stated 
that FDA’s proposal to combine trans fat 
and saturated fat may mislead 
consumers, albeit misleading them for 
their own good, by causing them to 
misclassify trans fats as saturated fats or 
causing them to assume that the DV for 
saturated fat has been reduced (the 
effect of combining the quantitative 
amounts of trans and saturated fats and 
determining the % DV using the 
established DV for saturated fat). 
Further, several comments stated that 
adding trans fat to the amount of 
saturated fat declared may mislead and 
confuse consumers by leading them to 
incorrectly conclude that the amount of 
saturated fat has increased.
Other comments stated that, because 
of the magnitude of CHD risk in the 
prospective studies, trans fat should be 
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labeled more prominently than 
proposed in the November 1999 
proposal. These comments argued that 
listing the amount of trans fat in a 
footnote is more confusing and implies 
that it is unimportant. In addition, 
comments stated that footnotes, which 
can use smaller type size, are more 
difficult to read. One comment stated 
that it was not surprising that 
consumers were unfamiliar with the 
term since it was not allowed to appear 
on Nutrition Facts labels. This comment 
suggested that consumer knowledge 
about trans fat would improve as more 
dietary recommendations are made for 
limiting trans fats and as they are listed 
in food labeling.
Other comments objected to including 
trans fats when calculating the % DV for 
saturated fat stating that the effects of 
trans fat on LDL–C have not been 
proven to equal the effects of saturated 
fat on LDL–C, so they should not be 
held to the same standard. These 
comments argued that including trans 
fat in the calculation of % DV assumes 
that trans fat is equivalent to saturated 
fat on a gram-for-gram basis, whereas 
the agency admitted in the proposal that 
available studies do not allow for such 
a conclusion. The comments stated that 
no authoritative bodies have 
recommended that trans fat be 
considered as a part of the dietary 
recommendation for saturated fat. Also, 
they stated that including trans fat, in 
effect, lowers the DRV for saturated fat 
and there is no new data on saturated 
fat that supports this action, i.e., that 
there is no basis for concluding that 
saturated fats are now sufficiently worse 
than previously believed to justify an 
apparent reduction in recommended 
intakes. One comment also argued that 
if the declaration of % DV changed on 
a product as a result of including trans 
fat with saturated fat, consumers may 
incorrectly assume a change has been 
made which made the product less 
healthy when, in fact, no such change 
had occurred.
One comment said that FDA should 
not include trans fat in the calculation 
of % DV unless the DRV for saturated 
fat is increased to 22 g since the agency 
had actually rounded down the DRV for 
saturated fat from 22.2 g (equivalent to 
10 percent of calories from a 2,000 
calorie diet) to 20 g when implementing 
the 1990 amendments (see 58 FR 2206 
at 2219). Another comment objected to 
the idea of increasing the DRV for 
saturated fat because products that do 
not contain trans fat would appear 
healthier (i.e., have a lower % DV) even 
though the amount of saturated fat in 
the product would remain the same.
Based on comments received, FDA is 
persuaded that there are inherent 
weaknesses and inconsistencies in its 
proposed option. Therefore, the agency 
has reconsidered its proposal to include 
trans fats in the declaration of saturated 
fat with a footnote indicating the 
amount of trans fat. The agency 
acknowledges that declaring the amount 
of saturated fat and trans fat together, 
even with the proposed footnote, could 
lead some consumers to believe that the 
two types of fatty acids are chemically 
and physiologically the same. Clearly, 
trans fats contain double bonds and 
thus, are chemically distinct from 
saturated fat. Likewise, although both 
saturated and trans fats do raise LDL–
C levels, physiologic distinctions 
between the two types of fatty acids do 
exist as discussed previously in 
Comments 10 and 11. While findings on 
some of these distinctions are 
preliminary, they do not support the 
position which the agency took in the 
November 1999 proposal that the two 
fatty acids should be declared as one 
combined entity because of similar 
physiological effects.
The agency re-evaluated its position, 
noted in the final rules implementing 
the 1990 amendments, that there is 
insufficient knowledge about the 
physiological effects of particular fatty 
acids to use anything other than a 
chemical definition for saturated fats (58 
FR 2079 at 2089). In that rulemaking, 
FDA reconsidered its regulatory 
position in place since 1973 (38 FR 2132 
at 2134, January 19, 1973) of linking the 
definition of saturated fatty acids to 
effects of particular fatty acids on blood 
total and LDL–C and determined that a 
chemical definition was a more 
appropriate approach. The agency stated 
that a chemical definition avoids much 
of the controversy regarding blood 
cholesterol effects of short to medium 
and certain very long chain fatty acids 
because the definition is not subject to 
changes in knowledge about the 
physiological effects of a particular fatty 
acid. In addition, the agency stated that 
a chemical definition approach to 
labeling fatty acids avoids the 
uncertainty about physiological effects 
other than those related to CHD (58 FR 
2079 at 2089). Based on its re-review of 
the position noted in the final rules 
implementing the 1990 amendments, 
the comments received on proposed 
rule opposing a contrary position, and 
current science on trans fat, the agency 
is persuaded that it would be important 
to approach trans fat labeling on the 
basis of using a chemical definition and 
not based on physiological effects. 
Accordingly, the agency concludes that 
it is necessary to disassociate saturated 
and trans fats on the nutrition label so 
that consumers do not misinterpret the 
declaration of saturated fat by thinking 
that trans fats are included in that 
definition.
The agency also acknowledges the 
concerns expressed in comments about 
the prominence given to the information 
on trans fat. Current food labeling 
regulations do allow for a smaller type 
size for footnotes (§ 101.9(d)(1)(iii)) and 
limit the declaration of amounts in 
footnotes to statements saying that the 
food is not a significant source of 
specified nutrients (e.g., § 101.9(c)(3)). 
Consequently, consumers may overlook 
quantitative information on trans fat 
content placed there.
In the November 1999 proposal, FDA 
expressed concern that consumers may 
not yet know what trans fats are or 
know about their impact on health (64 
FR 62746 at 62755). The agency agrees 
with the comment that suggested that 
consumer knowledge would improve as 
more dietary recommendations are 
made for limiting trans fats and as they 
are listed in nutrition labeling. In 
addition, the agency notes that media 
attention to trans fat has been 
widespread since publication of the 
November 1999 proposal. For example, 
public awareness about trans fats was 
increased as reports of the IOM/NAS 
report on trans fatty acids were issued 
(Ref. 140), as consumer and health 
groups issue press releases and reports 
about trans fats (Refs. 147 and 148), as 
food manufacturers add information 
about the trans fat content of products 
to labels, and as industry 
announcements are made about the 
trans fat content of packaged and 
restaurant foods (Refs. 149 and 150). In 
addition, the agency is planning a 
consumer education program discussed 
later in Comment 28 to further heighten 
consumers’ knowledge of what trans 
fats are and their impact on health. 
Thus, the agency no longer believes that 
its prior reasoning, i.e., that trans fat 
would need to be included in the 
declaration of saturated fats in order for 
consumers to understand that trans fats 
are heart unhealthy is necessarily true. 
Consumers should be more aware of 
trans fat based on the public exposure 
to information on trans fat over the past 
years and FDA efforts before the rule 
becomes effective.
In the November 1999 proposal, FDA 
tentatively concluded that, in the 
absence of dietary recommendations for 
trans fats, it was reasonable to include 
trans fats in the % DV for saturated fat 
(46 FR 62746 at 62756). Consequently, 
FDA proposed that the % DV be 
calculated by combining the amount of 
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saturated fat and trans fat in a food and 
dividing by the DRV for saturated fat (20 
g). In effect, this is equivalent to having 
a combined DRV for saturated and trans 
fat of 20 g. FDA agrees with the 
comments that suggest that this 
approach is problematic in that by 
displacing the DV for saturated fat with 
trans fat, the DV, in essence, is lowered 
for saturated fat. However, the DV for 
saturated fat has not changed. Therefore, 
it would be scientifically more accurate 
to keep the DV for saturated fat intact, 
without displacing it with trans fat. This 
approach would be consistent with the 
recent IOM/NAS macronutrient report 
(Ref. 140) that does not treat saturated 
and trans fats together. FDA concludes 
that there is an insufficient scientific 
basis at this time for combining the 
declared amounts of trans and saturated 
fats and calculating the % DV. 
Additionally, FDA is persuaded by the 
arguments discussed previously that 
point to the differences between 
saturated fat and trans fat that it is 
inappropriate to do so.
Accordingly, the agency concludes 
that other options that disassociate trans 
fat from the listing of saturated fat 
would be preferable to the proposed 
option. The other options identified in 
the proposal and those suggested in 
comments are discussed later.
2. Option to List Saturated and Trans 
Fat on Same Line
(Comment 14) Several comments 
preferred the option identified in the 
November 1999 proposal that would list 
‘‘Saturated + trans fat’’ with the amount 
in grams and the % DV based on the 
combined value, and the individual 
amounts of both saturated and trans fats 
in a footnote. One comment suggested 
that the footnote declare the specific 
amount of trans fat only, while another 
suggested that the individual amounts 
be listed in separate lines immediately 
below the combined amount rather than 
in a footnote. These comments stated 
that this type of declaration shows that: 
(1) There are two different fatty acid 
categories, thereby maintaining the 
chemical definitions of trans fat and 
saturated fat and indicating equal 
importance to health; (2) gives them 
equal prominence with poly- and 
monounsaturated fats; (3) suggests to 
consumers that trans fats have similar 
cholesterol-raising properties as 
saturated fats; and (4) provides an easy 
method for comparing the ‘‘heart-
unhealthy’’ fat content of foods. The 
comments also argued that this type of 
declaration indicates the combined total 
amount of saturated and trans fats, a 
number that would stay constant when 
saturated and trans fats are substituted 
for each other, and it was therefore 
clearer to declare the sum of both.
Alternatively, a few comments 
recommended declaring the individual 
amounts for saturated fat and trans fat 
on one line in the nutrition label, i.e.,. 
‘‘Saturated fat __g + trans fat __g.’’ 
These comments pointed out that 
declaring saturated and trans fats in this 
way would be consistent with the 
chemical definitions for each type of 
fatty acid and would help consumers 
see that trans fats are different from 
saturated fats. The comments argued 
that research may elucidate new 
properties or biological effects of both 
saturated and trans fatty acids, 
warranting this distinction between 
them. From a consumer perspective, one 
of the comments also argued that, if 
FDA begins to mandate the placement of 
nutrient content information in 
locations other than the current nutrient 
list, consumers may become 
increasingly confused about where on 
the food label to locate information that 
they need.
Two comments urged the agency to 
harmonize its trans fat labeling policy 
internationally, noting that this format, 
i.e., ‘‘Saturated fat _ g + trans fat _g,’’ 
was proposed by Canada in June 2001, 
for use in mandatory nutrition labeling 
in that country (Ref. 103).
Other comments did not favor listing 
saturated and trans fats on the same line 
as ‘‘Saturated + trans fat’’ for the same 
reasons expressed in opposition to the 
proposed option, namely because trans 
and saturated fats are chemically 
different, because they have different 
effects on HDL–C, and because, 
according to preliminary data, trans fat 
may have effects on non-heart disease 
risks that saturated fats are not reported 
to have. In addition to concerns about 
the chemical and physiological 
differences between trans and saturated 
fats, some comments expressed 
opposition to labeling the two on the 
same line because public health and 
scientific organizations that are 
instrumental in establishing daily 
reference intake values have not yet 
established a DV for trans fat. Many 
other comments objected to having 
saturated and trans fats on one line, in 
any manner, if it resulted in trans fat 
being included in the calculation of the 
% DV for saturated fat. Specific 
arguments against including trans fat 
when calculating the % DV for saturated 
fat are discussed in the preceding 
comment.
The agency is not persuaded by 
comments supporting this option. While 
this option does indicate more clearly 
than the proposed rule that saturated 
and trans fats represent two different 
categories of fat, it would still 
necessitate a displacement of the % DV 
for saturated fat by trans fat and would 
not disassociate the two fats in terms of 
potential physiologic effects. Based on 
the reasons set forth in response to 
Comment 13, we believe that it would 
be scientifically more accurate to not 
displace the % DV for saturated fat with 
trans fat. In addition, this option would 
not be consistent with our rationale, as 
explained in the response to Comment 
13, for why a chemical definition 
approach to labeling is preferred. Such 
an approach avoids the uncertainty 
about physiological effects now or in the 
future. While the two fatty acids do both 
lead to increased LDL–C, advisory 
groups (as noted in comment 10 of this 
document) have stated that substitution 
of trans fat for saturated fat lowers 
HDL–C. Low levels of HDL–C can be a 
predictor of CHD. While evidence 
concerning the differing effects of 
saturated fat and trans fat on other 
disease risk factors is preliminary, FDA 
is convinced by comments that it is 
preferable to disassociate the two fatty 
acids and maintain a chemical 
definition approach to labeling. 
Accordingly, the agency finds this 
option unacceptable.
Those comments stating that saturated 
and trans fat are substituted for each 
other recognized that the two types of 
fats have some functional similarities. 
However, comments were not 
unanimous in stating that the combined 
total amount of saturated and trans fats 
would stay constant when one of the 
two fatty acids was raised or lowered. 
Some comments indicated that trans 
fats could be reduced significantly with 
a smaller concomitant increase in 
saturated fat. In addition, FDA points 
out that the intent of this rulemaking is 
not to make such substitutions easier 
from a labeling perspective but to 
encourage the reduction of both types of 
fats to assist consumers in maintaining 
healthy dietary practices.
FDA recognizes that Canada has 
issued final rules on nutrition labeling 
that declare saturated fat and trans fat 
on one line. However, FDA has 
determined, based on comments to this 
final rule, that such declaration would 
not be an appropriate approach for the 
agency at this time. Such an option 
would not account for the chemical and 
physiological differences between 
saturated and trans fat, and thus, would 
be inconsistent with the agency’s past 
approach to labeling that is based on 
chemical differences. Further, there are 
additional differences between Canada’s 
new nutrition labeling rule and existing 
U.S. regulations, under § 101.9, that will 
need to be reviewed by both countries. 
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After further review and discussion, the 
United States and Canada can consider 
the possibility of mutual recognition of 
nutrition labels.
3. Option to Include Trans Fat as a Part 
of Total Fat
(Comment 15) Several comments 
recommended a new option that would 
place an asterisk (or other symbol) after 
the declaration of total fat (i.e., ‘‘Total 
Fat*’’) that references a footnote stating 
the number of grams of trans fat 
included in the total fat declaration 
(e.g., ‘‘*Includes___g trans fat’’). A few 
comments proposed an alternative to 
this option that would declare trans fat 
in a parenthetical statement on the same 
line with ‘‘total fat’’ (i.e., ‘‘Total Fat __ 
g (includes__ g trans fat)’’).
Some of these comments suggested 
that declaring trans fat as a part of total 
fat alleviates many of the concerns 
voiced about the proposed option. The 
comments stated that this option 
discloses the amount of trans fat in 
scientifically accurate terms and is 
consistent with current regulations that 
include the quantity of trans fat within 
the amount declared for total fat. A 
comment said that this option should be 
used until a DRV is established for trans 
fat. Another comment suggested that the 
DRV for total fat should be increased to 
accommodate trans fat. Other comments 
stated that current dietary guidelines 
recommend monitoring both total fat 
and saturated fat intake, especially for 
consumers concerned about their heart 
health, and that the AHA recommends 
focusing on the total amount of fat 
consumed to address concerns about 
trans fat consumption.
The comments stated that placing the 
asterisk beside ‘‘total fat’’ has 
advantages for consumers. At least one 
comment stated that this type of listing 
may be more readily seen by consumers 
since it gives greater prominence to the 
trans fat information. Other comments 
stated that including trans fat as a part 
of total fat avoids the confusion that 
consumers would experience with 
FDA’s proposed option when amounts 
declared for saturated fat would appear 
to have increased.
The agency disagrees with those 
comments suggesting that concerns 
about trans fat consumption can be 
addressed by focusing on the total 
amount of fat consumed. FDA agrees 
that trans fats are chemically a 
component of total fat; however, that is 
also true for saturated, polyunsaturated, 
and monounsaturated fatty acids that 
are listed as subcomponents of total fat 
in many food labels. Therefore, the 
agency does not agree that trans fatty 
acids should be listed only as a part of 
total fat until there is an established 
DRV for trans fatty acids, particularly 
since DRVs also have not been 
established for poly- or 
monounsaturated fatty acids. The 
agency also points out that the current 
DRV for total fat includes all fatty acids, 
so does not need to be increased to 
accommodate trans fatty acids.
Further, placing an asterisk after 
‘‘Total Fat’’ on the label with a footnote 
stating the grams of trans fat, or a 
statement of the grams of trans fat 
beside the total fat on the label likely 
would lead to the same types of 
objections that were raised when that 
approach was considered for saturated 
fat. Moreover, previous comments in 
comment 13 raised concerns about 
consumers overlooking quantitative 
information in a footnote. Further, 
comments raised concern about not 
maintaining the chemical distinction for 
individual fatty acids, as has been the 
past agency practice. Placing trans fat 
on the same line of total fat may raise 
questions about how trans fat is to fit 
within the % DV for total fat. The 
agency is not persuaded by any the 
comments that the problems with this 
option would be any different than 
those with the option to label trans fat 
on the same line as saturated fat. Thus, 
the agency is not persuaded that the 
nutrition label should identify levels of 
trans fat in the total fat declaration 
through the addition of a footnote or 
parenthetical listing.
Moreover, while total fat in the diet is 
important, the composition of that total 
fat intake is at least equally, if not more, 
important. Recent recommendations 
from the Dietary Guidelines 2000 (Ref. 
87) and the Dietary Guidelines Advisory 
Committee (Ref. 88) have emphasized 
reducing intake of both saturated and 
trans fats while placing less emphasis 
on reducing total fat intake. For 
example, while the 1995 edition of the 
Dietary Guidelines recommended that 
Americans choose a diet ‘‘low’’ in fat 
and saturated fat (Ref. 6), the 2000 
edition now recommends ‘‘moderate’’ 
total fat (Ref. 87) with guidance that 
consumers needing to reduce their total 
fat intake do so by cutting back on 
saturated and trans fats. Similarly, the 
2000 AHA Guidelines specifically 
recommend limiting ‘‘intake of foods 
with high content of cholesterol-raising 
fatty acids’’ (i.e., saturated and trans 
fatty acids) rather than total fat (Ref. 91). 
The 2001 NCEP report increased the 
recommendation for individuals with 
elevated LDL–C for total fat intake from 
30 to 35 percent of calories provided 
that saturated and trans fats be kept low 
(Ref. 89).
The comments suggesting that trans 
fat information would have greater 
prominence and be more readily seen 
when related to total fat rather than 
saturated fat did not provide any data to 
support this position. While doing so 
would move trans fat up one line in the 
Nutrition Facts label, FDA has no basis 
to conclude that this would make it 
more prominent to consumers.
The agency acknowledges that the 
options of using an asterisk next to total 
fat with a footnote listing trans fat or 
listing trans fat parenthetically next to 
total fat would avoid any possible 
confusion experienced by consumers as 
a result of the proposed option if levels 
of saturated fat appeared to have 
increased when, instead, amounts of 
trans fat were added to the amount of 
saturated fat. However, other options, 
such as the option of declaring trans fat 
on a separate line would also avoid the 
possibility of such confusion and, at the 
same time, would more clearly identify 
trans fat as a separate subcomponent of 
total fat, in a manner similar to the other 
subcomponents, i.e., saturated, poly- 
and monounsaturated fats.
For the reasons noted previously, the 
agency is not persuaded that the 
nutrition label should identify levels of 
trans fat in the total fat declaration 
through the addition of a footnote or 
parenthetical listing.
4. Option to Include a Separate Line for 
Trans Fats
(Comment 16) Many comments 
recommended that trans fat content be 
declared on a separate line on the 
Nutrition Facts panel because of the 
problems ascribed to the proposed 
option. In general, these comments 
stated that there is no scientific 
evidence to support FDA’s proposal to 
combine saturated and trans fatty acids 
because both of these fatty acids have 
different chemical structures and 
physiological effects. They asserted that 
a separate line on the nutrition label for 
trans fats would fully inform consumers 
about the kind of fats that are in the 
foods they select and consume. These 
comments urged the agency to list trans 
fat in the same way as other 
subcomponents of total fat, i.e., 
saturated and poly- and 
monounsaturated fats. They stated that 
doing so would clarify the chemical 
differences between the fatty acids, 
including saturated fatty acids, and 
would be easier for consumers to 
understand since it eliminates the need 
for a footnote. Comments also noted that 
adding a separate line for trans fat 
would be consistent with FDA’s 
regulatory precedent, which was 
established with the 1993 mandatory 
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nutrition labeling regulations, of 
classifying nutrients based on their 
chemical definition or structure, rather 
than their physiological effect (58 FR 
2079 at 2089). Moreover, the comments 
argued that listing trans fat on a separate 
line now would avoid having to do it 
later if future scientific research shows 
that the effects of trans fat consumption 
are significantly different from the 
effects of saturated fat consumption.
Several comments argued that by 
providing a separate line for trans fat, 
consumers can be educated more easily 
about the health effects of trans fatty 
acids. These comments disagreed with 
FDA’s position in its November 1999 
proposal that trans fat should be 
combined with saturated fat because 
consumers lack knowledge about trans 
fat information and do not understand 
the term trans fat. Also, some comments 
stated that FDA’s rationale for not 
listing trans fat more prominently (i.e., 
that consumers are not familiar with the 
term ‘‘trans fat’’) is not justified since 
consumers do not generally know much 
about mono- or polyunsaturated fats yet 
quantitative information may be 
provided for them in nutrition labeling 
and must be provided when claims are 
made about fatty acids or cholesterol. A 
few comments also stated that creating 
a separate line for trans fat establishes 
a basis for current and future consumer 
education about the health risks and 
benefits of a variety of fatty acids that 
affect LDL–C and HDL–C levels.
A few comments in favor of a separate 
line for trans fat in nutrition labeling 
specifically addressed the need to 
establish a DRV for trans fat. One 
comment stated that FDA could 
establish a DRV for trans fat based on 
international recommendations for trans 
fat consumption. Another comment 
indicated that a DRV for trans fat could 
be established at a level equal to or 
below the average daily intake of trans 
fat. One other comment stated that the 
only basis for establishing a daily value 
would be the amount of naturally-
occurring trans fat in ruminant (dairy) 
products since they have not been 
shown to be associated with increased 
risk of CHD; otherwise, the DRV for 
trans fats formed through partial 
hydrogenation should be zero. However, 
the majority of those commenting stated 
that scientific evidence is not sufficient 
to support the establishment of a DRV 
for trans fat because no public health or 
scientific organization has proposed 
guidelines for dietary intake levels of 
trans fat at this time. Some of these 
comments said that trans fat should be 
treated in a manner consistent with 
poly- and monounsaturated fats, i.e., 
without a % DV, until such time as 
there is a basis for establishing a DRV 
for trans fat. A few comments suggested 
waiting until the IOM/NAS completes 
its report on DRIs for macronutrients. A 
few comments noted that listing trans 
fat on a separate line with no % DV 
would be less useful to consumers 
because they would not be able to 
determine if the amount were high or 
low in the context of the daily diet. One 
comment stated that if there is enough 
scientific evidence to require the 
mandatory labeling of trans fat, the 
agency should provide the information 
that will help consumers to interpret the 
magnitude of the amount in the food. 
Additionally, other comments stressed 
the importance in helping consumers 
understand the relevance of the nutrient 
amount in the context of the total diet.
One comment objected to the option 
of having a separate line for trans fat on 
the basis of consumer confusion. It said 
that adding a fourth line of fatty acid 
information would confuse consumers 
because they would have to look at 
several separate values when comparing 
food products. This comment also was 
concerned that the use of a separate line 
would not encourage the food industry 
to reduce ‘‘heart-unhealthy’’ fat in the 
food product.
FDA agrees with comments that point 
out that there are chemical differences 
between saturated and trans fatty acids. 
The agency noted these differences in 
its November 1999 proposal when it 
proposed to include the amount of trans 
fat in the declaration of saturated fat. 
The intent was to assist consumers in 
understanding the cholesterol-raising 
properties of the food by declaring the 
two fatty acids under the name 
‘‘saturated fat’’ without changing the 
definition of saturated fat, but FDA 
acknowledged that this action ‘‘may 
confuse consumers and lead some to 
misclassify trans fatty acids as saturated 
fats’’ (64 FR at 62746 62755). The 
agency is persuaded by the large 
number of comments on this issue that 
the proposed action was, in fact, 
interpreted by many as incorrectly 
classifying the two different fatty acids 
as ‘‘saturated fat’’ and that it is 
necessary to disassociate trans fat from 
saturated fat to prevent misleading 
consumers in this way.
FDA also acknowledges that while the 
two types of fatty acids have similar 
effects on LDL–C, there are other 
physiological distinctions between 
them. Because the overall weight of 
scientific evidence in support of the 
finding that consumption of trans fat, 
like saturated fat, contributes to 
increased LDL–C levels increasing the 
risk of CHD, was sufficiently compelling 
to warrant trans fat labeling, the agency 
did not focus on other physiological 
effects of trans fat. While studies on a 
variety of physiological effects of trans 
fat are ongoing and results preliminary, 
the agency is persuaded by comments 
that the declaration of trans fat on a 
separate line will best accommodate 
future scientific development. This will 
be helpful if future research more 
clearly elucidates the physiological 
mechanisms of each and confirms that 
trans fat does have adverse effects on 
other CHD risk factors or health 
conditions that differ significantly from 
saturated fat.
As pointed out by comments, doing so 
has the advantage of being consistent 
with: (1) The format used to list the 
other subcomponents of total fat, 
namely saturated, polyunsaturated and 
monounsaturated fats; (2) the 
declaration of quantitative amounts 
contiguous to the listing of the nutrient 
rather than in a footnote; and (3) the 
agency’s regulatory precedent of 
classifying nutrients based on their 
chemical definition or structure. 
Consistency with the existing format 
can be expected to assist consumers in 
recognizing trans fat as a subcomponent 
of total fat. It will also be responsive to 
consumer interest in knowing the full 
breakout of fatty acids since, when poly- 
and monounsaturated fats are declared, 
the amounts for saturated, trans, 
polyunsaturated, and monounsaturated 
fats will add up to the amount of total 
fat except for minor deviations that may 
result from application of rounding 
rules in § 101.9(c)(2).
The agency agrees with the majority 
of the comments that the scientific 
evidence is not sufficient to support the 
establishment of a DRV for trans fat at 
this time. The comments that attempted 
to suggest a basis for doing so did not 
suggest particular values or submit 
scientific evidence to justify the 
establishment of such values. FDA 
emphasizes that existing DRVs are based 
on quantitative dietary intake 
recommendations developed from 
extensive scientific evidence that 
establishes values that will promote 
public health (58 FR 2206 at 2217). 
DRVs have not been based on 
international recommendations, which 
may not be germane in the United 
States, or on average dietary intake 
levels, which may not represent healthy 
dietary consumption patterns. The FDA 
is not aware of any international 
recommendations that it could rely on, 
nor did the comment provide any such 
specific recommendations. The agency 
has relied extensively on reports from 
the IOM/NAS in developing the current 
Reference Dietary Intake (RDIs) and 
DRVs. However, the recent IOM/NAS 
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report on DRIs for macronutrients (Ref. 
140) did not make quantitative 
recommendations for trans fat for 
establishing a DRV. Accordingly, in the 
absence of a scientific basis or 
recommendation by an authoritative 
body, FDA is not establishing a DRV for 
trans fat. FDA intends to revisit this 
issue when there is more scientific 
information that the agency can use to 
establish an appropriate reference level 
for trans fat intake.
The agency recognizes that the 
absence of a DRV, and thus, the absence 
of a % DV for trans fat on food labels, 
nutrition educators will need to direct 
efforts at educating consumers further 
about the effects of trans fat on LDL–C 
levels and CHD risk. However, because 
of the public health impact of CHD in 
the United States, the agency believes it 
is necessary to proceed at this time with 
this final rule to list trans fat in 
nutrition labeling so that consumers 
will have quantitative information to 
use in implementing dietary guidelines 
to cut back on trans fat. By adding 
quantitative information on trans fat 
content, consumers will have 
information to use in comparing 
products and making diet selections that 
will reduce their intake of trans fat in 
the context of their daily diet by 
substituting lower trans fat products for 
those previously consumed that were 
higher in trans fat.
The agency does not believe it would 
be any more difficult for consumers to 
look at a separate line for information 
on trans fats than it has been for any 
other separate fat listing. Listing them 
separately will allow consumers to 
readily see levels of each in food 
products and make decisions 
accordingly. In addition, the agency 
stated earlier that it believes public 
awareness about trans fat has increased 
since publication of the November 1999 
proposal as a result of media attention, 
press releases, label statements, and 
industry announcements. FDA 
concludes that this increased awareness, 
in conjunction with an education 
program about the change, will allow 
consumers to use this new information 
to help maintain healthy dietary 
practices and will minimize any 
confusion caused by the change. To 
maximize the impact of declaring trans 
fat in the Nutrition Facts panel, a 
coordinated educational effort among 
public health professionals and 
organizations focusing on all three 
cholesterol-raising dietary components, 
i.e., saturated fat, trans fat, and 
cholesterol, will be required. Such a 
program is discussed in Comment 28 
below.
The comment that was concerned that 
use of a separate line for trans fat would 
not encourage industry to reduce ‘‘heart-
unhealthy’’ fats did not present any data 
to show the effectiveness of the various 
options in achieving this goal. 
Following implementation of mandatory 
nutrition labeling rules in 1993, the 
industry reformulated many foods 
products to reduce levels of nutrients 
about which consumers were concerned 
(Ref. 96). Accordingly, FDA believes 
that the required addition of 
information on trans fat content to 
nutrition labels, coupled with a 
consumer education program on the 
health effects of dietary trans fat, will 
provide incentive to the food industry to 
minimize the level of trans fat present 
in individual food products. Some parts 
of the food industry have responded to 
consumer concerns, e.g., levels of trans 
fat in margarine products have been 
lowered (Ref. 104), and companies have 
announced plans to use reformulated 
fats that are lower in trans fat (Refs. 149 
and 150). The agency believes that 
requiring trans fat labeling will prompt 
others in the food industry to 
reformulate some of their products to 
offer lower trans fat alternatives.
Accordingly, FDA is revising 
§ 101.9(c) by adding paragraph 
§ 101.9(c)(2)(ii) to require the 
quantitative declaration of trans fat in 
the Nutrition Facts panel. This new 
paragraph requires the listing of trans 
fat on a separate line under the 
statement for saturated fat. As is the 
case for all subcomponents of total fat, 
it is to be indented and separated by a 
hairline, with the amount expressed as 
grams per serving to the nearest 0.5 g 
increment below 5 g and to the nearest 
gram increment above 5 g. If the serving 
contains less than 0.5 g, the content 
must be expressed as 0, except when the 
statement ‘‘Not a significant source of 
trans fat’’ is used. In addition, the 
agency is clarifying that the word 
‘‘trans’’ may be italicized to indicate its 
Latin origin. This provision to allow for 
italics provides an exception to 
§ 101.9(d)(1)(ii)(A) that requires that a 
single easy-to-read type style be used 
throughout the nutrition label. 
Therefore, paragraph (d)(1)(ii)(A) is 
being revised to state that ‘‘except as 
provided for in paragraph (c)(2)(ii) of 
this section,’’ a single easy-to-read type 
style is to be used throughout the 
nutrition label.
As a result of adding paragraph 
(c)(2)(ii) for trans fat, the agency is 
redesignating current paragraph (c)(2)(ii) 
(polyunsaturated fat) as paragraph 
(c)(2)(iii) and current paragraph 
(c)(2)(iii) (monounsaturated fat) as 
(c)(2)(iv).
(Comment 17) In response to the 
November 2002 reopening of the 
comment period on the November 1999 
proposal to require a footnote stating 
‘‘Intake of trans fat should be as low as 
possible’’ when trans fat is listed, FDA 
received some comments that supported 
the proposed footnote statement. A few 
comments noted that the proposed 
footnote was needed to raise consumer 
awareness and understanding about the 
relevance of trans fat in the diet and to 
assist them in making healthy food 
choices. Another comment stated that 
the footnote is consistent with the IOM/
NAS report on macronutrients. Two of 
the comments strongly recommended 
that the footnote be modified to state 
that ‘‘Combined total intake of saturated 
and trans fats should be as low as 
possible.’’ The comments argued that 
the footnote proposed by FDA gives 
undue emphasis to trans fat and will 
cause some consumers to evaluate 
products based on the content of trans 
fat instead of on the content of both 
trans and saturated fats, as is 
recommended in dietary guidance. One 
of the comments included the results of 
a national online survey that tested the 
communication effectiveness of the 
proposed footnote relative to no 
footnote and to the alternative footnote 
‘‘Combined total intake of saturated and 
trans fats should be as low as possible.’’ 
Respondents were faced with a food 
comparison that required them to take 
both saturated fat and trans fat into 
account to correctly identify the ‘‘more 
healthful’’ of two food products, 
described by the comment as the 
product with the lowest total amount of 
saturated and trans fats combined. The 
two foods being compared were both 
high in saturated fat (70% DV (14 g) and 
35% DV (7 g) saturated fat) but the food 
highest in saturated fat (14 g) had no 
trans fat (food 1) while the one with half 
as much saturated fat (7 g) had 2g of 
trans fat (food 2). With no footnote, over 
half of the respondents who identified 
a product as more healthful (57 percent) 
correctly identified the more healthful 
food (food 2) and 12 percent chose food 
1. In the presence of the FDA proposed 
footnote, 39 percent of the respondents 
who identified a product as more 
healthful incorrectly chose food 1 as 
more healthful, presumably focusing on 
the zero trans fat content in the higher 
fat food, with only 45 percent choosing 
the food with the lowest total amount of 
saturated and trans fats combined. In 
the presence of the alternative footnote, 
which mentioned the need to keep the 
intake of both saturated and trans fats 
low a majority of respondents again 
correctly chose food 2 (69 percent) as 
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more healthful, with 17 percent 
choosing food 1.
The majority of the comments 
strongly opposed the proposed footnote 
statement and recommended that FDA 
drop the footnote and finalize the 
quantitative (grams per serving) label 
declaration of trans fat on a separate 
line below saturated fat with no % DV. 
Several comments stated that the 
proposed footnote statement is 
inconsistent with the IOM/NAS 
macronutrient report and incorrectly 
establishes a de facto DV or UL of zero 
for trans fat intake that the IOM/NAS 
never intended to establish. Some of 
these comments explained that the 
proposed footnote statement takes into 
consideration part of the 
recommendation from the IOM/NAS 
report that recommends the intake of 
trans fat be as low as possible, while 
ignoring the part that states ‘‘* * * 
while consuming a nutritionally 
adequate diet.’’ The comments claimed 
that the omission of the latter part of the 
recommendation significantly changes 
the meaning of the statement and the 
recommendation of the IOM/NAS, 
namely that the IOM did not intend to 
recommend that trans fat be totally 
eliminated from the daily diet. These 
comments noted that the IOM/NAS 
report did not establish an UL for trans 
fat despite the relationship between 
intake of trans fat and CHD stating that 
trans fatty acids are unavoidable in 
ordinary, nonvegan diets, and to attempt 
to eliminate them would require 
significant changes in dietary intake 
patterns which may result in unknown 
and unquantifiable health risks. The 
comments went on to say that the IOM 
committee indicated that ‘‘[I]t is 
possible to consume a diet low in trans 
fatty acids by following the dietary 
guidance provided in Chapter 11’’ of 
their report. The comments concluded 
that the proposed footnote statement is 
inconsistent with the IOM/NAS report 
and could mislead consumers into 
substituting more foods with saturated 
fat in an effort to avoid foods containing 
trans fat.
Similarly, several comments 
described the proposed footnote 
statement as an unjustified warning 
statement on the label of foods that 
contain trans fat. Some of these 
comments stated that consumers will 
perceive the footnote as a de facto % DV 
of zero and will not understand the 
meaning of the portion of the proposed 
footnote statement ‘‘as low as possible;’’ 
consumers will perceive it as a warning 
to avoid trans fat-containing foods at all 
costs. Several comments stated that the 
footnote would be misleading because 
consumers would be confused about the 
relative impact of saturated fat (by 
thinking up to 20 g, i.e., the DV for 
saturated fat, is heart healthy) compared 
to trans fat (thinking trans fat intake 
must be kept to zero to be heart 
healthy). Some of these comments 
mentioned that the dietary 
recommendation to reduce saturated fat 
is a well established goal of federal 
agencies and other health organizations 
and that Americans consume much 
more saturated fat than trans fat. The 
comments stressed, therefore, that any 
footnote statement on the nutrition label 
about trans fat should not undermine 
the important health message 
consumers have learned over the years 
about limiting saturated fat intake.
Comments also criticized the 
proposed footnote for being more 
prescriptive than, and inconsistent with, 
other Federal Government dietary 
recommendations, such as the Dietary 
Guidelines for Americans 2000 and the 
NCEP Adult Treatment Panel III Report, 
2001. According to the comments, the 
recommendations of these reports 
support the need for Americans to 
choose diets that are low in saturated fat 
and cholesterol and moderate in fat 
while reducing, not eliminating, dietary 
consumption of trans fat.
Comments also pointed out that the 
IOM/NAS report gives essentially 
identical advice for saturated fat and 
cholesterol as it gives for trans fat, yet 
FDA’s proposed footnote singled out 
only their recommendation for trans fat. 
The comments argued that this placed 
undue emphasis on the role of trans fat 
in heart health.
Many of the comments expressed 
concern that the proposed footnote 
statement is potentially misleading to 
consumers and will undermine the key 
goals of this rulemaking. To that end, 
the comments strongly recommended 
that FDA drop the proposed footnote 
statement from the final rule and take 
time to conduct consumer research to 
determine the impact of the proposed 
footnote statement on consumers’ 
understanding and comprehension. A 
few comments cited FDA’s obligation 
under the 1990 amendments (paragraph 
2(b)(1)(A)) to ensure that nutrition 
labeling is ‘‘conveyed to the public in a 
manner which enables the public to 
readily observe and comprehend such 
information and to understand its 
relative significance in the context of a 
total daily diet.’’ The comments argued 
that the proposed footnote statement 
should be consumer tested to ensure 
that the nutrition information provides 
meaningful guidance to consumers and 
drives the market in a nutritionally 
beneficial direction. The majority of 
comments that opposed the proposed 
footnote statement commented that even 
in the absence of a DV, consumers can 
still find quantitative information useful 
(similar to the listing of 
monounsaturated and polyunsaturated 
fats on the nutrition label).
Many of the comments recommended 
that FDA not move forward with the 
proposed footnote until the IOM/NAS 
completes a study, which is underway, 
of the uses of DRIs in nutrition labeling. 
The comments noted that the IOM is 
under contract with FDA, USDA and 
Health Canada to assess the objectives, 
rationale, and recommendations for the 
methodology for selecting reference 
values for nutrition labeling of foods 
based on DRIs and will identify guiding 
principles for use in setting reference 
values for nutrients on the food label. 
The comments also noted that the IOM 
committee is expected to complete its 
work on this project in mid–2003 and to 
issue a report in September 2003.
One comment stated that the 
prescriptive nature of the proposed 
footnote may also violate international 
obligations of the United States under 
the World Trade Organization (WTO). 
The comment stated that WTO’s 
Agreement on the Sanitary and 
Phytosanitary (SPS) Measures requires 
that SPS measures intended to protect 
human health be based upon sound 
science. The comment questions this 
regarding the proposed footnote 
statement because it implies a benefit to 
consumers who avoid consuming trans 
fat foods when the IOM/NAS suggests 
that eliminating trans fats entirely in the 
diet would lead to greater harm by 
impeding dietary intake of essential 
nutrients. The comment also stated that 
if the proposed footnote statement was 
not a SPS measure, it would violate 
WTO’s Agreement on Technical Barriers 
to Trade, which requires that 
‘‘technical’’ regulations fulfill a 
legitimate purpose and be no more trade 
restrictive than necessary. The comment 
expressed the opinion that the proposed 
footnote statement oversimplifies and 
misrepresents the IOM/NAS report on 
which it is based and that the statement 
is more trade restrictive than necessary 
because alternatives to such a footnote 
statement, such as a consumer 
education program, are available to 
assist consumers in understanding the 
quantitative trans fat labeling in the 
absence of a DV.
Some comments expressed concern 
that the proposed footnote statement 
would provide a disincentive to the 
industry such that many foods would be 
reformulated to reduce or remove trans 
fat but, as a result, saturated fat content 
would be increased. Other comments 
expressed concern about the lack of 
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label space for the proposed footnote 
statement. One comment stated that the 
Nutrition Facts panel would no longer 
be simple and uncluttered and, as a 
result, consumers would be discouraged 
from reading the label. Other comments 
complained that the 30-day comment 
period for the November 2002 proposal 
was inadequate to address footnote 
issues and to conduct needed consumer 
research.
Many of the comments stated that 
FDA did not carry its burden under the 
first amendment. The comments argued 
that the proposed footnote statement 
fails to serve a substantial government 
interest in alleviating a genuine public 
harm, does not directly advance that 
interest and is not narrowly tailored. 
Several comments stated that the 
footnote statement is tantamount to a 
warning statement and is misleading.
Some comments stated that the use of 
the footnote statement would be 
establishing a new precedent by 
providing guidance, not just 
quantitative information on the 
Nutrition Facts panel. They argued that 
there were no consumer data to show 
that the footnote will help consumers 
understand the information. Comments 
stated that the agency had such data 
when it decided on the Nutrition Facts 
panel labeling format that only included 
quantitative information and should 
have consumer data here, where a new 
precedent is being considered.
Lastly, a few comments opposed 
FDA’s offer to consider exercising our 
enforcement discretion to allow 
products to begin declaring trans fat and 
include the proposed footnote statement 
prior to publication of the final rule. 
One comment stated that the agency 
should publish a ‘‘clarification notice’’ 
to stop companies that are changing 
their labels now.
The agency is persuaded by 
comments that the statement it 
proposed may have unintended 
consequences. It was not FDA’s intent to 
distract consumers from dietary 
guidance to minimize intake of 
saturated fat, but rather, in the absence 
of a DV for trans fat, to inform 
consumers of recommendations 
concerning its consumption.
While the online survey was small, its 
results support concerns expressed by 
the food industry that some consumers 
would interpret the footnote as a de 
facto DV of zero or as a warning 
statement that they should avoid all 
trans fat. The agency agrees with 
comments that this interpretation is 
inconsistent with dietary guidance 
given in the IOM/NAS report to keep 
intake of trans fat ‘‘as low as possible 
while consuming a nutritionally 
adequate diet’’ (Ref. 140), as well as 
guidance in the Dietary Guidelines 2000 
to cut back on saturated and trans fats 
when reducing total fat intake (Ref. 87) 
or in the 2001 NCEP report to keep the 
intake of trans fatty acids low (Ref. 89). 
FDA also agrees that these scientific 
reviews have similar dietary 
recommendations for the intake of 
saturated fat and cholesterol that are 
important for consumers to take into 
consideration when making decisions 
about heart-healthy dietary choices. The 
agency addressed only trans fat in the 
footnote statement, not because 
saturated fat or cholesterol had different 
recommendations or were less 
important, but because they have 
established DVs from which to 
determine the % DV for nutrition 
labeling purposes.
The agency agrees with comments 
that support consumer testing to ensure 
that information on the food label 
provides meaningful guidance to 
consumers and drives the market in a 
nutritionally beneficial direction. FDA 
concludes, therefore, that based on 
arguments presented in the comments, 
that while the footnote would provide 
guidance on dietary recommendations 
for trans fat, it is premature to require 
the use of the proposed footnote 
statement in the nutrition label without 
further research. Consumer research 
would likely need to provide 
information on the impact of the 
statement in a footnote on consumers’ 
food selections.
Accordingly, as a result of concerns 
expressed in the comments, asserting 
that consumers may place undue 
emphasis on trans fat information 
relative to other heart-unhealthy fats 
from the presence of the trans fat 
proposed footnote, the agency is not 
proceeding at this time to incorporate a 
requirement for a footnote statement in 
this final rule. Instead, FDA is issuing 
an ANPRM elsewhere in this issue of 
the Federal Register that will solicit 
comment and additional consumer 
research on the use of a footnote and the 
language that may be used in a footnote 
to better reflect the dietary 
recommendations given in the 
previously-mentioned scientific 
reviews. The ANPRM will also solicit 
information and data that potentially 
could be used to establish new nutrient 
content claims about trans fat, to 
establish qualifying criteria for trans fat 
in current nutrient content claims for 
saturated fat and cholesterol, lean and 
extra lean claims, and health claims that 
contain a message about cholesterol 
raising fats, and to establish disclosure 
and disqualifying criteria for trans fat.
The agency is also requesting 
comments on whether it should 
consider statements about trans fat, 
either alone or in combination with 
saturated fat and cholesterol, as a 
footnote in the Nutrition Facts panel or 
as a disclosure statement in conjunction 
with claims to enhance consumer’s 
understanding about cholesterol-raising 
lipids. In light of the need for consumer 
research to evaluate consumers’ 
understanding of the totality of dietary 
recommendations that address the 
selection of foods for a heart-healthy 
diet, the agency notes in the ANPRM 
that it intends to conduct such research 
and looks forward to receiving 
additional research from other 
interested parties.
In the meantime, as noted in the 
preceding comment, FDA is issuing this 
final rule to require the quantitative 
declaration of trans fat in the Nutrition 
Facts panel. To help consumers 
understand more about this heart-
unhealthy fat, the agency plans to 
initiate consumer education programs 
about this final rule following 
publication (see Comment 28). As noted 
earlier, most comments that opposed the 
proposed footnote stated a belief that 
even in the absence of a DV, consumers 
can still find quantitative information 
useful, and pointed to current labeling 
of mono- and polyunsaturated fats. In 
light of previous research that shows 
that consumers often use information on 
the Nutrition Facts panel to compare 
levels of nutrients in two or more foods, 
FDA concludes that it is important to 
proceed to list the quantitative 
information on trans fat at this time so 
that consumers will have information to 
use in comparing products and making 
dietary selections to reduce their intake 
of trans fat. The agency believes a 
footnote or other labeling approach 
about saturated fat, cholesterol, and 
trans fat may provide additional 
assistance to convey the relative 
importance of each of these fats to 
consumers in a manner which enables 
them to understand their relative 
significance, to each other and in the 
context of a total daily diet. However, 
because of the public health impact of 
CHD in the United States and the 
additional time it will take to conduct 
the necessary consumer research, the 
agency concludes that it is essential to 
proceed at this time to mandate the 
listing of the quantitative information 
on trans fat so that consumers will be 
able to use that information to help 
maintain healthy dietary practices and 
to address an added footnote statement 
at a later time.
FDA acknowledges concerns, 
expressed in response to the November 
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2002 notice (67 FR 69171) to reopen the 
comment period, about the shortness of 
the comment period and requests to 
extend the comment period. However 
due to the high level of interest in the 
public health and economic aspects of 
this rule, the agency did not believe it 
was in the public interest to provide for 
additional time for comment. A longer 
comment period, however, will be 
provided for the ANPRM being 
published elsewhere in this issue of the 
Federal Register.
(Comment 18) A few comments 
requested that the term ‘‘trans fatty 
acids’’ not be used interchangeably with 
‘‘trans fat’’ as proposed in 
§ 101.9(c)(2)(i)(B) in the November 1999 
proposal. These comments stated that 
the term ‘‘fatty acid’’ would be 
confusing to consumers and is 
inconsistent with the terminology used 
in nutrition labeling and claims for 
other fatty acids, i.e., ‘‘saturated fat,’’ 
‘‘polyunsaturated fat,’’ and 
‘‘monounsaturated fat.’’ The comments 
stated that while ‘‘fatty acid’’ is 
technically correct, labels should use 
the easier term to understand, i.e., 
‘‘trans fat.’’
The agency agrees that there should 
be consistent terminology used on the 
food label and notes that proposed 
§ 101.9(c)(2)(i)(B), which dealt primarily 
with the proposed footnote about trans 
fat content, is deleted from this final 
rule. The agency did not move the 
sentence providing for the use of the 
term ‘‘trans fatty acids’’ to new 
§ 101.9(c)(2)(ii). Therefore, the term 
‘‘fatty acids’’ is not to be used on the 
Nutrition Facts panel.
Conforming Amendments
Because this final rule is making trans 
fat a mandatory nutrient to be placed on 
a separate line in nutrition labeling, 
there are a number of conforming 
amendments throughout § 101.9 that 
must be made. Section 101.9(c) requires 
that information on mandatory 
nutrients, such as saturated fat and trans 
fat, be included in all nutrition labeling 
unless otherwise excepted from such 
labeling as provided for in specified 
paragraphs.
Special provisions within § 101.9(c) 
allow for shortened formats that provide 
manufacturers flexibility to omit 
noncore nutrients (i.e., mandatory 
nutrients other than calories, total fat, 
sodium, total carbohydrate, and protein) 
that are present in insignificant amounts 
from the list of nutrients and group 
them in a summary statement at the 
bottom of the label that states ‘‘Not a 
significant source of ______’’ (see 58 FR 
2079 at 2083, Comment 8, January 6, 
1993). These special provisions are 
found in § 101.9(c)(1)(ii) for calories 
from fat, § 101.9(c)(2)(i) for saturated fat, 
§ 101.9(c)(3) for cholesterol, 
§ 101.9(c)(6)(i) for dietary fiber, 
§ 101.9(c)(6)(ii) for sugars, and 
§ 101.9(c)(8)(iii) for vitamin A, vitamin 
C, calcium, or iron. For consistency 
with the labeling scheme for these other 
noncore mandatory nutrients, new 
§ 101.9(c)(2)(ii) provides that if the trans 
fat content is not required and, as a 
result, not declared, the statement ‘‘Not 
a significant source of trans fat’’ must be 
placed at the bottom of the table of 
nutrient values. Also, for added 
consistency, new § 101.9(c)(2)(ii) will 
point to an exception to this 
requirement under § 101.9(f). Section 
101.9(f) provides for a simplified format 
to be used on labels of products 
containing insignificant amounts of 
more than half the nutrients required to 
be in the Nutrition Facts label. Except 
as specified in § 101.9(f)(4), products 
that qualify for the simplified format do 
not have to use the statement ‘‘Not a 
significant source of ______’’ for noncore 
nutrients that are omitted from the label 
under § 101.9(c). An example of such an 
exception would include when 
nutrition claims are made for the 
product.
Current § 101.9(c)(2)(i) requires label 
declaration of saturated fat content 
information on a separate line (the ‘‘Not 
a significant source of ____’’ statement 
would not be an option), if claims are 
made about fat or cholesterol and if 
‘‘calories from saturated fat’’ is declared. 
In the November 1999 proposal, 
§ 101.9(c)(2)(i) was amended to also 
require label declaration of saturated fat 
content information when claims are 
made about fatty acids. Current 
§ 101.9(c)(2)(i) did not include claims 
about fatty acids because at the time that 
regulation was proposed (56 FR 60478, 
November 27, 1991), it was thought 
unnecessary since no claims were 
proposed for fatty acids that were 
present at less than 0.5 g per reference 
amount. However, when the ‘‘saturated 
fat free’’ claim was established in the 
final rules (58 FR 2302 at 2331), FDA 
inadvertently did not amend 
§ 101.9(c)(2)(i) to require the declaration 
of saturated fat content on a separate 
line when fatty acid claims were made. 
As a result, the declaration of saturated 
fat content was not required when 
‘‘saturated fat free’’ claims were made. 
This is inconsistent with regulations 
governing claims for all other nutrients 
that require the listing of the nutrient 
that is the subject of the claim within 
the Nutrition Facts panel so that 
consumers can easily find quantitative 
information supporting claims made for 
a product. Because no comments 
objected to the proposed requirement in 
the November 1999 proposal for a label 
declaration of saturated fat content 
when fatty acid claims are made, which 
would require that saturated fat content 
be listed when a ‘‘saturated fat free’’ 
claim is used, FDA is finalizing this part 
of the regulation as proposed. Similarly, 
new § 101.9(c)(2)(ii) also requires label 
declaration of trans fat content 
information if claims are made about fat, 
fatty acids, or cholesterol.
In reference to the statement ‘‘Not a 
significant source of ______’’ that is to 
be placed at the bottom of the list of 
nutrient values, the agency proposed in 
the November 1999 proposal (64 FR 
62746 at 62757) to remove the phrase 
‘‘in the same type size’’ in 
§ 101.9(c)(2)(i) where it refers to the size 
of the statement. This action was 
intended to correct a technical error in 
the regulations caused by the fact that 
current § 101.9(d)(1)(iii) allows the 
statement, along with all footnotes, to be 
in type size no smaller than 6 point type 
while it requires the listing of nutrient 
values to be in type size no smaller than 
8 point type. Accordingly, the phrase 
‘‘in the same type size’’ in 
§ 101.9(c)(2)(i) would require the ‘‘Not a 
significant source of ____’’ statement to 
be in 8 point type, conflicting with 
§ 101.9(d)(1)(iii). This technical error 
was addressed in amendments 
published on August 18, 1993 (58 FR 
44063 at 44065–66). To correct the 
problem, FDA stated at that time (58 FR 
44063 at 44065–66) that it was removing 
the sentence from § 101.9(c)(8)(iii) that 
required the ‘‘Not a significant source of 
___’’ statement to be in the same type 
size as nutrients listed in the Nutrition 
Facts panel. However, the agency failed 
to notice the same error in 
§ 101.9(c)(2)(i), (c)(3), (c)(6)(i), and 
(c)(6)(ii). Inadvertently, the conflicting 
sentence was never removed from 
§ 101.9(c)(8)(iii), nor were the 
statements requiring ‘‘in the same type 
size’’ removed from any of the other 
paragraphs. In this final rule, FDA is 
making the correction in § 101.9(c)(2)(i) 
and in new § 101.9(c)(2)(ii). The agency 
intends to remove the phrase ‘‘in the 
same type size’’ from the remaining 
sections of § 101.9(c) in the future.
In addition, current nutrition labeling 
rules provide exemptions for select 
nutrients when food products qualify 
for simplified formats (see § 101.9(f)).
FDA is revising § 101.9(f) that pertains 
to the use of a simplified format when 
a food product contains insignificant 
amounts of seven or more of the 
mandatory nutrients. This section 
implements section 403(q)(5)(C) of the 
act, which states that ‘‘If a food contains 
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insignificant amounts ... of more than 
one-half the nutrients required * * * to 
be in the label or labeling of the food, 
the Secretary shall require the amounts 
of such nutrients to be stated in a 
simplified form prescribed by the 
Secretary.’’ Current regulations 
considered 13 required nutrients 
(calories, total fat, saturated fat, 
cholesterol, sodium, total carbohydrate, 
dietary fiber, sugars, protein, vitamin A, 
vitamin C, calcium, and iron) and 
calculated ‘‘more than one-half’’ to 
mean that seven or more nutrients must 
be at insignificant levels for a product 
to use the simplified format (58 FR 2709 
at 2140, comment 173). Accordingly, in 
conformance with the statutory 
requirements, the inclusion of trans fat 
as a mandatory nutrient results in a total 
of 14 required nutrients. This new total 
necessitates changing the number of 
nutrients that must be present in 
insignificant amounts in § 101.9(f) from 
seven to eight to qualify a food for the 
simplified format. Therefore, FDA is 
revising § 101.9(f) to state ‘‘The 
declaration of nutrition information may 
be presented in the simplified format set 
forth herein when a food product 
contains insignificant amounts of eight 
or more of the following: Calories, total 
fat, saturated fat, trans fat, cholesterol, 
sodium, total carbohydrate, dietary 
fiber, sugars, protein, vitamin A, 
vitamin C, calcium, and iron * * *’’
FDA is modifying sample labels 
throughout § 101.9 to be consistent with 
the revisions described previously. The 
citations for the sample labels that have 
been modified are as follows: 
§ 101.9(d)(11)(iii) (the tabular display of 
the nutrition label), paragraph (d)(12) 
(the full nutrition label), paragraph 
(d)(13)(ii) (an example of an aggregate 
nutrition label), and paragraph (e)(5) 
(nutrition information presented for a 
food ‘‘as purchased’’ and ‘‘as 
prepared’’). Likewise, the sample labels 
in § 101.9(j)(13)(ii)(A)(1) and 
(j)(13)(ii)(A)(2) (tabular display and 
linear displays, respectively, of 
nutrition labels for foods in packages 
with a total surface area available to 
bear labeling of 40 or less square inches) 
are also being revised to include trans 
fat.
Other conforming amendments to 
§ 101.9 that are required as a result of 
this rulemaking include revisions to 
paragraphs (g)(5) and (g)(6) that inform 
the industry of how FDA will determine 
compliance with this section. Paragraph 
(g)(5) addresses those nutrients for 
which dietary guidance generally 
recommends limitations on intake. 
Accordingly, FDA will include trans fat 
as one of the nutrients that are deemed 
to be misbranded under section 403(a) 
of the act if the nutrient content of the 
composite sample is greater than 20 
percent in excess of the value for that 
nutrient declared on the label. Likewise, 
§ 101.9(g)(6) is being revised to state that 
reasonable deficiencies in a food of 
calories and specified nutrients, 
including trans fat, under labeled 
amounts are acceptable within current 
good manufacturing practice.
Section 403(q)(5)(F) of the act 
specifies that dietary supplement 
products shall bear nutrition labeling 
‘‘in a manner which is appropriate for 
the product and which is specified in 
regulations... .’’ Accordingly, FDA 
issued regulations in § 101.36 that 
specify the nutrition information that 
must be on the label or labeling of 
dietary supplements (62 FR 49826, 
September 23, 1997). In the November 
1999 proposal, FDA proposed to amend 
§ 101.36 to maintain consistency in the 
nutrition labeling of conventional foods 
and of dietary supplements. Comments 
unanimously supported revising 
§ 101.36 to be consistent with § 101.9 as 
it pertains to the provisions for trans fat. 
Accordingly, FDA is revising paragraph 
§ 101.36(b)(2)(i) to provide for trans fats 
in the nutrition labeling of dietary 
supplements.
This final rule also impacts on the 
voluntary nutrition labeling program of 
raw fruits, vegetables, and fish in that 
§ 101.45(a)(2) requires that nutrients be 
declared in accordance with § 101.9. 
However, because section 403(q)(4)(A) 
of the act requires the Secretary, and by 
delegation FDA, to furnish nutrition 
information for that program and the 
agency has proposed to update those 
values (67 FR 12918, March 20, 2002), 
the agency is deferring action on 
§ 101.45 until a final rule is published 
on that rulemaking.
C. Definition of Trans Fatty Acids
In the November 1999 proposal, FDA 
defined trans fatty acids as ‘‘unsaturated 
fatty acids that contain one or more 
isolated (i.e., nonconjugated) double 
bonds in a trans configuration (64 FR 
62746 at 62757).
(Comment 19) Most of the comments 
on the definition of trans fat supported 
the proposed definition that excludes 
fatty acids with conjugated bonds, 
stating that trans fatty acids with 
conjugated bonds are metabolized 
differently than those with 
nonconjugated bonds and that this 
definition adequately identifies the fatty 
acids intended to be covered by the rule. 
A few comments recommended that 
trans fatty acid precursors of conjugated 
linoleic acid (CLA) should also be 
excluded from the definition. These 
comments noted that trans-vaccenic 
acid (trans–11 18:1), which is the 
dominant trans fatty acid in products of 
ruminant origin (e.g., cows’ milk), can 
be desaturated in the body and 
converted to CLA. For this reason, the 
comments recommended that trans fatty 
acids of ruminant origin not be included 
in the definition of trans fatty acids.
Other comments stated that trans fatty 
acids with conjugated bonds should be 
included in the definition of ‘‘trans fatty 
acids.’’
Another comment requested that FDA 
explicitly state that the rules on the 
labeling and claims for trans fatty acids 
apply equally to naturally occurring 
trans fats.
FDA notes that the comments 
requesting that trans vaccenic acid and 
other trans fatty acids of ruminant 
origin be excluded from the definition 
of trans fatty acids and that fatty acids 
with conjugated bonds be included 
focused on functional or metabolic 
aspects of these compounds (e.g., their 
metabolic transformations to other types 
of fatty acids) rather than on their actual 
chemical structures. Since most of the 
comments agreed with the proposed 
definition, which identifies trans fatty 
acids by their chemical structures, the 
agency is taking no action in response 
to suggestions to define trans fatty acids 
by their functional attributes. Thus for 
the purposes of this rule, the origin of 
the trans fatty acid does not matter. 
Trans vaccenic acid, a trans fatty acid 
with a single double bond, and other 
trans fatty acids of ruminant origin with 
either a single double bond or 
nonconjugated double bonds are 
included in this chemical definition of 
trans fatty acids. Trans fatty acids with 
conjugated bonds will not be included 
because they do not meet the Agency’s 
regulatory chemical definition of trans 
fatty acids which is ‘‘all unsaturated 
fatty acids that contain one or more 
isolated double bonds in a trans 
configuration.’’ FDA notes also that 
while the proposal combined saturated 
fat and trans fatty acids on a single line, 
this final rule provides for a separate 
line for trans fat. The declarations of 
saturated fat and trans fat will now be 
separate and both declarations will be 
based on chemical definitions of these 
components. Again, trans fatty acids, 
regardless of origin, that meet the above 
definition are to be included in the label 
declaration of trans fat.
FDA notes that, in classifying fatty 
acids, the IOM report on macronutrients 
uses a chemical definition of trans fatty 
acids that differs from FDA’s regulatory 
chemical definition. The IOM report 
includes all fatty acids with a double 
bond in the trans configuration in the 
broad category of trans fatty acids (Ref. 
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140). Thus, the IOM definition includes 
both conjugated and non-conjugated 
double bonds in the trans configuration, 
whereas FDA’s definition only includes 
trans fatty acids with nonconjugated 
double bonds. In addition, the IOM 
report considers conjugated linoleic 
acid as a collective term for geometric 
and positional fatty acids in which the 
double bonds (trans and/or cis) are 
conjugated. In the IOM report, the 
categories, trans fatty acids and 
conjugated linoleic acid, overlap. Under 
FDA’s definition, conjugated linoleic 
acid would be excluded from the 
definition of trans fat. Thus, using 
FDA’s regulatory chemical definition, 
the categories ‘‘trans fatty acids’’ and 
‘‘conjugated fatty acids’’ are mutually 
exclusive. The definition of trans fatty 
acids, excluding fatty acids with 
conjugated double bonds, is consistent 
with the way that cis isomers of 
polyunsaturated fatty acids are defined 
in redesignated § 101.9(c)(2)(iii).
D. Methodology
(Comment 20) One comment asked 
whether the Association of Official 
Analytical Chemists (AOAC) Official 
Method 996.01 can be used for 
measuring trans fat in foods. The 
comment noted that, at present, AOAC 
Official Method 996.01 is the ideal 
method for the measurement of total fat, 
saturated fat, and mono- and 
polyunsaturated fat in foods. The 
comment noted further that AOAC 
Official Method 996.01 was originally 
intended for cereal products containing 
0.5–13 percent total fat and that 
recently, a study by Ali et al. (Ref. 30) 
demonstrated its applicability to all 
types of food matrices with fat contents 
ranging from 0.7 to 97.5 g/100 g food. 
The comment noted that the method of 
Ali et al. (Ref. 30) used an SP–2560 
fused silica capillary column (100 
meters (m) x 0.25 millimeter (mm)) and 
can be used for the accurate 
determination of trans fatty acids. The 
comment noted that if appropriate gas 
chromatography (GC) operating 
conditions are selected, the SP–2560 
column as well as columns of similar 
polarity give a very good separation of 
cis and trans isomers.
FDA notes that, as currently written, 
AOAC Official Method 996.01 is not 
suitable for quantifying trans fatty acids 
for food labeling purposes because the 
capillary column specified (i.e., 30 m x 
0.25 mm id., 0.2 µm film, non-bonded 
90 percent cyanopropyl, 10 percent 
phenyl siloxane) is not sufficiently long 
to obtain adequate separation of the cis 
and trans fatty acids. Ali et al., (Ref. 30) 
modified the method and used a 100 m 
flexible fused silica column (SP–2560, 
100 m x 0.25 mm id., 0.20 µm film 
thickness) to obtain better separation of 
isomers in food samples. Specifically, 
better resolution in the complex 18:1 
and 18:2 regions was obtained with the 
longer column. FDA has found that 
when appropriate operating conditions 
are selected, the SP–2560 column and 
other columns of similar polarity give a 
very good separation of cis and trans 
isomers. We point out, however, that the 
modification described by Ali et al., 
(Ref. 30) has not been subjected to a 
collaborative study and is not an official 
method.
It is important to note that FDA 
regulations do not specify the 
methodology that firms are to use in 
obtaining values for nutrition labeling 
purposes. Rather, under § 101.9(g)(2), 
FDA determines compliance with 
nutrition labeling rules by using 
appropriate analytical methods ‘‘as 
given in the ‘Official Methods of 
Analysis of the AOAC International’ 
15th Ed. (1990) or, if no AOAC method 
is available or appropriate, by other 
reliable and appropriate analytical 
procedures.’’ Firms may choose to use a 
method other than that which the 
agency uses to determine compliance, 
but the firm would be subject to, for 
compliance purposes, a method the 
agency considers appropriate under 
§ 101.9(g). With respect to analysis of 
fats (including trans fat), FDA 
laboratories utilize the most recent 
editions (including revisions of methods 
from the Association of Official 
Analytical Chemists International 
(AOACI; Official Methods of Analysis of 
AOAC International, 17th edition, 
Revision 1, 2002; AOAC International, 
Gaithersburg, MD) (Ref. 143) and the 
American Oil Chemists Society (AOCS; 
Official Methods and Recommended 
Practices of the AOCS, 2002–2003 
Methods-Additions and Revisions, 
AOCS Press, Champaign, IL) (Ref. 144)).
(Comment 21) Several comments 
asked that FDA recognize AOAC 
Method 996.06 as modified in the 
Journal of the Association of Official 
Analytical Chemists in January 2000, as 
a suitable method for the analysis of 
trans fatty acids for food labeling 
purposes.
FDA points out that recommendations 
for the modification of AOAC Official 
Method 996.06 (Ref. 105) were 
published in the Journal of the 
Association of Official Analytical 
Chemists (Ref. 106). The 
recommendations are based on the work 
of DeVries et al. 1999 (Ref. 107). DeVries 
and coworkers report that while 
quantitation of fat in foods has been 
performed successfully with AOAC 
Official Method 996.06, a number of 
situations have been encountered that 
render the following method note 
inaccurate: ‘‘For any unknown or 
uncalibrated peaks, use the nearest 
calibrated fatty acid response factors 
and conversion factors’’ (Ref. 107). 
Specifically, the identification of 
extraneous compounds and availability 
of additional standard fatty acid methyl 
esters combined with mass spectral data 
led to the recommendation of 
modifications in AOAC Official Method 
996.06.
Specific recommendations for 
modifications include recommendations 
that the column requirements for the 
method be changed to a performance-
based specification such that a capillary 
column capable of separating adjacent 
peaks of C18:3 and 20:1 and the fatty 
acid methyl ester trio of adjacent peaks 
of C22:1, C20:3 and C20:4 with a 
resolution of 1 or greater be used. 
Column SP–2560, 100 m x 0.25 mm 
with a 0.20 µm film was identified as a 
suitable column.
The recommendations referenced in 
the paragraph above have now been 
incorporated into AOAC Method 996.06 
(Official Methods of Analysis of AOAC 
International, 17th edition, Revision 1, 
2002; chapter 41.1.28A) (Ref. 105). This 
method is suitable for use in a wide 
range of food matrices for measuring 
trans fat for labeling purposes.
AOAC Method 996.06 cited above for 
trans fat analysis is the most current 
AOAC gas chromatography method 
available and FDA will consider it an 
appropriate method under § 101.9(g)(2) 
for determining compliance with 
nutrition labeling provisions for trans 
fat. AOAC Method 996.06 is not 
included in the 15th edition (1990) of 
Official Methods of Analysis of AOAC 
International (which is incorporated by 
reference in § 101.9(g)(2)) because the 
process of development and validation 
of this method was not completed until 
1996. Therefore, AOAC Method 996.06 
as it is reported in Revision 1, 2002 of 
the 17th edition of Official Methods of 
Analysis of AOAC International (Ref. 
105) may be used as an ‘‘other reliable 
and appropriate analytical procedure’’ 
as provided for in § 101.9(g)(2). FDA 
intends to propose amendments in the 
future on the edition of the AOAC 
method listed in § 101.9(g)(2) and other 
needed revisions of § 101.9.
(Comment 22) One comment noted 
that detection methodology is not 
sophisticated enough to accurately 
measure trans fat in all food products. 
The comment stated that significant 
work is needed to validate the AOCS 
methods for food matrices other than fat 
and oils.
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FDA disagrees with this statement. 
While the agency recognizes that AOCS 
methods have not been extended to 
cover matrices other than fats and oils, 
the AOAC method 996.06 (Official 
Methods of Analysis of AOAC 
International, 17th edition, Revision 1, 
2002) (Ref. 105) is suitable for the 
analysis of trans fat in a wide range of 
foods of varying fat content. As noted in 
comment 19, above, AOAC Method 
996.01 is not suitable for quantifying 
trans fatty acids for food labeling 
purposes because the capillary column 
specified is not sufficiently long to 
obtain adequate separation of the cis 
and trans fatty acids.
(Comment 23) A few comments 
recommended that FDA consider listing 
amounts of trans fat to the nearest tenth 
or hundredth of a gram, rather than to 
the nearest 0.5 g. One of these 
comments stated that Canada has 
established a rounding limit of 0.1 g for 
food labeling indicating that analytical 
methods are capable of detecting that 
amount.
FDA disagrees with these 
recommendations. FDA notes that while 
these recommended levels might be 
quantifiable by laboratories using GC 
methodology such as that described in 
AOAC method 996.06 (Official Methods 
of Analysis of AOAC International, 17th 
edition, Revision 1, 2002) (Ref. 105), 
they will pose a problem for laboratories 
that are set up to quantify trans fatty 
acids by infrared spectroscopy (IR) 
methodology because the detection 
limits of the currently available IR 
methods are higher than those of the GC 
methods. More importantly, however, 
there are no unambiguous methods for 
confirming the very low levels 
suggested by the comment.
Moreover, FDA notes that the 
increment for listing trans fat is 
consistent with increments used for 
listing total fat and saturated fat. 
Therefore, the agency is finalizing 
§ 101.9(c)(2)(ii) to state that trans fat 
shall be expressed, as proposed, to the 
nearest 0.5 g increment below 5 g and 
to the nearest gram increment above 5 
g.
(Comment 24) One comment noted 
that the IR method of choice in the 
November 1999 proposal, AOCS 
Recommended Practice Cd 14d–96 (Ref. 
45), generally overestimates trans fat at 
low levels because of interferences and 
issues with both accuracy and detection 
limits. The comment noted further that 
the AOCS GC method Ce 1f–96 (Ref. 46) 
has better sensitivity, but has not been 
validated for many types of food 
products and that significant work is 
needed to validate this method for other 
food matrices.
FDA agrees that the detection limits of 
the AOCS GC method (Ce 1f-96) 
(Revised 2002, Ref. 146) are lower than 
those of the AOCS IR recommended 
practice (Cd 14d-96) (Revised 1999, Ref. 
145). FDA notes that AOCS 
Recommended Practice Cd-14d-96 is 
applicable to the determination of 
isolated trans double bonds in natural 
or processed oils and fats with trans 
levels equal or greater than about 0.8 
percent. The lower limit of quantitation 
for this IR recommended practice may 
be higher (i.e., the method may be less 
accurate for determination of low levels 
of trans fat) for complex systems such 
as commercial food products (Ref. 145).
The AOCS Official Method Ce 1f–96 
(Ref. 146) is designed to evaluate the 
level of trans isomers formed during 
refining or during hydrogenation of 
vegetable oils or fats and the scope of 
the method does not extend beyond 
these matrices. FDA notes that the 
recent improvements in AOAC Official 
Method 996.06 as referenced in 
Revision 1, 2002 (Ref. 105), have 
resulted in the applicability of this GC 
method to a wide range of food 
products.
(Comment 25) One comment asked if 
trans fat values below 0.5 g are to be 
declared as ‘‘0,’’ how FDA will address 
the labeling of foods like butter, where 
trans fat content fluctuates seasonally 
above and below 0.5 g per serving. The 
comment stated that FDA should err on 
the side of conservatism and require 
that labeling be based on the highest 
levels found in such products over the 
entire year.
FDA has long recognized that 
variations occur naturally in the 
nutrient content of foods. The 
compliance procedures that FDA 
follows, which are found in 
§ 101.9(g)(2), provide that a sample for 
nutrient analysis must consist of a 
composite of 12 subsamples, taken one 
from each of 12 randomly chosen 
shipping cases. FDA will then analyze 
the nutrient content of this composite 
test sample. Upon determination of the 
laboratory analyses, FDA uses the 
compliance procedures set forth in 
§ 101.9(g)(5) and (g)(6) to determine if 
the values declared for those nutrients 
that have recommended dietary limits, 
such as saturated fat and cholesterol, 
misbrand the label. The content of a 
sample composite of these nutrients is 
in compliance if the analyzed value is 
no more than 20 percent greater than the 
value declared on the label. Stated 
another way, for nutrients listed in 
§ 101.9(g)(5), the ratio between the 
nutrient level obtained by laboratory 
analysis and the product’s label value, 
multiplied by 100, cannot be greater 
than 120 percent for the product to be 
in compliance. For example, if the 
laboratory value is 4 grams, and a 
product’s label value is 2 gram, the ratio 
(4/2) x 100 = 200 percent. This value is 
greater than 120 percent, hence, the 
product is out of compliance.
FDA did not address this issue in the 
proposal because the declaration of 
‘‘saturated fat’’ included trans fats, and 
saturated fats are addressed in 
§ 101.9(g)(5) and (g)(6). Now that FDA is 
requiring that trans fat be declared in 
the main body of the nutrition label (i.e., 
the amount of trans fat is not in a 
footnote), FDA is making a conforming 
amendment to § 101.9(g)(5) and (g)(6) to 
include trans fatty acids.
FDA’s policy since the 1970s assigns 
the manufacturer the responsibility for 
assuring the validity of a product label’s 
stated nutrient values (Ref. 108). 
Accordingly, the source of the data used 
to calculate nutrition labeling values is 
the manufacturer’s prerogative, but 
FDA’s policy recommends that the 
nutrient values for labeling be based on 
product composition, as determined by 
laboratory analysis of each nutrient. If a 
manufacturer knows that a nutrient is 
likely to vary over seasons or due to 
other factors (e.g., location, growing 
conditions, product transport, or 
processing practices), in order to assure 
compliance, the manufacturer should 
analyze samples of the product over the 
various seasons or relative to other 
factors to account for variability of 
nutrient content.
To ensure that label values will 
accurately represent the nutrient 
content of food products to consumers 
and also have a high probability of being 
in compliance with nutrition labeling 
regulations, FDA recommends the 
calculation of a one-sided 95 percent 
prediction interval as the most 
appropriate and the preferred method to 
use in computing label values (Ref. 108).
Prediction intervals take into account 
the variability of a nutrient. Mean 
values do not. A manufacturer of a 
product, like butter, whose trans fat 
content fluctuates seasonally, would 
want to analyze samples of trans fat 
during each season and statistically 
consider using 95 percent prediction 
intervals to calculate the nutrition label 
value for trans fat. A predicted value on 
a nutrition label may sometimes 
indicate a level of a nutrient such as 
saturated fat at a higher level than is 
actually in the product, but it will never 
show a lower level than the product 
contains. While sometimes predicted 
values and mean values round to the 
same nutrient level, products bearing 
mean values on their nutrition labels 
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have a lower probability of meeting FDA 
compliance requirements.
VI. Nutrient Content Claims, Health 
Claims, Disclosure and Disqualifying 
Levels
In its November 1999 proposal, FDA 
proposed a definition for the nutrient 
content claim ‘‘trans fat free’’ and 
proposed limits on the amounts of trans 
fat wherever saturated fat limits are 
placed on nutrient content claims, 
health claims, or disclosure and 
disqualifying levels. Several comments 
to that proposal requested that the final 
rule define the claim ‘‘reduced trans 
fat’’ or amend the claim ‘‘reduced 
saturated fat’’ to require a reduction of 
saturated and trans fats combined. To 
address this issue, the agency reopened 
the comment period (65 FR 75887) to 
consider ‘‘reduced trans fat’’ and 
‘‘reduced saturated and trans fat’’ 
claims.
With regard to the specific 
definitions, FDA proposed that ‘‘trans 
fat free’’ and ‘‘saturated fat free’’ should 
be defined as less than 0.5 g trans fat 
and less than 0.5 g saturated fat per 
reference amount and per labeled 
serving; ‘‘low saturated fat’’ as 1 g or 
less of saturated fat and less than 0.5 g 
of trans fat per reference amount and 
not more than 15 percent of calories 
from saturated fat and trans fat 
combined; ‘‘reduced saturated fat’’ as at 
least 25 percent less saturated fat and at 
least 25 percent less saturated fat and 
trans fat combined; ‘‘lean’’ as 4.5 g or 
less of saturated fat and trans fat 
combined; and ‘‘extra lean’’ as less than 
2 g of saturated fat and trans fat 
combined. In addition, cholesterol 
claims were allowed only on foods 
containing 2 g or less of saturated fat 
and trans fat combined, and 
disqualifying and disclosure levels were 
set at 4 g or less of saturated fat and 
trans fat combined. FDA did not 
propose to define ‘‘low trans fat.’’
The comments relating to claims were 
very diverse and indicated strongly 
opposing views. With regard to the 
‘‘trans fat free’’ claim, some comments 
favored the proposed definition, while 
other comments suggested increasing 
the saturated fat limit, eliminating the 
saturated fat limit , or not defining this 
claim. Similarly, some comments 
supported the ‘‘saturated fat free’’ claim, 
while other comments recommended 
that the trans limit be increased to 2 g. 
For ‘‘low saturated fat’’ some comments 
favored the proposed definition, while 
others suggested increasing the trans fat 
limit as high as 2 g. One comment 
recommended that this claim be less 
than or equal to 1.5 g of saturated and 
trans fats combined.
A number of comments supported 
having a ‘‘reduced trans fat’’ claim and 
others were against it. The vast majority 
of the comments in favor of this claim 
suggested that trans fat be reduced by at 
least 25 percent, but there was little 
agreement on the secondary saturated 
fat criterion. The comments ranged from 
no limit on saturated fat, to no increase 
in the level of saturated fat, a limit of 
less than or equal to 2 g, or at least a 
25 percent reduction. The comments on 
‘‘reduced saturated’’ fat were similar to 
the comments on ‘‘reduced trans fat’’ in 
that there was no agreement on the level 
of the secondary criterion, i.e., trans fat 
for this claim. In addition, some 
comments recommended having the 
claim ‘‘reduced saturated and trans fats’’ 
for greater flexibility, while others 
opposed such a claim. Of those in favor, 
some comments recommended a 
reduction of at least 25 percent in 
saturated and trans fats combined, one 
comment favored a 33 to 50 percent in 
saturated and trans fats combined, and 
one comment wanted a 25 percent 
reduction in saturated fat and a 25 
percent reduction in trans fat.
Finally, the comments on disclosure 
and disqualifying levels were equally 
divergent. Some comments favored the 
proposed criterion of 4 g or less of 
saturated and trans fats combined, 
while others recommended a limit of 4 
g of saturated fat and 4 g of trans fat, or 
believed that there should be no limit 
on trans fat. One comment stated that 
trans fat thresholds should be 
incorporated into the criteria defining 
nutrient content claims and health 
claims only to the extent that such 
criteria are necessary to prevent the 
claim from misleading consumers. The 
comment stated that this is the approach 
FDA applied in establishing the 
saturated fat thresholds for cholesterol 
content claims in § 101.62(d) and is an 
appropriate construct for nutrient 
content claims about trans fat.
The objections in the comments 
against the proposed definitions were 
generally based on scientific, legal, or 
economic arguments. Some of the 
comments believed that the agency is 
acting in advance of sufficient scientific 
justification, while others stated that the 
agency should have acted sooner. There 
was disagreement as to whether the 
adverse effects of trans fat are 
comparable to that of saturated fat. 
Some of the comments stated that the 
proposed definitions assume that trans 
fat and saturated fat are 
‘‘bioequivalent.’’ These comments 
particularly objected to changing the 
disclosure and disqualifying level of 4 g 
of saturated fat to 4 g of saturated and 
trans fat combined (i.e, holding the 
current level constant and including 
trans fat). These comments argued that 
the effects of saturated fat and trans fat 
have not been proven to be the same on 
a gram-for-gram basis and, therefore, 
should not be treated interchangeably. 
Other comments stated that there is no 
scientific evidence showing any adverse 
effects on serum cholesterol levels or 
cardiovascular health from trans fat in 
a mixed diet to support FDA’s proposed 
definitions for nutrient content claims.
Other comments argued that the 
proposed claims should be included in 
the final rule for public health reasons, 
while others argued that less restrictive 
claims would benefit the public health 
to a greater extent because they would 
encourage more reformulation. Some of 
these comments pointed out that the 
‘‘trans fat free’’ claim, in particular, is 
not meaningful because very few foods 
could meet the proposed criteria and 
therefore would not be used enough to 
be helpful.
Several comments asserted that FDA 
did not meet its burden under the first 
amendment because the threshold levels 
proposed by FDA for trans fat for certain 
nutrient content and health claims, 
which, if exceeded, would prohibit the 
use of the claims on food and have the 
effect of restricting the use of specific 
claims that would be truthful and not 
misleading. The comments reasoned 
that FDA could only limit claims where 
the level of trans fat in a food product 
would make the claim misleading. 
Further, the comments reasoned that, 
before FDA could prohibit a claim, FDA 
would need to establish that the use of 
a disclaimer on the label or the 
disclosure of trans fat on the label could 
not prevent the claim from being 
potentially misleading.
Economic concerns regarding the 
proposed nutrient content claims are 
discussed in section IX of this 
document.
FDA has carefully reviewed the 
comments and finds that it has 
insufficient scientific information at this 
point in time to support a decision on 
the appropriate definition for the 
nutrient content claims discussed in the 
November 1999 proposal and the 
December 5, 2000, notice to reopen the 
comment period. The comments that 
expressed a preference for a specific 
threshold level of trans fat for various 
claims did not provide a scientific 
rationale to support the level. In the 
past, the development of definitions for 
nutrient content claims and the 
establishment of disclosure and 
disqualifying levels generally have been 
dependent upon scientific agreement of 
appropriate quantitative reference 
values for daily consumption of the 
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nutrient that is the subject of the claim. 
In proposing nutrient content claims, 
the agency stated that ‘‘With the 
exception of the term ‘‘sugar free’’ and 
terms related to caloric levels in foods, 
the agency has limited the proposed 
definitions to nutrients for which there 
are proposed DRVs or RDIs’’ (56 FR 
60421 at 60429, November 27, 1991). 
The approach of having an appropriate 
reference value for daily consumption 
provides a consistent and quantitative 
basis for defining claims. As stated in 
section V of this document, in the 
absence of the type of quantitative 
information from authoritative scientific 
groups on which the agency could 
support the establishment of a DRV for 
trans fat, the agency is providing for 
mandatory trans fat labeling, without a 
%DV. The agency does not believe that 
the current level of scientific evidence 
supports the establishment of such a 
value for trans fat at this time. Many 
comments supported this position. As a 
result of the absence of an appropriate 
reference value for trans fat, the agency 
has been hampered in developing an 
integrated approach that responds to the 
issues raised in the comments. 
Accordingly, the agency is withdrawing 
those sections of the November 1999 
proposal pertaining to the establishment 
of a definition for ‘‘trans fat free,’’ 
consideration of ‘‘reduced trans fat’’ and 
‘‘reduced saturated and trans fat’’ claims 
and limits on the amounts of trans fatty 
acids wherever saturated fatty acid 
limits are placed on nutrient content 
claims, health claims, or disclosure and 
disqualifying levels. FDA plans to 
continue to evaluate the evolving 
science and, when the science has 
evolved to a point where the agency 
believes it can proceed with 
scientifically-based definitions and 
levels for these claims, it will proceed 
to do so through a new rulemaking. FDA 
will seek to ensure that it acts consistent 
with its obligations under the first 
amendment to allow truthful and 
nonmisleading speech.
As discussed under comment 17, FDA 
is issuing an ANPRM elsewhere in this 
issue of the Federal Register that will 
solicit comment and data that 
potentially could be used to establish 
new nutrient content claims about trans 
fat, to establish qualifying criteria for 
trans fat in current nutrient content 
claims for saturated fat and cholesterol, 
lean and extra lean claims, and health 
claims that contain a message about 
cholesterol raising fats, and to establish 
disclosure and disqualifying criteria for 
trans fat.
VII. Other Issues
(Comment 26) Several comments 
requested that FDA defer rulemaking on 
trans fat labeling until both FDA and 
USDA are able to concurrently take this 
action.
FDA consulted with USDA and both 
agencies agree that it is important that 
nutrition labeling rules for both agencies 
be consistent and that labeling of trans 
fat is necessary to assist consumers in 
maintaining healthy dietary practices. 
USDA is considering a similar policy for 
trans fat labeling based on the view that 
the approach to nutrition labeling 
should be consistent, but currently does 
not have a rulemaking on trans fat 
labeling on its regulatory agenda. 
Because trans fat levels are expected to 
be higher in foods regulated by FDA, as 
compared to foods under USDA 
jurisdiction, and because FDA has a 
citizen petition on the labeling of trans 
fat, FDA has determined that it is 
necessary to proceed with this final rule 
based on the public health interest. FDA 
notes that it is committed to cooperating 
with USDA, as needed, on trans fat 
labeling in any future action that USDA 
may consider.
(Comment 27) Some comments 
requested that trans fat not be used in 
restaurant food or its use be reduced.
These comments are outside the scope 
of this rule on the nutritional labeling of 
trans fat. This rulemaking is about trans 
fat labeling and not about whether or 
not trans fat is used in food generally or 
in particular food products. Although 
restaurant foods are not required to 
provide full nutrition labeling, they are 
required under § 101.10 (21 CFR 
101.10), ‘‘Nutrition Labeling of 
Restaurant Foods,’’ to provide 
information on nutrients that are 
relevant to any nutrient content claims 
made. Further guidance on labeling of 
restaurant foods may be found in 
‘‘Questions and Answers Volume II, A 
Guide for Restaurants and Other Retail 
Establishments’’ (Ref. 111).
(Comment 28) A number of comments 
to the November 1999 proposal and the 
November 2002 notice reopening the 
comment period of the November 1999 
proposal stated that there is a great need 
for consumer education about trans fatty 
acids and the nutrition label.
FDA agrees that consumer education 
will be needed as a result of this final 
rule so that consumers are better able to 
utilize the new trans fat labeling 
information to assist them in 
maintaining healthy dietary practices. 
Since the first edition of ‘‘Dietary 
Guidelines for Americans’’ in 1980 (Ref. 
112), Americans have been advised to 
avoid too much saturated fat to reduce 
the risk of heart disease. This message 
has also been a major factor in the 
National Cholesterol Education 
Program, which has been in existence 
since 1985 (http://www.nhlbi.nih.gov/
about/ncep/index.htm) that focuses on 
individuals at higher risk for CHD. 
Some success of these educational 
programs was demonstrated by the third 
National Health and Nutrition 
Examination Survey (Ref. 89) conducted 
during 1988–94, that showed that the 
public’s intake of saturated fat has 
declined since the previous survey 
conducted from 1976–80 (Ref. 113). 
Also, the 1994–96 CSFII showed a 
decline in the public’s intake of 
saturated fat since a previous survey 
conducted in 1989–91 (Ref. 142). 
Therefore, in introducing new messages 
about trans fatty acids, FDA intends to 
work with existing public health 
programs to build upon the extensive 
work done by them to educate 
consumers about saturated fatty acids 
and cholesterol and their relationship to 
heart health.
The agency also plans to initiate a 
variety of outreach and consumer 
education programs about this final rule 
following publication. Electronic 
dissemination of this information will 
be provided at FDA’s Web site and 
briefings will be provided to 
representatives of a variety of health 
professionals, government agencies, 
industry representatives, trade 
associations, and press and consumer 
groups so that they can communicate 
trans fat information to their 
constituencies. To assist in this effort, 
education and press materials will be 
developed to facilitate communication 
to consumers about changes they will 
see as trans fat is added to the nutrition 
label and how they can use that 
information in their efforts to maintain 
a healthy diet.
(Comment 29) A few comments 
suggested using color coding to help 
consumers quickly recognize unhealthy 
products, including those containing 
trans fat. One of the comments 
mentioned applying this technique to 
ingredient listing and another comment 
said that a graphic could show the 
proportion of saturated, trans, 
polyunsaturated, and monounsaturated 
fats. The latter comment noted that 
horizontal color bars were used quite 
successfully in the introduction of 
canola oil in the United States.
These comments are outside the scope 
of this final rule on the nutrition 
labeling of trans fatty acids. The agency 
notes that manufacturers are free to use 
color bars on the product label outside 
of the Nutrition Facts panel (i.e., the 
box), to illustrate the kinds of fatty acids 
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in their products, provided it is done in 
a manner that is not misleading, but the 
panel itself is to be in compliance with 
this final rule.
(Comment 30) FDA received only one 
comment in response to the November 
1999 proposal to deny the petitioner’s 
request to require that ‘‘partially 
hydrogenated’’ fat be listed on food 
labels as ‘‘partially saturated’’ fat (64 FR 
62746 at 62762). The comment 
concurred with the agency’s tentative 
conclusion to deny the request stating 
that ‘‘partially hydrogenated’’ fat is the 
most appropriate terminology for use on 
food label ingredient statements.
The agency concurs with the 
comment and, accordingly, is denying 
this request.
(Comment 31) Although a great many 
comments supported CSPI’s petition in 
general, these comments did not 
specifically address the petitioner’s 
request to limit ‘‘vegetable oil’’ claims to 
foods that are low in saturated and trans 
fats combined.
In the November 1999 proposal, the 
agency referred to § 101.65(c)(3), which 
states, in part, that a claim ‘‘that a food 
is made only with vegetable oil is a 
claim that the food is low in saturated 
fat,’’ and tentatively concluded that the 
petitioner’s request was being addressed 
by the action taken in the proposed rule 
to limit the amount of trans fat in foods 
bearing ‘‘low in saturated fat’’ claims (64 
FR 62746 at 62762). However, in this 
final regulation those sections of the 
proposed rule pertaining to limiting the 
amount of trans fat in foods making a 
‘‘low in saturated fat’’ claim are being 
withdrawn. Therefore, the agency is not 
restricting ‘‘vegetable oil’’ claims as 
proposed or as petitioned at this time.
As discussed in section VI of this 
document, FDA plans to proceed with a 
new rulemaking pertaining to limits on 
the amount of trans fat in claims 
relating to saturated fat when the 
science on trans fat has evolved to a 
point where the agency believes it can 
proceed with scientifically-based 
definitions and levels for these claims.
VIII. Effective Date
In the November 1999 proposal, the 
agency proposed that any final rule that 
may issue based upon the proposal 
become effective in accordance with the 
uniform effective date for compliance 
with food labeling requirements that is 
announced by notice in the Federal 
Register and that it not be sooner than 
1 year following publication of any final 
rule based on the proposal. Also, the 
agency said it will not object to 
voluntary compliance immediately 
upon publication of the final rule.
(Comment 32) FDA received several 
comments about the effective date for a 
final rule. One comment stated that the 
proposed effective date was appropriate 
while a few other comments 
recommended that it be sooner than 
proposed. Several comments suggested 
that the effective date be 24 months after 
publication of the final rule or January 
1, 2004, whichever comes later. Some 
comments, however, requested that the 
effective date be extended several years 
(e.g., 4 to 7 years) for small businesses. 
These comments stated that it was 
important for small businesses to be 
able to phase in the cost associated with 
the new label requirements so that they 
have extra time to absorb the costs of 
these changes. Many small 
manufacturers reported that they have 
significant inventories of labels. Also, 
smaller manufacturers indicated that 
they would incur costs including loss 
and disposal of obsolete packaging 
inventories, product in obsolete 
packages, and new printing plates. 
These small businesses believe that a 
longer compliance period would allow 
these companies to more easily manage 
their inventories and phase in the trans 
fat labeling requirements along with 
other scheduled labeling revisions. This 
will help minimize unnecessary 
labeling costs and costs passed on to 
consumers. At least one comment 
requested that the effective date be one 
year after establishment of an official 
AOAC method for measuring trans fatty 
acids in complex food matrices.
To minimize the need for multiple 
labeling changes and to provide 
additional time for compliance by small 
businesses to allow them to use current 
label inventories and phase in label 
changes, the agency is setting the 
effective date at January 1, 2006, the 
next uniform effective date following 
publication of this rule. This allows 
firms more than 2 years to implement 
this final rule providing some regulatory 
relief and economic savings for small 
businesses. Extending the effective date 
for products containing trans fat would 
delay the benefits of this rule to the 
public health.
The agency notes that there are 
several methods for measuring the 
amounts of trans fat in food products 
including but not limited to AOAC 
Method 996.06, as modified (17th 
edition of the ‘‘Official Methods of 
Analysis of the AOAC International’’) 
(Refs. 105 and 106). Consequently, the 
agency does not believe that there is any 
need to extend the effective date 
because of the lack of appropriate 
methodology.
Although the effective date of the 
final rule is some time away, FDA 
encourages manufacturers to have new 
labels printed that are in compliance 
with these final rules so they may be 
used as soon as current inventories are 
exhausted to ensure a smooth and 
timely changeover. The agency will not 
object to voluntary compliance 
immediately upon publication of the 
final rule.
IX. Final Regulatory Impact Analysis
FDA has examined the economic 
implications of this final rule as 
required by Executive Order 12866. 
Executive Order 12866 directs agencies 
to assess all costs and benefits of 
available regulatory alternatives and, 
when regulation is necessary, to select 
regulatory approaches that maximize 
net benefits (including potential 
economic, environmental, public health 
and safety, and other advantages; 
distributive impacts; and equity). 
Executive Order 12866 classifies a rule 
as significant if it meets any one of a 
number of specified conditions, 
including: Having an annual effect on 
the economy of $100 million, adversely 
affecting a sector of the economy in a 
material way, adversely affecting 
competition, or adversely affecting jobs. 
A regulation is also considered a 
significant regulatory action if it raises 
novel legal or policy issues. FDA has 
determined that this final rule is a 
significant regulatory action as defined 
by Executive Order 12866.
The Small Business Regulatory 
Enforcement Fairness Act of 1996 
(Public Law 104–121) defines a major 
rule for the purpose of congressional 
review as having caused or being likely 
to cause one or more of the following: 
An annual effect on the economy of 
$100 million; a major increase in costs 
or prices; significant adverse effects on 
competition, employment, productivity, 
or innovation; or significant adverse 
effects on the ability of U.S.-based 
enterprises to compete with foreign-
based enterprises in domestic or export 
markets. In accordance with the Small 
Business Regulatory Enforcement 
Fairness Act, Office of Management and 
Budget (OMB) has determined that this 
final rule is a major rule for the purpose 
of congressional review.
A. The Current Situation and the Need 
for This Regulation
Current nutrition labeling regulations 
do not allow manufacturers to disclose 
information about trans fat content of 
their products in the Nutrition Facts 
panel of product labels. The regulation, 
in § 101.9(c) reads, in part, ‘‘No 
nutrients or food components other than 
those listed in this paragraph as either 
mandatory or voluntary may be 
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1 Using Method 1 (LDL–C), described later in 
section IX.E, and the factors shown in tables 8 and 
9 below, replacement of 0.1 percent of energy from 
trans fat would decrease CHD risk by 0.072 percent 
when replaced with the same percent of energy 
from half cis-monounsaturated fat and half 
saturated fat (-0.1 x 0.74 x 0.7 x 1.4 = -0.072) and 
by 0.163 when replaced with half cis-
monounsaturated fat and half cis-polyunsaturated 
fat (-0.1 x 1.66 x 0.7 x 1.4 = -0.163).
2 Using Method 2 (LDL–C and HDL–C), 
replacement of 0.1 percent of energy from trans fat 
would decrease CHD risk by 0.237 percent when 
replaced with the same percent of energy from half 
cis-monounsaturated fat and half saturated fat (-0.1 
x -0.47 x -2.5 x 1.4 = -0.165 and -0.072 plus -0.165 
= 0.237) and by 0.293 when replaced with half cis-
monounsaturated fat and half cis-polyunsaturated 
fat (-0.1 x -0.37 x -2.5 x 1.4 = -0.130 and -0.163 plus 
-0.130 = -0.293).
included within the nutrition label.’’ 
Some of the nutrients listed are total fat, 
saturated fat, polyunsaturated fat 
(voluntary), and monounsaturated fat 
(voluntary). Prior to publication of this 
final rule trans fat was not included as 
either mandatory or voluntary, and 
therefore, no information about trans fat 
could have been included in the 
Nutrition Facts panel.
As explained in the November 1999 
proposal and in section IV of this 
document, there is a scientifically 
established link between the 
consumption of trans fat and CHD. As 
described in table 1 of this document, 
for purposes of economic analysis, FDA 
estimated trans fat intake based on 
dietary intakes reported in a national 
food consumption survey. FDA 
estimates that average trans fat intake 
from partially hydrogenated fat is about 
2.03 percent of energy, and average total 
trans fat intake, including trans fat of 
ruminant origin, is about 2.55 percent of 
energy. Because trans fat increases 
serum LDL–C (‘‘bad’’ cholesterol), 
reducing trans fat intake reduces CHD 
risk. The amount of risk reduction 
depends on what replaces trans fat in 
the diet (64 FR 62746 at 62768 to 
62770). For example, as shown later in 
this section, reducing trans fat intake by 
0.1 percent reduces CHD risk by 0.072 
to 0.163 percent.1 CHD is a common 
disease in the general U.S. population, 
with about 1.1 million heart attacks 
annually, 40 percent of them fatal (Ref. 
134). Therefore, a small decrease in risk 
corresponds to a large number of heart 
attacks and deaths prevented. Thus, as 
shown later in this section, reducing 
trans fat intake by about 0.04 percent of 
energy (projected to decrease CHD risk 
by about 0.05 percent), prevents 
approximately 600 heart attacks per 
year, including 200 fatal heart attacks. 
Preventing these heart attacks is valued 
at $4.1 billion per year (present value 
discounted at 7 percent).
Although the effect of trans fat on 
LDL–C and CHD risk is the primary 
basis for trans fat labeling, trans fat may 
also increase CHD risk by lowering 
high-density lipoprotein cholesterol 
(HDL–C) (‘‘good’’ cholesterol). In a 
second method for estimating the health 
benefits of trans fat labeling, the 
expected changes in LDL–C and HDL–
C can be considered together (64 FR 
62746 at 62768 to 62770). For example, 
as shown later in this section, each 0.1 
percent of energy decrease in trans fat 
intake reduces CHD risk by 0.237 to 
0.293 percent.2 Thus, as shown later in 
this section, reducing trans fat intake by 
about 0.04 percent of energy (projected 
to decrease CHD risk by about 0.1 
percent), prevents approximately 1,200 
heart attacks, including 480 fatal heart 
attacks, annually, valued at $8.3 billion 
per year (present value discounted at 7 
percent).
This final regulation is needed to 
amend existing regulations so that 
manufacturers will be able to provide 
important health-related information to 
consumers regarding the amount of 
trans fat in food products.
FDA believes that the requirements of 
this final rule will provide consumers 
with information they need so that they 
may consider the amount of trans fat in 
products in their food purchasing 
decisions. Increased consumer attention 
to trans fat content because of nutrition 
labeling may also provide an incentive 
to food manufacturers to reduce the 
amount of trans fat in their products.
B. Regulatory Alternatives
In the analysis of the proposed rule, 
FDA listed a number of regulatory 
alternatives regarding trans fat, 
including: (1) Take no new regulatory 
action; (2) take the proposed regulatory 
action; (3) propose to permit the 
voluntary labeling of trans fat and to 
permit trans fat nutrient content claims; 
(4) alter the proposed regulatory 
action—propose reporting of trans fat on 
a separate line below saturated fat; (5) 
alter the proposed regulatory action—
propose to report trans fat differently 
than in the proposal; (6) expand the 
proposed regulatory action—propose 
‘‘low trans fat’’ and ‘‘reduced trans fat’’ 
claims; (7) expand the proposed 
regulatory action—propose labeling at 
food service establishments. We 
evaluated these regulatory alternatives 
in the economic discussion of the 
proposed rule, although we lacked 
sufficient data to evaluate all of the 
options quantitatively. FDA received no 
comments on the economic discussion 
of these alternatives, so we do not 
include them in this document. In 
addition to the alternatives described in 
the proposed rule, FDA considered and 
asked for comments on a proposed 
required footnote. Because the agency is 
withdrawing the proposed requirement 
for a footnote and intends to ask for 
comments in an ANPRM published 
elsewhere in this issue of the Federal 
Register, we will not estimate the costs 
and benefits of that option in this 
document.
C. Changes Resulting From This Rule
As stated in the analysis to the 
proposed rule (64 FR 62746 at 62764), 
to estimate the impacts of this rule, FDA 
is following the general approach used 
to estimate the health benefits for the 
implementation of the 1990 
amendments (56 FR 60856 at 60869, 
November 27, 1991). Accordingly, FDA 
is estimating: (1) The changes in trans 
fat intakes that would result from 
labeling changes; (2) the changes in 
health states that would result from 
changes in trans fat intakes; and (3) the 
value of changes in health states in 
terms of life-years gained, number of 
cases or deaths avoided, and dollar 
value of such benefits.
1. Changes in Existing Labeling 
Regulations
This final rule requires the mandatory 
declaration in the nutrition label of the 
amount of trans fat present in foods. 
According to this final rule, the amount 
of trans fat must be on a separate line 
immediately under the amount of 
saturated fat, but it will not include a % 
DV that is required for some of the other 
mandatory nutrients, such as saturated 
fat. These changes must be made within 
a period of 30 months. This change to 
the existing regulations will increase the 
information available to consumers that 
they can use to maintain a healthy diet. 
It will also change the constraints and 
incentives faced by producers of food.
The final rule will increase the 
information provided to consumers on 
food packages. This change in the 
nutrition label will reduce the cost to 
consumers of obtaining information on 
the trans fat content of food. FDA 
anticipates that, once the rule takes 
effect, consumers will use information 
on the Nutrition Facts panel to adjust 
their purchasing practices among foods, 
consistent with their consumption 
preferences.
The final rule will also change the 
incentives and constraints that food 
producers face in manufacturing and 
marketing their products. Because these 
provisions will not be effective until 
months after publication of the final 
rule, food manufacturers can use the 
time between publication of the final 
rule and its effective date to study the 
requirements of the rule and the 
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composition of their products, to 
anticipate the response of consumers 
and competitors to the new information, 
to change the labeling, and possibly to 
change the composition of their existing 
food products. Even after the effective 
date of the rule, food manufacturers will 
observe the response of consumers to 
the information on trans fat, and some 
may develop and market new products 
with less trans fat than similar existing 
products.
FDA assumes that producers will 
decide whether or not to change the 
composition of existing products on a 
product-by-product basis, depending on 
expected private returns. They will 
choose to reformulate the existing 
products when the expected private 
benefits exceed the expected private 
costs of reformulating the products. In 
other words, if a product is expected to 
lose market share without reformulation 
because of the new disclosure, then 
manufacturers will compare the private 
costs from decreased sales to the cost of 
reformulation.
2. Anticipated Changes in Trans Fat 
Intake
FDA anticipates that, taken together, 
changes in food purchases by 
consumers and reformulation by 
producers in response to this rule will 
result in an overall decrease in trans fat 
intake in the U.S. population. In the 
November 1999 proposal, FDA 
developed four scenarios to demonstrate 
potential quantitative changes in trans 
fat intake (64 FR 62746 at 62767). FDA 
also estimated the current trans fat 
intake of the population as a starting 
point for its scenarios for projected 
intake changes.
a. Revised estimate of current trans fat 
intake. In section IV of this document, 
FDA discussed the uncertainties 
associated with estimates of trans fat 
intake from: (1) National food 
consumption survey, (2) national 
disappearance data, and (3) food 
frequency questionnaires done in 
observational studies of U.S. population 
groups. Although there are uncertainties 
associated with each type of estimate, 
FDA chose estimation of trans fat intake 
based on a national food consumption 
survey as most suitable for use in this 
economic analysis. Estimates of intake 
based on national disappearance data 
generally overestimate intake dues to 
losses in processing and use, and food 
groups derived from disappearance data 
correspond to commodities rather than 
to foods as consumed. Therefore, an 
estimate based on a national food 
consumption survey was better suited to 
the present analysis than was an 
estimate based on national 
disappearance data. Estimates of trans 
fat intake based on food frequency 
questionnaires may have the advantage 
of having been validated versus 
biomarkers such as trans fat content of 
adipose tissue. Such estimates are 
suitable for their intended use in 
ranking and classifying trans fat intake 
of subjects in observation studies. 
However, food frequency questionnaires 
are not necessarily designed to provide 
accurate absolute (numerical) intake 
estimates. As described in the 
November 1999 proposal (64 FR 62746 
at 62753), estimates of nutrient intakes 
based on food frequency data may be 
subject to systematic bias toward either 
over- or underestimation of intake, 
depending on the design of the food 
frequency questionnaire (Ref. 27). 
Available estimates of trans fat intake 
from food frequency questionnaires in 
observational studies are lower than 
estimates of trans fat intake from a 
national food consumption survey (Ref. 
26), as summarized in the November 
1999 proposal (64 FR 62746 at 62752 to 
62753) and in section IV of this 
document. Additionally, the available 
food frequency results pertain to the 
intake of specific U.S. population 
groups in the observation studies, not to 
the overall U.S. population. Therefore, 
an estimate based on a national food 
consumption survey was better suited to 
the present analysis than was an 
estimate based on food frequency 
questionnaires done in observational 
studies. One disadvantage of an estimate 
based on a national food consumption 
survey is that, as described in section 
IV, food intake is generally under-
reported in consumption surveys (Ref. 
26). Therefore, intake of trans fat, in 
grams, estimated from a national 
consumption survey is likely to 
underestimate actual intake. However, 
intake of trans fat from national 
consumption survey data is likely to 
underestimate actual intake to a lesser 
extent than does the lower reported 
intake of trans fat from food frequencies 
done in observation studies. 
Additionally, intake of trans fat, as a 
percent of total energy, from a national 
consumption survey is more likely to be 
an unbiased estimate (Ref. 26).
As described in the November 1999 
proposal (64 FR 62746 at 62765), 
information on trans fat content of foods 
is limited, and there have been few 
estimates of trans fat intake based on 
national dietary surveys using food 
records or recalls. As described in 
section IV of this document and in the 
November 1999 proposal (64 FR 62746 
at 62752 and 62765), an available 
estimate by Allison et al. (Ref. 26), based 
on CSFII 1989–91, reported mean trans 
fat intake of 5.3 g/day (d) (2.6 percent 
of energy). However, for the purposes of 
economic analysis, FDA needed to 
estimate the mean intake of trans fat 
from specific food groups. Therefore, in 
the November 1999 proposal, FDA 
indirectly estimated trans fat intake 
based on a report from the Research 
Triangle Institute (RTI) (Ref. 73). The 
RTI report used a special 1995 USDA 
database of trans fat content of foods 
(Ref. 40), together with the mean intake 
of food groups from USDA’s CSFII 
1994–96, and matched the CSFII 1994–
96 food groups with Standard Industrial 
Classification (SIC) Codes for food 
product categories. FDA limited its 
estimate to foods with trans fat from 
partially hydrogenated fats and oils (64 
FR 62746 at 62765). (Although trans fat 
does occur naturally in dairy foods, it is 
generally present in dairy products at 
less than 0.5 g trans fat per serving, and 
therefore most dairy products would not 
have been affected by the November 
1999 proposal (64 FR 62746 at 62775)).
In the November 1999 proposal, FDA 
estimated that current average trans fat 
intake from hydrogenated fat was 2.91 
percent of energy (calories) for adults, 
which is about 7.62 g/d for men and 
5.54 g/d for women (Ref. 73 and 64 FR 
62746 at 62765). Among food product 
categories, average trans fat intake of 
adults, as a percent of energy, was: 
margarine, 0.39 percent; bread/cake, 
0.67 percent; cookies/crackers, 0.98 
percent; other food groups, 0.87 percent. 
The estimated intake of trans fat from 
margarine included FDA’s adjustment 
based on the assumption that 
approximately 30 percent of margarines 
currently on the market had already 
been reformulated to remove trans fat.
(Comment 33) Comments generally 
agreed that FDA’s estimate of current 
trans fat intake was reasonable and in 
the range of other estimates of trans fat 
intake. Comments from the margarine 
industry agreed with FDA’s overall 
estimate of trans fat intake from 
margarine but stated that FDA had 
overestimated the percent of margarines 
(30 percent) that had already been 
reformulated to remove trans fat. One 
comment indicated that the proportion 
of margarines with less than 0.5 g trans 
fat per serving is about half of FDA’s 
estimate, or 15 percent of margarines. 
Some comments pointed out the 
importance of trans fat intake from food 
groups that were not itemized separately 
in FDA’s summary table, including 
chips and snacks and French fried 
potatoes. Because FDA had restricted its 
estimate to trans fat intake from 
partially hydrogenated fats and oils, 
some comments requested clarification 
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regarding whether naturally-occurring 
trans fat of ruminant origin would be 
regulated by the provisions of the 
proposed rule. One comment from a 
manufacturer agreed with FDA that the 
USDA trans fatty acid database contains 
relatively few foods. This comment 
recommended that a large database be 
developed of trans fat food values that 
have been analyzed using standardized 
methods, and that the database be used 
to establish reference or ‘‘normative’’ 
intake data on trans fat in the U.S. 
population. The comment stated that 
this information would be helpful in 
developing a Daily Value for trans fat 
intake. A comment from the dressings 
and sauces industry disagreed with 
FDA’s statement that ‘‘some salad 
dressings contain substantial amounts of 
trans fatty acids’’ (64 FR 62746 at 
62752). The comment stated that the 
oils used in dressing and sauce products 
contain less than one percent trans fatty 
acids. Additionally, according to the 
comment, the contribution of trans fat of 
ruminant origin is negligible in 
dressings and sauces that contain dairy 
products, as demonstrated in the 
reference cited by FDA regarding trans 
fat in salad dressings (Refs. 29 and 30).
FDA’s original estimate that about 30 
percent of margarine had been 
reformulated to remove trans fat was 
based on an informal market survey in 
the Washington, DC area (Ref. 80 and 64 
FR 62746 at 62781). FDA accepts the 
comment’s estimate that 15 percent of 
margarines currently on the market 
contain less than 0.5 g per serving. In its 
own estimate of total intake, FDA did 
include the contribution to average 
trans fat intake of other food groups 
containing partially hydrogenated fat, 
such as chips and French fried potatoes. 
These food groups were itemized in the 
RTI report (Ref. 73) but FDA 
summarized them under ‘‘All other’’ in 
the November 1999 proposal.
In response to the comments 
requesting clarification about whether 
naturally-ocurring trans fat of ruminant 
origin would be regulated by this rule, 
FDA reiterates that this final rule 
applies to all FDA-regulated foods and 
covers all fatty acids that meet the 
regulatory definition of ‘‘trans fatty 
acids,’’ regardless of origin. Naturally 
occurring trans fat in dairy products and 
in ruminant meat (e.g., meat from cows 
and sheep) present in FDA-regulated 
food products will be subject to this 
rule. FDA did not include trans fat of 
ruminant origin in its original intake 
estimate in the November 1999 proposal 
because, in these products, trans fat is 
generally present at less than 0.5 g per 
serving and declaration of the amount of 
trans fat in these products would not 
have been required by the November 
1999 proposal. As noted later in this 
section, we have revised our estimate of 
trans fat intake and extended our 
revised estimate to include trans fat of 
ruminant origin. Although FDA agrees 
with the comment stating that 
development of a large database of trans 
fat food values would be beneficial, 
database development is beyond the 
scope of the present rulemaking. FDA 
agrees with the comment regarding the 
trans fat content of dressing and sauces 
and acknowledges that FDA’s earlier 
statement about trans fat in salad 
dressings (64 FR 62746 at 62752) was 
inaccurate. However FDA’s earlier 
statement was part of a general 
summary of possible limitations of data 
regarding trans fat intake of the 
population, and was not incorporated 
into FDA’s estimates of trans fat intake 
in the November 1999 proposal. As 
noted previously, FDA based its 
estimates of trans fat intake on the 
special 1995 USDA database of trans fat 
content of selected foods.
As described previously in this 
section, although there are uncertainties 
associated with each type of estimate, 
FDA chose estimation of trans fat intake 
based on a national food consumption 
survey as most suitable for use in this 
economic analysis. In reevaluating its 
November 1999 trans fat intake estimate 
based on a national survey, CSFII 1994–
96, FDA notes that the CSFII 1994–96 
food group categories used to generate 
the estimate were very broad (Refs. 73 
and 114) and the match between the 
broad CSFII food group categories and 
the SIC Codes was not always exact. 
Recently, USDA has published more 
detailed tables of food group intake for 
CSFII 1994–96 (Ref. 115). FDA has used 
the new tables to recalculate its estimate 
of average trans fat intake in the United 
States. For clarity, FDA now includes 
the itemized trans fat intake for the 
various food groups rather than creating 
a summary category for ‘‘All other.’’ 
FDA has also extended its estimate to 
incorporate trans fat of ruminant origin. 
FDA has estimated the intake of trans 
fat from margarine from the USDA 
intake data, without assumptions 
regarding the percent of margarine that 
may have been reformulated to remove 
trans fat. We will describe our 
assumptions about current margarine 
reformulation in later sections of this 
document.
The revised estimate of average trans 
fat intake of adults in the United States 
for this economic analysis is shown in 
table 1 of this document. The revised 
estimate is slightly lower than that in 
the November 1999 proposal. Table 1 
shows that average trans fat intake from 
partially hydrogenated vegetable oils is 
about 5.36 g/d for men and 3.89 g/d for 
women, or about 2.03 percent of energy. 
Adding the trans fat of ruminant origin 
gives an overall total trans fat intake of 
6.86 g/d for men and 4.78 g/d for 
women, about 2.55 percent of energy. 
Major sources of trans fat intake as a 
percent of energy include margarine, 
0.42 percent; cake and related products, 
0.61 percent; cookies and crackers, 0.25 
percent; fried potatoes, 0.21 percent; 
chips and snacks, 0.12 percent; and 
household shortening, 0.11 percent.
TABLE 1.—AVERAGE Trans FAT INTAKE OF U.S. ADULTS FROM FOOD GROUPS
CSFII 94–961 Men Women All All 
Mean daily energy intake, kcal2 ....................................................................................... 2455 1646 2058
Mean daily trans fat intake3 4
Food group ................................................................................................................... Grams Grams Grams % of energy
Hydrogenated products
Total yeast bread ................................................................................................... 0.475 0.330 0.404 0.177%
Cakes, pies, doughnuts, sweet rolls, biscuits, muffins, quick breads, pancakes, 
waffles, tortillas .................................................................................................. 1.607 1.163 1.391 0.607%
Cookies, crackers .................................................................................................. 0.624 0.515 0.571 0.249%
Ready to eat breakfast cereal ............................................................................... 0.093 0.074 0.084 0.037%
French-fried, home-fried potatoes ......................................................................... 0.635 0.332 0.486 0.213%
Potato chips, corn chips, popcorn ......................................................................... 0.345 0.215 0.281 0.123%
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TABLE 1.—AVERAGE Trans FAT INTAKE OF U.S. ADULTS FROM FOOD GROUPS—Continued
CSFII 94–961 Men Women All All 
Pourable and mayo type salad dressing ............................................................... 0.181 0.136 0.159 0.069%
Total candy containing chocolate .......................................................................... 0.048 0.040 0.044 0.019%
Total margarine ..................................................................................................... 1.072 0.859 0.967 0.423%
Household shortening ............................................................................................ 0.277 0.222 0.250 0.109%
Total hydrogenated products ................................................................................. 5.357 3.886 4.637 2.026%
Animal products
Total milk, including on cereal ............................................................................... 0.125 0.085 0.105 0.046%
Ice cream and ice milk .......................................................................................... 0.092 0.057 0.075 0.033%
Total cheese and cottage cheese ......................................................................... 0.227 0.148 0.188 0.083%
Total beef, ground and not ground ....................................................................... 0.569 0.319 0.447 0.195%
Total frankfurter and lunch meat ........................................................................... 0.360 0.188 0.276 0.121%
Total fluid and sour cream .................................................................................... 0.061 0.044 0.052 0.023%
Total butter ............................................................................................................ 0.071 0.049 0.060 0.026%
Total animal products ............................................................................................ 1.505 0.890 1.203 0.527%
Total all products .......................................................................................................... 6.862 4.776 5.840 2.553%
1 Continuing Survey of Food Intakes of Individuals, 1994–1996
2 kcal: kilocalories
3 Source of trans fat content of foods: Ref. 40.
4 Source of food intake data: Smiciklas-Wright H., D.C. Mitchell, S.J. Mickle, A.J. Cook and J.D. Goldman. Foods Commonly Eaten in the 
United States. Quantities per Eating Occasion and in a Day, 1994–1996. U.S. Department of Agriculture NFS Report No 96–5, pre-publication 
version, 2002. www.barc.usda.gov/bhnrc/foodsurvey/Products9496.html.
The revised estimate of trans fat 
intake based on CSFII 1994–96 and 
shown in table 1 is slightly lower than 
the estimate in the November 1999 
proposal (64 FR 62746 at 62765). Table 
1 shows that average trans fat intake 
from partially hydrogenated vegetable 
oils is about 5.36 g/d for men and 3.89 
g/d for women, or about 2.03 percent of 
energy. Adding the trans fat of ruminant 
origin gives an overall total trans fat 
intake of 6.86 g/d for men and 4.78 g/
d for women, about 2.55 percent of 
energy. For comparison, FDA also 
calculated the trans fat intake based on 
CSFII 1989–91, using the same method 
as for the estimate based on CSFII 1994–
96 (Ref. 116 and 117). The overall total 
trans fat intake from CSFII 1989–91 is 
6.47 g/d for men, 4.51 g/d for women 
and 5.32 g/d for all adults, or 2.71 
percent of energy (not shown in table 1), 
very similar to the 6.86 g/d for men and 
4.78 g/d for women and 5.84 g/d for all 
adults, or 2.55 percent of energy intake 
based on CSFII 1994–96 (table 1 of this 
document) (Ref. 116). FDA’s estimates 
of 2.55 percent of energy from trans fat 
based on CSFII 1994–96 and 2.71 
percent of energy based on CSFII 1989–
91 can be compared with other available 
estimates from national food 
consumption surveys. FDA’s estimates 
are very similar to the intake estimated 
by Allison et al. based on CSFII 1989–
91 (Ref. 26), using a different method. 
As described in the November 1999 
proposal, Allison et al. reported that 
average trans fat intake for persons age 
3 and older was 2.6 percent of energy, 
or 5.3 g/d (64 FR 62746 at 62752 and 
62765).
Allison et al. linked the special 1995 
USDA database of trans fat content of 
foods to the food intake reported by 
each individual in CSFII 1989–91 (Ref. 
26). They also separated the ingredients 
in food mixtures, so that the trans fat 
content of the ingredients could be 
included in the total intake. These 
researchers reported the trans fat intake 
for various age and gender groups in the 
United States, but did not report the 
amount of trans fat contributed by 
various foods and food groups. To make 
its estimate, FDA began with USDA 
reports of average intake of food groups 
in CSFII 1989–91 and 1994–96 (Refs. 
115 and 117). In its reports, USDA also 
separated the ingredients in food 
mixtures. For example, in CSFII 1994–
96, USDA found that the average intake 
of margarine reported separately by 
survey participants was 2.8 g/d. 
However, when margarine, used as an 
ingredient in other foods, was added to 
the total, the average margarine intake 
rose to 7.0 g/d. FDA then linked the 
average intake of the food groups with 
the trans fat content of foods from the 
special 1995 USDA database (Ref. 40) to 
give the trans fat intake estimate in table 
1 of this document. The similarity of the 
estimates of FDA and of Allison et al. 
can be explained by use of common 
data—the CSFII intake report and the 
1995 USDA trans fat database. Linking 
the two data sets resulted in comparable 
overall trans intake, whether linked at 
the level of each individual’s intake by 
Allison et al., or linked at the level of 
average intake of food groups by FDA.
FDA’s estimates are also similar to a 
recently-published estimate from 
another national food consumption 
survey, the National Health and 
Nutrition Examination Survey III 
(NHANES III), 1988–94 (Refs. 152 and 
153). The estimate from NHANES III for 
mean trans fat intake for age 20 to 59 
was 5.6 g/d or 2.2 percent of energy 
(mean energy intake was 2,325 kcal/d, 
and (5.6 g/d x 9 kcal/g x 100)/2,325 kcal 
= 2.2 percent of energy).
b. Projected change in trans fat intake. 
In the November 1999 proposal, we 
developed four scenarios of projected 
changes in trans fat intake due to 
labeling. Scenario 1 demonstrated the 
effect of the hypothetical removal of all 
of the trans fat originating from partially 
hydrogenated fats and oils, 
corresponding to a decrease of 2.91 
percent of energy from trans fat. 
Scenarios 2 through 4 predicted three 
possible levels of product reformulation, 
together with an estimate of consumer 
behavior. We estimated that trans fat 
intake would have decreased by 0.58 
percent of energy, 0.50 percent of energy 
and 0.42 percent of energy in Scenarios 
2, 3 and 4, respectively (64 FR 62746 at 
62767). For each scenario, the full 
health benefits would have been 
realized years after the rule took effect: 
10, 8, and 3 years after the effective date 
for Scenarios 2, 3, and 4. These time 
periods included the time for 
reformulation and the 3 years that 
would have passed before changes in 
diet would have begun to reduce the 
risk of CHD.
Consumer awareness
(Comment 34) Several comments 
suggested that FDA overstated consumer 
response to the proposed change to food 
labeling. Some comments said that a 
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footnote might be ignored. Some 
comments said that consumers rarely 
look at any nutrition information 
beyond calories and total fat and that 
consumer concerns about fat have 
dwindled. One comment argued that 
consumers have not significantly altered 
their dietary habits because of the 
implementation of the 1990 
amendments. One comment stated that 
educated consumers probably already 
know enough to look for and avoid trans 
fat. There was also one comment 
arguing that shelf labeling is more likely 
to attract consumer attention than are 
product labels, and the use of shelf 
labeling is probably more prevalent than 
that of product labels. One comment 
stated that FDA has underestimated 
consumer awareness of trans fatty acids. 
Another comment stated that consumer 
awareness is likely to increase as trans 
fat dietary recommendations 
accumulate and consumer education 
devotes more attention to trans fat.
FDA is not going forward with the 
proposed asterisk for saturated fat and 
footnote listing the amount of trans fat. 
Instead, this final rule requires trans fat 
to be listed on a separate line 
immediately below saturated fat. 
Consumers who look at the Nutrition 
Facts panel for information on total fat 
and its fatty acid subcomponents are 
likely to notice the information on trans 
fat.
In the November 1999 proposal, FDA 
used results of earlier research and 
estimated that direct consumer choice 
in response to trans fat labeling would 
result in a 1 percent decrease in trans 
fat intake (64 FR 62746 at 62766). This 
final rule requires that the amount of 
trans fat be declared in nutrition labels 
on a separate line immediately under 
the line for saturated fat. This placement 
of trans fat is more prominent than the 
footnote specified in the November 1999 
proposal and may be more readily 
noticed by consumers. In the November 
1999 proposal, the amount of trans fat 
was to be included in the amount and 
% DV declared for saturated fat. This 
association of trans fat with saturated 
fat, which also may have assisted 
consumers in using the information on 
trans fat, is absent in this final rule. 
Also, as a result of this final rule, 
consumer response to trans fat 
information will be based solely on the 
declaration of the amount of trans fat in 
grams. As discussed in section V of this 
document, there will not be information 
on a % DV for trans fat. In the 
November 1999 proposal, the agency 
proposed to define the nutrient content 
claim for ‘‘trans fat free’’ and also 
proposed that the amount of trans fat be 
limited wherever saturated fat limits are 
placed on nutrient content claims, 
health claims, or disclosure and 
disqualifying levels. As explained in 
sections V and VI of this document, this 
final rule does not establish definitions 
for nutrient content claims about trans 
fat and does not place trans fat limits on 
claims regarding saturated fat, 
cholesterol or other nutrients. In 
summary, the declaration of trans fat in 
this final rule is prominent and 
straightforward. This feature of the final 
rule may tend to increase the magnitude 
of consumer response to the trans fat 
information. However, the provisions of 
this final rule also do not link trans fat 
with saturated fat or with a % DV for 
trans fat and do not change existing 
regulations regarding claims. The 
absence of these features in the final 
rule may tend to decrease the magnitude 
of consumer response to the trans fat 
information.
Based on previous research, the 
November 1999 proposal projected a 1 
percent decrease in trans fat intake from 
direct consumer choice in response to 
trans fat labeling (64 FR 62746 at 
62766). This overall 1 percent decrease 
in trans fat intake could be thought of 
as a 2.2 percent decrease in trans fat 
intake by the 45 percent of consumers 
shown in previous research to use food 
labels to make purchase decisions (Refs. 
68 and 74) (64 FR 62746 at 62766).
In the process of evaluating these 
comments about consumer awareness, 
FDA has identified additional data 
relevant to these issues. In the 1999 
Discovery Health survey, 66 percent of 
those responding to the survey knew 
that saturated fat was related to disease 
and 31 percent knew that partially 
hydrogenated fat was related to disease 
(Ref. 118). In the 2001–2002 Consumer 
Attitudes About Nutrition survey, 83 
percent of respondents reported that 
saturated fat is unhealthy, 46 percent 
reported that trans fat is unhealthy and 
44 percent reported that hydrogenated 
fat is unhealthy (Ref. 135). These results 
indicate that survey respondents were 
about half as likely to know that 
partially hydrogenated fat was 
‘‘unhealthy’’ or related to disease as to 
know that saturated fat was related to 
disease. If these surveys are 
representative of the population, this 
indicates a significant level of 
awareness of the health effect of 
partially hydrogenated fat, and its 
component, trans fat, even though 
consumers have very little easily 
obtainable information on trans fat and 
even though nutrition education efforts, 
until very recently, have focused on 
saturated fat to the exclusion of trans 
fat. Once nutrition education efforts 
include trans fat in their messages and 
once consumers have information on 
nutrition labels about trans fat content, 
consumer awareness of the relationship 
between saturated fat, trans fat, and 
cholesterol and heart disease will 
increase. Another recent study, by Kim 
et al., estimated that food label use has 
a large effect on nutrient intake. (Ref. 
119) This study reported that 73 percent 
of individuals surveyed use nutrition 
labels and look for information on 
saturated fat.
In the study by Kim et al., 73 percent 
of individuals surveyed who use 
nutrition labels and look for information 
on saturated fat had 15 percent lower 
saturated fat intake than those who did 
not use nutrition labels. This 
corresponds with an overall 11 percent 
decrease (0.15 x 73 percent = 11 
percent) in saturated fat intake because 
of nutrition labeling. Thus, the study by 
Kim et al. gave a high estimate of an 11 
percent decrease in saturated fat intake 
because of nutrition labeling and FDA’s 
earlier research gave a low estimate of 
a 1 percent decrease in saturated fat 
intake.
The Discovery Health study and the 
Consumer Attitudes About Nutrition 
survey indicated that consumer 
awareness of a nutrient-disease 
relationship involving trans fat was 
about half as prevalent as consumer 
awareness of a nutrient-disease 
relationship involving saturated fat. 
Accounting for the lower prevalence of 
awareness of the nutrient-disease 
relationship for trans fat, would reduce, 
by about one-half, the estimates for 
decreases in saturated fat intake. This 
would give a high estimate of a 5.5 
percent decrease and a low estimate of 
a 0.5 percent decrease in trans fat intake 
because of labeling.
The estimates for decreases in trans 
fat intake due to nutrition labeling may 
also be affected by the features of this 
final rule. As noted previously, the 
prominence of the declaration of trans 
fat in this final rule may tend to increase 
the magnitude of consumer response to 
the trans fat information. However, the 
magnitude of consumer response to the 
trans fat information may decrease 
because there is no link with saturated 
fat or with a % DV and there are no 
changes in existing regulations 
regarding claims. Recognizing that 
different features of this final rule may 
tend to either increase or decrease 
consumer response to the trans fat 
information, FDA acknowledges 
considerable uncertainty in 
incorporating the features of this final 
rule into its estimate of the consumer 
response to trans fat labeling. One 
possibility is that the increased and 
decreased responses related to features 
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of the rule will be about equal and will 
cancel each other out. This would leave 
a high estimate of 5.5 percent decrease 
and a low estimate of a 0.5 percent 
decrease in trans fat intake as discussed 
above. However, for the purpose of this 
final analysis, FDA has chosen a very 
low estimate of consumer response to 
the new label. FDA is using an estimate 
even lower than the low estimate above: 
a decrease of 0.1 percent of trans fat 
intake. The actual change that occurs 
may be larger. However, FDA chose this 
amount so as not to overestimate 
benefits of this rule. To the extent that 
actual consumer response is higher than 
FDA’s estimate, this analysis will 
underestimate the benefits of trans fat 
labeling.
i. Margarine reformulation. In the 
November 1999 proposal, in scenarios 2 
through 4, FDA estimated that 30 
percent of margarine products had 
already been reformulated to eliminate 
trans fat, and that all of the remaining 
margarine products would be 
reformulated to remove trans fat by the 
effective date for trans fat labeling.
(Comment 35) A comment stated that 
FDA had overestimated the proportion 
of margarine that had already been 
reformulated and said that the actual 
amount was about 15 percent of 
margarine products. Several comments 
disagreed with FDA’s estimate that all 
margarine would reformulate by the 
effective date for trans fat labeling. 
These comments noted that 
reformulation is very expensive, 
requires a long time to accomplish, and 
would, under certain circumstances, 
require the use of more expensive 
inputs. Other comments stated that 
private benefits of reformulating 
margarine products would not exceed 
the private costs for manufacturers 
unless the margarine products could 
make nutrient content claims. These 
comments gave a number of examples to 
demonstrate that even reformulated 
margarines were not likely to be able to 
comply with the proposed definitions 
for nutrient content claims.
FDA accepts the comment about 
current margarine products. For this 
analysis, FDA estimates that about 15 
percent of margarine has already been 
reformulated to remove trans fat. In 
response to the comments about 
projected margarine reformulation, FDA 
notes that the analysis for the November 
1999 proposal did include the cost of 
reformulation and the time needed for 
reformulation. In that analysis, FDA did 
not include higher ingredient costs for 
margarine reformulation, because the 
price of reformulated margarine 
products that are already on the market 
is no higher than the price of margarine 
products containing 0.5 g or more per 
serving of trans fat. The different 
ingredients used in the products appear 
to have had no impact on the cost of 
production. However, in response to the 
comments, FDA acknowledges that, as 
greater numbers of products are 
reformulated, the increased demand for 
the substitute ingredients may increase 
costs.
As noted earlier regarding consumer 
response to trans fat labeling, the 
declaration of trans fat in this final rule 
is prominent and straightforward. This 
feature may tend to increase the 
incentives for manufacturers to 
reformulate their products to be lower 
in trans fat. However, the provisions of 
this final rule also do not link trans fat 
with saturated fat or with a % DV for 
trans fat and do not change existing 
regulations regarding claims. The 
absence of these features may tend to 
decrease the incentives for 
manufacturers to reformulate their 
products to be lower in trans fat in 
comparison to the incentive that would 
have been introduced by the proposed 
rule. Therefore, in response to the 
comments regarding projected 
margarine reformulation, FDA 
recognizes that different features of this 
final rule may tend to either increase or 
decrease the incentive for reformulation 
in comparison to the incentive that 
would have been introduced by the 
proposed rule.
Although FDA acknowledges 
considerable uncertainty in the 
likelihood of additional margarine 
reformulation, FDA is aware of evidence 
suggesting that at least some margarine 
products are likely to reformulate in 
response to trans fat labeling. As stated 
in the analysis for the proposed rule, in 
several European countries, the actual, 
demonstrated market response to 
consumer concern about trans fat is that 
margarine products have been 
reformulated to reduce or eliminate 
trans fat (64 FR 62746 at 62781) (Refs. 
102, 124, 125, and 127). Also, many 
people who now consume margarine 
products do so in order to consume a 
more heart-healthy product than butter. 
Because the rule would require the 
prominent declaration of the amount of 
trans fat on a separate line below 
saturated fat, these margarine 
consumers are likely to search for 
margarine products with lower levels of 
both saturated fat and trans fat. 
Additionally, publicity generated about 
the issue by consumer groups and the 
media has highlighted margarine as a 
source of trans fat and has given 
prominent attention to reformulated 
margarine products. As more margarine 
products are reformulated, consumer 
groups may shift their focus to those 
remaining margarine products that have 
not reformulated. This suggests that 
with sufficient information on trans fat 
content consumers are likely to pressure 
margarine producers to reduce trans fat. 
This consumer pressure will generate 
some competitive pressures among 
margarine producers to reduce trans fat 
content even in the absence of nutrient 
content claims.
In response to comments received, 
because of the absence of trans fat 
claims in this rule, and recognizing the 
uncertainty, FDA is using a low estimate 
of margarine reformulation in this final 
rule. FDA estimates that reformulation 
will reduce the trans fat content of 
margarines as a whole by 10 percent due 
to trans fat labeling. Because the trans 
fat in margarine accounts for about 0.36 
percent of energy intake, this reduction 
corresponds to a decrease in trans fat 
intake of 0.036 percent of energy. The 
actual decrease may be larger, but FDA 
chose this lower amount so as not to 
overestimate benefits of this rule. The 
additional 10 percent margarine 
reformulation will mean that, including 
previous reformulations, about 23 
percent of trans fat will have been 
removed from margarine. This estimated 
reduction is far lower than the 100 
percent reduction seen in several 
European countries. The estimated 10 
percent reformulation has the advantage 
of being an underestimate. To the extent 
that more trans fat is removed from 
margarine than FDA’s estimate, this 
analysis will underestimate the benefits 
of trans fat labeling.
ii. Reformulation of other products. In 
two scenarios in the November 1999 
proposal, FDA projected that some 
baked products would be reformulated 
to remove trans fat (64 FR 62746 at 
62767). In that analysis, the baked 
products were separated into two 
categories corresponding to SIC codes: 
breads, cakes and similar products (SIC 
code 2051) and cookies and crackers 
(SIC code 2052). Considering the trans 
fat contributions of the two categories of 
baked goods (64 FR 62746 at 62765), the 
overall projected reformulation of baked 
goods corresponded to a 5 percent 
reduction in trans fat intake in scenario 
3 and a 10 percent reduction in scenario 
2.
(Comment 36) A number of comments 
stated that FDA had overestimated the 
proportion of baked goods products that 
would reformulate or the proportion of 
trans fat that could realistically be 
removed from baked goods by 
reformulation. Some comments noted 
that reformulation was very expensive, 
required a long time to accomplish, and 
would under certain circumstances 
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require the use of more expensive 
inputs. Some of these comments, from 
the shortening or baked products 
industries, gave examples of recently 
developed commercial shortenings that 
were lower in trans fat than currently 
used shortenings. Several comments 
stated that, although alternative 
shortenings exist, they may not be a 
practical solution for reformulation 
because of expense or limited supply of 
the alternative shortenings and because 
time and expense for product 
development for reformulation would 
still be needed. Other comments stated 
that the private benefits of reformulation 
would not exceed private costs unless 
the declaration of trans fat on the food 
label was on a separate line on the 
Nutrition Facts panel or was in some 
way more prominent than in the 
November 1999 proposal. Some 
comments emphasized the 
disadvantages of reformulation for the 
cookies and crackers category, stating 
that FDA’s estimate of 15 percent 
reduction in trans fat from those 
products was an overestimate.
In response to the comments about 
difficulties of reformulation, FDA notes 
that the analysis for the November 1999 
proposal did include the cost of 
reformulation and the time needed for 
reformulation, but did not include 
higher ingredient costs for 
reformulation. In the long run, 
ingredient costs may not actually 
increase, because of increased industrial 
capacity to produce ingredients made 
with new technologies. In response to 
the comments about the cookies and 
crackers category, FDA acknowledges 
that its own projection of much higher 
reformulation for this category than for 
other baked products may have been 
unrealistic. Also in response to the 
comments, FDA notes that the 
emergence of commercial shortenings 
with lower trans fat content indicates 
that the reformulation of some baked 
products is feasible. Moreover, within 
these baked product categories there is 
a significant variation in trans fat 
content. Therefore, products with 
significantly higher than average 
amounts of trans fat compared with 
competing products will face 
competitive pressures to reduce the 
amount of trans fat in their products. In 
response to the comment about 
prominence of trans fat on the nutrition 
label, FDA notes that, in this final rule, 
the declaration of trans fat is prominent 
and straightforward, on a separate line 
below trans fat.
After consideration of the comments 
and our own re-evaluation, we continue 
to believe that, ultimately, some 
proportion of baked products will be 
reformulated in most subcategories: 
Crackers, cookies, biscuits, tortillas, 
quick breads and muffins, doughnuts 
and sweet rolls, cakes, pies, pancakes 
and waffles. (In the categories of yeast 
breads and rolls, it is unlikely that 
reformulation will occur because yeast 
breads are relatively low in fat and 
typically contain less than 0.5 g trans fat 
per labeled serving.) However, there 
were disparate views among the 
comments regarding the availability of 
reformulated shortenings and the 
technical difficulty of baked product 
reformulation. Therefore, because of this 
uncertainty, we have opted for a more 
conservative approach and are not 
including a quantitative estimate of 
reformulation of baked goods in the 
analysis of the benefits and cost of trans 
fat labeling. We chose not to include a 
quantitative estimate of reformulation of 
baked goods so as not to overestimate 
the benefits of this rule. To the extent 
that reformulation of baked goods does 
occur, this analysis will underestimate 
the benefits of trans fat labeling.
Because of the existence of 
commercial shortenings with lower 
trans fat content, as pointed out in 
comments, FDA evaluated whether 
trans fat labeling might also result in 
reformulation of household shortenings 
to be lower in trans fat. Current 
household shortenings are lower in 
trans fat than current commercial 
shortenings, with some household 
products having only about half as 
much trans fat as some commercial 
products. This fact suggests that the 
potential for lowering the trans fat 
content of household shortening is not 
as great as the potential for lowering the 
trans fat in current commercial 
shortenings. However, some household 
shortenings are currently making 
comparative saturated fat claims related 
to butter, and household shortenings 
may experience competitive pressure 
from some reformulated stick 
margarines due to trans fat labeling. 
Because of the uncertainty, FDA chose 
not to include a quantitative estimate of 
reformulation of household shortening 
so as not to overestimate benefits of this 
rule. To the extent that reformulation of 
household shortening does occur, this 
analysis will underestimate the benefits 
of trans fat labeling.
(Comment 37) Some comments 
discussed reformulation of other 
products, including potato chips, corn 
chips and similar snacks, microwave 
popcorn, and candy. Several of these 
comments emphasized the difficulty of 
reformulating products in these 
categories because of the expense, the 
time required, and the need for costly 
ingredients. Some of the comments 
suggested that, because of the 
difficulties of reformulation, trans fat 
labeling would put these categories of 
products at a competitive disadvantage. 
Other comments suggested that FDA’s 
projected decrease in trans fat intake 
was an overestimate because trans fat 
labeling would not apply to a major 
source of trans fat: foods eaten at 
restaurants, especially French fried 
potatoes.
FDA did not project quantitative 
decreases in trans fat intake due to 
reformulation of other products, such as 
chips, microwave popcorn and candy, 
because these products contribute a 
smaller proportion of trans fat intake 
and because FDA did not have enough 
information to make quantitative 
reformulation estimates for these 
product categories. FDA is aware of the 
development of stable frying oils low in 
trans fat and suitable for chips, and 
notes that there is interest in 
development of fats and oils lower in 
trans fat for many product categories 
(Refs. 120 to 122 and 151). At least one 
manufacturer has announced the 
reformulation of its snacks and chips to 
decrease trans fat (Ref. 150). To the 
extent that these product categories 
reformulate to decrease trans fat, the 
decrease in trans fat intake projected in 
this analysis will be an underestimate.
FDA acknowledges that a large 
proportion of the U.S. French fried 
potato intake is consumed in 
restaurants. Foods typically consumed 
in restaurants also include other food 
sources of trans fat. Restaurant food is 
not subject to mandatory nutrition 
labeling requirements, unless a 
nutrition-related claim is made. In its 
estimate of reformulation, FDA did not 
project reformulation of French fries or 
of baked goods. Therefore, FDA’s 
estimate did not assume reformulation 
of restaurant foods. However, FDA is 
aware of some interest by restaurants in 
using the absence of trans fat as a 
marketing device to gain competitive 
advantage (Ref. 123). If, as seems 
possible, frying oils and shortenings are 
developed for reformulation of packaged 
foods and become available in the 
market, they may become competitive 
choices with traditional fats and oils, 
even for restaurants that do not wish to 
use absence of trans fat for competitive 
advantage. To the extent that restaurants 
adopt reformulated baking and frying 
oils and purchase other products 
reformulated to be lower in trans fat, the 
decrease in trans fat intake projected in 
this analysis will be an underestimate.
iii. Quantitative decrease in intake. 
Table 2 of this document summarizes 
FDA’s revised estimate of projected 
decreases in trans fat intake due to 
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labeling. In table 2, current trans fat 
intake from margarine is 0.359 percent 
of energy, reduced 15 percent from the 
0.423 percent of energy intake in table 
1 of this document to adjust for the 
estimated 15 percent of margarine that 
has already been reformulated to 
remove trans fat. This adjustment 
reduces the total trans fat intake from 
hydrogenated products to 1.96 percent 
of energy in table 2, compared with 2.03 
percent of energy in table 1. Table 2 
shows that, by the effective date of the 
rule, FDA projects that trans fat intake 
will decrease by 0.0378 percent of 
energy. This decrease will be composed 
of 0.0359 percent of energy due to 
removal of 10 percent of trans fat from 
margarine by reformulation, and an 
additional 0.0019 percent of energy due 
to direct consumer choice. The 
additional 0.0019 percent of energy 
represents 0.1 percent of all remaining 
trans fat from hydrogenated fat after 
margarine reformulation (1.964 percent 
- 0.0359 percent = 1.928 percent; 0.1 
percent x 1.928 percent = 0.0019 
percent).
TABLE 2.—ESTIMATED DECREASES IN Trans FAT INTAKE AND CONTRIBUTION FROM FOOD GROUPS DUE TO LABELING, AT 
EFFECTIVE DATE OF RULE
Food group 
Before Effective Date of Rule 
Change at Effective 
Date of Rule 
Mean daily trans intake1
Decrease in trans fat 
contribution from food 
group Decrease in trans fat intake 
Percent of energy from trans fat 
Percent decrease in 
trans fat 
Decrease in percent of energy 
from trans fat 
Total Margarine 0.359%2 10% 0.0359%
Other food groups with partially hydrogenated 
fats and oils
1.605% none
Total from hydrogenated products 1.964%
Total decrease due to reformulation 0.0359%
Additional decrease due to consumer choice 0.0019%3
Total decrease 0.0378%
1 Trans fat intake for men and women age 20 and over from CSFII 1994–96, see table 1 of this document.
2 Trans fat intake from margarine, 0.359 percent of energy, already decreased by 15 percent from intake in table 1, to account for margarine 
that has already been reformulated to decrease trans fat.
3 Estimated decrease due to consumer choice at effective date is 0.1 percent of all remaining trans fat from hydrogenated fat after margarine 
reformulation.
iv. Substitutions for trans fat. In the 
November 1999 proposal, FDA assumed 
that manufacturers would most likely 
replace trans fat in margarine with: (1) 
Cis-monounsaturated fat, (2) 50 percent 
cis-monounsaturated fat and 50 percent 
cis-polyunsaturated fat, or (3) 50 percent 
cis-monounsaturated fat and 50 percent 
saturated fat, and that they would most 
likely replace trans fat in baked 
products with 50 percent cis-
monounsaturated fat and 50 percent 
saturated fat (64 FR 62746 at 62771). In 
making these assumptions, FDA relied, 
in part, on a report from RTI estimating 
that current food technology would 
require the incorporation of about 0.5 g 
saturated fat for every 1 g trans fat 
removed by reformulation (64 FR 62746 
at 62767).
(Comment 38) Some comments stated 
that FDA had ignored the question of 
macronutrient substitutions, or had 
assumed that reformulation would 
replace trans fat with 100 percent cis-
monounsaturated fat. According to the 
comments, functional requirements for 
margarines, shortenings and baked 
products would require that some trans 
fat be replaced by saturated fat, and this 
requirement was not accounted for in 
FDA’s projections for reformulation. 
Other comments noted FDA’s 
assumptions regarding macronutrient 
substitutions, but stated that FDA had 
overestimated the extent to which trans 
fat could be replaced by cis-unsaturated 
fat, because of functional and cost 
requirements of various products. These 
comments generally implied that FDA 
had overestimated the expected amount 
of reformulation because saturated fat 
would need to replace trans fat in any 
reformulation. Comments pointed out 
that the amount of saturated fat, a 
cholesterol-raising fat, is already 
declared on the nutrition label. 
Therefore, according to the comments, 
replacement of trans fat with saturated 
fat would not provide a competitive 
advantage or an incentive to reformulate 
and, with higher total saturated fat, the 
reformulated product might not meet 
the criteria for proposed defined 
nutrient content claims.
In response to the comments, FDA 
notes that it did consider the type of 
macronutrients substituted for trans fat, 
and these were accounted for in the 
mathematical model used to calculate 
the health benefits (64 FR 62746 at 
62771). FDA is aware that there is a 
range of functional requirements for 
margarines and spreads, including tub 
and stick forms and regular and lower 
fat varieties. Therefore, FDA assumed a 
range of ingredient substitutions for 
margarines and spreads, including both 
saturated and cis-unsaturated fat. 
Replacement of trans fat with a range of 
combinations of saturated and cis-
unsaturated fat in margarines and 
spreads is consistent with reports from 
North America and Europe (Refs. 104, 
124, 125, 126, 127, and 128). In a survey 
of U.S. margarines, tub margarines with 
trans fat less than 0.5 g per serving did 
not have increased saturated fat 
compared with other tub margarines 
(Ref. 104). In the U.S. study, a stick 
margarine with less than 0.5 g trans fat 
per serving had higher saturated fat than 
other stick margarines with comparable 
fat content, but had lower saturated fat 
plus trans fat than the other stick 
margarines (Ref. 104). FDA is aware that 
the functional requirements for baked 
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products and shortenings may not allow 
the wide range of substitutions possible 
in margarines and spreads. Rather, the 
functional requirements for baked 
products will likely require replacement 
of at least some of the trans fat with 
saturated fat. This partial replacement of 
trans with saturated fat is consistent 
with reports by industry observers (Refs. 
121 and 122) and with the examples of 
the alternative commercial shortenings 
described in several of the comments. In 
these examples, the shortenings 
reformulated to be lower in trans fat 
were higher in saturated fat but were 
lower in total saturated fat plus trans fat 
than were the traditional, 
nonreformulated shortenings. Under 
this final rule, products lower in both 
saturated fat and trans fat will have a 
competitive advantage because the rule 
requires prominent declaration of both 
types of fat on the label.
Based on its consideration of the 
comments and its own evaluation, FDA 
continues to believe that the likely 
substitutions for trans fat for margarines 
will be as described in the November 
1999 proposal (64 FR 62746 at 62771). 
FDA does not have enough information 
to project the substitutions for trans fat 
due to direct consumer choice, and 
therefore assumes (for simplicity) that 
direct consumer choice will show the 
same range of substitutions as does 
margarine reformulation. We will 
describe the effects of these 
substitutions for trans fat on the health 
benefits of trans fat labeling in section 
VI.E of this document.
Because of the functional 
requirements for baked products, FDA 
continues to believe that the most 
plausible replacement for trans fat in 
baked products is 50 percent cis-
monounsaturated fat and 50 percent 
saturated fat. However, because of the 
uncertainty in quantitative estimation of 
baked product reformulation, FDA is 
not including baked product 
reformulation in its quantitative 
estimate of benefits and costs of trans fat 
labeling. As note earlier, to the extent 
that baked products are reformulated, 
this analysis will be an underestimate of 
the actual benefits of this rule.
D. Costs
The costs of this rule are the activities 
that change as a result of this rule. The 
total cost of these regulations is the sum 
of the total testing costs, total relabeling 
costs, and total reformulation costs. All 
labels must be in compliance with this 
final rule by a single effective date. All 
costs are estimated at the effective date, 
taken to be 30 months from the 
publication date of this final rule. If the 
effective date is more than 30 months 
from the date of publication, then the 
actual costs of this rule will be lower 
than estimated here.
1. Products Affected
This final rule covers all food and 
dietary supplement labeling within 
FDA’s jurisdiction. With a few 
exceptions, labeling for all FDA 
regulated foods and dietary 
supplements will have to be changed by 
the next uniform effective date 
following publication of this rule, or 
about 2 to 3 years after the date of 
publication. One exception is for 
products with less than 0.5 g trans fat 
per serving that also use the ‘‘simplified 
format’’ for labeling and that do not 
make nutrition claims or declare 
vitamins or minerals. The labeling for 
these products will not have to be 
changed. FDA does not have data to 
estimate how many products fall into 
this category, so the cost estimate does 
not reflect this exception and is 
therefore an overestimate of the actual 
cost of the rule. The other exception is 
for products that sell less than 100,000 
units per year in the United States, that 
are made by firms that have fewer than 
100 employees, that do not make 
nutrition or health claims, and that have 
filed a notification with FDA in 
accordance with § 101.9(j)(18). These 
products are not required to display the 
Nutrition Facts panel that is being 
amended by this rule. Again, FDA does 
not have data to estimate how many 
products fall into this category, so the 
cost estimate does not reflect this 
exception and is therefore an 
overestimate of the actual cost of the 
rule.
To estimate the costs of this rule, FDA 
has used the FDA Labeling Cost Model 
developed for FDA under contract by 
RTI International in April 2002 (Ref. 
129). This labeling model has more 
current data than the previous labeling 
cost model developed for the 
implementing rules of the 1990 
amendments (Ref. 74). The model 
indicates that there are approximately 
308,000 food and dietary supplement 
stock keeping units (SKUs) sold in the 
United States in categories for which 
some products will need to be relabeled. 
A SKU is a specific product sold in a 
specific size. For example, there is one 
SKU for 16 ounce (oz) containers of 
Brand X Diet Peach Tea. The same 
brand and flavor of tea (a product) in a 
12 oz container would be another SKU, 
and a 12 oz container of the same brand 
but different flavor of tea would be still 
another SKU. The model also indicates 
that there are about 154,000 products 
potentially affected by this rule. Table 3 
of this document shows the data on the 
number of SKUs and products affected. 
From the categories listed in table 3 as 
‘‘Selected Baking Ingredients,’’ 
‘‘Selected Candy,’’ ‘‘Selected 
Condiments, Dips and Spreads,’’ and 
‘‘Selected Dressings and Sauces,’’ FDA 
excluded products, such as baking 
powder, bottled water, gum, jam, and 
vinegar, that qualify for the ‘‘simplified’’ 
format and are certain not to be affected 
by this rule. Even with these products 
removed, this estimate is still certain to 
be an overestimate of the actual SKUs 
and products affected by this rule 
because FDA has imputed costs to all 
products and SKUs within these broad 
product categories. Labels on many 
products categories such as ‘‘Selected 
Beverages’’ and ‘‘Dietary Supplements’’ 
are not likely to need to be changed. 
However, FDA has no basis to make 
better estimates of the actual number of 
products and SKUs affected by this rule.
TABLE 3.—NUMBER OF SKUS AND PRODUCTS AFFECTED BY PRODUCT CATEGORY
Product Categories Number of SKUs Number of Products 
Baked Goods 47,200 29,600
Selected Baking Ingredients 7,700 3,300
Baby Foods 1,100 800
Selected Beverages 32,100 8,400
Breakfast Foods 3,600 2,400
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TABLE 3.—NUMBER OF SKUS AND PRODUCTS AFFECTED BY PRODUCT CATEGORY—Continued
Product Categories Number of SKUs Number of Products 
Selected Candy 20,600 12,200
Selected Condiments, Dips and Spreads 15,200 2,300
Dairy Foods 33,800 22,100
Desserts 10,700 7,200
Dietary Supplements 29,500 9,800
Selected Dressings and Sauces 14,200 11,300
Eggs 5,800 1,800
Entrees 10,300 7,900
Fats and Oils 3,100 1,900
Fruits and Vegetables 25,100 2,500
Seafood 6,800 4,200
Side Dishes and Starches 18,000 13,200
Snack Foods 17,800 10,000
Soups 3,700 2,800
Weight Control Foods 1,300 700
Total 307,600 154,400
2. Testing Costs
In the proposed analysis, FDA 
assumed that all product formulations 
that include partially hydrogenated oil 
as an ingredient would be tested to 
determine the quantity of trans fat 
(except for margarine products, which 
were all expected to reformulate). Some 
comments stated that FDA’s estimate of 
the number of products that would need 
to be tested was too low because 
products in other categories than those 
acknowledged by FDA could potentially 
contain a reportable amount of trans fat. 
Indeed, other comments stated that all 
products would have to be tested for 
trans content. FDA disagrees with the 
comment that all products need to be 
tested because manufacturers will know 
that some products do not contain trans 
fat, but does agree that more products 
need to be tested than previously 
estimated. In the proposed analysis, 
FDA estimated costs for testing only for 
the estimated portion of products 
containing partially hydrogenated oil in 
several categories of foods anticipated to 
be most affected by the rule (an 
estimated 42,000 products). In this final 
analysis, based on information in the 
FDA Labeling Cost Model (Ref. 129), 
FDA estimates that about 154,000 food 
products in categories that could 
possibly include trans fat will be tested 
for trans fat content as a result of this 
rulemaking.
In the proposed rule, FDA used a per 
product cost of testing for trans fat of 
$200. Some comments stated that this 
estimate is too low. They stated that 
tests had to be calibrated for each type 
of food to demonstrate accuracy of the 
test in the food matrix. FDA notes that 
manufacturers of many different types 
of foods have already had their products 
tested, so that much of the calibration 
has already been done. The new 
Labeling Cost Model includes data on 
the cost of testing for trans fat. Included 
in the analytical testing estimate is the 
cost of testing two samples of the 
product, one hour of labor to prepare 
and package the product (at $14.73 per 
hour) and delivery charges for one two-
pound package delivered overnight (at 
$26.30). The labor cost estimate was 
based on the average total compensation 
(wages and benefits) for handlers, 
equipment cleaners, helpers, and 
laborers in manufacturing industries. 
Overhead beyond benefits on the time to 
prepare a sample for testing is 
negligible. The model reports a range of 
testing costs for trans fat given in table 
4.
TABLE 4.—RANGE OF PER PRODUCT AND TOTAL TESTING COSTS
Low Medium High 
Cost per Product $261 $291 $371
Total Testing Cost $40,298,000 $44,930,000 $57,282,000
One comment suggested that butter 
and other products with high butter fat 
contents, such as some ice cream, would 
contain a reportable amount of naturally 
occurring trans fat, and that therefore, 
FDA had underestimated the costs of 
testing these products. In this final 
analysis, FDA has included testing and 
relabeling costs for all dairy products 
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including butter and other products that 
are high in butter fat.
3. Relabeling Costs
In the analysis of the proposed rule, 
FDA estimated that 39,000 SKUs were 
associated with the 32,000 products that 
would change their information panels 
at a cost of $30 million. During the 
comment period reopened November 
2002, FDA received comments that we 
would have to reestimate the relabeling 
costs for the final rule. Under this final 
rule many more labels will have to be 
changed than under the proposed rule. 
FDA has used the new Labeling Cost 
Model to reestimate the relabeling costs 
of this final rule. Based on information 
in the model, three-quarters of the labels 
normally will be scheduled to be 
changed during the 30 month 
compliance period. FDA estimates that 
about 78,000 (25 percent) of the almost 
308,000 SKUs will have to be changed 
earlier than would have been planned 
without this rule. Included in the cost 
of relabeling are administrative, graphic 
design, pre-press preparation, printing 
and engraving, and the lost value of 
discarded labels. Across product 
categories, the average low relabeling 
cost per SKU is about $1,100 and the 
average high relabeling cost per SKU is 
$2,600. The reported estimated costs of 
changing labels varies within a product 
category because different packaging 
converters and food manufacturers 
reported different costs to RTI 
International. Table 5 shows the total 
SKUs changed earlier than planned and 
the total estimated costs of relabeling 
per product category and for the entire 
industry.
TABLE 5.—RANGE OF RELABELING COSTS BY PRODUCT CATEGORY
Product Categories SKUs Changed Low Medium High 
Baked Goods 12,500 $10,941,000 $16,137,000 $27,231,000
Baking Ingredients 1,700 $1,615,000 $2,380,000 $3,899,000
Baby Foods 200 $164,000 $249,000 $404,000
Selected Beverages 9,000 $11,871,000 $16,659,000 $25,437,000
Breakfast Foods 1,000 $801,000 $1,237,000 $2,044,000
Selected Candy 4,100 $4,801,000 $6,974,000 $10,846,000
Selected Condiments, Dips and Spreads 3,700 $4,026,000 $5,970,000 $9,283,000
Dairy Foods 8,700 $10,744,000 $16,025,000 $25,032,000
Desserts 3,500 $2,762,000 $4,263,000 $7,042,000
Dietary Supplements 8,100 $13,449,000 $20,110,000 $34,041,000
Selected Dressings and Sauces 2,800 $2,908,000 $4,352,000 $6,757,000
Eggs 2,400 $1,983,000 $2,896,000 $5,086,000
Entrees 2,400 $2,012,000 $3,078,000 $5,032,000
Fats and Oils 800 $759,000 $1,160,000 $1,848,000
Fruits and Vegetables 7,500 $7,426,000 $10,915,000 $17,882,000
Seafood 1,400 $1,732,000 $2,541,000 $3,786,000
Side Dishes and Starches 4,100 $3,361,000 $5,124,000 $8,494,000
Snack Foods 3,600 $3,604,000 $5,288,000 $8,499,000
Soups 700 $809,000 $1,194,000 $1,854,000
Weight Control Foods 200 $196,000 $283,000 $489,000
Total 78,400 $85,964,000 $126,835,000 $204,986,000
4. Margarine Reformulation Costs
One consequence of this regulation 
will be the reformulation of some foods 
to reduce levels of trans fat. Because 
those changes in food composition are 
attributable to this rule, the costs of 
reformulation are counted here. The 
benefits to consumers of being able to 
choose reformulated foods containing 
less trans fat will be counted in section 
VI.E of this document. In the analysis of 
the proposed rule, FDA estimated the 
average reformulation would cost 
$440,000 per product and would take a 
full year. Some comments stated that 
reformulation was very expensive, 
required a long time to accomplish and 
would, under certain circumstances, 
require the use of more expensive 
inputs. No comments contradicted 
FDA’s estimate of the per product cost 
of reformulation or provided 
information to change that estimate, so 
FDA will continue to use a per product 
reformulation cost of $440,000. In the 
proposed analysis FDA assumed that 
only large firms would reformulate. 
There was no controversy over this 
assumption.
As mentioned previously, based on 
comments, FDA estimates that 15 
percent of margarine products have 
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already been reformulated to eliminate 
trans fat. For margarine reformulation, 
FDA has estimated no increase in 
ingredient costs, because the price of 
reformulated margarine products that 
are already on the market is no higher 
than the price of margarine products 
containing 0.5 g or more per serving of 
trans fat. The different ingredients used 
in the products appear to have had no 
impact on the cost of production. 
However, as greater numbers of 
products are reformulated, the increased 
demand for the substitute ingredients 
may increase costs. However, given that 
increases in costs of inputs, if any, have 
not been passed on with a change in 15 
percent of margarine products, it seems 
quite reasonable that an additional 
smaller change (10 percent) will not 
result in significant increases in 
ingredient costs.
Therefore, FDA estimates that 10 
percent of the margarine products that 
have not yet been reformulated will be 
reformulated to reduce trans fat content 
to less than 0.5 g per serving. We 
assume that reformulating 10 percent of 
margarine products will result in a 10 
percent reduction in the average trans 
fat content of margarine as a product 
category. The reformulation will 
therefore reduce the trans fat content of 
margarines as a whole by 10 percent. In 
the analysis for the proposed rule, FDA 
estimated that there were 820 margarine 
products. Data in the new Labeling Cost 
Model indicate only 300 margarine 
products. The new data was used to 
estimate that 30 margarine products will 
reformulate as the result of this rule 
from 8 (10 percent of 84) to 82 (10 
percent of 820), if 10 percent of the total 
number of margarine products are 
reformulated. Table 6 shows the cost of 
margarine reformulation.
TABLE 6.—COST OF MARGARINE REFORMULATION
Cost of Reformulating per Product $440,000
Products Reformulating 30
Total Cost $13,200,000
FDA has not attempted to estimate the 
ongoing increased cost of substitutes for 
partially hydrogenated oil. Competition 
provides producers with incentives to 
use the least expensive ingredients that 
are acceptable for the quality of product 
they are making. Therefore, in general, 
any change in existing formulations 
(such as is expected to occur as a result 
of this rule) can increase the cost of 
ingredients. Even a very small increase 
in the price of a minor ingredient can 
amount to an increase in production 
costs of millions of dollars when 
multiplied by millions of units. 
However, there is good reason to believe 
that, in the long run, ingredient costs 
may not increase. To the extent that 
producers rely on newly formulated 
ingredients made with new 
technologies, the price of these 
ingredients largely depends on the 
industrial capacity to produce them. As 
the demand for such ingredients 
increases, producers will have more 
incentive to increase capacity and the 
prices of these ingredients will fall. In 
the case where producers make use of 
different mixes of oils, agricultural 
inputs are well known for being able to 
be supplied in greater and greater 
quantities without an increase in price. 
FDA does not have sufficient 
information on the types of substitutes 
that will be used, on the volume of 
substitutes that will be needed, or on 
the future price of the substitutes at the 
time that reformulation is completed.
5. Cost Summary
Costs for testing, relabeling, and 
reformulation are all expected to occur 
by the first effective date of the final 
rule, or about 2 to 3 years after 
publication. Table 7 shows the estimates 
of total cost.
TABLE 7.—RANGE OF COSTS BY CATEGORY AND TOTAL COST
Cost Category Low Medium High 
Testing $40,298,000 $44,930,000 $59,282,000
Relabeling $85,964,000 $126,835,000 $204,986,000
Reformulation $13,200,000 $13,200,000 $13,200,000
Total $139,000,000 $185,000,000 $275,000,000
FDA acknowledges that there is a 
significant degree of uncertainty in the 
cost estimates provided here. The most 
significant source of potential 
divergence from the reported estimates 
would be an ongoing increased cost of 
substitutes for partially hydrogenated 
oil for producers of reformulated 
products. FDA has not included any 
costs for this item in this analysis, so 
that, if substitute oils do cost more, the 
costs here are underestimates.
Reformulation is a second significant 
area of uncertainty. The unknowns 
include the number of products that 
will be reformulated, the cost of 
reformulation, the number of abandoned 
attempts at reformulation, the length of 
time actually needed to reformulate 
products, and the degree to which the 
reformulation of some products reduces 
the cost of reformulating other products 
of the same or different type. The 
estimates that are provided in this 
analysis might be either over- or 
underestimates of the actual costs of 
reformulation.
A third major area of uncertainty 
includes the number of labels that will 
be changed. Actual costs are likely to be 
lower than those estimated here because 
this analysis estimated costs based on 
broad categories of products some of 
which will not have to change their 
labels.
E. Benefits
To estimate the health benefits of 
trans fat labeling in the November 1999 
proposal, FDA followed the general 
approach used to estimate the health 
VerDate Jan<31>2003 15:26 Jul 10, 2003 Jkt 200001 PO 00000 Frm 00046 Fmt 4701 Sfmt 4700 E:\FR\FM\11JYR2.SGM 11JYR2
41479Federal Register / Vol. 68, No. 133 / Friday, July 11, 2003 / Rules and Regulations 
benefits for the implementation of the 
1990 amendments (56 FR 60856 at 
60869, November 27, 1991). 
Accordingly, FDA estimated: (1) The 
changes in trans fat intake that would 
result from labeling changes; (2) the 
changes in health states that would 
result from changes in trans fat intakes; 
and (3) the value of changes in health 
states in terms of life-years gained, 
number of cases or deaths avoided and 
dollar value of such benefits. The rule 
may generate other benefits, but we do 
not quantify them. For example, 
consumers who are aware of the risks 
associated with trans fat will more 
readily find information on the trans fat 
content of various foods. The value of 
the reduction in search time for those 
consumers is an additional benefit of 
this final rule.
1. Changes in Trans Fat Intake
FDA has estimated the current trans 
fat intake of the population and the 
estimated changes in trans fat intake. 
Based on comments received and on its 
own reevaluation, FDA revised its 
estimate of current trans fat intake, 
shown in table 1 (section IX.C) and its 
projected estimate for changes in trans 
fat intake due to labeling (table 2, 
section IX.C). The estimate projects 
quantitative decreases in trans fat intake 
with implementation of the final rule, 
and discusses the qualitative 
replacement of trans fat by other types 
of fat.
2. Changes in Health States
In the November 1999 proposal, FDA 
used two methods to estimate the 
potential decrease in CHD likely to 
result from decreased intake of trans fat 
in response to the labeling change.
a. Method 1. Decrease in CHD risk due 
to decreased serum concentrations of 
LDL–C.
b. Method 2. Decrease in CHD risk 
due to decreased serum concentrations 
of LDL–C and increased serum 
concentrations of HDL–C. FDA also 
reviewed the association of CHD risk 
with trans fat intake found in large 
prospective observational cohort 
studies.
As described in section IV of this 
document, in the November 1999 
proposal FDA concluded that the effects 
of trans fatty acids on serum LDL–C 
should be the primary criterion for 
whether trans fatty acids influence CHD 
risk. In Method 1, FDA used changes in 
the primary criterion, serum LDL–C, to 
evaluate the effects of trans fat intake on 
CHD risk (64 FR 62746 at 62768). 
Additionally, as described in section IV 
of this document, although FDA did not 
place primary reliance upon the 
relationships among trans fat intakes 
and adverse effects on HDL–C and CHD 
risk in deciding that nutrition labeling 
was warranted, FDA also recognizes this 
possible relationship, so concerns about 
possible adverse effects cannot be 
ignored. Therefore, the economic 
analysis used changes in both HDL–C 
and LDL–C as a second method to 
quantify the effects of trans fat intake on 
CHD risk, with the noted qualification 
that the primary basis for the rule was 
the effect of trans fat on LDL–C (64 FR 
62746 at 62769).
Section IV of this document notes that 
observational epidemiological studies 
can provide evidence of an association 
between a risk factor and a disease, but 
cannot establish direct cause and effect. 
Therefore, FDA considered the evidence 
from observational epidemiological 
studies, including large prospective 
(cohort) studies, as indirect evidence for 
a relationship between trans fat intake 
and CHD risk. In the November 1999 
proposal, FDA found that the 
prospective studies of trans fat intake 
and CHD risk consistently reported a 
greater risk of CHD attributable to trans 
fat intake than would be accounted for 
by either Method 1 (changes in LDL–C) 
or by Method 2 (changes in both LDL–
C and HDL–C) (64 FR 62746 at 62770 to 
62771). The estimates in Method 1 and 
Method 2 are calculated using factors 
from regression equations summarizing 
the results of short-term feeding trials 
(intervention studies). In the 
intervention studies, trans fat is fed to 
people for a few weeks, changes in 
serum lipids are measured, and it is 
assumed that the CHD risk associated 
with trans fat intake occurs through the 
mechanism of changes in LDL–C and 
possibly HDL–C. In contrast, the 
prospective studies measure actual CHD 
occurrence in a large group of people 
over a period of years, and describe all 
CHD risk associated with trans fat 
intake, regardless of the mechanism of 
action by which trans fat intake may be 
associated with CHD. Thus, the results 
of the prospective studies suggest that 
there may be additional mechanisms by 
which trans fat contributes to CHD risk. 
Because prospective studies do not 
show direct cause and effect, and 
because the relative risks determined in 
observational studies are imprecise, 
FDA did not use the results of the 
prospective studies in quantitative 
estimates of changes in trans fat intake 
and CHD risk. However, FDA noted 
that, if there are additional mechanisms 
by which trans fat contributes to CHD 
risk, as suggested by the prospective 
studies, then the actual benefits may be 
greater than estimated using either 
Method 1 (changes in LDL–C) or 
Method 2 (changes in LDL–C and HDL–
C) (64 FR 62746 at 62771).
As described in the November 1999 
proposal (64 FR 62746 at 62768 and 
62769), the regression equations of 
Katan et al. (Ref. 62) and Zock et al. (Ref. 
69) were based on five intervention 
studies that made, in total, six dietary 
comparisons between consumption of 
trans fat and cis-unsaturated fat (Refs. 7, 
8, and 11 through 13). The regression 
equation for LDL-C showed that each 
additional percent of energy from trans 
fat was predicted to increase LDL-C by 
1.5 mg/deciliter (dL) (0.040 millimol/
liter) (R2 = 0.86, p = 0.0028) when 
substituted for the same percent of 
energy from cis-monounsaturated fat, 
holding total energy intake constant. 
The regression equation for HDL-C 
showed that each additional percent of 
energy from trans fat was predicted to 
decrease HDL-C by 0.4 mg/dL (0.013 
millimol/liter) (R2 = 0.88, p = 0.0019), 
when substituted for the same percent 
of energy from cis-monounsaturated fat. 
The regression lines were forced 
through the origin because a zero 
change in intake will produce a zero 
change in lipoprotein concentrations 
(Refs. 62, 69, and 154). In carrying out 
the regression, differences between diets 
in fatty acids other than trans fat and 
cis-monounsaturated fat were adjusted 
for by using regression coefficients from 
a previous meta-analysis of 27 
intervention studies (Ref. 65).
Sample calculations using Method 1 
and Method 2 are summarized in table 
8 in this document. The table illustrates 
a decrease in trans fat intake of 0.1 
percent of energy (calories) and shows 
the factors FDA used to relate a given 
decrease in trans fat intake to a 
corresponding change in CHD risk. To 
estimate the change in CHD risk with 
change in trans fat intake, for each type 
of serum lipid, LDL-C and HDL-C, we 
multiplied the change in trans fat intake 
by three factors, representing: (1) the 
change in serum lipid with change in 
trans fat intake, (2) the change in CHD 
risk with change in serum lipid, and (3) 
an adjustment for regression dilution. 
Table 8 shows that, for Method 1, based 
on changes in LDL-C, replacement of 0.1 
percent of energy from trans fat with the 
same percent of energy from cis-
monounsaturated fat would decrease 
CHD risk by 0.147 percent (-0.1 percent 
of energy from trans fat x 1.5 mg LDL-
C/dL per percent of energy from trans 
fat x 0.7 percent change in CHD risk per 
mg LDL-C/dL x 1.4 adjustment factor for 
regression dilution = -0.147 percent 
change in CHD risk). Based on changes 
in HDL-C, replacement of 0.1 percent of 
energy from trans fat would decrease 
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CHD risk by 0.140 percent (-0.1 percent 
of energy from trans fat x -0.4 mg HDL-
C/dL per percent of energy from trans 
fat x -2.5 percent change in CHD risk per 
mg HDL-C/dL x 1.4 adjustment factor 
for regression dilution = -0.140 change 
in CHD risk based on changes in HDL-
C). For Method 2, based on changes in 
both LDL-C and HDL-C, the decrease in 
CHD risk would be 0.287 percent (-0.147 
percent based on LDL-C plus -0.140 
percent based on HDL-C = -0.287 
percent based on LDL-C + HDL-C). FDA 
used these estimation methods to 
project the decrease in CHD risk in the 
November 1999 proposal (64 FR 62746 
at 62767).
TABLE 8.—SAMPLE CALCULATION FOR CHANGE IN CHD RISK WITH SUBSTITUTION OF Cis-MONOUNSATURATED FAT FOR 
Trans FAT
Estimation Method 
Change in 
Trans Intake 
(% of Energy) 
Type of Serum 
Lipid 
Factor for 
Change in 
Serum Lipids 
(mg/dL per 1% 
of Energy) 
Factor for 
Change in 
CHD Risk (% 
per mg/dL) 
Factor for 
Adjustment of 
Regression 
Dilution 
Change in 
CHD Risk (%) 
Method 1 LDL -0.1 LDL 1.5 0.7 1.4 -0.147
Method 2 LDL + HDL -0.1 LDL 1.5 0.7 1.4 -0.147
HDL -0.4 -2.5 1.4 -0.14
LDL+HDL -0.287
In the scientific literature, cis-
monounsaturated fat is commonly used 
as a reference point in describing effects 
of trans fat intake. Therefore, FDA first 
estimated the effect on CHD risk by 
assuming that a given amount of trans 
fat would be replaced by the same 
amount of cis-monounsaturated fat in 
the diet (table 8 in this document and 
64 FR 62746 at 62767). However, it is 
likely that trans fat in the diet would 
actually be replaced by a combination of 
cis-monounsaturated fat, cis-
polyunsaturated fat, and saturated fat. 
Therefore, FDA also considered the 
changes in LDL–C and HDL–C 
associated with replacement of trans fat 
by different types of fatty acids or 
carbohydrate (64 FR 62746 at 62767 to 
62770). Table 9 in this document 
summarizes the factors for changes in 
LDL–C and HDL–C with different 
macronutrients and combinations of 
macronutrients replaced by trans fat. 
The first four columns of data show the 
factors for substitution of trans fat for 
100 percent of individual types of fatty 
acids or carbohydrate. We project that, 
due to trans fat labeling, trans fat will 
be replaced by combinations of different 
types of fatty acids or carbohydrate. By 
combining the factors in the first four 
data columns, we obtained the factors 
for substitution of trans fat for 
combinations of different fatty acids and 
carbohydrate, shown in the last three 
data columns.
We generated the factors in table 9 by 
combining the results of two sets of 
metaanalyses. Table 9 shows the result 
of linking: (1) The regression equation 
coefficients of Katan et al. (Ref. 62) and 
Zock et al. (Ref. 69), for substitution of 
trans fat for cis-monounsaturated fat 
and (2) the regression equation 
coefficients of Mensink and Katan (Ref. 
65), for substitution of saturated and cis-
unsaturated fat for carbohydrate. The 
regression equations of Mensink and 
Katan (Ref. 65) were based on 27 
intervention studies that made dietary 
comparisons for consumption of 
carbohydrate, saturated fat, cis-
polyunsaturated fat and cis-
monounsaturated fat. The regression 
equation for LDL-C included 57 dietary 
comparison data points from 24 studies, 
and showed that, holding total energy 
intake constant, when substituted for 
one percent of energy from 
carbohydrate, each additional percent of 
energy from saturated fat was predicted 
to increase LDL-C by 1.28 mg/dL (0.033 
millimol/liter) (p < 0.001), each 
additional percent of energy from cis-
monounsaturated fat was predicted to 
lower LDL-C by 0.24 mg/dL (0.006 
millimol/liter) (p = 0.114) and each 
additional percent of energy from cis-
polyunsaturated fat was predicted to 
lower LDL-C by 0.55 mg/dL (0.014 
millimol/liter) (p = 0.002). The 
regression equation for HDL-C included 
59 dietary comparison data points from 
25 studies, and showed that holding 
total energy intake constant, when 
substituted for one percent of energy 
from carbohydrate, each additional 
percent of energy from saturated fat was 
predicted to increase HDL-C by 0.47 mg/
dL (0.012 millimol/liter) (p < 0.001), 
each additional percent of energy from 
cis-monounsaturated fat was predicted 
to increase HDL-C by 0.34 mg/dL (0.009 
millimol/liter) (p < 0.001) and each 
additional percent of energy from cis-
polyunsaturated fat was predicted to 
increase HDL-C by 0.28 mg/dL (0.007 
millimol/liter) (p = 0.002).
Comparison with the observed data 
showed that the predicted regression 
lines explained 64 percent of the 
variation in changes in LDL-C and 88 
percent of the variation in changes in 
HDL-C. The coefficients of Mensink and 
Katan (Ref. 65) are expressed as 
substitution of each type of 
macronutrient for carbohydrate, but the 
coefficients of Katan et al. (Ref. 62) and 
Zock et al. (Ref. 69) are expressed as 
substitution of trans fat for cis-
monounsaturated fat. For comparability 
with the coefficients for trans fat, we 
expressed the coefficients of Mensink 
and Katan in terms of substitution of 
each type of macronutrient for cis-
monounsaturated fat. As stated in the 
November 1999 proposal (64 FR 62746 
at 62769), when substituted for one 
percent of energy from cis-
monounsaturated fat, saturated fat 
raised LDL-C by 1.52 mg/dL, cis-
polyunsaturated fat lowered LDL-C by 
0.31 mg/dL, and carbohydrate raised 
LDL-C by 0.24 mg/dL. When substituted 
for one percent of energy from cis-
monounsaturated fat, saturated fat 
raised HDL-C by 0.13 mg/dL, cis-
polyunsaturated fat lowered HDL-C by 
0.06 mg/dL, and carbohydrate lowered 
HDL-C by 0.34 mg/dL. We then 
combined these coefficients with the 
coefficients for trans fat, to obtain the 
changes in lipoprotein levels with trans 
fat substituted for different 
macronutrients, as shown in table 9.
Table 9 also gives examples of 
changes in CHD risk with replacement 
of 0.1 percent of energy from trans fat 
by different macronutrients and 
combinations of macronutrients. Table 8 
shows the general method and 
illustrates the calculation of estimated 
changes in CHD risk with replacement 
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of trans fat by cis-monounsaturated fat. 
To account for each type of 
macronutrient substitution, we used the 
corresponding factors from table 9 for 
changes in serum lipids. For example, 
for cis-polyunsaturated fat, table 9 gives 
the factor, 1.81 mg LDL-C/dL, for 
replacement of 1 percent of energy from 
cis-polyunsaturated fat by trans fat. For 
Method 1, based on changes in LDL-C, 
the replacement of 0.1 percent of energy 
from trans fat with the same percent of 
energy from cis-polyunsaturated fat 
would decrease CHD risk by 0.177 
percent (-0.1 percent of energy from 
trans fat x 1.81 mg LDL-C/dL per 
percent of energy from trans fat x 0.7 
percent change in CHD risk per mg LDL-
C/dL x 1.4 adjustment factor for 
regression dilution = -0.177 percent 
change in CHD risk). As noted 
previously, we project that, due to trans 
fat labeling, trans fat will be replaced by 
combinations of different types of fatty 
acids or carbohydrate. The changes in 
CHD risk associated with specific 
combinations of fatty acids or 
carbohydrate are shown in the last three 
data columns. The first four data 
columns show the change in CHD risk 
associated with each individual type of 
fatty acid and carbohydrate. The column 
showing trans fat replaced by 100 
percent saturated fat is included in table 
9 for completeness in illustrating the 
data and methods we used to estimate 
changes in CHD risk with different 
macronutrient substitutions. The 
inclusion of this column does not 
indicate that FDA projects that trans fat 
will be replaced by 100 percent 
saturated fat, or that FDA would 
encourage such an inappropriate 
substitution. Rather, the substitutions 
for trans fat that FDA considers most 
likely are shown later, in table 10.
As mentioned earlier, and in the 
November 1999 proposal (64 FR 62746 
at 62769), the economic analysis used 
changes in both LDL-C and HDL-C as a 
second method to quantify the effects of 
trans fat intake on CHD risk, with the 
noted qualification that the primary 
basis for the rule was the effect of trans 
fat on LDL-C. To allow readers to 
reproduce all of our estimated changes 
in CHD risk, table 9 shows changes in 
CHD risk based on Method 2, LDL-C and 
HDL-C, as well as Method 1, LDL-C. In 
addition, the cells that show a decrease 
in CHD due to a 100 percent 
replacement of trans fat for saturated fat 
represent the relationship between HDL-
C and CHD, a relationship that is more 
uncertain than the causal relationship 
between LDL-C and CHD. FDA 
accounted for the replacement of trans 
fat with different combinations of 
macronutrients by projecting a range of 
changes in health states in terms of life-
years gained, number of cases or deaths 
avoided, and dollar value of such 
benefits (64 FR 62746 at 62771–62773).
TABLE 9.—SUMMARY OF CHANGES IN SERUM LIPIDS AND CHD RISK WITH DIFFERENT MACRONUTRIENT SUBSTITUTIONS 
A. CHANGE IN SERUM LIPIDS WITH SUBSTITUTION OF Trans FATTY ACIDS FOR DIFFERENT TYPES OF FATTY ACIDS 
OR CARBOHYDRATE
Macron-
utrient 
Cis-
monounsaturated 
Fatty Acid 
Cis-
polyunsaturated 
Fatty Acid 
Saturated 
Fatty Acid 
Carbohydrate Half cis-
monounsaturated 
and half cis-
polyunsaturated 
Half cis-
monounsaturated 
and half saturated 
Half cis-
monounsaturated 
and half
carbohydrate Change in 
Serum 
Lipid 
When Re-
placed by 
Trans Fat 
mg/dL per 1% of 
energy 
mg/dL per 1% 
of energy 
mg/dL per 
1% of energy 
mg/dL per 
1% of energy mg/dL per 1% of 
energy 
mg/dL per 1% of 
energy mg/dL per 1% of energy 
LDL 1.5 1.81 -0.02 1.26 1.66 0.74 1.38
HDL -0.4 -0.34 -0.53 -0.06 -0.37 -0.47 -0.23
B. CHANGE IN CHD RISK WITH REPLACEMENT OF Trans FATTY ACIDS BY DIFFERENT TYPES OF FATTY ACIDS OR 
CARBOHYDRATE
Macronutrient Cis-
monounsatura-
ted Fatty Acid 
Cis-
polyunsat-
urated Fatty 
Acid 
Saturated 
Fatty Acid 
Carbohydrate Half cis-
monounsatura-
ted and half 
cis-
polyunsatura-
ted 
Half cis-
monounsatura-
ted and half 
saturated 
Half cis-
monounsatura-
ted and half
carbohydrate 
Change in CDH Risk With 
Replacment of Trans Fat Percent per 0.1% of 
energy 
Percent per 
0.1% of 
energy 
Percent per 
0.1% of 
energy 
Percent per 
0.1% of 
energy Percent per 
0.1% of 
energy 
Percent per 
0.1% of 
energy 
Percent per 
0.1% of 
energy 
Method 1, LDL -0.147 -0.177 0.002 -0.123 -0.162 -0.073 -0.135
HDL -0.140 -0.119 -0.186 -0.021 -0.130 -0.163 -0.081
Method 2, LDL + HDL -0.287 -0.296 -0.184 -0.144 -0.292 -0.235 -0.216
(Comment 39) As described 
previously in this document, FDA 
received numerous comments in 
support of the November 1999 proposal. 
Several of these comments noted 
specifically that labeling of trans fat has 
the potential for substantial public 
health benefits. A number of comments 
noted that consumption of trans fat 
increases the risk of CHD by increasing 
total blood cholesterol and LDL–C, and 
that trans fat labeling would enable 
consumers to decrease their trans fat 
intake and therefore decrease their risk 
of CHD. Some comments added that, 
because trans fat also increases the risk 
of CHD by decreasing HDL–C, therefore 
the health benefits of trans fat labeling 
would be greater than the benefits 
associated with the effect of trans fat on 
LDL–C alone. A few comments 
VerDate Jan<31>2003 15:26 Jul 10, 2003 Jkt 200001 PO 00000 Frm 00049 Fmt 4701 Sfmt 4700 E:\FR\FM\11JYR2.SGM 11JYR2
41482 Federal Register / Vol. 68, No. 133 / Friday, July 11, 2003 / Rules and Regulations 
specifically stated that the prospective 
studies suggest that there may be other 
biological mechanisms by which trans 
fat contributes to CHD, in addition to 
the effects of trans fat on LDL–C and 
HDL–C. These comments therefore 
supported the possibility that the actual 
benefits of trans fat labeling may be 
greater than FDA’s estimate using either 
Method 1 (LDL–C) or Method 2 (LDL–
C and HDL–C).
Other comments, which were 
opposed to the November 1999 proposal 
or some of its provisions, questioned 
FDA’s conclusions regarding the net 
health benefits of trans fat labeling. 
Some comments stated that the 
potential harm to the public remedied 
by trans fat labeling was not sufficient 
to outweigh the cost burden to specific 
industries. These comments suggested 
that, although trans fat was shown to 
increase LDL–C in some studies, the 
evidence was inconclusive on how to 
quantify the increase in LDL–C and 
CHD risk due to trans fat intake and on 
whether the increase in LDL–C and CHD 
risk due to trans fat intake were as large 
as those due to saturated fat. These 
comments suggested that FDA’s 
estimate of health benefits of trans fat 
labeling was too high. One comment 
stated that it is premature to conclude 
that trans fat intake lowers HDL–C 
because many intervention studies 
showed that trans fat intake causes only 
a small decrease or has no effect on 
HDL–C. The comment implied that 
consumption of trans fat may not 
increase CHD risk by decreasing HDL–
C. A few comments cited an FDA 
statement from the November 1999 
proposal that no dose-response 
relationship had been demonstrated 
between trans fat intake and CHD (64 
FR 62746 at 62752). The comments 
argued that, therefore, it is not possible 
to project quantitative health benefits 
due to trans fat labeling. One comment 
also stated that the health benefits 
estimate was inaccurate because it did 
not account for either other CHD risk 
factors, such as obesity, or other CHD 
prevention efforts.
A few comments questioned whether 
health benefits could result from trans 
fat labeling because the in the 
intervention studies the intakes of trans 
fat were very high and not 
representative of U.S. intakes of about 
5.3 g/d (3 percent of calories). Some 
comments stated that, even if trans fat 
has adverse health effects at higher 
levels of intake, there is no clinical 
evidence that lower levels of intake, 
such as 0.5 g trans fat in a serving of a 
food product, has any adverse effect. 
These comments therefore questioned 
whether health benefits could result 
from labeling of trans fat present in 
relatively small amounts in individual 
foods. Other comments suggested that 
the emphasis on trans fat in the 
proposed labeling regulations was out of 
proportion to the emphasis on saturated 
fat, because the overall amount of 
saturated fat in the diet is approximately 
five times that of trans fat. The 
comments stated that, therefore, 
decreased trans fat intake has much less 
potential for lowering CHD risk than 
does decreased saturated fat intake, and 
this should be considered when 
estimating the health benefits of trans 
fat labeling.
Regarding the comments that 
questioned whether the increase in 
LDL–C and CHD risk due to trans fat 
intake could be quantified and whether 
the increase in LDL–C and CHD risk due 
to trans fat intake were as large as those 
due to saturated fat, FDA stated in the 
review of the science in the 1999 
proposal (64 FR 62746 at 62753) that the 
available studies did not provide a 
definitive answer about whether trans 
fat has an effect on LDL–C and CHD risk 
equivalent to saturated fat on a gram-for-
gram basis. FDA noted that 
interpretation of the intervention 
studies is complicated because, in the 
individual studies, trans fatty acids 
replace other dietary fatty acids that also 
affect serum cholesterol levels (64 FR 
62746 at 62751). This evaluation was 
based on a review and analysis of the 
individual studies, it was not done for 
purposes of an economic analysis. To 
overcome the difficulties in interpreting 
individual intervention studies, in the 
November 1999 proposal FDA used 
regression equations based on a meta-
analysis of intervention trials to 
quantitatively estimate the relationship 
between trans fat and LDL (Refs. 62, 65, 
and 69) in its calculation of the health 
benefits of trans fat labeling (64 FR 
62746 at 62768–62770). As noted in 
section IV of this document, and in the 
November 1999 proposal, the regression 
equations do predict a very similar 
increase in LDL–C with each one 
percent of energy increase in either 
saturated fat or trans fat. Thus, table 9 
in this document shows that the change 
in LDL–C is negligible when one 
percent of energy from trans fat is 
substituted for saturated fat. Therefore, 
FDA disagrees with the comments that 
stated that the increases in LDL–C and 
CHD risk due to trans fat intake could 
not be quantified and were not as large 
as those due to saturated fat and that 
FDA’s estimate of these health benefits 
of trans fat labeling was too high.
Regarding the comment suggesting 
that it is premature to conclude that 
trans fat intake lowers HDL–C, section 
IV of this document states that Federal 
Government advisory groups (Refs. 88 to 
90, 140) and an advisory group of health 
professionals (Ref. 91) have stated that 
substitution of trans fat for saturated fat 
lowers HDL–C. Specifically, the Dietary 
Guidelines 2000 Advisory Report states 
that trans fatty acids tend to lower a 
protective form of serum cholesterol 
(HDL cholesterol) (Ref. 88). NCEP 2001 
states that randomized clinical trials 
show that when trans fatty acids are 
substituted for saturated fatty acids, 
HDL cholesterol levels are lower, with 
a dose response effect observed (Ref. 
89). The IOM/NAS states that the 
preponderance of the data suggest that 
hydrogenated fat/trans fatty acids, 
relative to saturated fatty acids, result in 
lower HDL cholesterol concentrations 
(Ref. 90). AHA 2000 states that it has 
been established that dietary trans-
unsaturated fatty acids can increase LDL 
cholesterol and reduce HDL cholesterol 
(AHA 2000, p. 2300) (Ref. 91). 
Therefore, FDA disagrees with the 
comment that it is premature to 
conclude that trans fat intake may lower 
HDL–C. As described in Section IV of 
this document, although FDA did not 
place primary reliance upon the 
relationships among trans fat intakes 
and adverse effects on HDL–C and CHD 
risk in deciding that nutrition labeling 
was warranted, FDA also recognizes this 
possible relationship, so concerns about 
possible adverse effects cannot be 
ignored. Therefore, we used changes in 
both HDL–C and LDL–C as a second 
method to quantify the effects of trans 
fat intake on CHD risk, with the noted 
qualification that the primary basis for 
the rule was the effect of trans fat on 
LDL–C (64 FR 62746 at 62769).
Regarding the comments discussing 
FDA’s statement in the November 1999 
proposal (64 FR 62746 at 62752) that no 
dose response relationship had been 
demonstrated between trans fat intake 
and CHD, this statement referred to the 
effect of trans fat on CHD risk in the 
observational studies, not to the effect of 
trans fat on LDL–C which was used to 
estimate the health benefits in Method 
1 (LDL–C) and Method 2 (LDL–C and 
HDL–C). FDA’s statement was a 
generalization regarding the 
observational studies overall, including 
both case control studies and 
prospective observational studies. 
However, the four large prospective 
studies did all show dose-response 
relationships between trans fat intake 
and CHD risk, but in two of the studies 
the dose-response relationship was not 
statistically significant in all analyses. 
In the Nurses Health Study, the dose 
response relationship at both 8 years 
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and 14 years of followup was highly 
statistically significant (Refs. 21 and 38). 
In a Finnish study, the dose response 
relationship of trans fat with risk of 
CHD death was significant (p = 0.004), 
but was not significant for risk of major 
coronary event (p = 0.158) (Ref. 20). In 
a study of U.S. men, the dose response 
relationship was significant after 
statistical adjustment for major CHD risk 
factors (p = 0.01) but was not significant 
after additional adjustment for dietary 
fiber (p = 0.2) (Ref. 19). Therefore, the 
prospective studies were consistent 
with a dose-response relationship, 
although the relationship was not 
statistically significant in all analyses. 
Moreover, as discussed previously in 
this section, FDA’s quantitative estimate 
of health benefits was not based on the 
prospective studies, but was based on 
the regression equations summarizing 
the results of the intervention feeding 
studies (tables 8 and 9 in this document 
and 64 FR 62746 at 62757–62770). The 
regression equations summarizing the 
effect of trans fat on LDL–C and HDL–
C in the intervention studies did show 
a dose response relationship, as 
discussed in the November 1999 
proposal and noted in section IV of this 
document. Additionally, the regression 
equations used by FDA in this 
document and in the November 1999 
proposal were for purposes of making a 
quantitative estimate of the health 
benefits as part of an economic analysis 
and are consistent with newer 
regression equations in a study 
published in 2001 (Ref. 130). Therefore, 
FDA does not agree with the comment 
that it is not possible to calculate health 
benefits because there is no dose-
response relationship for the adverse 
effects of trans fat.
FDA disagrees with the comment that 
the health benefits estimate did not 
account for other CHD risk factors. In 
the health benefits estimate, FDA used 
the factors shown in table 8 to calculate 
the amount of CHD risk associated with 
the expected amount of change in LDL–
C and HDL–C. These factors were 
derived from large population studies of 
serum lipids and CHD risk, in which 
statistical methods accounted for other 
positive and negative risk factors for 
CHD.
Regarding the comment about the 
level of trans fat intake in the 
intervention studies, Section IV of this 
document explains that, because of 
uncertainty in intake estimates, caution 
must be exercised to avoid over-
interpretation of the available dietary 
intake estimates and their relationship 
to the trans fat levels used in the 
intervention trials. However, in 
response to the comment, FDA notes 
some specific examples of intervention 
studies with lower trans fat intake. One 
example is the study of Judd et al., 1998 
(Ref. 34), which found a significant 
increase in LDL–C with a difference in 
trans fat intake of 1.5 percent of calories 
between the trans fat test diet (3.9 
percent of calories from trans fat) and 
the comparison diet (2.4 percent of 
calories from trans fat). Another 
example is the study of Lichtenstein and 
coworkers (Ref. 82) which studied six 
test diets and reported a positive 
coefficient, i.e., a linear trend, for the 
association of the change in LDL–C 
levels among diets with the change in 
trans fat intake (including trans fat 
changes of 0.4 percent and 2.8 percent 
of calories). Such a linear trend does 
suggest that trans fat intakes below 3 
percent of calories may influence LDL–
C levels, and thus, CHD risk. Therefore, 
significant increases in LDL were found 
in specific intervention studies with 
trans fat intake at or below the reported 
average intake for the U.S. population.
FDA disagrees with the comment that 
disclosure of 0.5 g trans fat or greater in 
a food product has no public health 
importance and that health benefits may 
not result from labeling of trans fat 
present in relatively small amount in 
individual foods. As described earlier in 
sections III and V of this document, 
FDA does not need to demonstrate 
adverse health effects of 0.5 g trans fat 
in a food product in order to justify 
requiring disclosure of 0.5 g trans fat on 
food labels. Rather, FDA determined 
that the consistent provision of trans fat 
information on foods consumed 
throughout the day is of public health 
importance and can assist consumers in 
maintaining healthy dietary practices. 
Further, FDA has determined that the 
absence of trans fat information on 
foods requiring mandatory labeling 
would be misleading. However, for the 
purposes of economic analysis, the 
health benefits of decreasing trans fat 
intake by 0.5 g can be estimated 
quantitatively. In a 2,000 calorie diet, 
0.5 g trans fat corresponds to 
approximately 0.2 percent of energy. 
(This correspondence holds because 1 g 
of fat = 9 kcal, so (0.5 x 9 x 100)/2000 
= 0.2 percent of energy). Using the 
factors in table 8, replacement of 0.2 
percent of energy from trans fat with cis-
monounsaturated fat would decrease 
CHD risk by 0.29 percent based on LDL–
C and 0.57 percent based on LDL–C and 
HDL–C. Because CHD is so common in 
the U.S. population, a relatively small 
decrease in risk corresponds to a large 
number of cases and deaths avoided and 
large dollar value of such benefits, as 
shown in the example in section IX.A of 
this document. Awareness of trans fat 
contributions from food products 
containing 0.5 g and above will assist 
individual consumers in maintaining 
healthy dietary practices, reducing the 
average 2.6 percent of energy from trans 
fat consumed throughout the day.
FDA agrees with the comments that 
average saturated fat intake in the 
United States is about 5 times greater 
than average trans fat intake. FDA stated 
in the November 1999 proposal that it 
did not want to distract consumers from 
years of dietary guidance messages 
about saturated fat (64 FR 62746 at 
62755). But the potential health benefits 
from decreasing trans fat intake 
compared with decreasing saturated fat 
intake do not depend solely upon the 
average total amount of each in the diet. 
The potential health benefits also 
depend upon the feasibility of 
decreasing intake of saturated fat 
compared with trans fat. Average U.S. 
saturated fat intake in 1980 was about 
13 percent of energy and decreased to 
11 or 12 percent of energy by the mid-
1990s (Ref. 113). Many additional heart 
attacks and deaths might be prevented 
if saturated fat intake could be 
decreased to the recommended less than 
10 percent of energy. The targeted 
decrease in saturated fat intake of one or 
two percent of energy can be compared 
with the average trans fat intake of 2 
percent of energy from partially 
hydrogenated fats and oils. Labeling of 
trans fat will create new potential for 
decreased trans fat intake by providing 
an incentive to food manufacturers to 
reduce the amount of trans fat in their 
products and by providing consumers 
with information they need to include 
trans fat content in their food 
purchasing decisions.
(Comment 40) Among the comments 
that supported the potential public 
health benefits of trans fat labeling, 
many noted that benefits would result 
from provision of trans fat information 
on product labels so that consumers 
could incorporate this information into 
their purchasing decisions. Several 
comments also specifically noted the 
likelihood that trans fat labeling would 
result in reformulation of products to be 
lower in trans fat, and suggested that the 
public health benefits would be large 
because reducing trans fat intake as a 
result of reformulation requires little 
effort by consumers. However, some 
comments did not agree that trans fat 
labeling would be read or understood by 
consumers, or that the labeling would 
affect purchasing decisions. These 
comments suggested that the net health 
benefits of trans fat labeling would be 
much smaller than FDA’s estimate. 
Other comments did not agree that 
VerDate Jan<31>2003 15:26 Jul 10, 2003 Jkt 200001 PO 00000 Frm 00051 Fmt 4701 Sfmt 4700 E:\FR\FM\11JYR2.SGM 11JYR2
41484 Federal Register / Vol. 68, No. 133 / Friday, July 11, 2003 / Rules and Regulations 
products could be reformulated in a 
manner that would result in net health 
benefits. Some of these comments stated 
that trans fat is beneficial because foods 
with trans fat replace foods with higher 
amounts of saturated fat. Some 
comments stated that feasible 
reformulations that would lower trans 
fat would also increase saturated fat, 
thereby reducing or eliminating health 
benefits. Other comments emphasized 
that manufacturers need competitive 
incentives in order to incur the costs of 
reformulation, and did not agree that the 
Nutrition Facts panel and label claims 
in the November 1999 proposal 
provided sufficient incentives for 
reformulation.
In the November 1999 proposal, FDA 
based its estimate of health benefits on 
scenarios of projected decreases in trans 
fat intake due to labeling and 
reformulation. As summarized in 
section VI.C of this document, FDA 
received specific comments regarding 
the likely decrease in trans fat intake 
due to expected consumer responses to 
trans fat labeling and due to the 
projected amount of product 
reformulation. Based on the comments 
received, on the provisions of this final 
rule and on its own reevaluation, FDA 
has revised its estimate of the expected 
decrease in trans fat intake due to 
labeling (table 2, section VI.C). Because 
of uncertainties regarding the magnitude 
of consumer response to trans fat 
labeling we have chosen a very low 
estimate of consumer response to the 
new label, a decrease of 0.1 percent of 
trans fat intake (section VI.C.). As 
described in section IV of this 
document, current dietary guidance 
does not consider trans fat to be 
beneficial, but recommends that intake 
of both trans fat and saturated fat should 
be limited. When products containing 
partially hydrogenated fats or oils are 
reformulated to lower the trans fat 
content, functionality may require the 
reformulated products to have more 
saturated fat than the original product. 
However, as shown in a number of 
examples included with comments, the 
total amount of saturated fat plus trans 
fat in the reformulated product is 
commonly lower than in the original 
product. Substitution of the 
reformulated product for the original 
product in the diet would have net 
health benefits using Method 1, LDL–C, 
and even higher health benefits using 
Method 2, LDL–C and HDL–C. FDA 
acknowledges that different products 
have different functionality 
requirements for fats and oils, and the 
constraints on reformulation 
alternatives are different for tub and 
stick margarines and spreads, household 
shortenings, frying fats for snacks and 
chips, and baking fats for cookies, 
crackers, cakes and other baked goods. 
FDA has summarized specific 
comments regarding reformulation 
alternatives in section IX.C of this 
document, has taken these into account 
in projecting the expected amount of 
margarine reformulation (table 2), and is 
accounting for the replacement of trans 
fat with different combinations of 
macronutrients in its models for 
calculating changes in valuation of 
health states in section IX.E.3 of this 
document. Therefore, FDA does not 
agree with the comments that feasible 
reformulations would eliminate health 
benefits by increasing saturated fat. In 
section V of this document, FDA 
stressed the importance of providing 
information on trans fat on the nutrition 
label to assist consumers in choosing 
healthier diets. As described in section 
IX.E.3 of this document, in response to 
comments regarding reformulation, FDA 
recognizes that different features of this 
final rule may tend to either increase or 
decrease the incentives for 
reformulation. Therefore, because of this 
uncertainty, in this analysis FDA is 
using a deliberately low estimate, 10 
percent, for the decrease in trans fat 
intake due to margarine reformulation. 
Also, FDA is not using a quantitative 
estimate for any decrease in trans fat 
intake due to reformulation of baked 
products or of other products containing 
hydrogenated fats and oils. To the 
extent that the decrease in trans fat 
intake due to reformulation is greater 
than FDA’s estimate, this analysis will 
underestimate the benefits of trans fat 
labeling.
(Comment 41) As summarized in 
section IV.9 of this document, one 
comment recommended that 
comparisons of the health effects of 
saturated fat and trans fat should be 
explicit and consistent throughout the 
final rule. The comment noted that in 
FDA’s November 1999 proposal, the 
preliminary regulatory impact analysis 
estimated that the effects of trans fat and 
saturated fat on LDL–C were similar for 
a given percent of energy, but the review 
of the science did not make a gram-for-
gram comparison of the effects of 
saturated and trans fat. The comment 
stated that if there is uncertainty about 
the comparative effects of saturated fat 
and trans fat on LDL–C, then this 
should be reflected in FDA’s estimate of 
health benefits. The comment also noted 
that, in the preliminary regulatory 
impact analysis, use of Method 2, LDL–
C and HDL–C, would approximately 
double the expected health benefits of 
trans fat labeling, compared with 
Method 1, LDL–C. The comment 
suggested that if the adverse health 
effects of trans fat are approximately 
double those of saturated fat, this 
should be taken into account in the 
provisions for labeling and claims. This 
comment also suggested that FDA had 
misinterpreted the relative risk results 
of the prospective observational studies 
and questioned whether these studies 
actually indicated that the risk of CHD 
due to trans fat intake was much greater 
than would be expected due to LDL–C 
and HDL–C. According to the comment, 
relative risk estimates in prospective 
studies depend on the base risk used for 
comparisons. Individuals in some study 
groups, such as the Nurses Health 
Study, may have lower overall CHD risk 
than individuals in the general 
population because the participants are 
volunteers whose lifestyles may be 
healthier than average. A systematic 
difference between the study and 
general populations may result in 
inaccuracies when the relative risk from 
the study population is related to the 
absolute risk in the general population.
A few comments to the November 15, 
2002, notice to reopen the trans fat 
comment period questioned the 
scientific validity of certain of the 
observations and conclusions in the 
IOM/NAS report. The comments stated 
that the IOM/NAS report relied upon a 
regression equation in an article by 
Ascherio et al. (Ref. 83), published in 
the NEJM, for its observation that trans 
fatty acids may have a more adverse 
effect on CHD risk than saturated fatty 
acids and for its conclusion that, similar 
to saturated fatty acids, there is a 
positive linear trend between trans fatty 
acid intake and LDL–C and risk of CHD. 
The comments stated that the Ascherio 
et al. article was a commentary that was 
not peer-reviewed and should not be 
accorded the weight given by the IOM 
report. Additionally, comments 
suggested that additional research is 
needed to establish whether there is a 
positive linear trend between trans fat 
intake and LDL–C. The comments 
asserted that there may be an alternate 
explanation for the results described by 
Ascherio et al., and mentioned 
unpublished work done at the 
University of Cincinnati. The comments 
did not mention the existence of any 
other evidence for a linear trend 
between trans fat intake and LDL–C, 
and implied that, in the absence of the 
Ascherio article (Ref. 83), there would 
be no basis for the existence of such a 
linear trend.
As stated in section IV.9 of this 
document, regardless of whether FDA 
reviewed the effects of saturated fat and 
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trans fat on LDL–C and CHD risk for the 
science section or the regulatory impact 
section, the basic conclusion about 
those effects is the same. That is, both 
trans fatty acids and saturated fatty 
acids raise LDL–C levels, a major risk 
factor for CHD risk. FDA did state in the 
review of the science in the 1999 
proposal (64 FR 62746 at 62753) that the 
available studies did not provide a 
definitive answer about whether trans 
fat has an effect on LDL–C and CHD risk 
equivalent to saturated fat on a gram-for-
gram basis. However, as stated 
previously in both this section and 
section IV of this document, to 
overcome the difficulties in interpreting 
individual intervention studies, in the 
November 1999 proposal FDA used 
regression equations based on a meta-
analysis of intervention trials to 
quantitatively estimate the relationship 
between trans fat and LDL (Refs. 62, 65, 
and 69) in its calculation of the health 
benefits of trans fat labeling (64 FR 
62746 at 62768–62770). The regression 
equations do predict a very similar 
increase in LDL–C with each one 
percent of energy increase in either 
saturated fat or trans fat. The regression 
equations used by FDA in this 
document and in the November 1999 
proposal are appropriate for purposes of 
making a quantitative estimate of the 
health benefits as part of an economic 
analysis and are consistent with newer 
regression equations in a study 
published in 2001 (Ref. 130).
As previously described in this 
section and in section IV of this 
document, although FDA did not place 
primary reliance upon the relationships 
among trans fat intakes and adverse 
effects on HDL–C and CHD risk in 
deciding that nutrition labeling was 
warranted, FDA also recognizes this 
possible relationship, so concerns about 
possible adverse effects cannot be 
ignored. Therefore, we used changes in 
both HDL–C and LDL–C as a second 
method to quantify the effects of trans 
fat intake on CHD risk, with the noted 
qualification that the primary basis for 
the rule was the effect of trans fat on 
LDL–C (64 FR 62746 at 62769). As 
discussed in section V of this document, 
because of chemical and physiologic 
distinctions between saturated and trans 
fats, the agency has reconsidered the 
position that the two fatty acids should 
be declared as one combined entity. 
Declaration of the amount of trans fat on 
a separate line from saturated fat on the 
nutrition label is consistent with the 
possibility that the health benefits of 
trans fat labeling may be due to changes 
in LDL–C alone (Method 1), or to 
changes in both LDL–C and HDL–C 
(Method 2).
In response to the comment about 
relative risk in the prospective studies, 
FDA acknowledges that relative risk 
estimates in prospective studies will 
depend on the base risk used for 
comparisons and this dependence on 
base risk may result in inaccuracies 
when the relative risk is related to the 
absolute risk in other studies or in the 
general population. However, FDA does 
not agree that this difference would 
change the basic conclusion of the 
prospective studies, that the CHD risk 
associated with trans fat in the 
prospective studies is much greater than 
the CHD risk expected due to either 
Method 1 (LDL–C) or Method 2 (LDL–
C and HDL–C). In the 14-year followup 
of the Nurses Health Study (Ref. 38), the 
increased risk of CHD associated with 
trans fat intake compared with 
carbohydrate intake was more than ten 
times the increased risk for the same 
amount of saturated fat compared with 
carbohydrate. This comparison between 
trans fat and saturated fat was in 
contrast to the prediction based on 
Method 1 (LDL–C) or Method 2 (LDL–
C and HDL–C). In Method 1, trans fat 
would be predicted to be associated 
with about the same increased risk as 
saturated fat, and in Method 2, trans fat 
would be predicted to be associated 
with about twice as much increased risk 
as saturated fat, comparing both with 
carbohydrate. This comparison was 
within a single study, so the difference 
between the results of this study and 
what would have been expected due to 
Method 1 or 2 cannot be attributed to 
any differences in baseline risk between 
studies. Moreover, although participants 
in large prospective studies have 
different baseline risks of CHD, the 
increased risk associated with known 
risk factors is often reasonably 
consistent across many of the studies. 
For example, the increased CHD risk 
associated with saturated fat for female 
nurses from 1980 to 1994 (Ref. 38) was 
quite similar to that for male employees 
of Western Electric Co. from 1958 to 
1976 (Ref. 67) (64 FR 62746 at 62771). 
The changes in CHD risk associated 
with total cholesterol and HDL–C for 
male physicians from 1982 to 1987 was 
comparable to that for men and women 
from Framingham, MA in the 1970s 
(Ref. 131).
A meta-analysis of the relative risk of 
CHD associated with trans fat intake 
was recently published (Ref. 102). The 
meta-analysis used the results of 
prospective observational studies in 
four cohorts: Women in the United 
States, men in the United States, men in 
Finland, and men in the Netherlands. 
The results showed a pooled variance-
weighted relative risk of 1.25 (95 
percent confidence interval 1.11 to 1.40) 
for CHD associated with 2 percent of 
energy intake from trans fat. For 0.1 
percent of energy intake from trans fat, 
the meta-analysis results would predict 
a relative risk of 1.0112 (confidence 
interval 1.0052 to 1.0170). That is, for 
0.1 percent of energy intake from trans 
fat, the increase in CHD risk would be 
1.12 percent (confidence interval 0.52 to 
1.70 percent). In comparison, the largest 
change in CHD risk shown in table 9, 
associated with 0.1 percent of energy 
intake from trans fat, is 0.162 percent 
using Method 1 and 0.292 percent using 
Method 2. Thus, the increase in CHD 
risk for 0.1 percent of energy intake 
from trans fat based on a meta-analysis 
of prospective studies is larger than the 
associated CHD risk estimated using 
either Method 1, LDL-C or Method 2, 
LDL-C and HDL-C. (The calculation of 
relative risk at different levels of trans 
fat intake is based on taking the natural 
logarithm. For 2 percent of energy 
intake from trans fat, the estimated 
relative risk was 1.25. The coefficient in 
the logistic regression is the natural 
logarithm of 1.25 = 0.223; 0.223/2 = 
0.1116, the coefficient for 1 percent of 
energy from trans fat; 0.1116 x 0.1 = 
0.0112, the coefficient for 0.1 percent of 
energy from trans fat; the antilogarithm 
of 0.0112 = 1.0112, the relative risk 
associated with 0.1 percent of energy 
from trans fat.)
Thus, FDA disagrees with the 
comment about relative risk in the 
prospective studies, and maintains that 
the prospective studies do suggest that 
there may be additional mechanisms, 
besides changes in LDL–C and HDL–C, 
by which trans fat contributes to CHD 
risk. However, as discussed previously 
in this section, and in the November 
1999 proposal (64 FR 62746 at 62771), 
FDA did not use the results of the 
prospective studies in its quantitative 
estimate of the health benefits of trans 
fat labeling. The sole use of the 
prospective studies was to suggest that 
there may be additional mechanisms by 
which trans fat contributes to CHD. The 
prospective studies thus indicate the 
direction of the uncertainty in the 
benefits estimate: That the actual 
benefits may be higher than the benefits 
estimated using Methods 1 and 2.
In response to the comments about 
the Ascherio et al. regression equation 
as discussed in the IOM/NAS report 
(Ref. 140), FDA notes that according to 
the NEJM, all submissions to the journal 
are peer-reviewed before publication. 
The comments did not cite any 
published articles questioning the 1999 
Ascherio et al. paper (Ref. 83), and did 
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not submit data from the unpublished 
work that the comments asserted could 
provide an alternate explanation for the 
Ascherio et al. results. As noted in 
section IV of this document, the paper 
by Ascherio et al. is not the only 
information that the IOM/NAS used in 
concluding that trans fatty acid 
consumption should be as low as 
possible while consuming a 
nutritionally adequate diet (see 
comment 3). Additionally, the Ascherio 
paper is not the only information in the 
IOM/NAS report that supports a 
positive linear trend for trans fat intake 
and LDL–C and risk of CHD. For 
example, as mentioned previously in 
this section (see comment 39), the study 
of Lichtenstein et al. (Ref. 82), using six 
test diets at different levels of trans fat 
intake, found a positive linear trend for 
trans fat intake and LDL–C level. In 
discussing trans fat intake and HDL–C, 
the IOM/NAS report references work by 
Zock, Mensink, and Katan (Refs. 69 and 
154). These papers pertain not only to 
HDL–C but also to LDL–C. The work of 
Zock and colleagues (Refs. 62, 69, and 
154) gives one regression equation 
showing a positive linear trend between 
trans fat intake and LDL–C and another 
regression equation showing a negative 
linear trend between trans fat intake and 
HDL–C.
As noted in section IV and in this 
section of this document, FDA’s primary 
rationale for trans fat labeling is the 
effect of trans fat intake on LDL–C. 
Additionally, the economic analysis 
uses changes in both HDL–C and LDL–
C as a second method to quantify the 
effects of trans fat intake on CHD risk, 
with the noted qualification that the 
primary basis for the rule is the effect of 
trans fat on LDL–C. Therefore, as stated 
in the November 1999 proposal (64 FR 
62746 at 62770), for purposes of 
economic analysis we used the 
equations of Zock et al. (Refs. 62 and 69) 
to estimate the effects of trans fat on 
LDL–C and HDL–C separately and did 
not use the equation of Ascherio et al. 
(Ref. 83), which estimates the positive 
linear trend between trans fat intake and 
the lipid ratio, LDL/HDL. FDA’s Method 
2, using the equations of Zock et al. 
(Refs. 62 and 69) for changes in both 
LDL–C and HDL–C, is different than the 
method of Ascherio et al. (Ref. 83), 
which uses changes in the lipid ratio, 
LDL/HDL. However, what FDA’s 
Method 2 and Ascherio’s method have 
in common is that they each provide a 
quantitative estimate of the adverse 
effects of trans fat on CHD risk using 
changes in both LDL–C and HDL–C.
As stated previously in this section 
(see comment 39), the regression 
equations of Zock et al. (Ref. 69), 
showing a positive linear trend between 
trans fat intake and LDL–C, are 
consistent with newer regression 
equations in a study published in 2001 
by Muller et al. (Ref. 130). Thus, there 
is a body of research, including the 
work of Ascherio et al. (Ref. 83), Zock 
et al. (Refs. 62, 69 and 154), Lichtenstein 
et al. (Ref. 82) and Muller et al. (Ref. 
130), that supports the existence of a 
linear trend for trans fat intake and 
LDL–C levels, consistent with the 
conclusions of the IOM/NAS (Ref. 140). 
As discussed in the IOM/NAS report, 
the existence of a linear trend of 
saturated fat and LDL–C is very well-
established, as shown by three sets of 
regression equations described in the 
IOM/NAS report (Ref. 140, Figure 8–3, 
pp. 8–47 to 8–48). Thus, the existence 
of a positive linear trend for trans fat 
intake and LDL–C, as shown by a body 
of research (Refs. 62, 69, 82, 83, 130, 
and 154) and recognized by the IOM/
NAS (Ref. 140) is not unusual, 
considering that there is also a positive 
linear trend between saturated fat intake 
and LDL–C. Therefore, FDA is not 
convinced by the comments questioning 
the existence of linear trends between 
trans fat and lipid levels. FDA finds 
that, for the purposes of economic 
analysis, it is appropriate to quantify the 
health benefits of trans fat labeling 
using regression equations (Refs. 62 and 
69) describing a positive linear trend 
between trans fat intake and LDL–C and 
a negative linear trend between trans fat 
intake and HDL–C.
(Comment 42) One comment stated 
that FDA’s estimate of benefits of the 
November 1999 proposal neglected to 
account for the overall reductions of 
mortality and morbidity from heart 
disease that have been occurring in the 
United States for the past few decades. 
According to the comment, FDA should 
have projected the future reduction in 
heart disease that would be expected in 
the absence of labeling. With such a 
projection, the baseline for heart disease 
morbidity and mortality would be 
progressively lower over time, and the 
numbers of heart attacks and deaths 
avoided due to trans fat labeling would 
be commensurately reduced compared 
with FDA’s estimate. One comment 
stated that an overall decline in CHD 
from 1970 to 1990 coincided with a 
decline in intake of fat and saturated fat. 
The comment stated that margarine 
intake (per person) was constant during 
this period. Therefore, the comment 
concluded that substituting margarine 
for high saturated fat and cholesterol 
products had proved beneficial in 
decreasing CHD.
FDA agrees that the rate of heart 
disease mortality and morbidity in the 
United States has been decreasing for 
several decades (Refs. 132 and 133). For 
example, the age-adjusted death rate 
from CHD declined from approximately 
290 per 100,000 in 1979 to 190 per 
100,000 in 1996 (Ref. 133). However, 
because the risk of CHD is greater at 
older ages and the U.S. population is 
aging, the decline in the overall (crude) 
CHD death rate in this period was more 
modest, from approximately 225 per 
100,000 to 180 per 100,000. Moreover, 
because of the increase in the total 
population, the decline in annual CHD 
deaths in this period was even more 
modest, from approximately 550,000 to 
500,000, about a 10 percent decrease 
over 17 years. The number of deaths 
was fairly level during the period, 1992 
through 1996. Thus, the baseline 
number of CHD deaths, as opposed to 
age-specific rates, has historically 
declined at a modest rate, and has been 
fairly level in recent years. Therefore, 
FDA did not correct for this in its 
projection of heart attacks and deaths 
avoided due to trans fat labeling. In 
response to the comment about 
correcting its estimate for overall 
reductions in heart disease over time, 
FDA acknowledges that, if the actual 
number of CHD deaths declines in the 
future, omitting this correction would 
result in a modest overestimate of the 
health benefits of trans fat labeling.
Regarding the comment about 
correlations of changes in dietary intake 
with declines in CHD from 1970 to 
1992, information on trans fat intake is 
limited, as noted in section IV of this 
document. Therefore, although 
margarine intake was approximately 
constant, it is not known whether 
overall trans fat intake increased, 
decreased or remained the same during 
this period. Furthermore, the causes of 
the decrease in CHD over this time 
period have not been identified. 
Decreases in CHD risk factors, such as 
serum lipids, and decreases in saturated 
fat intake probably played a role, but the 
relative contributions of decreases in 
various risk factors and changes in 
medical care for heart attack patients are 
not adequately explained (Ref. 132). 
Therefore, FDA disagrees with the 
comment’s conclusion that time trends 
in CHD incidence demonstrate a 
beneficial effect of margarine intake on 
incidence of CHD.
Based on the comments received and 
its own re-evaluation, FDA is not 
making any changes in the sample 
calculations for changes in CHD risk 
(table 8) or in the factors for changes in 
serum lipids and the examples of 
changes in CHD risk and the factors for 
changes in serum lipids with 
substitution of different macronutrients 
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(table 9), described earlier in this 
section. Earlier in this section, FDA has 
revised its estimate of projected 
decreases in trans fat intake due to 
labeling (table 2) and discussed the 
likely substitutions of different types of 
fat for trans fat. Using this information, 
FDA revised the expected changes in 
CHD risk due to trans fat labeling.
As shown in table 2, a 0.0378 percent 
of energy decrease in trans fat intake is 
expected to occur by the effective date 
of the rule. Approximately 3 years will 
be needed for predicted changes in trans 
fat intake to result in changes in CHD 
risk (Ref. 137). Table 10 shows the 
decreases in CHD risk that would be 
expected, 3 years after the effective date, 
for different examples of macronutrient 
substitutions for trans fat. The three 
specific substitutions shown in table 10 
are those that FDA used to represent the 
range of likely ingredient substitutions 
for trans fat in margarine: (1) 100 
percent cis-monounsaturated fat, (2) a 
mixture of 50 percent cis-
monounsaturated and 50 percent cis-
polyunsaturated fat, or (3) a mixture of 
50 percent cis-monounsaturated and 50 
percent saturated fat (Ref. 73). Table 10 
shows that, using one of these three 
substitutions, the predicted decrease in 
CHD risk would range from 0.027 
percent to 0.061 percent for Method 1 
and from 0.090 percent to 0.110 percent 
for Method 2.
FDA has identified these likely 
substitutions, but recognizes that once 
reformulation begins, different 
combinations of ingredients may 
emerge. In order to estimate the health 
effects of reformulation, however, it is 
less important to identify the exact 
formulas to be used than it is to identify 
the range of possible changes in CHD 
risk. To estimate the potential health 
benefits from the reformulation of 
margarine, FDA used a probabilistic 
model with a distribution of effects 
based on the distribution of possible 
changes in CHD risk associated with the 
three ingredient substitutions. FDA used 
a distribution rather than a weighted 
average because we did not know which 
combination was most likely, or what 
distribution of combinations would 
emerge. (The formal distribution we 
used was a BetaPERT, which uses three 
points: A minimum, an intermediate, 
and a maximum. The model used the 
change in CHD risk for a mixture of 50 
percent cis-monounsaturated and 50 
percent saturated fat as the minimum, 
the change with 100 percent cis-
monounsaturated fat as intermediate, 
and the change for a mixture of 50 
percent cis-monounsaturated and 50 
percent cis-polyunsaturated fat as the 
maximum. The mean of a BetaPERT 
distribution = (minimum + (4 x 
intermediate) + maximum)/6.)
As shown in table 10, the 
probabilistic model of substitutions for 
trans fat predicted a decrease in CHD 
risk of 0.052 percent using Method 1 
and 0.106 percent using Method 2.
TABLE 10.—PREDICTED CHANGES IN CHD RISK DUE TO Trans FAT LABELING ACCORDING TO MACRONUTRIENT 
SUBSTITUTION FOR Trans FAT
Time after
Effective Date for 
Final Rule1
Decrease in Trans 
Fat Intake (% of 
Energy) 
Source of
Decrease 
Substitution for 
Trans Fat 
Percent Decrease in CHD Risk 
Method 1, LDL HDL Method 2, LDL and HDL 
3 years 0.0378 Consumer choice 
and margarine 
reformulation 
mono -0.056% -0.053% -0.108%
mono+ poly -0.061% -0.049% -0.110%
mono+ sat -0.027% -0.062% -0.090%
Substitution from 
probabilistic 
model.
-0.052% -0.054% -0.106%
1 The time after the effective date for the final rule includes 3 years for decreases in trans fat intake to result in changes in CHD risk.
Approximately 3 years will be needed 
for predicted changes in trans fat intake 
to result in changes in CHD risk (Ref. 
137). Table 10 shows that the 0.0378 
percent of energy decrease in trans fat 
intake expected to occur by the effective 
date of the rule will result, 3 years after 
the effective date, in a 0.052 percent 
decrease in CHD risk using Method 1 
and a 0.106 percent decrease in CHD 
risk using Method 2. FDA estimated 
these decreases in risk using a 
mathematical model that accounted for 
the three likely substitutions for trans 
fat in reformulation of margarine and 
direct consumer choice, discussed 
previously. Table 10 shows the 
predicted decrease in CHD risk for each 
of the substitutions separately, and the 
overall estimate from the mathematical 
model.
3. Value of Changes in Health
In the previous sections, FDA 
presented potential changes in food 
markets because of this final rule and 
described calculations of the decreases 
in CHD that would result from those 
market changes. Uncertainties in these 
analyses include:
• The size of consumer substitutions 
among existing products;
• The amount of producer 
reformulation to avoid losing market 
shares;
• The types of ingredient substitutions 
producers will make to reduce the 
amount of trans fat in their products; 
and,
• The decrease in CHD that will result 
from decreased trans fat in the diet.
FDA used three specific substitutions 
to represent the range of likely 
ingredient substitutions for trans fat in 
margarine: (1) 100 percent cis-
monounsaturated fat, (2) a mixture of 50 
percent cis-monounsaturated and 50 
percent cis-polyunsaturated fat, or (3) a 
mixture of 50 percent cis-
monounsaturated and 50 percent 
saturated fat (Ref. 73).
FDA estimated the benefits from the 
final rule for two methods. The two 
methods give low and high estimates of 
the change in CHD risk brought about by 
changing intakes of trans fat. Method 1 
assumes that the reduction in CHD risk 
associated with reduced trans fat 
intakes comes about only through the 
reduction in LDL–C. Method 2 assumes 
that the reduction in CHD risk comes 
about through a combination of 
reducing LDL–C and increasing HDL–C. 
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Method 2 results in higher benefit 
estimates than Method 1.
The reduction in CHD risk is highly 
uncertain primarily because of the 
difficulties in estimating the amount of 
reformulation, consumer response, and 
the reduction in CHD risk due to a 
decrease in trans intake. Also, these 
changes will occur over time and can be 
affected by other, unanticipated events. 
FDA dealt with the uncertainty by 
estimating a range of possible 
reductions in CHD risk associated with 
the final rule. The low and high 
estimated benefits can be interpreted as 
a range of potential effects. When we 
lacked direct evidence on uncertain 
values, we dealt with the uncertainty by 
choosing values that generated lower-
bound estimates of benefits. This 
practice and the evidence in the 
previous section both imply that the 
actual realized benefits may exceed the 
range given by the two methods.
a. CHD morbidity and mortality 
prevented. FDA calculated the benefits 
from the final rule as the reduction 
(from the baseline) in CHD multiplied 
by the value of preventing both fatal and 
nonfatal cases of CHD. FDA assumed 
that the cases of CHD prevented by this 
rule will have the same proportions of 
fatal and nonfatal cases as currently 
exist in the population. The AHA 
estimates that 1.1 million heart attack 
cases of CHD occur annually, with 40 
percent of them fatal (Ref. 134). The 
average years of life lost per fatal case 
is 13, or 8 years discounted to the 
present at 7 percent or 11 years 
discounted to the present at 3 percent. 
FDA used these estimates as the 
baseline for the estimated benefits. The 
number of cases varies from year to 
year, so FDA treated the annual number 
of cases as a distribution with a mean 
equal to 1.1 million (and a standard 
deviation of 110,000). FDA applied the 
estimated decline in the probability of 
CHD to the baseline to get estimates of 
the number of cases and fatalities 
prevented by the final rule. FDA used 
these estimates in the analysis for the 
proposed rule, and comments on this 
are discussed in the previous section on 
changes in health states. FDA estimated 
the effects using Method 1, which 
considers changes only in LDL–C, and 
using Method 2, which considers 
changes in both LDL–C and HDL–C.
The benefits are expected to begin 3 
years after the effective date. The 3-year 
lag occurs because a dietary change 
takes several years to begin to affect the 
CHD risk (Ref. 137). With Method 1, 
FDA estimated that 3 years after the 
effective date, the final rule would 
annually prevent 600 cases of CHD and 
240 deaths. Preventing 240 deaths 
would annually save about 1,920 
discounted life years (240 deaths x 8 
years) using a 7 percent discount rate, 
or 2,640 discounted life years (240 
deaths x 11 years) using a 3 percent 
discount rate. With Method 2, FDA 
estimated that 3 years after the effective 
date, the final rule would annually 
prevent 1,200 cases of CHD and 480 
deaths, saving about 3,840 discounted 
life years (480 deaths x 8 years) using 
a 7 percent discount rate, or 5,280 
discounted life years (480 deaths x 11 
years) using a 3 percent discount rate. 
Because the association between trans 
fat consumption and CHD through 
changes in LDL–C is more conclusive, 
the benefits estimated using Method 1 
should be regarded as more certain than 
the benefits estimated using Method 2.
For nonfatal cases, FDA estimated the 
cost to be the sum of the medical costs, 
the cost of functional disability, and the 
cost of pain and suffering. The 
functional disability, and pain and 
suffering combine to reduce the quality 
of life for victims. In a recent study, 
Cutler and Richardson (Ref. 77) 
estimated from National Center for 
Health Statistics data that the quality 
adjusted life year for a CHD survivor 
was 0.71, which indicates that the 
annual loss to the victim is 0.29 quality 
adjusted years. This loss represents the 
combined effects of functional disability 
and pain and suffering. FDA assumed 
that the loss lasts for 13 years, or 8.4 
discounted years. FDA did not estimate 
the extent to which nonfatal cases 
reduce life expectancy or increase other 
health costs. Because nonfatal cases 
probably do have these effects, FDA 
may have underestimated the health 
benefits from preventing nonfatal cases.
The medical costs for nonfatal CHD 
are also important. The American Heart 
Association estimates that the cost of a 
new event is about $22,700 and the total 
annual costs are $51.1 billion (Ref. 75). 
If 1.1 million cases lead to $22,700 per 
case, then all theses cases cost about $25 
billion. The remaining 13.9 million 
cases average about $1,900 per year 
(($51.1 billion - $25 billion) /13.9 
million). FDA, therefore, estimated 
medical costs per case as $22,700 in the 
first year and about $1,900 per year 
thereafter.
The total cost per nonfatal case is the 
sum of lost quality-adjusted life years 
multiplied by $100,000 per life year 
plus the medical costs of $22,700 plus 
$1,900 per year times the discounted 
life years. FDA estimated the morbidity 
cost per case to be about $282,000 ((0.29 
x $100,000 x 8.4) + ($1,900 x 8.4) + 
$22,700).
b. Value of CHD morbidity and 
mortality prevented. In a May 30, 2003 
Memorandum to the President’s 
Management Council, OIRA 
Administrator John D. Graham 
recommended that agencies, when 
performing benefit cost-analysis, present 
results using both VSL and VSLY 
methods. Below we present estimates 
using both methods. The Memorandum 
also recommends that agencies present 
analyses with larger VSLY estimates for 
senior citizens. Since many of the 
beneficiaries of this final rule are senior 
citizens, larger VSLY values than the 
ones we have used will increase benefits 
further.
FDA therefore estimates the benefits 
of this rule using two approaches that 
reflect different methods used in the 
economics literature. First, it calculates 
benefits as the extensions to longevity 
multiplied by the value of such 
increases in life-years gained, plus the 
number of nonfatal cases prevented 
multiplied by the costs of nonfatal 
cases, plus the savings in medical costs 
associated with reductions in nonfatal 
CHD. Its second calculation is like the 
first, except that it values reductions in 
mortality risk as the number of 
statistical deaths prevented multiplied 
by the willingness to pay to reduce the 
risk of death (rather than the extensions 
to longevity multiplied by the value of 
increases in life-years gained), and 
calculates the value of reducing the 
number of nonfatal cases as simply the 
savings in medical costs. This section 
presents these two approaches in turn, 
beginning with benefits as the 
extensions to longevity multiplied by 
the value of such increases in life-years 
gained, plus the prevented costs of 
nonfatal cases and medical costs.
Under the first approach, FDA 
estimated the costs of nonfatal cases to 
be the sum of the medical costs, the cost 
of functional disability, and the cost of 
pain and suffering. The functional 
disability, and pain and suffering 
combine to reduce the quality of life for 
victims. In a recent study, Cutler and 
Richardson (Ref. 77) estimated from 
National Center for Health Statistics 
data that the quality adjusted life year 
for a CHD survivor was 0.71, which 
indicates that the annual loss to the 
victim is 0.29 quality adjusted years. 
This loss represents the combined 
effects of functional disability and pain 
and suffering. FDA assumed that the 
loss lasts for 13 years, or 8.4 discounted 
years (discounted at 7 percent) and 10.6 
discounted years (discounted at 3 
percent). FDA did not estimate the 
extent to which nonfatal cases reduce 
life expectancy or increase other health 
costs. Because nonfatal cases probably 
do have these effects, FDA may have 
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underestimated the health benefits from 
preventing nonfatal cases.
There are also medical costs for 
nonfatal cases of CHD. The American 
Heart Association estimates that the cost 
of a new CHD case is about $22,700 and 
the total annual costs are $51.1 billion 
(Ref. 75). If 1.1 million cases lead to 
$22,700 per case, then all these cases 
cost about $25 billion. The remaining 
13.9 million cases average about $1,900 
per year (($51.1 billion - $25 billion) 
/13.9 million). FDA, therefore, estimated 
medical costs per case as $22,700 in the 
first year and about $1,900 per year 
thereafter.
Under the first approach, the total 
cost per nonfatal case is the sum of lost 
quality-adjusted life years multiplied by 
a value per life year plus the medical 
costs of $22,700 plus $1,900 per year 
times the discounted life years. FDA 
estimates the morbidity cost per case to 
be about $282,000 ((0.29 x $100,000 x 
8.4) + ($1,900 x 8.4) + $22,700), 
assuming a value of $100,000 per 
quality-adjusted life year (VSLY).
In the first approach, FDA uses a 
range to estimate the value of an 
additional year of life to reflect the 
uncertainty in the literature. As a lower 
bound, FDA uses $100,000 per (quality-
adjusted) statistical life year. Cutler and 
Richardson (Ref. 77) use a similar 
estimate, and Garber and Phelps (Ref. 
157) conclude that estimates of the 
value of a life year are about twice the 
level of income, though they present a 
broad range to reflect uncertainty 
associated with risk aversion and 
discount rates. Updating Garber and 
Phelps’ estimates suggests that $100,000 
per life year is a reasonable estimate, 
given that median family income in 
2002 was about $51,000 (Ref. 158). 
Moreover, this estimate is close to the 
estimate used in FDA’s economic 
analysis of the regulations 
implementing the 1990 amendments. 
FDA received no public comments on 
that estimate. To reflect other 
underlying literature, and following 
suggestions from other Federal agencies, 
we begin with an estimate of the value 
of a statistical life (VSL) of $6.5 million. 
This estimate is consistent with the 
survey by Viscusi and Aldy (Ref. 159) 
on the premium for risk observed in 
labor markets. Annuitizing this value 
over 35 years at 3 percent and at 7 
percent discount rates, as is consistent 
with OMB guidance, implies estimates 
of a value of an additional year of life 
of about $300,000 and $500,000. 
Therefore, table 11a shows estimated 
benefits for three estimates of VSLYs: 
$100,000, $300,000 and $500,000, for 
both of the methods of estimating gains 
in life years. Total benefits differ from 
mortality-related benefits by including 
the value of reduced morbidity and 
health care costs.
TABLE 11A.—BENEFITS FOR DIFFERENT VALUES OF STATISTICAL LIFE YEARS
Value of Statis-
tical Life Years 
Gained 
Discount 
Rate 
Number of Discounted Life Years 
Gained 
Mortality Related Benefits Estimated In 
Year 3 After the Effective Date and An-
nually Thereafter (in millions) 
Total Benefits (in millions) 
Method 1 Method 2 Method 1 Method 2
Method 1 Method 2
$100,000 7 percent 1,920 3,840 $192 $384 $234 $477
$300,000 3 percent 2,640 5,280 $792 $1,584 $968 $1,973
$500,000 7 percent 1,920 3,840 $960 $1,920 $1,127 $2,295
In applying the second approach to 
calculating benefits, FDA assumes 
values of a statistical life of $5 million 
and $6.5 million. These values represent 
reasonable central tendencies for a 
larger range of VSL estimates reported 
in the literature: $1 million to $10 
million (Ref. 159). The two values FDA 
uses here are also consistent with one 
reasonable interpretation of studies of 
willingness to pay to reduce mortality 
risks (Refs. 159 and 160). FDA uses the 
lower value to reflect the fact that many 
of the estimates of willingness to pay to 
reduce mortality risk from papers not 
surveyed by Viscusi and Aldy are 
relatively low. Table 11B shows the 
annual benefits estimated in this way 
for the two different VSLs using both a 
3 and 7 percent discount rate. The totals 
in the final 2 columns of the table are 
discounted, so direct multiplication of 
the previous columns does not give the 
totals in the final columns.
TABLE 11B.—BENEFITS FOR DIFFERENT VALUES OF STATISTICAL LIFE AND DISCOUNT RATES
VSL and Discount Rate 
Expected Deaths Averted 
Average Med-
ical Costs per 
Nonfatal Case 
Expected Nonfatal Cases 
Averted 
Total Benefits Estimated in 
Year 3 After the Effective Date 
and Annually Thereafter (in 
millions) Method 1 Method 2 Method 1 Method 2
Method 1 Method 2
$5,000,000 (3%) $43,000 $1,112 $2,225
$6,500,000 (3%) 240 480 $43,000 360 720 $1,442 $2,884
$5,000,000 (7%) $39,000 $991 $1,982
$6,500,000 (7%) $39,000 $1,285 $2,570
F. Overview of Benefits and Costs
To provide an overview of this 
analysis, we can compare the estimated 
total benefits and costs and summarize 
the sources of information used in 
making these estimates.
1. Summary of Benefits and Costs
Table 12 shows the timing of the 
discounted benefits and costs estimated 
for this rule, as well as the totals. The 
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benefits reported in table 12 are based 
on a VSLY of $300,000 and a discount 
rate of 3 percent. The effectiveness of 
this final rule can also be seen in the 
relatively low cost per life year saved. 
For example, if we express the one time 
costs as annualized cost over 20 years 
(discounted at 3 percent), the medium 
cost estimate in table 12 comes to about 
$12 million per year. With Method 1, 
the cost per life year saved would be 
about $4,500 ($12 million/2,600 life 
years). These ratios would be even 
lower if we included the quality-
adjusted life years associated with 
nonfatal cases. The deaths prevented 
alone demonstrate the effectiveness of 
this final rule.
TABLE 12.—SUMMARY OF COSTS AND BENEFITS BY YEAR AFTER PUBLICATION, DISCOUNTED TO EFFECTIVE DATE, IN 
MILLIONS OF DOLLARS
Years After 
Publication 
Effective Date 
2 3 4 5 6 7
Cummulative 
Total as of 
Year 20
Costs
Low $139 none none none none none ... $139
Medium $185 none none none none none ... $185
High $275 none none none none none ... $275
Benefits
Method 1 Annual none none none $968 $940 $913 ...
Cumulative $968 $1,908 $2,821 ... $13,130
Method 2 Annual none none none $1,973 $1,916 $1,860 ...
Cumulative $1,973 $3,889 $5,784 ... $26,757
2. Summary of Information Sources
Table 12A summarizes the inputs, 
data sources, and assumptions used in 
the Final Regulatory Impact Analysis for 
this final rule.
TABLE 12A.—SUMMARY OF INPUTS, DATA SOURCES, AND ASSUMPTIONS
Name of Input Value or Distribution Used Type of Estimate Source of Data or Assumption 
Current trans fat intake. Total intake, 2.55% of en-
ergy; intake from hydro-
genated fat, 2.03% of en-
ergy (table 1 of this docu-
ment).
FDA’s best estimate from 
available data.
USDA trans fat food composition database, 
(Ref. 40); USDA food group data from CSFII. 
1994-96, (Ref. 115).
Adjustment of trans fat in-
take for current level of 
margarine reformulation.
0.063% of energy, decrease 
in current amount of trans 
fat intake from margarine 
(table 2 of this document).
FDA’s best estimate from 
available data.
15% decrease in current amount of trans fat in-
take from margarine based on industry com-
ments on proposed rule.
Change in trans fat intake 
due to margarine reformu-
lation.
0.0359% of energy decrease 
(table 2 of this document).
Low assumption based on 
uncertainty.
Assume 10% decrease in remaining trans fat 
from margarine.
Change in trans fat intake 
due to consumer choice.
0.0019% of energy decrease 
(table 2 of this document).
Low assumption based on 
uncertainty.
Assume 0.1% decrease in remaining trans fat 
intake from hydrogenated fat after margarine 
reformulation.
Overall change in trans fat 
intake due to labeling.
0.0378% of energy decrease 
(tables 2 and 10 of this 
document).
Low assumption based on 
uncertainty. Excludes pos-
sible reformulation of prod-
ucts other than margarine.
Sum of two previous values.
Number of products to be 
tested.
154,000 (table 3 of this doc-
ument).
High estimate based on un-
certainty. Includes many 
products that have already 
been tested.
Main data sources: RTI labeling cost model 
(Ref. 129) for number of products likely to be 
affected and our judgement about what cat-
egories of products are likely to be affected.
Per product cost of testing. $261 to $371 (table 4 of this 
document).
Data. RTI labeling cost model, Ref. 129.
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TABLE 12A.—SUMMARY OF INPUTS, DATA SOURCES, AND ASSUMPTIONS—Continued
Name of Input Value or Distribution Used Type of Estimate Source of Data or Assumption 
Percent of SKU label 
changes that can be co-
ordinated with scheduled 
labeling changes.
84% of branded SKUs, 50% 
of private label SKUs.
FDA interpolation of informa-
tion on 24 and 36 month 
compliance period propor-
tions.
RTI labeling cost model, Ref. 129.
Per product category cost of 
relabeling.
Varies (table 5 of this docu-
ment).
Data. RTI labeling cost model, Ref. 129.
Number of margarines refor-
mulated.
30 (table 6 of this docu-
ment).
Low assumption based on 
uncertainty.
Assume 10% of margarine products reformu-
late.
Per product cost of reformu-
lation.
$440,000 (table 6 of this 
document).
Data. Industry supplied information (64 FR 62745 at 
62782, November 17, 1999).
Overall change in CHD risk 
per change in trans fat in-
take.
0.147% decrease in CHD 
risk per 0.1% of energy 
decrease in trans fat in-
take. Method 1 (table 8 of 
this document).
Low estimate, assuming 
change in CHD risk is en-
tirely through effect of 
trans fat on LDL-C.
Multiply change in trans fat intake by factors 
below: -0.1% x 1.5 x 0.7 x 1.4 = -0.147%, de-
crease in CHD risk.
Overall change in CHD risk 
per change in trans fat in-
take.
0.287% decrease in CHD 
risk per 0.1% of energy 
decrease in trans fat in-
take. Method 2 (table 8 of 
this document).
Intermediate estimate, as-
suming change in CHD 
risk is through effect of 
trans fat on both LDL-C 
and HDL-C. Excludes 
other possible mecha-
nisms linking trans fat to 
CHD risk.
Multiply change in trans fat intake by factors 
below: -0.1% x -0.4 x -2.5 x 1.4 = -0.140%, 
decrease in CHD risk due to change in HDL-
C. Add to result from Method 1: -0.147% + (-
0.140%) = -0.287%, decrease in CHD risk, 
Method 2.
Change in LDL-C with 
change in trans fat intake.
1.5 mg/dL per 1% of energy 
from trans fat substituted 
for cis-monounsaturated 
fat (table 8 of this docu-
ment).
Data. Published meta-analyses, Refs. 62 and 69.
Change in HDL-C with 
change in trans fat intake.
-0.4 mg/dL per 1% of energy 
from trans fat substituted 
for cis-monounsaturated 
fat (table 8 of this docu-
ment).
Data. Published meta-analyses, Refs. 62 and 69.
Changes in LDL-C and HDL-
C with substitutions of 
other macronutrients for 
trans fat.
Various coefficients shown 
in table 9 of this docu-
ment.
FDA’s best estimate from 
available data.
Published meta-analyses, Ref. 65, combined 
with meta-analyses in Refs. 62 and 69.
Changes in CHD risk with 
changes in LDL-C.
0.7% increase per 1 mg/dL 
increase in LDL-C (table 8 
of this document).
Data. Published meta-analyses, Refs. 59, 60, and 61.
Changes in CHD risk with 
changes in HDL-C.
2.5% increase per 1 mg/dL 
decrease in HDL-C (table 
8 of this document).
Data. Published meta-analyses, Refs. 59, 60, and 61.
Adjustment for regression di-
lution.
Factor of 1.4 increase in re-
lationship of change in 
CHD risk with changes in 
LDL-C and HDL-C (table 8 
of this document).
Data. Published data, Ref. 64.
Overall change in CHD risk 
due to labeling.
-0.052%, Method 1;-0.106%, 
Method 2 (table 10 of this 
document).
Factors above combined with 
probabilistic model to ac-
count for macronutrient 
substitutions.
BetaPERT distribution, using the change in 
CHD risk for a mixture of 50% cis-
monounsaturated and 50% saturated fat as 
the minimum, the change with 100% cis-
monounsaturated fat as intermediate, and the 
change for a mixture of 50% cis-
monounsaturated and 50% cis-polyunsat-
urated fat as the maximum. The mean of a 
BetaPERT distribution = (minimum + (4 x in-
termediate) + maximum)/6.
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TABLE 12A.—SUMMARY OF INPUTS, DATA SOURCES, AND ASSUMPTIONS—Continued
Name of Input Value or Distribution Used Type of Estimate Source of Data or Assumption 
Time lag between effective 
date of labeling and first 
health benefits.
3 years (table 10 of this doc-
ument).
Data. 3 years for serum lipid changes from dietary 
change. Ref. 137.
Heart attacks per year. Mean 1.1 million cases, std. 
dev. 110,000 cases.
Data for mean. Assumption 
for std. dev.
Published data, Ref. 134.
Percent of heart attacks per 
year that are fatal.
40%. Data. Published data, Ref. 134.
Life-years saved. 13, or 8.4 years discounted 
to the present at 7% (table 
10 of this document).
FDA’s best estimate from 
available data.
Published data, Refs. 75, 76, and 134.
Life-years saved. 13, or 10.6 years discounted 
to the present at 3% (table 
10 of this document).
FDA’s best estimate from 
available data.
Published data, Refs. 75, 76, and 134.
Medical Costs saved per 
non-fatal case.
$39,000 at 7% discount rate; 
$43,000 at 3% discount 
rate (table 11 of this docu-
ment).
FDA’s best estimate from 
data and life expectancy 
calculations.
Published data, Ref. 134.
Value of Statistical Life Year 
(VSLY).
$100,000; $300,000; 
$500,000 (table 11 of this 
document).
Data and FDA’s best esti-
mate from available data.
$100,000 from Refs. 77 and 68; $300,000 from 
$6.5 million for value of statistical life dis-
counting 35 remaining years at 3%; $500,000 
from $6.5 million for value of statistical life 
discounting 35 remaining years at 7% (Ref. 
159).
Value of Statistical Life 
(VSL).
$5 million; $6,5 million (table 
11 of this document).
Data. General VSL literature (Ref. 159).
G. Peer Review
FDA submitted this economic 
analysis to the Interagency Economic 
Peer Review (IEPR) for peer review. The 
IEPR is a voluntary review process 
composed of, but not limited to, Federal 
economists and analysts who review 
Regulatory Impact Analyses and 
Regulatory Flexibility Analyses prior to 
OMB clearance to improve the quality of 
economic analysis.
Two Federal economists reviewed 
this analysis. Their specific comments 
and FDA’s responses are detailed in Ref. 
155. FDA made the following changes to 
the analysis in response to the 
comments of the reviewers:
• Added several sections to repeat 
information contained in the analysis 
that accompanied the proposal to 
provide more background and context 
for the reader,
• Made some style changes for clarity,
• Added explanations for how some 
numbers were calculated,
• Added references for the European 
market experience with margarine 
reformulation,
• Addressed the comments on costs 
more explicitly,
• Explained why the costs of 
reformulation are included in the 
analysis,
• Added an introduction describing 
the plan of the benefits model and the 
linkages between the various parts of 
the model,
• Corrected our description of study 
subjects in the 1994–1996 Diet and 
Health Knowledge Survey (DHKS) in 
discussing Ref. 119.
X. Final Regulatory Flexibility Analysis
A. Introduction
FDA has examined the economic 
implications of this final rule as 
required by the Regulatory Flexibility 
Act (5 U.S.C. 601–612). If a rule has a 
significant economic impact on a 
substantial number of small entities, the 
Regulatory Flexibility Act requires 
agencies to analyze regulatory options 
that would lessen the economic effect of 
the rule on small entities. FDA finds 
that this final rule would have a 
significant economic impact on a 
substantial number of small entities.
B. Economic Effects on Small Entities
1. Number and Type of Small Entities 
Affected
FDA used data from the 1999 County 
Business Patterns (Ref. 136) to estimate 
the number of small businesses affected 
by this rule. Table 13 shows the number 
of small businesses affected by the 
North American Industry Classification 
System (NAICS). The final rule will 
affect almost all manufacturers of 
packaged, labeled food sold in the 
United States, with the exception of 
exempt manufacturers. The criteria for 
exemption are: (1) Annual sales of fewer 
than 100,000 units; (2) no claims or 
other nutrition information on product 
labels, labeling, or advertising; (3) fewer 
than 100 full-time employees; and (4) 
filing of a notice with the Office of Food 
Labeling (§ 101.9(j)(18) 2002). FDA has 
previously estimated that the exemption 
for all foods would affect about 1.8 
percent of FDA regulated foods by 
volume (see 58 FR 2927 at 2928, January 
6, 1993). FDA estimated the effects of 
exemptions only for the total costs to 
small businesses.
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TABLE 13.—NUMBER OF SMALL ESTABLISHMENTS BY NAICS CODE
Category Description NAICS Code No. of Establishments 
Rice 311212 60
Refined or Blended Fats and Oils 311225 140
Breakfast Cereals and Related Products 311230 60
Chocolate and Confectionery Products Made from Cacao Beans 311320 150
Nonchocolate Confectionery Products 311340 590
Frozen Fruits and Vegetables 311411 230
Frozen Specialties, NEC 311412 380
Specialty Canned Food 311422 140
Dried and Dehydrated Foods 311423 180
Fluid Milk 311511 570
Creamery Butter 311512 30
Cheese 311513 520
Dry, Condensed and Evaporated Milk 311514 210
Ice Cream and Frozen Desserts 311520 420
Fresh and Frozen Seafood 311712 660
Commercial Bakery Products 311812 2760
Frozen Bakery Products 311813 230
Cookies and Crackers 311821 390
Flour Mixes and Dough Made from Purchased Powder 311822 230
Other Snack Foods 311919 400
Mayonnaise, Dressings and Other Prepared Sauces 311941 340
Spices and Extracts 311942 280
Perishable Prepared Food 311991 480
All Other Miscellaneous Food Preparations 311999 850
Pharmaceutical Preparations (NAICS classification for dietary supplements 325412 880
Total 11,180
2. Costs to Small Entities
FDA calculated the costs to small 
businesses with the same basic model 
that we used in section IX.D of this 
document to estimate the total costs. 
Although the basic model is the same 
for large and small firms, the individual 
components of costs differ for large and 
small firms. On average, small firms 
produce fewer products, and market 
fewer labels. FDA assumes that the 
estimated margarine reformulation will 
be done by large producers.
FDA estimated the total costs of the 
final rule to small business by 
estimating the individual categories of 
costs and summing them. The first 
category is testing costs. Small 
businesses would need to test their 
products to determine the amounts of 
trans fats. FDA did not have direct 
estimates of the number of products 
produced by the small businesses 
affected by the final rule. FDA estimated 
the number of products produced by 
small businesses by using a sample from 
the Enhanced Establishment Database 
(EED) and assuming that the proportion 
of all products produced by small 
businesses was the same as the sample 
proportion (85 percent). FDA then 
multiplied the 60,000 products 
estimated to be tested (table 3 of this 
document) by the proportion of 
products produced by small businesses 
(85 percent) to estimate that 51,000 
products will be tested by small 
businesses. Table 14 shows the range of 
testing costs for all small businesses.
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TABLE 14.—RANGE OF PER PRODUCT AND TOTAL TESTING COSTS FOR SMALL BUSINESSES
Low Medium High 
Cost per Product $261 $291 $371
Total Testing Cost $13,311,000 $14,841,000 $18,921,000
Under this final rule many more 
labels will have to be changed than 
under the proposed rule. FDA has used 
the new Labeling Cost Model to re-
estimate the relabeling costs of this final 
rule. FDA estimated reprinting costs for 
information panels on a per label (SKU) 
basis. FDA assumed that the proportion 
of SKUs from small businesses as a 
whole equaled the proportion in the 
EED (73 percent). Across product 
categories the average low relabeling 
cost per SKU is about $1,100 and the 
average high relabeling cost per SKU is 
$2,600. The reported estimated costs of 
changing labels varies within a product 
category because different packaging 
converters and food manufacturers 
reported different costs to RTI 
International. Table 15 shows the total 
estimated costs of relabeling per product 
category and for all small businesses 
affected.
TABLE 15.—RANGE OF RELABELING COSTS FOR SMALL BUSINESSES BY PRODUCT CATEGORY
Product Categories SKUs Changed Low Medium High 
Baked Goods 9,100 $7,987,000 $11,870,000 $19,879,000
Baking Ingredients 1,200 $1,179,000 $1,737,000 $2,846,000
Baby Foods 100 $120,000 $182,000 $295,000
Selected Beverages 6,600 $8,666,000 $12,161,000 $18,569,000
Breakfast Foods 700 $585,000 $903,000 $1,492,000
Selected Candy 3,000 $3,505,000 $5,091,000 $7,819,000
Selected Condiments, Dips and 
Spreads 2,700 $2,939,000 $4,358,000 $6,777,000
Dairy Foods 6,400 $7,843,000 $11,698,000 $18,273,000
Desserts 2,600 $2,016,000 $3,112,000 $5,141,000
Dietary Supplements 5,900 $9,818,000 $14,680,000 $24,850,000
Selected Dressings and Sauces 2,000 $2,123,000 $3,177,000 $4,933,000
Eggs 1,800 $1,448,000 $2,114,000 $3,713,000
Entrees 1,800 $1,469,000 $2,247,000 $3,673,000
Fats and Oils 600 $554,000 $847,000 $1,349,000
Fruits and Vegetables 5,500 $5,421,000 $7,968,000 $13,054,000
Seafood 1,000 $1,264,000 $1,855,000 $2,764,000
Side Dishes and Starches 3,000 $2,454,000 $3,741,000 $6,201,000
Snack Foods 2,600 $2,631,000 $3,860,000 $6,204,000
Soups 500 $591,000 $872,000 $1,353,000
Weight Control Foods 100 $143,000 $207,000 $357,000
Total 57,200 $62,754,000 $92,590,000 $149,640,000
Table 16 of this document shows the 
total costs to small businesses of the 
final rule. The adjusted total costs of the 
final rule equal the unadjusted total 
minus 1.8 percent of the total cost of the 
rule to all businesses (see 58 FR 2927 at 
2928, January 6, 1993). The average cost 
per small business is about $12,000.
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TABLE 16.—TOTAL COSTS FOR SMALL BUSINESSES
Cost Category Low Medium High 
Testing $34,713,000 $38,703,000 $49,343,000
Relabeling $62,754,000 $92,590,000 $137,891,000
Total $97,467,000 $131,293,000 $187,234,000
Adjustment for Exemption -$1,754,000 -$ 2,363,000 -$3,370,000
Adjusted Total $96,000,000 $129,000,000 $195,000,000
FDA has attempted to place the 
burden that these costs will place on 
small businesses in the context of the 
entire environment in which small 
businesses exist. Eastern Research 
Group under contract with FDA has 
developed a model for estimating the 
impact of regulatory costs on the 
survival of small businesses. (Reference: 
Eastern Research Group, ‘‘Model for 
Estimating the Impacts of Regulatory 
Costs on the Survival of Small 
Businesses and Its Applications to Four 
FDA-Regulated Industries,’’ 2002.) This 
model does not cover the entire range of 
products covered by this final rule, so 
it is not possible to estimate the burden 
of this rule. However, table 16a gives a 
sense of the impact that this rule may 
have on three industry categories that 
have many small businesses. The model 
estimates the additional number of 
small businesses that will have negative 
cash flow as a result of the costs of 
complying with a regulation. These 
estimates are likely to be larger than the 
actual effects because the model is 
neither able to take into account the 
exemption from nutrition labeling that 
is available to some small businesses, 
nor can it take into account the 
compliance period of over 2 years 
which allows small businesses to budget 
and plan ahead for the expense of the 
label change.
TABLE 16A.—ILLUSTRATIONS OF IMPACTS ON SMALL BUSINESS
Product Category NAICS Code Total Number of Small Businesses 
Average Number 
SKUs Changed 
Early per Firm 
Range of Costs 
per Firm 
Standard Number 
of Small Busi-
nesses Lost Re-
gardless of 
Regulation 
Additional Small 
Businesses Lost 
Due to Compli-
ance Costs of 
This Rule 
Nonchocolate Confec-
tionery Products 311340 590 6 $8,700–$18,100 30–80 0–30
Cheese 311513 520 6 $7,500–$16,300 40–90 0–20
Commercial Bakery 
Products 311812 2,760 4 $4,200–$9,800 560 10–60
C. Regulatory Options
The Regulatory Flexibility Act 
requires that FDA consider options for 
regulatory relief for small entities.
1. Exemption for Small Businesses
The exemption of small businesses 
from the provisions of the final rule 
would provide regulatory relief. Table 
16 of this document shows that small 
businesses are expected to bear total 
costs of about $130 million as a result 
of the final rule, an average of $12,000 
per small business. As a first 
approximation, then, exempting small 
businesses would reduce the burden by 
an average of $12,000 per small 
business.
FDA believes that this option would 
not be desirable. On the one hand, 
because so many of the businesses in 
the food processing industry are 
classified as small by the Small 
Business Administration, if small 
businesses are exempted, most of the 
potential benefits from the final rule 
would not be realized. On the other 
hand, exempt businesses may be forced 
by market pressures to adopt the final 
label in any case. In addition, under 
section 403(q)(5)(E) of the act and 
implementing regulations, very small 
producers (those with fewer than 100 
full-time employees) that: (1) File a 
notice with the Office of Nutritional 
Products, Labeling, and Dietary 
Supplements; (2) make very low volume 
products (fewer than 100,000 units 
annually); and (3) place no claims or 
other nutrition information on product 
labels, labeling, or advertising would 
already be exempt from this final rule.
2. Longer Compliance Period for Small 
Businesses
Longer compliance periods provide 
regulatory relief for small businesses. 
Some comments requested that the 
compliance period be extended several 
years (e.g., 4 to 7 years) for small 
businesses. These comments stated that 
it was important for small businesses to 
be able to phase in the cost associated 
with the new label requirements so that 
they have extra time to absorb the costs 
of these changes. Some small 
manufacturers reported that they have 
significant inventories of labels. Also, 
smaller manufacturers indicated that 
they would incur costs, including, loss 
and disposal of obsolete packaging 
inventories, product in obsolete 
packages, and new printing plates. 
These small businesses believe that a 
longer compliance period would allow 
them to more easily manage their 
inventories and phase in the trans fat 
labeling requirements along with other 
scheduled labeling revisions. This will 
help minimize unnecessary labeling 
costs and costs passed on to consumers.
To minimize the need for multiple 
labeling changes and to provide 
additional time for compliance by small 
businesses to allow them to use current 
label inventories and phase in label 
changes, the agency is setting the 
effective date at January 1, 2006, the 
VerDate Jan<31>2003 15:26 Jul 10, 2003 Jkt 200001 PO 00000 Frm 00063 Fmt 4701 Sfmt 4700 E:\FR\FM\11JYR2.SGM 11JYR2
41496 Federal Register / Vol. 68, No. 133 / Friday, July 11, 2003 / Rules and Regulations 
next uniform effective date following 
publication of this rule. This allows 
firms more than 2 years to implement 
this final rule providing some regulatory 
relief and economic savings for small 
businesses. This should be long enough 
for most small businesses to coordinate 
the label change for this rule with other 
label changes and reprinting. However, 
in this final rule, FDA has decided not 
to extend the compliance period for 
small businesses beyond what is given 
for all businesses. Because this final rule 
does not affect nutrient content or 
health claims, no small businesses will 
have to change the principal display 
panels or marketing of their products, 
which could be very costly.
With small businesses producing 85 
percent of the products and 73 percent 
of the SKUs, extending the compliance 
period for small businesses to the 
uniform effective date after January 1, 
2006, would leave most labels not 
listing trans fat for almost 5 years after 
publication. This could result in 
significant confusion for consumers 
looking for trans fat content on labels 
and would make the Nutrition Facts 
panel inconsistent across product 
categories. This inconsistency would be 
contrary to the intent of the 1990 
amendments. It also would undermine 
the policy goal of providing consistent 
nutrition information to consumers. 
Also, extending the effective date for 
products containing trans fat would 
delay the benefits of this rule to the 
public health.
3. Exemptions for Small Entities
FDA has chosen not to exempt small 
entities because consumption of trans 
fat results in consequences to the 
consumer. Consumers may increase or 
decrease their risk of CHD based on the 
level of trans fat in their diets. Thus, the 
presence or absence of trans fat in a 
food product is a material fact under 
section 201(n) of the act.
Consumers must know the amount of 
trans fat in food products that they 
select as part of their total daily diet to 
choose products that would allow them 
to reduce their intake of trans fat, and 
thus, reduce the risk of CHD. Section IV 
of this document discusses the scientific 
evidence for why trans fat consumption 
places consumers at risk for CHD. 
Absent mandatory labeling, consumers 
would not be able to understand the 
relative contribution that foods make to 
their total daily intake of trans fat. First, 
because polyunsaturated and 
monounsaturated fats are not subject to 
mandatory labeling, simply including 
trans fat as part of the total fat 
contribution would not allow 
consumers to calculate the trans fat 
content by finding the difference 
between the sum total of all the 
mandatory fats listed on the label and 
the total fat content. Second, even if all 
component fats were required to be 
listed, it would not be realistic to expect 
consumers to do such calculations on 
each product to compare the relative 
trans fat contribution of each. Further, 
the fact that an individual food product 
may contain zero gram trans fat, and 
thus, not contain a level of trans fat that 
would contribute to CHD risk, does not 
prevent the absence of that fact on the 
label to no longer be considered a 
‘‘material fact’’ for that food. In the 
context of mandatory labeling of 
nutrients in a nutrition facts panel, the 
relative contribution of various food 
products to the total day’s consumption 
of a heart unhealthy fat is important for 
consumers ‘‘to readily observe and 
comprehend the information and to 
understand the relative significance of 
that information in the context of the 
total daily diet’’ (section 2(b)(1)(A) of 
Public Law 101–535).
Further, section 403(q)(2)(A) of the act 
provides that mandatory labeling would 
be appropriate when information about 
a nutrient would assist consumers to 
maintain healthy dietary practices. 
Information on the trans fat content of 
food would assist consumers in this 
way. Consumers need the information 
on trans fat content of all foods that they 
consume so that they can reduce their 
intake of trans fat. The fact that a food 
may have no trans fat or a small amount 
of trans fat is useful information to the 
consumer so that food choices can be 
made and the consumer can put that 
product, along with many other 
products consumed as part of the daily 
diet, into the context of the total daily 
diet to maintain healthy dietary 
practices. There is ample discussion in 
section IV of this document about the 
heart unhealthy effects of consuming 
trans fat and strong consensus among 
the scientific community for reducing 
trans fat intake.
Survey data show that consumers rely 
on the Nutrition Facts label as a guide 
to choosing foods that meet their dietary 
objectives. As consumers learn more 
about the dietary significance of trans 
fat and the dietary advice to limit its 
consumption, the Nutrition Facts panel 
is where label users will expect to find 
this information. If they cannot find 
information on trans fat content there or 
if it is only there when claims are made 
about fatty acids or cholesterol, they 
will be hampered in their ability to 
implement the most recent dietary 
guidance, and are likely to be misled 
about a food’s basic characteristics.
Consumers need the trans fat 
information on products in order to 
determine how each product fits into 
their individual health goal for reducing 
trans fat intake in the context of their 
total daily diet. Thus, the agency is 
requiring trans fat labeling, regardless of 
whether claims are made or the levels 
of other fats are declared, to prevent 
products from being misleading under 
sections 403(a)(1) and 201(n) of the act. 
Therefore, as described in section III of 
this document, in this rulemaking FDA 
is relying on its authority under those 
sections as well as its authority under 
section 403(q)(2)(A) of the act to require 
that information on trans fat be 
included in nutrition labeling to assist 
consumers in maintaining healthy 
dietary practices. Not requiring such 
information on labels, whether or not 
voluntary nutrients are listed or claims 
are made about fatty acids or 
cholesterol, would be inconsistent with 
statutory directives for nutrition 
labeling in section 403(q) of the act.
Furthermore, the benefits of covering 
products made by small businesses 
exceed the costs that would be saved by 
exempting them. The medium estimated 
cost of covering small businesses is a 
one time cost of $129 million dollars 
(table 16). If we assume no benefits from 
small businesses reformulating, then the 
benefits associated only with changing 
labels on all food products is $48 
million per year using Method 1 ($99 
million using Method 2). If small 
businesses produce at least 22 percent 
of food consumed annually, then 
benefits of covering products made by 
small businesses will exceed the costs 
that would be saved by exempting them 
after 20 years discounted at 3 percent. 
Using Method 2 for calculating benefits, 
small businesses would only need to 
account for production of at least 11 
percent of food consumed. Since the 
Small Business Administration 
definition of small business includes the 
vast majority of food firms, products, 
and SKUs, even the 22 percent amount 
is quite plausible.
D. Recordkeeping and Reporting 
Requirements
The Regulatory Flexibility Act 
requires FDA to include a description of 
the recordkeeping and reporting 
required for compliance with this final 
rule. This final rule does not require the 
preparation of a report or a record.
E. Summary
FDA finds that under the Regulatory 
Flexibility Act (5 U.S.C. 605(b)) this 
final rule will have a significant 
economic impact on a substantial 
number of small entities. Approximately 
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10,300 small businesses could be 
affected by the rule. The total burden on 
small entities is estimated to be between 
$96 and $184 million, or about $9,300 
to $17,900 per entity.
XI. Unfunded Mandates
The Unfunded Mandates Reform Act 
of 1995 (Public Law 104–4) requires 
cost-benefit and other analyses for rules 
that would cost more than $100 million 
in 1 single year. The final rule qualifies 
as a significant rule under the statute. 
FDA has carried out the cost- benefit 
analysis in sections IX.C and IX.D of 
this document. The other requirements 
under the Unfunded Mandates Act of 
1995 include assessing the rule’s effects 
on the following:
1. Future costs;
2. Particular regions, communities, or 
industrial sectors;
3. National productivity and 
economic growth;
4. Full employment and job creation; 
and,
5. Exports.
A. Future Costs
Most of the costs of this rule will be 
incurred during the compliance period. 
Future costs beyond that period would 
likely be small, because the food 
industry would have adjusted to the 
new requirements by that time.
B. Particular Regions, Communities, or 
Industrial Sectors
The final rule applies to the food 
industry and would, therefore, affect 
that industry disproportionately. Any 
long run increase in the costs of food 
production would largely be passed on 
to the entire population of consumers.
C. National Productivity and Economic 
Growth
The final rule is not expected to 
substantially affect productivity or 
economic growth. It is possible that 
productivity and growth in certain 
sectors of the food industry could be 
slightly lower than otherwise because of 
the need to divert research and 
development resources to compliance 
activities. The diversion of resources to 
compliance activities would be 
temporary. Moreover, FDA anticipates 
that, because the health benefits are 
estimated to be significant, both 
productivity and economic growth 
would be higher than in the absence of 
the rule. In section IX.C.3 of this 
document, FDA estimated benefits from 
the reduction in functional disability 
associated with a reduction in nonfatal 
CHD. A reduction of functional 
disability would result in an increase in 
productivity. The increased health of 
the population and the reduction in 
direct and indirect health costs could 
increase both productivity and 
economic growth.
D. Full Employment and Job Creation
The human resources devoted to 
producing certain foods would be 
redirected by the final rule. The final 
rule could lead to some short-run 
unemployment as a result of the 
structural changes within the food 
industry, the rise of some product lines 
and decline of others. The growth of 
employment (job creation) could also be 
temporarily slower.
E. Exports
Because the final rule does not 
mandate any changes in products, 
current export products will not be 
required to change in any way. Food 
processors, however, do not necessarily 
distinguish between production for 
export and production for the domestic 
market. The effect of the final rule on 
U.S. food exports depends on how 
foreign consumers react to information 
about trans fats and to product 
formulations that contain lower 
amounts of partially hydrogenated oils. 
The new label and possible new 
formulations could either increase or 
decrease exports. Products in Germany 
and certain other European countries, 
for example, currently use partially 
hydrogenated oils to a lesser degree than 
in the United States, so the final rule 
could make U.S. exports of margarine 
more attractive to consumers in those 
countries than they have been. 
However, it could also make U.S. 
exports of unreformulated products that 
reveal the presence of trans fat less 
attractive to consumers in those 
countries than they have been.
XII. Environmental Impact
The agency has previously considered 
the environmental effects of this rule as 
announced in the proposed rule (64 FR 
62746, November 17, 1999). No new 
information or comments have been 
received that would affect the agency’s 
previous determination that there is no 
significant impact on the human 
environment and that an environmental 
impact statement is not required.
XIII. Paperwork Reduction Act
This final rule contains information 
collection provisions that are subject to 
review by OMB under the Paperwork 
Reduction Act of 1995 (44 U.S.C. 3501- 
3520). The title, description, and 
respondent description of the 
information collection provisions are 
shown below with an estimate of the 
annual reporting burden. Included in 
the estimate is the time for reviewing 
instructions, searching existing data 
sources, gathering and maintaining the 
data needed, and completing and 
reviewing each collection of 
information.
Title: Food Labeling; Trans Fatty 
Acids in Nutrition Labeling, Nutrient 
Content Claims and Health Claims.
Description: Section 403(q)(1)(A) and 
(q)(1)(B) of the act requires that the label 
or labeling of a food bear nutrition 
information on the amount of nutrients 
present in the product. Under these 
provisions of the act and section 2(b) of 
the 1990 amendments, FDA has issued 
regulations in § 101.9(c)(2) that require 
that the Nutrition Facts panel disclose 
information on the amounts of fat and 
certain fatty acids in the food product. 
This final rule establishes 
§ 101.9(c)(2)(ii) to require that the 
Nutrition Facts panel disclose 
information on the amount of trans fat 
in the food product. Similarly, under 
the provisions of section 403(q)(5)(F) of 
the act, FDA has issued regulations in 
§ 101.36(b)(2) that specify the nutrition 
information that must be on the label or 
labeling of dietary supplements. This 
final rule establishes § 101.36(b)(2) (21 
CFR 101.36(b)(2)) to specify that when 
nutrition information is declared on the 
label and in labeling, it must include the 
amount of trans fat.
The regulations set forth in this final 
rule require that trans fat be declared in 
the nutrition label of conventional foods 
and dietary supplements on a separate 
line immediately under the line for the 
declaration of saturated fat. 
Description of Respondents: Persons 
and businesses, including small 
businesses. 
FDA estimates the burden of this 
collection of information as follows:
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TABLE 17.—ESTIMATED REPORTING BURDEN1
21 CFR Section No. ofRespondents 
Responses 
per
Respondent 
Total No. of
Responses 
Hours per
Response Total Hours 
Operating 
Costs (in
thousands) 
101.9(c)(2)(ii) 10,490 27 278,100 2 556,200 $155,200
101.36(b)(2) 910 32 29,500 2 59,000 $16,500
Totals 615,200 $171,700
1 There are no capital costs and or maintenance costs associated with this collection of information.
The impact of these requirements 
concerning trans fatty acids would be 
largely a one-time burden created by the 
need for firms to revise food and dietary 
supplement labels. FDA used data from 
the 1999 County Business Patterns to 
estimate the number of respondents. 
The total number of responses is equal 
to the total number of SKUs being 
changed (table 3 of this document). 
Based upon its knowledge of food and 
dietary supplement labeling, FDA 
estimates that firms would require less 
than 2 hours per SKU (hours per 
response) to comply with the nutrition 
labeling requirements in this final rule. 
This 2 hour per SKU estimate is based 
on assumptions about the amount of 
time required per SKU to test a product 
for trans fat, to redesign the label as 
needed, and to order the change for the 
label. FDA received no comments 
objecting to this estimate.
Multiplying the total number of 
responses by the hours per response 
gives the total hours. FDA has estimated 
operating costs by combining the 
medium testing and relabeling costs 
from table 7 of this document ($44.9 
million + $126.8 million for relabeling) 
to get the total operating cost. This total 
was then apportioned between §§ 101.9 
and 101.36 according to the proportion 
of responses for each section. Based on 
the labeling cost model, FDA expects 
that, with a compliance period of over 
2 years, 75 percent of firms will 
coordinate labeling revisions required 
by this final rule with other planned 
labeling changes for their products.
The information collection provisions 
of this final rule have been submitted to 
OMB for review. Prior to the effective 
date of this final rule, FDA will publish 
a document in the Federal Register 
announcing OMB’s decision to approve, 
modify, or disapprove the information 
collection provisions in this final rule. 
An agency may not conduct or sponsor, 
and a person is not required to respond 
to, a collection of information unless it 
displays a currently valid OMB control 
number.
XIV. Federalism
FDA has analyzed this final rule in 
accordance with the principles set forth 
in Executive Order 13132. FDA has 
determined that the rule has a 
preemptive effect on State law. Section 
4(a) of the Executive order requires 
agencies to ‘‘construe * * * a Federal 
Statute to preempt State law only where 
the statute contains an express 
preemption provision, or there is some 
other clear evidence that the Congress 
intended preemption of State law, or 
where the exercise of State authority 
conflicts with the exercise of Federal 
authority under the Federal statute.’’ 
Section 403A of the act (21 U.S.C. 343–
1) is an express preemption provision. 
That section provides that ‘‘no State or 
political subdivision of a State may 
directly or indirectly establish under 
any authority or continue in effect as to 
any food in interstate commerce’’ 
certain food labeling requirements, 
unless an exemption is provided by the 
Secretary (and, by delegation, FDA). 
Relevant to this final rule, one such 
requirement that States and political 
subdivisions may not adopt is ‘‘any 
requirement for nutrition labeling of 
food that is not identical to the 
requirement of section 403(q) * * * ’’ 
(act section 403A(a)(4), 21 U.S.C. 343–
1(a)(4)). Prior to the effective date of this 
rule, this provision operated to preempt 
States from imposing nutrition labeling 
requirements concerning trans fat 
because no such requirements had been 
imposed by FDA under section 403(q) of 
the act. Once this rule becomes 
effective, States will be preempted from 
imposing any nutritional labeling 
requirements for trans fat that are not 
identical to those required by this rule.
Section 403A(a)(4) of the act (21 
U.S.C. 343–1(a)(4)) displaces both state 
legislative requirements and state 
common-law duties. Medtronic v. Lohr, 
518 U.S. 470, 503 (1996) (Breyer, J., 
concurring in part and concurring in the 
judgment); id. at 510 (O’Connor, J., 
joined by Rehnquist, C. J., Scalia, J., and 
Thomas, J., concurring in part and 
dissenting in part); Cippollone v. Liggett 
Group, Inc., 505 U.S. 504, 521 (1992) 
(plurality opinion); id. at 548–49 
(Scalia, J., joined by Thomas, J., 
concurring in part in the judgment and 
dissenting in part). Although this rule 
has preemptive effect in that it would 
preclude States from adopting statutes, 
issuing regulations, or adopting or 
enforcing any requirements that are not 
identical to the trans fat labeling 
required by this final rule, including 
State tort-law imposed requirements, 
this preemptive effect is consistent with 
what Congress set forth in section 
403(A) of the act.
Section 4(c) of the Executive order 
further requires that any ‘‘regulatory 
preemption of State law shall be 
restricted to the minimum level 
necessary’’ to achieve the regulatory 
objective. The agency is exercising its 
discretion under section 403(q)(2)(A) of 
the act, in a manner that is consistent 
with such section, to require that the 
amount of trans fat be listed in the label 
or labeling of food. This action is the 
minimum level necessary to achieve the 
agency regulatory objective. Further, 
section 4(e) of the Executive order 
provides that ‘‘when an agency proposes 
to act through adjudication or 
rulemaking to preempt State law, the 
agency shall provide all affected State 
and local officials notice and an 
opportunity for appropriate 
participation in the proceedings.’’ FDA 
sought input from all stakeholders 
through publication of the proposed 
rule in the Federal Register. Eight 
comments from State and local 
governmental entities were received; all 
supported the proposal. In addition, one 
supportive comment was received from 
a municipal health agency in response 
to the reopening of the comment period 
relating to the proposed footnote.
In conclusion, FDA has determined 
that the preemptive effects of the final 
rule are consistent with Executive Order 
13132.
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List of Subjects in 21 CFR 101
Food labeling, Nutrition, Reporting 
and recordkeeping requirements.
 Therefore, under the Federal Food, 
Drug, and Cosmetic Act and under 
authority delegated to the Commissioner 
of Food and Drugs, 21 CFR part 101 is 
amended as follows:
PART 101—FOOD LABELING
 1. The authority citation for 21 CFR 
part 101 continues to read as follows:
Authority: 15 U.S.C. 1453, 1454, 1455; 21 
U.S.C. 321, 331, 342, 343, 348, 371.
 2. Section 101.9 is amended by:
a. Redesignating paragraphs (c)(2)(ii) 
and (c)(2)(iii) as (c)(2)(iii) and (c)(2)(iv),
b. Adding new paragraph (c)(2)(ii), 
and
c. Revising paragraphs (c)(2)(i), 
(d)(1)(ii)(A), the first sentence of 
paragraph (f), the first sentence of 
paragraph (g)(5), the second sentence of 
paragraph (g)(6), and the sample labels 
in paragraphs (d)(11)(iii), (d)(12), 
(d)(13)(ii), (e)(5), (j)(13)(ii)(A)(1), and 
(j)(13)(ii)(A)(2).
 The revisions and additions are to read 
as follows:
§ 101.9 Nutrition labeling of food.
* * * * *
(c) * * *
(2) * * *
(i) ‘‘Saturated fat,’’ or ‘‘Saturated’’: A 
statement of the number of grams of 
saturated fat in a serving defined as the 
sum of all fatty acids containing no 
double bonds, except that label 
declaration of saturated fat content 
information is not required for products 
that contain less than 0.5 gram of total 
fat in a serving if no claims are made 
about fat, fatty acid, or cholesterol 
content, and if ‘‘calories from saturated 
fat’’ is not declared. Except as provided 
for in paragraph (f) of this section, if a 
statement of the saturated fat content is 
not required and, as a result, not 
declared, the statement ‘‘Not a 
significant source of saturated fat’’ shall 
be placed at the bottom of the table of 
nutrient values. Saturated fat content 
shall be indented and expressed as 
grams per serving to the nearest 0.5 
gram (1/2) gram increment below 5 
grams and to the nearest gram increment 
above 5 grams. If the serving contains 
less than 0.5 gram, the content shall be 
expressed as zero.
(ii) ‘‘Trans fat’’ or ‘‘Trans’’: A 
statement of the number of grams of 
trans fat in a serving, defined as the sum 
of all unsaturated fatty acids that 
contain one or more isolated (i.e., 
nonconjugated) double bonds in a trans 
configuration, except that label 
declaration of trans fat content 
information is not required for products 
that contain less than 0.5 gram of total 
fat in a serving if no claims are made 
about fat, fatty acid or cholesterol 
content. The word ‘‘trans’’ may be 
italicized to indicate its Latin origin. 
Trans fat content shall be indented and 
expressed as grams per serving to the 
nearest 0.5 (1/2)-gram increment below 
5 grams and to the nearest gram 
increment above 5 grams. If the serving 
contains less than 0.5 gram, the content, 
when declared, shall be expressed as 
zero. Except as provided for in 
paragraph (f) of this section, if a 
statement of the trans fat content is not 
required and, as a result, not declared, 
the statement ‘‘Not a significant source 
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of trans fat’’ shall be placed at the 
bottom of the table of nutrient values.
* * * * *
(d)(1) * * *
(ii) * * *
(A) Except as provided for in 
paragraph (c)(2)(ii) of this section, a 
single easy-to-read type style,
* * * * *
(11) * * *
(iii) * * *
(12) * * * (13) * * *
(ii) * * *
VerDate Jan<31>2003 15:26 Jul 10, 2003 Jkt 200001 PO 00000 Frm 00071 Fmt 4701 Sfmt 4700 E:\FR\FM\11JYR2.SGM 11JYR2 ER
11
JY
03
.0
00
</
G
PH
>
ER
11
JY
03
.0
01
</
G
PH
>
41504 Federal Register / Vol. 68, No. 133 / Friday, July 11, 2003 / Rules and Regulations 
VerDate Jan<31>2003 15:26 Jul 10, 2003 Jkt 200001 PO 00000 Frm 00072 Fmt 4701 Sfmt 4700 E:\FR\FM\11JYR2.SGM 11JYR2 ER
11
JY
03
.0
02
</
G
PH
>
41505Federal Register / Vol. 68, No. 133 / Friday, July 11, 2003 / Rules and Regulations 
* * * * *
(e) * * *
(5) * * *
(f) The declaration of nutrition 
information may be presented in the 
simplified format set forth herein when 
a food product contains insignificant 
amounts of eight or more of the 
following: Calories, total fat, saturated 
fat, trans fat, cholesterol, sodium, total 
carbohydrate, dietary fiber, sugars, 
protein, vitamin A, vitamin C, calcium, 
and iron; * * *
* * * * *
(g) * * *
(5) A food with a label declaration of 
calories, sugars, total fat, saturated fat, 
trans fat, cholesterol, or sodium shall be 
deemed to be misbranded under section 
403(a) of the act if the nutrient content 
of the composite is greater than 20 
percent in excess of the value for that 
nutrient declared on the label. * * *
(6) * * * Reasonable deficiencies of 
calories, sugars, total fat, saturated fat, 
trans fat, cholesterol, or sodium under 
labeled amounts are acceptable within 
current good manufacturing practice.
* * * * *
(j) * * *
(13) * * *
(ii) * * *
(A) * * *
(1) * * *
(2) * * *
* * * * *
 3. Section 101.36 is amended by 
revising paragraph (b)(2)(i) to read as 
follows:
§ 101.36 Nutrition labeling of dietary 
supplements.
* * * * *
(b) * * *
(2) * * *
(i) The (b)(2)-dietary ingredients to be 
declared, that is total calories, calories 
from fat, total fat, saturated fat, trans fat, 
VerDate Jan<31>2003 15:26 Jul 10, 2003 Jkt 200001 PO 00000 Frm 00073 Fmt 4701 Sfmt 4700 E:\FR\FM\11JYR2.SGM 11JYR2 ER
11
JY
03
.0
03
</
G
PH
>
ER
11
JY
03
.0
04
</
G
PH
>
ER
11
JY
03
.0
05
</
G
PH
>
41506 Federal Register / Vol. 68, No. 133 / Friday, July 11, 2003 / Rules and Regulations 
cholesterol, sodium, total carbohydrate, 
dietary fiber, sugars, protein, vitamin A, 
vitamin C, calcium and iron, shall be 
declared when they are present in a 
dietary supplement in quantitative 
amounts by weight that exceed the 
amount that can be declared as zero in 
nutrition labeling of foods in accordance 
with § 101.9(c) of this part. * * *
* * * * *
 4. Appendix B to Part 101 is amended 
by revising the sample label following 
the list of examples to read as follows:
Appendix B to Part 101—Graphic 
Enhancements Used by the FDA
* * * * *
Dated: May 7, 2003. 
Mark B. McClellan, 
Commissioner of Food and Drugs.
Dated: July 2, 2003. 
Tommy G. Thompson, 
Secretary of Health and Human Services.
[FR Doc. 03–17525 Filed 7–9–03; 8:45 am] 
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